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ABSTRACT 
Primary sclerosing cholangitis (PSC) is an immune-mediated cholangiopathy and 
extra-intestinal manifestation of inflammatory bowel disease (IBD). It is hypothesised 
that long-lived, 7+ CCR9+ effector memory T-cells generated within the intestine 
drive hepatobiliary injury in PSC, being recruited to the liver via hepatic endothelial 
expression of mucosal addressin cell adhesion molecule (MAdCAM)-1 and CCL25.  
 
Previous studies (mainly murine) claim CCL25 expression and CCR9
+
 T-cells as 
confined to small bowel under homeostatic and inflammatory conditions, whereas 
PSC is typified by colonic disease. However, I was able to illustrate that in man, a 
significant proportion of tissue-infiltrating T-cells do express CCR9 in colitis relative 
to low numbers in the absence of colonic inflammation. Moreover, CCL25 expression 
is not only apparent in colonic IBD but also correlates with inflammatory indices.  
 
Vascular adhesion protein (VAP)-1 is a potent amine oxidase capable of augmenting 
expression of other hepatic endothelial adhesion molecules through an enzyme-
dependent process. I found that hepatic VAP-1 enzyme activity is greater in PSC than 
other autoimmune liver diseases; mirrored by high circulating serum levels that 
correlate with patient clinical outcomes. I then examined the effect of several 
potential amine substrates on VAP-1 dependent expression of MAdCAM-1 by liver 
endothelium, illustrating cysteamine as the most potent – an amine that is notable for 
inducing colitis in mice. Targeted deletion of VAP-1 enzyme function did not confer 
protection against early sclerosing cholangitis in Mdr2
–/– 
mice. However, this model 
does not replicate links between colitis and liver inflammation seen in clinical PSC. 
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IL: Interleukin 
ILC: Innate lymphoid cell 
IEL: Intraepithelial lymphocyte 
IP: Immunoprecipitation 
IQR: Interquartile range 
KC: Kupffer cell 
KS: Kolmogorov-Smirnov 
KW: Kruskal-Wallis 
LD: Liver disease 
LFA: Lymphocyte function-associated antigen 1 
LOX(L): Lysyl oxidase (like) 
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LP: Lamina propria 
LPL: Lamina propria lymphocytes 
LPS: Lipopolysaccharide 
L-SIGN: Liver/lymph node-specific intracellular adhesion 
molecules-3 grabbing non-integrin 
LT: Lymphotoxin 
LYVE: Lymphatic vessel endothelial hyaluronan receptor 
MA: Methylamine 
MAdCAM: Mucosal addressin cell adhesion molecule 
MAIT: Mucosa-associated invariant T-cell 
MALT: Mucosa-associated lymphoid tissue 
MAO: Monoamine oxidase 
MCD: Methyl choline deficient 
mDC: Myeloid dendritic cell 
MdM: Monocyte-derived macrophage 
MDR: Multidrug resistant 
MDSC: Myeloid-derived suppressor cell 
MFI: Median fluorescence intensity 
MHC: Major histocompatibility complex 
MLN: Mesenteric lymph node 
MMP: Matrix metalloproteinase 
M.O.M.: Mouse-on-mouse 
MW: Mann-Whitney 
NAFLD: Non-alcoholic fatty liver disease 
NC: Normal / Non-inflamed colon 
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NFB: Nuclear factor kappa B 
NIHR: National Institute for Health Research 
NK: Natural killer 
NL: Normal liver 
NOD: Nucleotide-binding oligomerization domain-containing 
protein 
NSAID: Non-steroidal anti-inflammatory drug 
OR: Odds ratio 
OVA: Ovalbumin 
PAMP: Pathogen-associated molecular pattern 
PAO: Polyamine oxidase 
PBC: Primary biliary cirrhosis 
PBL: Peripheral blood lymphocyte 
PBS: Phosphate-buffered saline 
PCR: Polymerase chain reaction 
pDC: Plasmacytoid dendritic cell 
PDGF: Platelet-derived growth factor 
PF: Portal fibroblast 
PLZF: Transcription factor promyelocytic leukaemia zinc finger 
protein 
PRK: Serine-threonine protein kinase 
PRR: Pathogen recognition receptor 
PSC: Primary sclerosing cholangitis 
PSGL: P-selectin glycoprotein 
qRT-PCR: Quantitative real-time PCR 
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QC: Quality control 
Q-Q: Quantile-quantile 
RGD: Tripeptide sequence: Arginyl-glycyl-aspartic acid  
ROC: Receiver operator curve 
RTC: Rat tail collagen 
SB: Small bowel 
ScZ: Semicarbazide 
SD: Standard deviation 
SDS: Sodium-docecyl-sulphate 
SFM: Serum-free media 
SFRS4: Arginine/serine-rich splicing factor 
SS: Side scatter 
SSAO: Semicarbazide-sensitive amine oxidase 
SIK: Salt-inducible kinase 
TBS: Tris-buffered saline 
Tc Cytotoxic T-cell 
TCM Central memory T-cell 
TCR: T-cell receptor 
Teff Effector T-cell 
TEM Effector memory T-cell 
TGF: Transforming growth factor 
Th Helper T-cell 
TIMP: Tissue-inhibitor of metalloproteinase 
TLR: Toll-like receptor 
TNBS: Tri-nitrobenzene sulfonic acid 
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TNF: Tumour necrosis factor 
TRAIL: TNF-related apoptosis-inducing ligand 
UC: Ulcerative colitis 
VAP: Vascular adhesion protein 
VCAM: Vascular cell adhesion molecule 
VE: Vascular endothelial 
VEGF: Vascular endothelial growth factor 
VVO: Vesicovascular organelles 
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1 GENERAL INTRODUCTION 
1.1 Overview 
In order to cope with the daily exposure to a vast array of nutrients and microbes, the 
mucosal immune system has evolved specific compartments to respond to pathogens 
whilst continuously monitoring and providing tolerance to harmless commensals and 
food-borne antigens [1]. Nevertheless, microbes may penetrate intestinal defence 
mechanisms and enter the liver via the portal circulation where further levels of 
immune regulation operate [1]. In light of such close integration between mucosal and 
hepatobiliary immune systems, it is perhaps unsurprising that the liver can be affected 
by immune-mediated diseases primarily those affecting the gut [1]. The strong 
association between primary sclerosing cholangitis (PSC) and inflammatory bowel 
disease (IBD) led to the hypothesis that in this condition, liver disease is driven by 
lymphocytes generated in the intestine, which enter the portal circulation and trigger 
hepatic inflammation upon reactivation. This enterohepatic pathway is likely to be 
facilitated by aberrant expression of adhesion molecules and chemokines which under 
normal conditions are restricted to either the gut or liver [1,2].  
 
The focus of this thesis is to further interrogate mechanisms linking lymphocyte 
recruitment to the liver and gut in PSC/IBD, therein providing scope for new 
therapeutic approaches. Before reviewing tissue-specific mechanisms, the general 
principles of T-cell activation and differentiation, lymphocyte migration and 
trafficking and roles in tissue inflammation and fibrosis will be discussed. 
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1.2 The immune system 
The immune system is made up of a coordinated network of cells, tissues and organs, 
which exist to identify and control invading organisms, tumours and substances with 
the potential to cause host damage. Structural classification is divided into central 
(genesis site of undeveloped/immature leucocytes e.g., thymus and red bone marrow) 
and peripheral lymphoid tissues (locale of antigen presentation e.g., lymph nodes, 
spleen and mucosa-associated lymphoid tissues). Bone marrow represents the site 
where cells of erythroid (erythrocytes, platelets), myeloid (neutrophils, 
monocytes/macrophages, basophils, eosinophils, dendritic cells) and lymphoid (B- 
and T-lymphocytes, natural killer cells) lineages derive. During early gestation, 
haematopoiesis begins in the umbilical vesicle [3] and subsequently shifts to the 
foetal liver, before being taken over by bone marrow and spleen. The thymus 
represents the location of T-lymphoid cell education and maturation wherein 
progenitor T-cells differentiate into CD4
+
 or CD8
+
 subtypes.  
 
1.2.1 Innate and Adaptive Immune Responses  
Broadly speaking, responses to pathogens can be non-specific and short-lived 
(innate); or targeted and antigen-specific (adaptive) with potential for immunological 
memory and long-lasting, protective immunity. Innate immunity refers to ‗front line‘ 
mechanisms participating in early host defence in response to infection or tissue 
damage. Primary components comprise physical epithelial barriers (skin and 
gastrointestinal surfaces) and mucosal secretions (defensins, acidic pH exudations, 
lysozymes and phospholipase). Microorganisms penetrating these principal defences 
immediately encounter anti-microbial proteins (complement system, lactoferrins and 
transferrins and coagulation peptides) and phagocytic immune cells (neutrophils, 
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macrophages, eosinophils and natural killer (NK)-cells) bearing pattern-recognition 
receptors (PRR). Innate signalling pathways initiate when pathogen-associated 
molecular patterns (PAMPs) are recognised by host PRR [4], which although non-
antigen-specific, allow host discrimination of foreign molecules from self. NK-cells 
are a specialised cytotoxic lymphocyte subset, which belong to the innate lymphoid 
cell family. In addition to bearing phagocytic properties, NK-cells can release perforin 
and granzymes thereby inducing apoptosis or cell lysis. Morphologically, NK-cells 
resemble lymphocytes but are larger, bear numerous granules and do not require 
major histocompatibility complex (MHC)-bound peptides to exert their effector 
functions. 
 
Whereas the innate response is rapid, tissue-damage can result from a lack of antigen-
specificity, and as a consequence adaptive responses have evolved to be a more 
precise form of host-defence. Although mobilisation is relatively gradual (days – 
weeks), adaptive immunity leads to ‗immunological memory‘ so that subsequent 
exposure to the same antigen results in a more rapid, potent immune response [5]. 
Induction of the adaptive response begins following pathogen uptake and processing 
by antigen presenting cells (APC) the most important of which are dendritic cells 
(DC). This specialised phagocytic population are tissue-resident, relatively long-lived 
and share a common lineage with macrophages. However, their primary function is to 
transport associated antigens to peripheral lymphoid structures for presentation to T-
lymphocytes. When an immature DC ingests pathogen it becomes activated, matures 
into a highly effective APC, and processes and presents antigen to prime nearby 
antigen-specific lymphocytes. Activated DC secrete cytokines crucial in shaping 
innate and adaptive immune responses, making these ‗professional‘ APC essential 
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gatekeepers governing whether and how the immune system responds to the presence 
of infectious agents. 
 
Both B- and T-lymphocyte subsets are capable of recognising unique antigens and 
react in a highly specified manner. B-cells mediate the ‗humoral‘ component of 
adaptive immunity, their principal function being the production of specific 
antibodies. Secreted antibodies eliminate extracellular pathogens by blocking 
interactions with host cell entry receptors; and also through opsonisation, 
subsequently facilitating their recognition and ingestion by phagocytic cells. B-cells 
are also highly effective APC and evolve into memory cells upon activation through 
antigenic interaction, as well as being capable of mediating immune regulatory 
functions [6]. Cellular immunity is mediated by T-cells, specifically helper (Th) CD4
+
 
lymphocytes which can stimulate B-cells, facilitate other T-cell populations to mature 
and proliferate, attract neutrophils and enhance macrophage activity; as well as 
cytotoxic CD8
+
 (Tc) lymphocytes that directly kill pathogen-infected cells through 
secretion of toxic granules or activation of tumour necrosis factor (TNF) receptors. 
All T-cells originate from haematopoietic stem cells in the in the bone marrow but in 
contrast to their B-cell counterparts, first migrate to the thymus for differentiation. 
Therein, T-lymphocytes first experience a positive selection step, wherein cells 
capable of responding to potential harmful antigens presented by MHC are selected 
for survival; and a negative selection event in which T-cells reacting to self–peptide 
complexes undergo apoptosis [7]. The earliest ‗thymocytes‘ express neither CD4 nor 
CD8, and classed as ‗double-negative.‘ Subsequently, thymocytes develop as ‗double-
positive‘ precursors and finally mature to single-positive (CD4+ or CD8+) 
lymphocytes before release into peripheral tissues [8].  
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1.2.1.1 Activation of T-lymphocytes 
Early T-cell precursors must also create a unique T-cell receptor (TCR), a 
heterodimer consisting of a highly variable  and  chain co-expressed with the 
surface glycoprotein CD3. V(D)J recombination is the mechanism of genetic 
recombination taking place in the early stages of TCR (and immunoglobulin) 
production in primary lymphoid tissue, wherein variable (V), diverse (D) and joining 
(J) gene segments are randomly combined to encode a large number of variant 
receptors providing a repertoire than can recognise many potential antigens. Each T-
lymphocyte expresses clonal TCRs which identify specific antigens during physical 
contact with an APC, an interaction that elicits downstream T-cell activation [9]. 
Following development, naïve T-cells (never exposed to antigen) are carried by the 
blood to lymph nodes and secondary lymphoid structures where they can be activated 
by APCs bearing their specific antigen. Like all T-cells, they express the TCR-CD3 
complex. The TCR consists of both constant and variable regions, the latter 
determining the antigen repertoire to which a T-cell can respond. CD4
+
 T-cells 
express TCRs with affinity for antigenic peptides bound to MHC Class-II, whereas 
CD8
+
 T-cells recognise MHC Class-I. MHC-II is expressed on the surface of 
professional APC (macrophages, B-lymphocytes and DC), whereas MHC-I is present 
on almost every nucleated cell of the human body under physiological conditions. 
Presentation of antigenic peptide bound to MHC-II allows CD4
+
 T-lymphocytes that 
express specific TCRs to activate. When a Th–cell encounters and recognises antigen, 
the TCR-CD3 complex binds avidly to the peptide-MHC complex on the APC 
surface. CD4 represents a co-receptor, which binds to a different portion of the MHC 
molecule. These interactions facilitate activation of intracellular kinases present on 
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the TCR, CD3 and CD4, and via assistance of CD45 (protein tyrosine phosphatase 
receptor type C) trigger major Th cell intracellular pathways [9].  
 
Having received the first TCR/CD3 signal, naïve T-cells will only survive and 
differentiate if a second independent biochemical pathway is activated; this co-
stimulatory step acting as a protective measure to ensure that T-cells respond to 
foreign (as opposed to self) antigen. The second signal involves interaction between 
CD28 on the T-cell surface and either CD80 or CD86 on APC [7]. Once a naïve T-
lymphocyte has both pathways activated, the biochemical changes induced by the first 
TCR-CD3 signal are altered, allowing the T-cell to become activated and undergo 
further differentiation. If not, the T cell becomes anergic and fails to differentiate 
further [7]. Requirement for a verification signal upon antigenic re-exposure 
thereafter becomes redundant. Following activation, Th-cells secrete interleukin 2 (IL-
2) and produce the alpha sub-unit of the IL-2 receptor (CD25 or IL-2R) allowing 
auto–paracrine mediated cellular proliferation and clonal expansion [10].  
 
1.2.1.2 Differentiation of T-cell responses 
During ontogeny and subsequent differentiation, CD4
+
 T-cells undergo a sequence of 
complex and mechanistically distinct decision-making processes. These result in 
acquisition of effector or regulatory functions, which in turn orchestrate the outcome 
of an immune reaction [11,12]. The diversity of polarised T-cell responses is 
governed by a unique set of transcription factors as well the cytokine milieu produced 
by local APC as well as neighbouring leucocytes (Figure 1.1 [13]).  
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Effector Th1 immune responses are pivotal in activating macrophages and B-cells, 
whereas IFN+ IL-2+ cells represent precursors of Th1 memory cells; IL-2 stimulation 
of CD8
+
 cells also being critical for memory CD8
+
 T-cell generation [14]. In contrast, 
Th2 lymphocytes facilitate antibody class switching in B-cells, whilst IL-10 secretion 
suppresses Th1 proliferation and DC function [15]. Additional ‗partner‘ effector cells 
include eosinophils, basophils and mast cells. The Th17-effector subtype have evolved 
to deal with bacteria and fungal infection but also implicated in many organ-specific 
autoimmune diseases [16,17]. Th17 cells can amplify responses through the induction 
of many inflammatory (e.g. IL-6) and chemotactic cytokines (chemokines; e.g. IL-8, 
or CXCL8).  
 
Regulatory T-cells (Treg) are a subset which play a critical role in maintaining self-
tolerance as well as in regulating immune responses through suppression and down-
regulating induction and proliferation of effector T-cells [18]. Treg exert suppressive 
capabilities through several mechanisms some of which require cell-cell contact 
whereas others are exerted through production of cytokines including IL-10. TGF-β 
may also result in Treg induction from the naive CD4
+
 pool and is critical in regulating 
T-cell differentiation, homeostasis and tolerance [19,20]. Treg are defined by the 
transcription factor forkhead box P3 (FoxP3); expression of which is required for 
conventional Treg development through control of a genetic program specifying this 
cell's fate [21]. Treg also express high levels of the IL-2 receptor alpha chain (CD25) 
but absent/low-level expression of the IL-7 receptor subunit alpha (IL7R-α or CD127) 
– the latter historically being representative of T-cell activation status. Additional 
suppressor T-cell populations have been described including FoxP3
–
 IL10
+
 Tr1-cells, 
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and Th3-helper cells critically involved in regulating mucosal immunity through 
secretion of TGF- and IL-10.  
 
Mounting evidence suggests that a degree of plasticity exists between individual Th 
subsets [11], and given the appropriate cues Th17-lymphocytes can alter their 
differentiation program ultimately giving rise to either pathogenic or protective cells. 
Akin to conventional Treg, induction of phenotypic regulatory Th17-cells (rTh17) could 
play a favourable role in modulating autoimmune disease [22]. 
 
 
 
Figure 1.1: CD4
+
 T-cell responses based on Th-cell polarization 
Upon antigen presentation by an activated APC, naïve CD4
+
 T cells undergo several rounds of proliferation and 
polarise into distinct Th cell subsets. Helper cell differentiation is mediated by unique sets of transcription factors, 
the expression of which is determined by soluble cytokines acting in the local microenvironment.  
 
APC, antigen-presenting cell; Bcl6, B-cell lymphoma 6; CCR, CC chemokine receptor; CXCR, CXC receptor; 
FoxP3, Forkhead box p3; IFN, interferon; ROR, retinoic acid-related orphan receptor; TGF, transforming growth 
factor; Th, T helper; Treg, regulatory.  
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In contrast to their CD4
+
 helper counterparts, CD8
+
 lymphocytes are largely 
committed toward becoming cytotoxic effectors (Tc), which produce IFN-γ and kill 
transformed or infected target cells. However, much of the complexities of CD4
+
 
helper T-cell subsets may also apply to CD8
+
 T-cells [23]. The CD8
+
 T-cell pool may 
also consist of subsets such as Tc17s which express IL-17 [24]. Moreover, CD8
+
 T-
lymphocytes that produce IL-10, express FoxP3 and possess predominantly 
regulatory functions have been reported (25).  
 
Natural killer T (NKT)-cells represent a further subpopulation of T-cells, defined by 
simultaneous expression of TCR and the NK surface marker CD161. The commonest 
subtype, invariant (i)NKT-cells, differ from conventional αβ T-cells in that their 
TCRs are far more limited in diversity. Additionally, NKT-cells can be CD4
+
, CD8
+
 
or double-negative. NKT-cells recognise antigens presented by the MHC-I related 
molecule CD1 which is specially adapted for presentation of lipid antigens. Upon 
activation, NKT-cells are able to rapidly produce Th1, Th2 and Th17 cytokines, as well 
as contribute to release of cytotoxic molecules and kill infected cells through contact 
dependent (FAS/FASL–mediated) and perforin–dependent pathways. CD161 is also 
expressed by Th17-cells [26], likely indicative of a shared phenotypic and functional 
T-cell lineage [27]. 
 
Gamma-delta T-cells represent a relatively infrequent subset (2–10% of all human T-
cells) that possess a distinct TCR consisting of a  and chain as opposed to the 
conventional  dimer. This population are found with greatest abundance in the gut 
mucosa within a population of intraepithelial lymphocytes (IELs) and are often 
double negative (CD4
– 
CD8
– 
). Moreover,  T-cells do not require MHC presentation 
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of antigen rather recognise stress-inducible MHC class-I chain-related antigens [28], 
self-lipid presented antigen by CD1 [29], or small non-peptide antigens known as 
pyrophosphomonesters [30]. In addition to conventional type 1 T-helper functions, γδ 
T-cells are CD161
+
 and a source of IL-17, IL-22, granzyme B, perforin, TNF-α and 
IFN-γ, and promote myelopoiesis and neutrophil recruitment.  
 
1.2.1.3 Lymphocyte memory 
The continuous recirculation of lymphocytes from bone marrow/thymus to secondary 
lymphoid organs significantly enhances the rate of successful encounter with specific 
antigens. Naïve, antigen inexperienced cells pass directly from the blood to secondary 
lymphoid tissues through specialised high endothelial venules (HEVs) into 
surrounding T-cell zones [31]. Naïve B-cells follow the same route but instead 
migrate to adjacent B-cell follicles that contain follicular DC. If lymphocytes do not 
encounter an antigen in the lymph nodes, they return back to the peripheral circulation 
via lymphatic drainage. This continuous pathway between the blood and lymph ends 
only when the lymphocyte encounters its specific antigen, along with a co–
stimulatory molecule on the surface of APC in a peripheral lymphoid structure. 
 
Upon activation, lymphocytes proliferate and differentiate into effector cells. 
Activated B-cells within the lymphoid follicles undergo clonal expansion with the 
majority becoming antibody–producing plasma cells, and a small remainder surviving 
as long–lived memory cells. Activated T-cells differentiate into either CD4+ Th or 
CD8
+
 Tc subtypes, and after several days some of the effector cells leave the 
peripheral lymphoid organs and migrate through blood to the site of primary 
infection. This migration pattern is a consequence of activation, differentiation and 
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functional maturation of lymphocytes, and serves to re–programme expression 
profiles of adhesion molecules and chemokine receptors, promoting recruitment 
toward the tissue in which they were first primed [32,33]. A small proportion of 
‗antigen-experienced‘ T-cells can persist after exposure to a specific antigen has 
waned, rapidly expanding to generate large numbers of effectors upon re-exposure 
that serve as the host‘s immunological memory. These memory T-cells can be CD4+ 
or CD8
+
, and conventionally express a shortened isoform of CD45 (CD45RO). 
Human memory T-cells can be further subclassified as either effector memory (TEM) 
or central memory (TCM) cells; based on receptor expression and functional 
properties. TEM express receptors needed for migration into inflamed tissues and 
exhibit immediate effector functions upon antigen re-exposure (e.g., secretion of IFN-
 and IL-4). Central memory T-cells (TCM), by contrast, express homing receptors for 
entry into lymph-nodes (CCR7, L-selectin), and although they lack immediate 
effector functions, TCM can proficiently stimulate DC and bear the capacity to 
differentiate into effector T-cells upon stimulation [34]. 
 
1.3 Leucocyte recruitment 
Effective immune surveillance is dependent upon the continuous circulation of 
lymphocytes through tissues in the quest for antigens, in addition to local innate 
immune responses that detect the initial invasion of tissue by antigen. This 
recognition is initiated by PAMPs, released by invading microorganisms as well as 
damage-associated molecular patterns (DAMPs) consequential to damaged/dead-cells 
or in response to cellular stress [35]. In addition, activation of resident memory T-
cells can trigger recruitment of leucocytes via secretion of various primary 
inflammatory cytokines. Leucocytes must therefore be capable of traversing multiple 
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tissue-vascular beds; the key interaction herein occurring with endothelial cells lining 
vessels (Figure 1.2). Leucocyte egress from the bloodstream occurs through 
specialised post-capillary HEVs that exist in most secondary lymphoid organs and via 
microvascular endothelium within tissue. Under pro-inflammatory circumstances 
HEV–like structures can also be observed in non–lymphoid tissues thus supporting 
unremitting leucocyte recruitment to these sites [36].  
 
1.3.1.1 Rolling 
An initial capture step is required to bring the flowing leucocyte in the blood into 
contact with endothelium. In most tissues this is a rolling step, although in low flow 
vascular beds this phase becomes less important. Molecules which initiate the rolling 
step of leucocyte adhesion predominantly belong to the selectin family [37]. 
Expression of P-selectin and E-selectin are up-regulated on inflamed endothelium, 
whereas L-selectin is constitutively expressed by most B- and naïve T-cells, 
neutrophils, monocytes and eosinophils. The broad expression of L–selectin 
implicates a pivotal role in the trafficking of all leucocyte lineages; however, only a 
subpopulation of memory T-cells and natural killer (NK)-cells are L-selectin positive. 
P-selectin glycoprotein-1 (PSGL-1) exerts a dominant role, interacting with all 3 
selectins wherein binding facilitates secondary leucocyte capture or tethering [38,39]. 
Although PSGL-1 is expressed on almost all leucocytes (and some endothelial cells), 
it is functional only when glycosylated correctly; an action mediated by enzymes 
termed fucosyltransferases [40]. E-selectin also binds to glycosylated CD44 and E-
selectin ligand (ESL)-1 [41]. Selectins require the hydrodynamic forces of 
physiological shear stress to support adhesion; rolling cells undergoing detachment 
when flow ceases. In the low flow environment of hepatic sinusoids, selectins play 
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little role in recruitment [42,43]. Here rolling is attenuated as a consequence of the 
low flow and narrow sinusoidal channels allowing stochastic interactions with 
flowing leucocytes.  
 
Integrins can also participate in rolling by interacting with Ig superfamily ligands. 
Cell lines expressing the integrin 47 can roll on immobilised recombinant mucosal 
vascular addressin cell-adhesion molecule (MAdCAM)-1, and lymphocytes can also 
roll on immobilised vascular cell-adhesion molecule (VCAM)-1 via engagement of 
41. Moreover rolling of human lymphocytes is enhanced when intracellular cell 
adhesion molecule (ICAM-1) is co-expressed with L-selectin ligands [44].  
 
1.3.1.2 Activation and arrest  
The rolling step is an inherently unstable transition state, and firm leucocyte arrest is 
triggered by chemokines and other chemoattractants mediating downstream binding 
of leucocyte integrins to immunoglobulin superfamily members such as ICAM-1 and 
VCAM-1 expressed by endothelial cells. Under pro-inflammatory conditions, 
endothelial cells become activated and up-regulate expression of adhesion molecules, 
chemokines and other lipid chemoattractants. Chemokines can also be generated by 
proteolytic cleavage in platelets, thereafter being delivered to endothelial cells via 
circulating microparticles or exocytosis of intracellular granules [37]. 
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Figure 1.2: Leucocyte adhesion cascade 
In response to a diverse range of pro-inflammatory triggers, released danger signals stimulate 
leucocytes and vascular endothelial cells to initiate a cascade of adhesion responses. Rolling on the 
endothelial surface facilitates initial leucocyte capture and is largely mediated by selectins and 
integrin/cell adhesion molecule (CAM) family members. The leucocyte starts travelling along the 
endothelial lining at reduced velocity, sampling the microenvironment for appropriate chemotactic 
signals (chemokines), either soluble or those immobilised by glycosaminoglycans on the endothelial 
surface. Binding of chemokines to their respective receptors on the leucocyte surface activates rapid G-
protein coupled signalling pathways that trigger cytoskeletal rearrangement and integrin activation. 
Activated integrins subsequently undergo high affinity binding to their cognate ligands, which belong 
to the immunoglobulin superfamily of CAMs. This process promotes firm adhesion and allows the 
leucocyte to ‗crawl‘ on the endothelial surface searching for signals to transmigrate. Thereafter, the 
leucocyte can pass through the basement membrane through endothelial junctions (paracellular route) 
or directly through the endothelial body (transcellular route). 
 
DC, dendritic cell; ICAM, intracellular cell adhesion molecule; VCAM, vascular cell adhesion 
molecule; VE-cadherin, vascular endothelial cell cadherin.  
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1.3.1.2.1 Chemokines 
Chemokines encompass a group of small (8 – 12 kDa) heparin-binding cytokines with 
ability to attract leucocyte subsets to specific tissue sites [45]. Virtually any cell type 
can express chemokines upon stimulation including activated endothelial cells, 
epithelial cells and leucocytes themselves. Upon secretion, chemokines become 
immobilised to glycosaminoglycans on the endothelial surface and extracellular 
matrix. This process helps leucocytes to locate chemokines as well as maintaining the 
latter in a multimeric form, increasing affinity for cognate chemokine receptors [46]. 
Immobilised chemokines can persist at higher concentrations than the ‗freely 
diffusible‘ state [47]. Furthermore, different chemokines may enhance the function of 
one another (chemokine cooperativity [48]). Chemokines exert their functions 
primarily via specific G-protein-coupled receptors (GPCRs), leading to calcium flux 
and activation of phosphatidylinositol 3-kinase, or GTPase signalling pathways [49].  
 
Chemokine classification can be structural, based on the position of conserved 
cysteine residues (Table 1.1); or functional, depending on whether chemokines are 
induced in response to inflammation or constitutively expressed. Inflammatory 
chemokines are released following stimulation by pro-inflammatory stimuli, and 
secreted early in response to PRR–activation from epithelium, stromal cells and 
immune cells [1,45]. Herein, they recruit the first line of innate immune effectors such 
as neutrophils, monocytes, NK-cells, NKT-cells and immature DC that bear cognate 
chemokine receptors. Following activation, DC prime lymphocytes, and inflammatory 
chemokines promote localisation of T-effectors (Teff) to the site of injury. Treg can be 
recruited in a similar manner, with the balance between effector and regulatory 
lymphocytes heavily influencing the outcome of the immune response. Homeostatic 
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chemokines are ubiquitously expressed in lymphoid and non-lymphoid structures, 
where they mediate physiological trafficking and positioning of cells, antigen 
sampling and immune surveillance. Functional distinctions can however be 
misleading given that chemokines previously thought to be homeostatic are often 
induced and up-regulated at sites of chronic inflammation [45]. 
 
 
1.3.1.2.2 Integrins 
Integrins are heterodimeric membrane–bound glycoproteins composed of non-
covalently associated α- and β-subunit chains, which collectively mediate cell-
adhesion and migration through interactions with cell-adhesion molecules (CAMs) of 
the immunoglobulin superfamily or extracellular matrix components. Integrin chains 
have large, structurally complex extracellular domains containing three to four 
divalent cation–binding sites involved in ligand binding, a single–pass transmembrane 
helix, and cytoplasmic tails regulating function [50]. Chemokines are critical 
physiological activators of integrin-mediated adhesion and rapidly regulate their 
binding in a cell-specific manner through ligation of specific GPCRs and triggering 
complex intracellular signalling networks [51–53]. Such affinity modulation of an 
integrin for its ligand is recognised as a pivotal step in chemokine-induced arrest 
under flow, although the topology of integrin clustering may also play a role [54–56]. 
These mechanisms are particularly suited for controlling arrest under high-flow, 
shear-stress conditions, and integrin activation under physiological conditions is 
almost instantaneous.  
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Table 1.1: Chemokines/chemokine receptors in the human immune system 
Chemokine 
receptor 
Chemokine ligand 
Receptor  
distribution 
CXC subgroup  
CXCR1 CXCL6-8 Neutrophils, monocytes, mast cells 
CXCR2 CXCL1-3, 5-8 Neutrophils, monocytes, mast cells 
CXCR3 CXCL9-11 Helper T-cells, memory T-cells, NKT-cells 
CXCR4 CXCL12 T-cells, B-cells, Macrophages, Monocytes, NKT-cells 
CXCR5 CXCL13 B-cells 
CXCR6 CXCL16 CD4+ T-cells, CD8+ T-cells, NK-cells 
CC subgroup 
CCR1 
CCL3, 5, 7, 8, 
CCL13-16, 23 
Monocytes, memory T-cells, Th1-cells, NK-cells 
CCR2 CCL2, 7, 8, 13 Monocytes, memory T-cells, basophils, pDCs 
CCR3 
CCL5, 7, 11, 15, 
CCL16, 24, 26 
Eosinophils, basophils 
CCR4 CCL17, 22 Th2 cells, Treg, eosinophils, basophils, DC 
CCR5 CCL3-5, 8 Monocytes, Th1-cells, Treg, DC, NK-cells 
CCR6 CCL20 Memory T-cells, B-cells, Th17, immature DC,  
CCR7 CCL19, 20 Naïve T-cells, naïve B-cells, mature mDCs, Th1, Th2, Treg 
CCR8 CCL1 Monocytes, Th2-cells, Treg, NK-cells 
CCR9 CCL25 DC, memory T-cells, thymocytes  
CCR10 CCL27, 28 Memory T-cells, Treg 
CX3C and XC family 
CX3CR1 CX3CL1 Monocytes, Th1-cells, NK-cells 
XCR1 XCL1-2 NK-cells 
Structural distinction of chemokines and their receptors is based on the position of cysteine residues 
within a conserved tetracysteine motif. In CC chemokines, the first two cysteines lie adjacent to one 
another, whereas in CXC chemokines they are interceded by a non-conserved amino acid. These two 
subfamilies account for all but three of the known chemokines, the others being CX3CL1 (three 
intervening amino acids between the first cysteines) and XCL1 and XCL2, which lack two of four 
canonical cysteines. Some chemokines recognise multiple receptors whereas others only have one; 
conversely some receptors bind a single chemokine while others are highly promiscuous and bind 
several chemokine ligands (adapted (46)).  
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Integrins relevant to leucocyte arrest belong to 1, 2 and 7 subfamilies. β1-
integrins share a common β-chain (CD29) in association with varying α subunits 
(CD49a or 4, CD49f or 6) and avidly bind to extracellular matrix components such 
as fibronectin, laminin and collagen. β2 integrins (CD18) pair with α subunits CD11a 
(LFA-1 or L), CD11b (Mac-1 or M) or CD11c (X), and are expressed on 
lymphocytes (CD11a), neutrophils and monocytes (CD11a and CD11b) and DC 
(CD11a and CD11c). The α4β7 dimer when expressed on leucocytes mediates 
binding to fibronectin, VCAM-1 and most efficiently to MAdCAM-1, and is 
particularly associated with lymphocyte adhesion in the gut [57]; whereas αβ7 
integrin which is also constitutively expressed by intestinal intraepithelial 
lymphocytes mediates binding to E–cadherin. Cell-type specificity is conventionally 
ascribed to pre-defined patterns of integrin expression (and their ligands), in which 
chemokine-triggered signals regulate distinct integrin phenotypes across different 
leucocyte subtypes [37]. Additional diversity in leucocyte recruitment may be 
imparted from quantitative differences in pro-adhesive factors; for instance by the net 
tissue chemokine expression level or that of their receptors, and intrinsic affinity 
within. Collectively, such mechanisms have the capacity to regulate downstream 
activation of integrin-adhesion pathways [58].  
 
1.3.1.3 Migration 
Along with shear forces exerted upon an arrested leucocyte, the balance between up–
regulation of ligand binding at the leading edge and down–regulation at the caudal tail 
maintains forward slow motility (crawling). After adhesion and crawling, leucocytes 
move toward endothelial cell borders looking for signals in order to complete 
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transendothelial migration (diapedesis). For effective migration to occur, leucocytes 
must not only overcome the endothelial layer of the venular wall, but also a pericyte 
layer underneath. Both of these cell types contribute to the generation of a non-
specialised basement membrane which surrounds blood vessels. Whereas leucocyte 
migration through the endothelial-cell barrier can be rapid (<2–5 minutes), 
penetrating the endothelial-cell basement membrane takes far longer (>5–15 minutes) 
[37,59]. 
 
The interaction of integrins with endothelial CAMs is not only a pivotal step in 
leucocyte arrest, but is also able to stimulate endothelial cells in a manner that 
promotes transmigration. Adherent leucocytes can induce formation of 
'transmigratory cups', endothelial-cell projections rich in CAMs such as ICAM-1 and 
VCAM-1; and cytoskeletal components like vinculin, alpha-actinin and talin-1 
(60,61). Therefore interaction of a firmly arrested αLβ2+ leucocyte, together with 
expression of its cognate endothelial adhesion molecule, ICAM-1, can induce further 
clustering of ICAM-1 as a leucocyte approaches the endothelial cell border [60]. A 
similar phenomenon can be observed for other CAMs such as VCAM-1.  
 
Multimerisation of ICAM-1 on the surface transmits signal to the endothelial cell; the 
most important being increased intracellular Ca
2+
 which induces cell contraction and 
loosening of endothelial cell junctions thereby facilitating leucocyte transit through 
the endothelial barrier. Loosening of the endothelial junction is further mediated by 
effects on vascular endothelial (VE)-cadherin phosphorylation, a molecule necessary 
for cell adherens junction disassembly [62]. While the leucocyte is transmigrating, 
there is continuous recycling of membrane components from the lateral border 
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recycling compartment to positions where the leucocyte is migrating, providing 
increased contact surface area and un-ligated molecules for leucocytes to interact with 
before passing through the endothelial layer [63]. In the paracellular pathway of 
migration, ligation of ICAM-1 by leucocyte integrin leads to translocation of ICAM-1 
to actin and caveolae–rich regions. The latter represents recycling endosomes that 
contain ICAM-1 and are linked together forming vesico–vacuolar organelles (VVOs) 
which create an intracellular channel for leucocyte migration [37].  
 
Different molecules mediate leucocyte transmigration in a stimulus-specific manner. 
Platelet/endothelial-cell adhesion molecule-1 (CD31) and ICAM-2 appear to mediate 
leucocyte transmigration in response to IL-1 but not TNF [64], although direct 
leucocyte activation by TNF can bypass the need for these adhesion molecules. In 
contrast, other adhesion molecules demonstrate leucocyte specific recruitment 
patterns such as endothelial cell-selective adhesion molecule (ESAM) which 
preferentially mediates neutrophil over T-cell transmigration [65]. Other non-
conventional endothelial-cell molecules have also been implicated in leucocyte 
transmigration including scavenger receptors such as common lymphatic endothelial 
and vascular endothelial receptor-1 (CLEVER-1) and ectoenzymes such as vascular 
adhesion protein (VAP)-1 [66,67].  
 
1.4 Organisation of the enteric immune system 
1.4.1 Anatomy and function of the gut 
The wall of the gastrointestinal tract consists of four layers (Figure 1.3). The luminal 
mucosa lines the surface of the digestive tract, protecting the remaining layers through 
secretions as well as being an absorptive interface for the end products of digestion. 
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The mucosa is itself composed of several sub-layers of complexity including an 
epithelial barrier (columnar or stratified squamous), goblet cells which secrete mucus 
therefore protecting the epithelium from digestion, and endocrine cells responsible for 
hormonal secretion. Blood and lymphatic vessels penetrate the lamina propria (LP) 
and provide nutrients for the epithelial layer, distribute hormones secreted by the 
epithelium and further absorb end products of digestion from the lumen. In addition, 
the LP contains mucosa–associated lymphoid tissue (MALT) and nodules of 
lymphatic tissue bearing lymphocytes and macrophages offering protection from 
bacteria and other potential food-borne pathogens. The muscularis mucosa is the outer 
mucosal layer, which as the name suggests is composed of a thin layer of (smooth) 
muscle and nerve fibres responsible for generation of local movements but also in the 
stomach and small intestine generates folds that further increase surface area for 
absorption. 
Figure 1.3: Layers of the GI tract 
The gastrointestinal wall refers to a specialised series of tissue layers surrounding the lumen of the 
gastrointestinal tract: mucosa, submucosa, muscularis externa and serosa [68]. 
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The submucosa contains blood vessels, lymphatics and nerves, and in the small 
intestine bears several distinct characteristics such as Brunner‘s glands (restricted to 
the duodenum) which secrete alkaline mucus, as well as aggregated lymphatic 
nodules called Peyer‘s patches. The muscularis externa in the mouth and pharynx 
consists of skeletal muscle to aid swallowing, and in the rest of the GI tract smooth 
muscle with associated nerve fibres responsible for peristalsis and mechanical food 
digestion by segmentation. The outer serosal layer is a smooth membrane that 
comprises a thin layer of connective tissue and an underlying epithelial layer secreting 
serous fluid. 
 
1.4.2 The gut epithelial barrier 
The mucus layer offers the first line of protection in the gut, and is rich in anti-
bacterial substances such as alpha-defensins and immunoglobulin A (IgA), as well 
as a large number of commensal microbes which greatly exceed the total number of 
eukaryotic cells within the human body [69,70]. Invasion by pathogens is further 
impeded by the barrier function of the epithelial monolayer, which expresses toll-like 
receptors (TLR) and other PRR that recognise cellular injury or damage. This means 
that the mucosal epithelium is more than just a physical barrier, and activation of this 
―epimmunome‖ links barrier function to innate and adaptive immune responses [71–
73]. Mucosal epithelial cells express MHC-II molecules; however, given the absence 
of appropriate co-stimulation, interactions with CD4
+
 T-cells are biased toward 
tolerance rather than effector responses [74]. The ability of intestinal epithelial cells to 
secrete cytokines and chemokines in response to commensal bacteria, pathogens or 
injury allows them to play an active role in shaping the nature of local immune 
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responses and modulate sub-epithelial DC and lymphocyte positioning and activation 
[73]. Under normal conditions molecules that promote Treg and Type-2 responses such 
as IL-25 dominate to maintain an anti-inflammatory environment [75]. However, in 
response to epithelial damage or infection, activation of nuclear factor kappa (NFk) 
results in secretion of mediators including IL-1, IL-6, TNF and CCL20 which shift 
local differentiation toward pro-inflammatory Type-1 or Type-17 responses. Further 
regulation is provided through bidirectional paracrine interactions between epithelial 
cells and specialised subsets of tissue-associated T-cells [73]. For instance, IL-22 
secreted by Th-cells (so called Th22 cells) has paracrine effects on the epithelium. 
Thus, synergistic interactions between the epithelial/stromal compartment and sub-
epithelial DC and lymphocytes maintain epithelial integrity and regulate principal 
responses to injury or infection. 
 
1.4.2.1 Intraepithelial compartment 
The gut epithelial barrier does not completely prevent luminal antigens from entering 
tissue, and antigens can traverse through breaks in tight junctions, perhaps at villous 
tips where epithelial shedding occurs. As a result, the intestinal mucosa contains a 
large number of T-cells residing within the epithelium or underlying LP. 
Intraepithelial lymphocytes (IELs) are primarily CD8
+
 T-cells, which include γδ and 
αβ subsets as well as a population of CD8αα+ T-cells. Intestinal CD8αα T-cells are a 
group of CD161
hi 
CD8
+
 mucosal-associated invariant T (MAIT)-cells [76] and their 
development is independent of antigen presentation by MHC. In contrast, CD4
+
 and 
CD8αβ T-cells localise to mucosa after MHC-restricted activation in secondary 
lymphoid organs, and secrete TGF- and suppress inflammation to maintain tissue 
integrity [77,78]. IELs are CCR9
+
, and under normal conditions attracted by epithelial 
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CCL25 to the intraepithelial compartment, where they use CD103 to bind to E-
cadherin at the epithelial zonula adherens. However, in response to inflammation, 
recruitment pathways involving CXCR3 and other chemokine receptors may be more 
pertinent [79]. 
  
1.4.2.2 Lamina propria 
The sub-epithelial lamina propria contains numerous antigen-presenting, CX3CR1
+
 
DC which sample and process commensal and pathogenic bacteria from within the 
gut lumen [80]. These cells are able to receive antigen either from specialised 
microfold-cells (M-cells) or through dendritic processes protruding between gut 
epithelial cells [78,81]. DC, in particular those that express CD103, subsequently 
migrate to draining mesenteric lymph nodes (MLN) or Peyer‘s patches where they 
activate naïve lymphocytes [82]. Gut myeloid DC (mDCs) involved in taking up 
apoptotic enterocytes constantly ‗traffic‘ to draining lymph nodes but in the absence 
of danger signals are not fully activated and thus maintain tolerance rather than 
stimulating effector responses [83]. However, following an inflammatory response to 
injury or extrinsic infection, specific signals drive maturation and activation of mDCs 
which stimulate the development of an immune response shaped by the nature of the 
activating stimulus [84,85]. In contrast, plasmacytoid DC (pDCs) are recruited to 
inflamed tissues where they secrete Type-1 interferons and promote local 
differentiation of immunosuppressive Treg which in conjunction with non-classical 
regulatory cells (e.g. Th3-cells, Tr1-cells and iNKT-cells), help control inflammation 
and maintain tolerogenic immune responses to food and self-antigens [86].  
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The outcome of immune activation in the LP is largely dependent on a balance 
between activation of IFN-γ-secreting CD4+ T-cells, which drive inflammatory 
responses, and immunosuppressive regulatory cells that suppress and restrain 
inflammation. The importance of this interrelationship is emphasised by murine 
studies in which Treg depletion or dysfunction leads to fulminant colitis, reversed by 
reconstitution with Treg [87,88]. B-cell blasts also traffic to the LP where they 
differentiate into IgA-secreting plasma cells; and DC that contain live bacteria induce 
plasma cell differentiation more effectively than DC containing killed organisms [1]. 
It is probably for this reason that they are restricted from entering secondary lymphoid 
tissues, as an effort to localise the induction of immune responses and prevent 
carriage of bacterial organisms to other sites [1,80,89]. The outcome of the immune 
response is thus dictated by DC, the antigenic stimulus, and the resulting cytokine 
microenvironment (Figure 1.1). Th1 responses are driven by early secretion of IL-2, 
whereas IL-1, IL-6, and IL-23 result in Th17 induction. By contrast, leucocyte 
interactions with immature mDCs and some pDCs, or activation in the presence of IL-
10 and TGF-β, preferentially leads to induction of Treg. 
 
1.4.2.3 MAIT-cells and innate lymphoid cells 
MAIT-cells form a subset of non-conventional, innate-like T-cell whose TCR consists 
of an invariant Vα chain (iVα7.2-Jα33) combined with limited conserved Vβ chains, 
and are restricted to the evolutionarily conserved MHC-related molecule MR1 
[90,91]. MAIT cells although detectable in peripheral blood, use CCR6 and CXCR6 
to preferentially locate to the lamina propria and liver. They are phenotypically 
similar to NK-cells being characterised by CD161 expression and the NK-cell 
activating receptor NKG2D, are mostly CD8αβlo (or double-negative) and display an 
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effector (CD95
hi 
CD62L
lo 
CCR7
– 
) memory (CD27
+ 
CD45R0
+ 
CD45RA
lo 
CD122
+
) 
phenotype [92]. Intestinal CD8 T-cells are likely a sub-population of CD161hi 
CD8
+
 mucosal-associated invariant T-cells sharing common cytokine expression, 
chemokine-receptor phenotype and transcriptional profiles with counterpart CD8αβ+ 
T-cells [27,76]. The selective enrichment of MAIT-cells within intestine and liver 
suggests a close relationship with the host microbiome [93], and their rapid postnatal 
expansion and acquisition of memory markers is triggered by responses to colonising 
flora, as evidenced by murine studies in which germ-free mice have no detectable 
MAIT-cells until reconstituted with commensal bacteria [94].  
 
MAIT-cells display active anti-microbial functions in vivo and react with MR1-
expressing cells infected/co-cultured with selective bacteria and yeasts, but not 
viruses [95]. Recent reports suggest that vitamin B metabolites generated by unique 
biosynthetic pathways are ligands for MR1 [90,96]; however, it is unclear how 
MAIT-cells mediate anti-microbial functions and which particular cytokines are 
necessary for continued proliferation. It has been postulated that in the presence of an 
intact mucosal barrier and an absence of inflammation, MAIT-cells participate in the 
control of commensal flora or food-borne antigens by modulating APC function and 
epithelial cell homeostasis through release of IL-4 and IL-10, and secretion of anti-
microbial molecules [97]. MAIT-cells also express IL-2Rβ2, IL-18R and IL-23R, 
and activation of these receptors in association with MR1-bound ligands triggers 
secretion of IFN-γ, TNF-α, IL-17 and granzymes, and inhibition of intracellular 
bacterial replication [97]. This ‗dualistic‘ role coupled with their evolutionary 
conservation suggests a pivotal occupation in mucosal immunity. A key role of IL-23 
in the pathogenesis of chronic inflammatory disorders is supported by genome-wide 
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association studies (GWAS) identifying components of the IL-23 pathway as 
susceptibility alleles for IBD, autoimmune liver disease and ankylosing spondylitis 
[98]. IL-23 promotes Th17 responses but the ability to activate innate lymphoid cells 
(ILC) and MAIT-cells can drive T-cell-independent inflammation. ILC expressing 
RORt and IL-23R accumulate in the inflamed colon, secreting IL-17 in response to 
IL-23 and TNF-α produced by pathogen-activated CD103– DC. This illustrates how 
interactions between mucosal DC and ILC can define inflammatory responses to gut 
microbiota [99].  
 
1.4.3 Intestinal microbiota  
Development of the human intestinal microbiome, dominated by the bacterial phyla 
Firmicutes and Bacteroides, and less so Actinobacteria and Proteobacteria, is 
established early in life [70]. Gut-resident bacteria have co-evolved with the human 
host and perform essential functions such as vitamin synthesis and metabolism of 
indigestible dietary polysaccharides. Symbiosis between commensal flora and the 
host promotes defence against pathogenic bacteria by out-competing for nutritional 
and physical niches and induces specific responses shaping local T-cell polarisation 
[100]. Thus, the host immune system must establish a favourable environment for this 
vital community yet protect against invasion or outgrowth of pathogenic species 
[101,102].  
 
The gut epithelium is able to directly sense bacteria through specific PRR including 
TLR1–9, and nucleotide-binding oligomerisation domain-containing proteins (NOD)-
1 and NOD2, although how commensal bacteria are distinguished from pathogenic 
strains is unknown. Mutualism is illustrated by the fact that the activation of epithelial 
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TLR2 or TLR9 increases gut barrier function, and mice deficient in the downstream 
TLR-signalling molecule MyD88 are susceptible to experimentally-induced IBD 
[103,104]. Disturbances in immune or epithelial homeostasis can lead to gut 
inflammation and in certain circumstances commensal flora may act as pathogens. 
For instance, stimulation of mucosal CD4
+
 T-cells from Crohn's disease patients with 
their own commensal flora induces IFNγ secretion [105]. Moreover, GWAS have 
identified polymorphisms in NOD2 as Crohn‘s disease susceptibility factors [106]. 
Because NOD2 can regulate TLR signalling, such mutations may impair recognition 
of intestinal bacteria and promote secretion of pro-inflammatory cytokines in 
response to TLR stimulation in the gut and liver [107–111]. NOD2 is expressed in 
intestinal epithelial Paneth cells and NOD2-deficient mice are susceptible to intestinal 
infection with Listeria monocytogenes [112]. Further evidence to support impaired 
tolerance to commensal flora in IBD pathogenesis is provided by findings wherein 
mice subject to a congenital deletion of the tolerogenic cytokine IL-10 (Il10
–/–
 mice) 
fail to develop intestinal inflammation under germfree conditions [113]. In addition, 
colonic DC expression of TLR2 and TLR4 is significantly up-regulated Crohn‘s 
disease, and these cells more commonly exhibit an activated phenotype (CD40
+
) and 
enhanced production of the pro-inflammatory cytokine IL-6 [114,115]. 
 
Clinical observations support this hypothesis because Crohn‘s disease occurs most 
commonly in the terminal ileum and colon where bacterial load is the greatest and 
some patients improve after treatment with antibiotics. Indeed, changes in the 
composition of intestinal microflora are observed in human IBD [116–118], and it is 
conceivable that pathogenic bacteria weaken the intestinal lining resulting in 
translocation of commensals beyond the gut barrier and into the portal circulation. 
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This would facilitate entry into the liver where further levels of regulation exist to 
prevent uncontrolled systemic immune activation. However, if such protective 
mechanisms are overwhelmed then immune responses to gut bacteria could drive 
extraintestinal inflammation in the liver and other sites [117]. For instance, activation 
of TLR2 and TLR4 by PAMPs or commensal bacteria that enter the portal circulation 
may promote development of non-alcoholic fatty liver disease (NAFLD) [119–122]. 
The precise role and mechanisms of breakdown in intestinal barrier function 
comprising such responses remains to be defined. 
 
1.4.3.1 Intestinal leucocyte activation and recruitment  
Effective immune surveillance requires that leucocytes be recruited and positioned to 
specific tissue compartments and this is achieved through selective adhesion molecule 
and chemokine receptor expression. Under physiological conditions, CCL25 is 
constitutively expressed by epithelium and detected on mucosal vessels within the 
small bowel [123], which also expresses MAdCAM-1 [124]. This molecular 
combination is largely absent from other tissues in the absence of inflammation and 
serves as a molecular ‗postal code‘ for recruitment of lymphocytes expressing CCR9 
and . The expression of these two gut-homing receptors is selectively imprinted 
on lymphocytes by CD103
+
 DC within gut-associated lymphoid tissues (GALT) such 
as MLN and Peyer's patches [57,82], and favoured by an environment rich in IL-7 
[125].  
 
Once primed and activated by gut DC, lymphocytes lose the ability to re-enter 
lymphoid tissue by down-regulating expression of CCR7 and L-selectin whilst up-
regulating CCR9 and α4β7 in a process dependent on retinoic acid (Figure 1.4). The 
 56 
source of retinoic acid is unclear although may derive from a pool of bile retinoids 
delivered to the gut by the liver [126]. High levels of retinaldehyde dehydrogenase 
define the preferential activity of retinoic acid in gut DC, and such enzymes are 
expressed at much lower levels in DC from other sites like the skin, providing a 
mechanism by which gut DC can compartmentalise lymphocyte recruitment [126]. 
Engagement of CCR9 by CCL25 results in activation of the leucocyte integrin α4β7 
and facilitates stable binding to MAdCAM-1 on the endothelium of mucosal vessels 
[127]. In the presence of TGF- retinoic acid generating gut DC induce activation of 
gut-homing Treg, and synergise with IL-6 and IL-5 to induce CCR9
+
 + gut 
homing IgA-producing B-cells [128–130]. IgA-secreting B-cells and subsets of Treg 
also express CCR10 allowing them to engage with the mucosa through interactions 
with CCL28 [131], which unlike CCL25 is widely expressed on mucosal epithelium 
in the colon, small intestine, lung, bile ducts and exocrine glands, therefore likely 
embodies a common mucosal chemokine. 
 
MAdCAM-1 and CCL25 are critically involved in the homeostatic recruitment of 
lamina propria lymphocytes (LPL) and although expression increases in intestinal 
inflammation [132], effector cell recruitment also involves other adhesion molecules 
including VAP-1, ICAM-1 and VCAM-1 that are induced in response to pro-
inflammatory signals (Table 1.2). Moreover, LPL and IEL express CCR2, CCR5 and 
CXCR3 which may play a more important role during recruitment to the inflamed 
intestine [132,133].  
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Figure 1.4: Imprinting of a gut-homing phenotype 
Luminal antigens are sampled by resident DC either directly through their dendritic processes or by specialised M-cells. Antigen is then processed and transported to GALT where 
DC are able to interact with T-cells in order to program an immune response. DC–T-cell interactions not only activate naïve T-cells and imprint antigen recognition, but also induce 
a phenotype associated with gut-tropism. This process is dependent on RA generated by the DC, which drives expression of intestinal lymphocyte homing molecules α4β7 and 
CCR9 and allows activated T- and B-cells to respond to MAdCAM-1 and CCL25, respectively, on mucosal vessels. Although most of the recruited lymphocytes will remain in the 
lamina propria, a portion will migrate along a chemotactic CCL25 gradient to the intraepithelial compartment and become IEL [1]. 
DC, dendritic cell; M-cell, microfold cell; GALT, gut-associated lymphoid tissue; RA, retinoic acid; IEL, intraepithelial lymphocyte. 
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Table 1.2: Molecular determinants of leucocyte recruitment to the intestine [1] 
Site Constitutively expressed  Increased in response to inflammation 
Small 
bowel 
7 – MAdCAM-1 
-cadherin  
(intraepithelial compartment)
CCR6 – CCL20 
CCR9 – CCL25 
CCR10 – CCL28 
CXCR1 – CXCL5/6/8 
CXCR2 – CXCL1/2/5/6 
CXCR6 – CXCL16 
CX3CR1 – CX3CL1 
E-selectin 
P-selectin – PSGL-1 
α4β7 – MAdCAM-1 
VAP-1 
1 – VCAM-1 
L2 – ICAM-1 
CCR2 – CCL2/7/8 
CCR5 – CCL3/4/5/8 
CCR9 – CCL25  
CXCR3 – CXCL9/10/11 
CX3CR1 – CX3CL1  
 
 
 
Colon 7 – MAdCAM-1  
L-selectin* – PNAd / MAdCAM-1 
CCR5 – CCL3/4/5/8  
CCR6 – CCL20  
CCR10 – CCL28 
CX3CR1 – CX3CL1 
 
7 – MAdCAM-1 
L-selectin – PNAd/MAdCAM-1 
1 – VCAM-1 
L2 – ICAM-1 
VAP-1 
E-selectin  
P-selectin – PSGL-1  
CCR2–CCL2/7/8 
CCR3 – CCL11 (colitis) 
CXCR1 – CXCL5/6/8 
CXCR2 – CXCL1/2/5/6 
CXCR3 – CXCL9/10/11 
* L-selectin predominantly involved in recruitment of naïve T-cells
 
1.4.3.2 Stability of a gut-homing phenotype requires re-exposure to intestinal DC 
After an antigenic insult has been cleared, most effector lymphocytes die leaving a 
cohort of long-lived memory cells that can rapidly expand on re-encounter with 
antigen. Memory T-cells and IgA-secreting plasma cells imparted with gut tropism 
provide long-term protection against gut pathogens indicating a degree of stability of 
the intestinal-homing phenotype, possibly by epigenetic imprinting at the time of 
activation [2]. However, this requires continual re-encounter with intestinal DC 
because T-cells can be re-programmed following encounter with DC from different 
tissues [134]. For instance, reactivation of gut memory T-cells by skin-derived DC 
decreases CCR9 and 47-integrin expression whilst increasing expression of surface 
markers which promote homing to cutaneous sites, such as cutaneous lymphocyte 
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antigen [134]. Plasticity may reside in a subset of central memory T-cells which are 
CCR7
+
 thereby retaining an ability to migrate through lymph nodes and encounter DC 
from other tissues, in contrast to CCR7
–
 effector memory T-cells which retain tissue 
tropism. 
 
1.5 CCR9 and CCL25 
CCR9 is encoded on chromosome 3 in humans (chr. 9 in mice) and preferentially 
expressed by thymocytes and gut-tropic lymphocytes. In addition to being a marker 
for intestinal lymphocyte homing (small bowel), CCR9 is required for entry of 
double-negative T-cell progenitors into the thymus and consequently as they develop 
to double-positive cells and migrate to CCL25-rich medullary regions [135]. Gut-
tropic CD4
+
 and CD8
+
 lymphocytes express CCR9 together with 47, and 
selectively traffic to the small intestine under normal and TNF-stimulated conditions 
[136]. Interactions with CCL25 can also induce CD103 expression and positioning of 
CD8 lymphocytes to the intraepithelial compartment. The importance of CCR9 
expression is highlighted by observations wherein lymphocytes derived from 
knockout
 
mice are hampered in their ability to enter the gut as studied in competitive 
homing experiments [137]. However, Ccr9
–/–
 mice exhibit a mild phenotype under 
basal conditions with relatively minimal reduction in numbers of  IELs [138]. In 
fact, GALT-activated CD4
+
 T-cells can enter the intestine through CCR9-dependent 
and independent mechanisms, suggesting that CCR9 expression is not an absolute 
prerequisite for lymphocyte homing to the small bowel, in stark contrast to 7 
integrin [139]. 
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The only known ligand for CCR9 is CCL25, expression of which is largely restricted 
to thymic and small bowel epithelium, although under specific pro-inflammatory 
conditions it can be detected in the liver and lung [127,140,141]. The CCL25 gene is 
located on chromosome 19 in humans (chr. 8 in mice) although mechanistic insights 
into its transcriptional regulation remain speculative. Overexpression of early growth 
response protein (EGR)-1 and caudal-related homeobox transcription factor (CDX) 
have been reported to increase CCL25 transcription and protein expression in 
endothelial cells, whereas effects of conventional inflammatory stimuli such as TNF-
 remain controversial [132,136].  
 
1.6 CCL25/CCR9 interactions in IBD 
CCR9
+
 IEL and LPL exhibit chemotaxis to CCL25 in a dose-dependent manner when 
studied in vitro [142]. There is a gradient of CCL25 expression in the small bowel, 
with highest tissue levels detected proximally in the duodenum and lowest in the 
ileum [137], implying a degree of compartmentalisation at least in murine studies. 
Furthermore, there appears to be a variable dependence on CCL25/CCR9-mediated 
recruitment in the LP in contrast to intestinal epithelium [79,142]. Regardless, 
patients with small-intestinal inflammation have increased numbers of peripheral 
blood CCR9
+ 
T-cells [143], and CCR9
+
 T-cells isolated from MLN of patients with 
Crohn's disease have a more activated phenotype, producing significantly more IFN-γ 
and IL-17 than lymphocytes extracted from normal MLN [144]. In stark contrast, 
several research groups demonstrate a paucity of CCR9
+
 lymphocytes and a distinct 
absence of CCL25 expression in the normal human colon at the transcriptional and 
protein level [123,142,143], and the CCR9-CCL25 axis is proposed to distinguish 
small from large bowel specific lymphocyte recruitment [142].  
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In a SAMP1/YitFc model of murine ileitis (developed through selective breeding), a 
significantly greater proportion of CD4
+
 and CD8
+
 lymphocytes were CCR9
+
 
compared with wild-types (~20% and 60% vs. 5% and 40%, respectively), and 
affected mice exhibited increased epithelial CCL25 expression indicated by enzyme-
linked immunosorbent assays (ELISA), correlating with the severity of inflammatory 
injury [145]. Neutralising antibodies to CCL25 have been shown to reduce adhesion 
of adoptively transferred intestinal LPL and IEL to small intestinal post capillary 
venules [136], and histological indices of early intestinal inflammation are reduced 
following administration of antibodies targeting the CCR9-CCL25 axis in murine 
models of small-intestinal IBD [145]. However, targeted deletion of CCR9 has been 
shown to exacerbate ileitis in animal models [146,147], and in a TNFARE model of 
ileal Crohn‘s, deficiency of CD4+CD25+FoxP3+ and CD8+CD103+ Treg were observed 
within the LP and MLN of Ccr9
-/- 
mice [146], and inflammation developed 
unperturbed in the context of CCL25 deficiency [148].  
 
There are several plausible explanations for these divergent reports. Imprinting of 
CCR9 is retinoic acid dependent, and in the presence of TGF- determines the 
induction of FoxP3. TGF- also promotes expression of CD103 [149], and Wermers 
et al. report high concordant expression of CCR9, FoxP3 and CD103 in mice, 
suggesting that their respective generation might be coupled within inductive 
compartments [146]. Indeed, Treg preferentially express CCR9 when compared to 
effector counterparts in the TNFARE model, and the CD8+CCR9+ subset was also 
shown to be suppressive through inhibition of proliferation of CD4
+
 T-cells in vitro. 
More concerning, CCL25-CCR9 interactions are critical for establishing early 
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thymocyte colonisation and selective maturation of T-cells tolerant to self antigens 
[150]. Collectively, these findings imply that although congenital absence has 
potentially harmful consequences, targeted therapy against CCL25/CCR9 may yet be 
therapeutically efficacious in prevention or treatment of small bowel inflammation. 
Indeed, patients with small-intestinal Crohn‘s disease significantly improve clinical 
and endoscopic parameters of disease severity following treatment with the CCR9-
antagonist Vercirnon (152).  
 
1.7 Mucosal immunity in liver autoimmunity 
Autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and PSC all nestle 
within the umbrella term of ‗autoimmune liver disease,‘ in which the end result is 
immune-mediated hepatocellular or hepatobiliary injury. All three are associated with 
gut inflammation; AIH and PSC in particular being linked to IBD, and PBC to coeliac 
disease [1]. This observation has stimulated several intriguing pathogenic concepts in 
which gut commensals, pathogens and intestinal antigens are all implicated in causing 
liver injury. Th17 cells have also been linked to AIH, PBC and more recently PSC. 
Given the intestine is a key regulator of immunopathogenic Th17 responses, this may 
underpin a common disease mechanism and open up novel treatment avenues based 
on rational targeting of immune pathways [1,22]. Moreover, the observations that 
long-lived mucosal memory T-cells can be recruited to the liver in response to 
endothelial-cell adhesion molecules and chemokines, which are normally ‗gut-
restricted,‘ could plausibly explain why these diseases are associated with site-
restricted tissue distributions and pave the way for therapeutic strategies based on 
modulating tissue specific lymphocyte homing [1,2,152]. That particular gene-
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polymorphisms exist which confer combined PSC/IBD susceptibility, underscores the 
fundamental role of mucosal immunogenicity [1,98].  
 
1.7.1 Anatomy of the human liver 
The liver is the largest internal organ in the human body, being morphologically 
divided into 4 anatomical lobes: right, left, quadrate and caudate. The vast majority 
(~80%) of the liver‘s blood supply is derived from the hepatic portal vein, a vessel 
that delivers deoxygenated yet nutrient-rich blood from the gastrointestinal tract. 
Arterial and portal venous bloods permeate the hepatic sinusoids generating a mixed 
arterio-venous perfusion draining into a central vein.  
 
Ultrastructurally the intrinsic functional unit is represented by the liver lobule, a 
polyhedral prism limited by four to five portal triads each containing a bile duct, 
hepatic artery and hepatic portal vein (Figure 1.5). Within each lobule hepatocytes 
(epithelial cells of the liver) are arranged in layers that radiate from a central vein, 
interspersed by hepatic sinusoids. Up to 80% of the liver cell population consists of 
metabolically active hepatocytes, arranged into cell plates separated by sinusoids 
lined with endothelial cells. Hepatocyte cellular machinery is responsible for 
numerous metabolic functions, including synthesis of plasma proteins, complement, 
growth factors, cytokines and clotting factors, and synthesis of lipids and bile. Bile 
consists of bile salts, bilirubin, phospholipids (including lecithin), cholesterol and 
various ions. Following secretion from the liver, bile is delivered to the small bowel 
(duodenum) via bile ducts where it is responsible for assimilation of nutrients, in 
particular lipids. Another important function lies in the metabolism of amino acids, 
plasma proteins and vitamins, as well as glycogenesis and glycogenolysis. In addition, 
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the liver acts as a storage site of fat-soluble vitamins and also responsible for 
xenobiotic detoxification by cytochrome P450 enzymes. For these functions to be 
efficiently served, hepatocytes must extract nutrients, as well as waste and toxins 
from the blood circulating through the sinusoids. 
 
 
 
Figure 1.5: The hepatic lobule 
A hepatic triad consists of three vessels, one branch of the hepatic portal vein, one branch of the hepatic 
artery and one bile duct. Hepatic triads are located at the corners of the polyhedral (usually hexagonal) 
lobules. Arterial and portal venous blood percolate through the hepatic sinusoids into the central veins 
that coalesce into hepatic veins and finally drain into the inferior vena cava [2].  
 
 
The hepatic sinusoidal lumen is narrow and penetrated by Kupffer cells, resident 
macrophages that patrol the entrance of sinusoids. Kupffer cells represent the largest 
population of tissue-resident macrophages within the human body and their 
predominant localisation toward the periphery of the liver lobule permit effective 
phagocytosis and clearance of antigens entering via portal venous blood, as well as 
intimate contact with circulating immune cells [153]. Kupffer cells thus play a crucial 
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homeostatic role in host protection and capable of inducing both immunogenic and 
tolerogenic immune responses [154]. Monocyte-derived macrophages (MdM) 
constitute a minority of the intrahepatic macrophage population within normal liver 
and preferentially localise to the perivascular zone [155]. However, in response to 
hepatic injury macrophage populations markedly differ, with a decrease in the number 
of Kupffer cells during hepatic inflammation and fibrogenesis [156,157]. Conversely, 
MdM populations markedly increase, indicative of a pro-fibrogenic role. 
 
The interval between hepatocytes and sinusoidal endothelial cells is known as the 
perisinusoidal space of Disse, and is characterised by extracellular matrix (ECM) 
components including collagen (type III > types I and IV), proteoglycans and 
fibronectin. The ECM serves as a docking point for cells, permitting intercellular 
communication and differentiation. Hepatic stellate cells (HSC) – precursors of tissue 
myofibroblasts are also located in the space of Disse. In addition to being crucial 
mediators of the inflammatory response, they serve as intracellular stores of vitamin 
A, control sinusoidal blood flow by contraction, and play a critical role in 
development and propagation of tissue fibrosis. 
 
1.7.2 Enterohepatic immune system 
In addition to resident Kupffer cells, hepatic sinusoids are lined by a unique 
fenestrated endothelium that bears intrinsic scavenging properties. The sinusoids are 
also patrolled by innate immune cells including NK-cells, NKT-cells and MAIT cells, 
which are enriched in the human liver. Thus the liver acts as a second ―firewall‖ to 
prevent the spread of infection that evades immune surveillance in the gut and also as 
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a second line of processing to determine whether gut antigens, including nutrients, 
mount an immune response or are tolerated.  
 
 
1.7.2.1 Biliary epithelium 
The biliary and gut epithelia are contiguous mucosal components, sharing common 
barrier functions and mechanisms to prevent invasion by pathogens. These include 
IgA secretion, expression of TLR and NOD-like receptors [158], and the presence of 
resident epithelial associated lymphocytes and DC. Intestine-derived PAMPs such as 
lipopolysaccharide (LPS), lipoteichoic acids and bacterial DNA fragments can be 
detected in portal blood and bile, and biliary epithelial cells (BEC) actively participate 
in leucocyte recruitment by up-regulating adhesion molecules and secreting 
chemokines including CXCL8, CX3CL1 and CXCL12 in response to cytokines or 
TLR agonists such as endotoxin [159–162]. In particular, epithelial CXCL16 
enhances the adhesion of CXCR6
+
 liver-infiltrating lymphocytes by activating α4β1, 
which binds to epithelial VCAM-1 induced in response to inflammation [163]. 
CXCR6 expression is increased on NK, NKT and Th1-cells in the liver, and may also 
localise CD8
+
 effector cells to biliary epithelium, which mediate bile duct destruction 
in cholangiopathies such as PBC and PSC [162,164]. Biliary CCL28 is also up-
regulated in inflammation and promotes recruitment of Treg which are CCR10
+
. As 
CCL28 expression is a feature of intestinal epithelium, this suggests shared signals 
localise Treg to the gut and liver [165].  
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1.7.2.2 The balance of intrahepatic immunity: activation vs. tolerance 
The liver‘s ability to promote immune tolerance is essential to prevent 
disproportionate immune responses to nutrients or commensals entering via the portal 
vein. However the liver needs to be able to respond appropriately to pathogens and 
does so in most cases including hepatitis A and hepatitis E, although pathogens such 
as malaria and hepatitis C, which are characterised by persistent host infection, may 
exploit the liver‘s tolerogenic properties to evade immune surveillance.  
 
In addition to conventional DC the liver is characterised by populations of resident 
non-professional APC that regulate local activation of T-cells [166]. The ability of 
hepatic sinusoidal endothelial cells (HSEC) and hepatocytes to interact with T-cells is 
facilitated by the specialised structure and characteristics of liver sinusoids, including 
fenestrations that not only facilitate solute transport, but permit hepatocytes to extend 
protrusions into the sinusoidal lumen. Furthermore, the low levels of flow in the 
sinusoids allow lymphocytes in transit to interact with endothelial cells, as well as 
Kupffer cells and hepatocytes which have been shown to extend cell protrusions 
through the fenestrations into the sinusoidal lumen. Of note, antigen presentation by 
hepatocytes can lead to T-cells entering hepatocytes following which they are 
degraded by suicidal emperipolesis [167]. HSEC also possess the ability to take up, 
process and present soluble antigens and apoptotic cells from the sinusoidal blood, 
and can directly cross-present antigen to naive CD8
+
 T-cells in a process that usually 
results in tolerance [168,169]. The contribution of HSEC to intrahepatic CD4
+
 T-cell 
priming is less clear [170–172]; murine studies suggest HSEC have an ability to 
prime naïve T-cells with a regulatory phenotype and that such activation impart 
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responding cells with gut-tropism, providing another potential link between the gut 
and liver [173–176].  
 
Liver-derived DC in mice and humans are also inherently tolerogenic, expressing low 
levels of co-stimulatory molecules required for full T-cell activation [177,178]. Liver-
derived DC preferentially secrete IL-10 and are capable of inducing peripheral 
Treg which suppress immune responses [179]. Recent studies have further illustrated 
that the liver microenvironment modulates the ability of bone-marrow derived APC to 
activate viable effector T-cells [180]. Activation of naïve T-cells in the liver induces 
lymphocytes to undergo apoptosis in part due to a failure of the protein Bcl-2 to 
counteract the pro-apoptotic effects of another protein, Bim. Such an outcome is not 
seen in other tissues suggesting that it is the liver microenvironment which determines 
this fate. One factor may be the secretion of IL-7 by hepatocytes which has been 
shown to regulate T-cell survival, or other cytokines such as IL-6, IL-10 or TGF- 
secreted by stromal cells or Kupffer cells [156,181].  
 
The importance of local IL-10 secretion is illustrated by studies of murine infection 
with the enteric pathogen Trichinella spiralis [182]. Wild-type animals infected orally 
develop gut infection and local expansion of CD4
+
 T-cells but no hepatitis, whereas 
IL-10 deficient mice develop severe hepatitis mediated by CD4
+
 T-cells activated in 
the gut. This illustrates that local regulatory networks in the liver are critical for 
protection against effector responses generated in the gut. Further evidence of the 
ability of the gut to regulate intrahepatic DC maturation and function comes from 
studies showing that intestinal commensals and bacterial products carried to the liver 
via portal vein regulate the threshold for DC maturation and activation in the liver 
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[183]. The constant exposure to bacterial products means that the liver is relatively 
insensitive to endotoxin, and Kupffer cells and HSEC respond by preferentially 
secreting immunosuppressive cytokines preventing the liver from being in a constant 
state of inflammation [184]. Plasmacytoid DC recruited to the liver in response to 
inflammation can also induce tolerance through anergy or apoptosis of antigen-
specific CD8
+
 T-cells [185]. This may be important for the elimination of antigen-
specific cytotoxic T-cells as part of the process of regulating cytotoxic T-lymphocyte 
responses to infection.  
 
Thus, under homeostatic conditions antigen presentation within the liver usually 
results in immune tolerance. However, the fate of intrahepatic immune responses is 
largely dependent on the local inflammatory microenvironment and the predominant 
site of antigen expression and lymphocyte activation. Early antigen expression within 
secondary lymphoid tissue can result in an effective cytotoxic T-lymphocyte response 
and hepatocellular injury, although when antigen is presented predominantly within 
the liver, CD8
+
 T-cell tolerance is likely to ensue [168]. Chronic infection under these 
circumstances (e.g. HCV infection) may be difficult to overcome because of 
exhaustion or depletion of Tc-cells. Nevertheless, recent studies from the Bonn group 
have illustrated that TLR-signalling is able to transiently induce intrahepatic 
aggregates of myeloid cells which enable population expansion of cytotoxic T-cells 
[186]. Lymphocyte proliferation under these circumstances appears restricted to 
stimuli provided by monocyte-derived CD11b
+
 cells. Signalling via TNF induces 
myeloid aggregate formation, and these dynamic structures, generated in a likely 
effort to overcome normal regulatory cues that normally limit Tc-cell expansion, may 
represent a putative avenue of therapeutic intercession in chronic hepatic infection. 
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1.7.2.3 Autoimmune liver disease and mucosal immune activation 
The targets of autoimmune hepatobiliary injury are hepatocytes in AIH, and 
cholangiocytes (BEC) in PBC and PSC, although the cholangiopathies are also 
characterised by varying degrees of interface hepatitis, and inflammatory bile duct 
lesions occur in some patients with AIH [187]. The factors that initiate and perpetuate 
immune-mediated liver injury are poorly understood but likely to be environmental 
triggers on a background of genetic defects in immune regulation, which allow 
persistent inflammation and breakdown in self tolerance [164,188,189].
 
All three of 
the major hepatic autoimmune diseases are associated with bowel disease, most 
strikingly PSC with IBD. 
 
1.7.2.3.1 Th17 cells and Treg in autoimmune liver disease 
All autoimmune liver diseases are associated with an inflammatory infiltrate 
consisting of macrophages, B-cells and T-cells, with the latter in particular playing a 
central role in the underlying pathogenesis. Defects in the number and function of 
intrahepatic and peripheral blood Treg have been demonstrated in AIH, PBC and PSC, 
although others argue no such deficit [25,190–193]. However, the fact that hepatitis is 
a common finding in both humans and mice with defective regulatory cell function 
suggests that they are important in maintaining tolerance to liver antigens.  
 
Th17-cells have been linked to PBC, AIH and PSC [16,194,195] and are abundant in 
the intestinal lamina propria where they are induced by commensal bacteria and 
provide protection against invading pathogens [196,197]. In mice, peripheral Th17-
cells secrete IL-17A which induces expression of CCL20 in the small intestine, and 
Th17-cells can then be redirected to the gut via CCR6-CCL20 interactions. In humans, 
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CCL20 is also expressed on inflamed bile ducts suggesting that the same chemokine 
pathway might promote accumulation in the inflamed liver [22,198]. CD161 
expression by human T-cells correlates with IL-17 secretion, and CD161
+
 T-cells 
include Th17 CD4
+
 T cells, CD8
+ 
Tc17 cells and IL17-producing MAIT-cells 
[92,199]. Many of these cells express CXCR6, which is involved in recruitment and 
targeting to hepatocytes and BEC in the inflamed liver. 
 
The terminal ileum produces IL-1 and IL-23 in the presence of commensal microbes 
and increased secretion of these cytokines is associated with the development of IBD 
[200,201]. ‗Spill-over‘ of Th17 cytokines including IL-23 into the systemic circulation 
has been proposed to lead to the development of immune mediated joint disease in 
IBD [202,203] and a similar mechanism might contribute to the hepatobiliary 
manifestations observed in ulcerative colitis (UC) and Crohn‘s disease [16]. Thus, 
there is evidence to implicate the gastrointestinal tract as a site for control of both 
Th17 and Tc17 cells.  
 
1.7.2.4 Lymphocyte recruitment in immune-mediated liver injury 
The normal human liver contains  and  CD4+ and CD8+ T-cells as well as NK-
cells, NKT-cells, innate lymphoid cells and MAIT cells. Most intrahepatic T-
lymphocytes are primed memory cells, which traffic under homeostatic conditions to 
maintain immune surveillance throughout the liver [2]. It is plausible that a proportion 
of these memory cells are actually activated in the intestine prior to undergoing 
hepatic recirculation, in an effort to generate ‗memory‘ of shared mucosal antigens 
encountered both in the gut and liver [1,204]. Indeed, mucosal memory T-cells 
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preferentially re-circulate through the liver under homeostatic conditions in a process 
not necessarily dependent on expression of gut-tropic homing receptors [205].  
 
The mechanisms of lymphocyte recruitment to the liver are complex and involve 
specific combinations of adhesion molecules and chemokines including the atypical 
endothelial adhesion molecule VAP-1. However, no tissue-specific homing receptor 
has been reported for the liver despite the presence of important differences in 
phenotype and function of hepatic vascular and sinusoidal endothelium [45]. 
Leucocytes can enter the liver at several sites including post-capillary portal venules, 
although the majority undergo adhesion and transmigration in the hepatic sinusoids 
(Table 1.3). There is increasing evidence that lymphocyte interactions within hepatic 
microvasculature does not conform to the classical pathways of leucocyte adhesion 
[206]; the low shear environment allowing for selectin-independent recruitment with 
only a brief rolling step leading to firm adhesion [207]. Indeed, under homeostatic 
conditions portal endothelium expresses low levels of selectins, ICAM-1, ICAM-2 
and VCAM-1; whereas sinusoidal endothelium constitutively expresses ICAM-1, 
with VCAM-1, P-selectin and E-selectin expression being minimal or undetectable 
[208]. Sinusoidal endothelial cells also express receptors more commonly associated 
with lymphatic endothelium including lymphatic vessel endothelial hyaluronan 
receptor (LYVE)-1, liver/lymph node-specific intracellular adhesion molecules-3 
grabbing non-integrin (L-SIGN), CLEVER-1 and VAP-1 [208].  
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Table 1.3: Molecular determinants of leucocyte recruitment to the liver [1] 
Site Constitutive expression Increased in response to inflammation 
Portal vessels CCR5 – CCL3/4/5 E-selectin  
P-selectin – PSGL-1  
CX3CR1 – CX3CL1 
Sinusoids VAP-1 
CLEVER-1 
ICAM-1 (low levels) - L2  
CXCR6 – CXCL16 
CXCR4 – CXCL12  
CXCR3 – CXCL9/10/11 (low) 
CD44 
VAP-1 
 – MAdCAM-1 
L2 – ICAM-1 
1 – VCAM-1 
CCR9 – CCL25  
CXCR3 – CXCL9/10/11  
CX3CR1 – CX3CL1 
CXCR4 – CXCL12 
Biliary 
epithelium 
CCR10 – CCL28 
  
L2 – ICAM-1 
1 – VCAM-1 
CCL20 – CCR6 
CXCR1 – CXCL8  
CXCR4 – CXCL12  
CXCR6 – CXCL16 
CX3CR1 – CX3CL1 
 
 
Animal models of immune-mediated hepatitis have demonstrated roles for endothelial 
ICAM-1 as well as inflammation induced VCAM-1, P-selectin and L-selectin and 
several pro-inflammatory chemokines [45,209–211], none of which are tissue-
specific. However, VAP-1 is constitutively expressed on the endothelial cell surface 
in human liver, with little detected elsewhere in the absence of active inflammation. 
In the inflamed liver, VAP-1 is further up-regulated on endothelium and expressed by 
pericytes/stellate cells together with ICAM-1 and VCAM-1; inhibition of which can 
reduce inflammation in models of immune-mediated hepatitis [212–214].  
 
Effector T-cells infiltrating the inflamed human liver express higher levels of 
CXCR3, CXCR6, CCR1 and CCR5 than circulating cells [45]. CXCR3 is highly 
expressed on Th1, Th17 and CD8
+
 T-cells, and its ligands CXCL9, CXCL10 and 
CXCL11 (induced by IFN- and TNF- can be detected on damaged bile ducts in 
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PBC [215]. CXCR3 ligands recruit Th1 and Th17-cells via the sinusoidal endothelium, 
although subsequent positioning within the liver may involve other chemokines 
including CCL20 which localises Th17 cells to bile ducts [198]. Plasma levels of 
CXCL9 and CXCL10 increase with advancing disease stage in PBC and AIH [216], 
and can be reduced with disease specific treatment [217].  
 
Liver infiltrating Treg express homing receptors such as CXCR3 that overlap with 
their effector counterparts, facilitating co-localisation in order to suppress 
inflammation. CXCR3 and 41 integrins mediate the recruitment of Treg via HSEC, 
and CCR4 ligands secreted by DC localise them to sites of chronic hepatitis [218]. 
Recently, CLEVER-1 was shown to preferentially induce transendothelial migration 
of CD4
+
 FoxP3
+
 Treg through liver endothelial cells in vitro, and may provide an 
organ-specific signal for Treg recruitment to inflamed liver [66]. 
 
1.7.3 Immune regulation in hepatic fibrosis 
Hepatic fibrosis represents the gradual wound-healing response following long-
standing injury, in which chronic inflammation from a variety of aetiologies results in 
ECM deposition, parenchymal death, angiogenesis and formation of scar tissue, with 
any potential for reversal decreased significantly once cirrhosis is established. 
Broadly speaking, accretion of ‗scar-tissue matrix‘ results from dysregulated matrix 
remodelling due to an imbalance between matrix metalloproteinases (MMP) that 
degrade ECM components, and tissue inhibitors of metalloproteinases (TIMP). The 
ECM is increasingly recognised as a dynamic structure, bearing a pertinent role in 
regulating cell behaviour rather than simply serving as an inert ‗scaffold.‘ 
Components of the ECM can mediate cell-matrix adhesion through integrin binding, 
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participate in cell-signal transduction, and bind soluble growth factors and regulate 
their distribution, activation, and presentation to cells [219]. 
 
Accumulation of myofibroblasts is a key feature of fibrosis, most deriving from 
activation of resident mesenchymal cells, called HSC. However, a subset of portal 
fibroblasts have also been proposed to mediate biliary-type fibrosis [220]. In chronic 
liver injury HSC become activated, up-regulate the expression of mesenchymal cell 
markers (SMA and collagen-I), and trans-differentiate to myofibroblasts 
characterised by increased proliferation and migration, secretion of ECM proteins, 
enhanced contractility and release of pro-inflammatory and pro-fibrogenic mediators 
such as TGF-β1.  
 
1.7.3.1 Ductular reaction in fibrosis 
Proliferation of BEC occurs with varying degrees in all causes of hepatic fibrosis, and 
activated proliferating epithelia can release many fibrogenic growth factors including 
TGF-β1/2, platelet derived growth factor (PDGF) and connective tissue growth factor. 
This ductular reaction (DR) also contributes to the production of basement membrane 
proteins, which can impart branching vascular and biliary structures with the 
necessary structural support through induced and de novo formed ECM. This process 
can progress unperturbed in fibrotic disease. During fibrogenesis, expression of αvβ6 
on activated epithelia can modify the cellular response to fibrogenic stimuli [221], 
through binding and activation of TGF-β precursors [222]. Activated myofibroblasts 
also express v integrin, and perpetuation of myofibroblast activation results from 
several auto/paracrine feedback loops involving (amongst others) expression of 
receptors for TGF-β and PDGF [223,224]. Moreover, αvβ6 is a receptor for 
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fibronectin and tenascin-C [225]; essential matrix components of granulation tissue. 
Binding these substrates augments epithelial cell activation and proliferation through 
mitogen activated kinases [222]. αvβ6 integrin expression is absent in uninjured 
human and mouse liver but up-regulated following activation of BEC and hepatocytes 
with features of ductular transformation, and correlates with fibrosis stage [222]. 
Furthermore, studies in mice and rats have illustrated that conditional deletion of the 
v subunit, or administration of antibodies targeting v6, attenuate bile ductular 
proliferation, peribiliary collagen deposition and favourably alter the expression of 
pro-fibrogenic vs. fibrolytic genes [221,222,226]. 
 
1.7.3.2 Pro-fibrotic vs. pro-resolution macrophage populations 
As well as being key mediators of ECM-production, HSC actively participate in the 
innate immune response, mediating a range of immunoregulatory effects through 
production of NADPH oxidases, reactive oxygen species and pro-inflammatory 
cytokines and chemokines including M-CSF and CCL2, CCL3, CCL4 and CCL5. 
HSC also express chemokine receptors CCR5, CCR7, CXCR3 and CXCR7 [154], 
react to bacterial components through TLR4 signalling and function as non-
professional APC in the injured liver [227]. Macrophages localise in proximity to 
activated myofibroblasts [228,229], and evidence of a major functional role is 
provided by studies in which unselected depletion (rats [230]), or conditional deletion 
(CD11b monocytes and macrophages in mice [228]), result in attenuated numbers of 
HSC-derived myofibroblasts and reduced liver fibrosis. Similar effects are obtained 
using clodronate arbitrated deletion in parenchymal and biliary models of fibrosis 
[231,232].  
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Monocyte-derived macrophages substantially expand following tissue injury, 
implying that the pro-fibrogenic macrophage population derives from within 
[156,157]. In mice, a subgroup of iNOS-producing pro-inflammatory macrophages, 
arise from Gr-1
+
 (subtype Ly6C) inflammatory monocytes, which are recruited to the 
liver via CCR2-dependent trafficking; and represent the key pro-fibrogenic population 
in carbon tetrachloride (CCl4)-induced murine fibrosis [233]. The 
Ly6C
hi
CD11b
+
F4/80
+
 susbet of hepatic macrophages is the most proliferative 
population in this setting [157], and believed to correlate to human intrahepatic 
CD16
+
 monocytes. Of interest, the latter represent precursors of inflammatory tissue 
macrophages and inflammatory DC in humans, which exhibit VAP-1–dependent 
migration across HSEC [234]. The crucial role of monocyte recruitment in hepatic 
fibrogenesis is further supported by studies in which inhibition of CCL2 (rats) or 
congenital absence of CCR2 (mice) abrogates macrophage infiltration and 
development of fibrosis [235,236]. 
 
A population of ‗restorative macrophages‘ have been described, which also reside 
close to hepatic fibrotic scar tissue [154]. This subset is opulent in MMP [229,237] 
and TNF-related apoptosis-inducing ligand (TRAIL), which mediate apoptosis of 
myofibroblasts. Moreover, phagocytosis of apotopes is able to further induce MMP 
expression (positive feedback) therein potentiate the degradation of ECM components 
[157,238]. This population in mice are characterised as being CD11b
hi
F4/80
int
Ly6C
lo
. 
That they derive from a phenotypic switch of the pro-inflammatory Ly6C
hi
 subset, 
possibly induced by ‗apophagocytosis,‘ highlights the critical importance of highly-
plastic monocyte-derived macrophages in both the response to liver injury and 
 78 
restitution of tissue architecture [157]. However, it is not yet apparent how 
imminently translatable these observations are to human disease [239,240].  
 
1.7.3.3 Adaptive immune responses in hepatic fibrosis 
The precise role of adaptive immune responses in hepatic fibrogenesis is less 
understood, and contributions of individual T-cell populations likely dependent on the 
underlying aetiological driver. Indirect evidence suggests that a skew toward Th2 
immune responses is influential in the fibrotic response. C57BL/6 mice (in which Th1 
cell responses predominate) have a weaker propensity towards fibrosis than BALB/c 
mice (more commonly exhibiting a Th2-type profile). Furthermore the Th2-associated 
cytokine IL-13 stimulates TGF-β1 synthesis [241], whereas antagonism of IL-13 
signalling ameliorates fibrosis [242]. In contrast, IFN-γ and IL-12 are anti-fibrotic and 
suppress collagen deposition and inhibition of MMP activity [243]. The IL-17 
receptor can be expressed on monocytes, Kupffer cells, BEC and HSC, and activation 
induces secretion of pro-inflammatory cytokines such as IL-1β, IL-6, TNF and TGF-β 
[154]. Indeed, Th17 and Tc17 lymphocytes can directly induce type-I collagen 
production in HSC through activation of STAT3 [244].  
 
Adoptive transfer experiments in mice also implicate cytotoxic T-cells in a pro-
fibrogenic role, and CD8+ T-cell–mediated liver fibrosis can be ameliorated by IL-10 
[245]. However, in a CCl4 model, mice deficient in CD4
+ or CD8+ T cells 
demonstrated little variation in their propensity toward hepatic fibrogenesis compared 
with wild-type controls [246]. iNKT-cells are also activated in acute or chronic liver 
injury, a process thought driven by CXCR6–CXCL16 interactions, and result in 
secretion of IFN- and IL-4. Moreover, Cxcr6
−/−
 mice have reduced macrophage 
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accretion and pro-inflammatory cytokine production following liver injury and are 
relatively protected from liver fibrosis; a phenotype reversed upon reconstitution with 
wild-type hepatic NKT-cells [247]. 
 
1.7.3.4 Biliary fibrosis 
BEC are the primary site of injury in chronic cholangiopathies such as PSC, and as 
fibrosis originates in the peri-ductular region, the portal localisation of portal 
fibroblasts (versus the peri-sinusoidal location of HSC) would make them attractive 
candidates as mediators of biliary fibrosis. Portal fibroblasts (PF) undergo 
myofibroblastic differentiation in the chronically injured liver and akin to typical 
myofibroblasts express large numbers of SMA–containing microfilament [220], as 
well as fibronectin, fibrillar collagen and elastin (248–251). In contrast to HSC 
however, PF do not store retinoids and can be identified through expression of 
Col51 [252]. 
 
Until recently, evidence regarding the relative contributions of various myofibroblast 
sources (and function) in fibrogenic liver disease was limited to studies of isolated 
cell populations, and the advent of in vivo cellular fate-tracing studies have 
significantly enhanced our understanding in this regard. In a landmark paper, 
Mederacke et al. studied several murine models of toxin-induced (CCl4, 
thioacetamide), steatotic (methionine-choline-deficient diet) and biliary (bile-duct 
ligation, Mdr2
-/-
) fibrosis [253], in which HSC were found exert a dominant role 
across all aetiologies. Indeed, HSC constituted the majority (>80%) of SMA and 
ECM (collagen)-producing cells even in cholestatic liver injury, with only low-level 
fibrotic gene expression by the less abundant PF-like population. The authors propose 
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HSC as universal responders in hepatic wound repair [253], irrespective of the 
underlying cause of injury. A higher proportion of portal myofibroblast populations 
were nevertheless observed in biliary injury, and whilst PF may not contribute 
significantly to hepatic fibrosis their localisation adjacent to bile ducts is likely 
indicative of more specialised functions.  
 
1.8 Mucosal immune activation and primary sclerosing cholangitis 
Given the intimate relationship and shared antigen exposure between the gut and 
hepatobiliary immune systems, it is perhaps unsurprising that the liver can be affected 
as an extra-intestinal complication of immune-mediated disease of the bowel. PSC is 
a chronic inflammatory cholangiopathy resulting in fibrotic stricturing of the 
intrahepatic and extrahepatic bile ducts (Figure 1.6). The majority (>80%) of patients 
develop concomitant IBD at some point in their lifetime whereas 2.5 – 7.5% of the 
IBD population may develop PSC. The clinical phenotype of IBD in PSC is unique, 
being characterised by rectal sparing, backwash ileitis and either pancolonic 
involvement or predominantly right–sided disease [254]. Despite the majority having 
relatively quiescent intestinal inflammation, there is a ~30% lifetime risk of colonic 
malignancy [255], imparting need for annual colonoscopic surveillance [256,257]. No 
known medical therapy has consistently proven to retard disease progression, with the 
majority of patients requiring liver transplantation (>50%) or developing 
hepatobiliary malignancy (~15%) [258]. Furthermore, issues relating to risk 
stratification are particularly marked in PSC given the dearth of validated tools or 
biomarkers. In this regard there is a desperate need to track PSC immunologically 
more precisely over time, in order to facilitate early disease intervention.  
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Figure 1.6: Primary sclerosing cholangitis 
Morphologically, primary sclerosing cholangitis is manifest by multi-focal stricturing of the 
hepatobiliary tree (A) as a result of inflammation and scar tissue formation of intra- and extra-hepatic 
bile ducts. The classical histological lesion (B) is characterised by dense, portal inflammation and 
concentric peri-ductal fibrosis (black arrow) around bile ducts (BD). Adapted from www.liver.ca 
 
 
1.8.1 The clinical impact of IBD on PSC 
The presence of IBD has a significant, negative impact on the clinical course of 
hepatobiliary disease in PSC. Patients with IBD are reported to have reduced survival 
and an increased cholangiocarcinoma (CCA) risk when compared to those without 
bowel disease [259]. Moreover, patients who develop CCA are likely to have 
experienced a significantly longer prior duration of colitis [260], and in one study all 
who developed CCA had evidence of concurrent IBD whereas no hepatobiliary 
malignancy was found in the absence of intestinal inflammation [261]. Liver 
transplant-free survival is also curtailed in patients with IBD [261]; however, the 
activity of hepatobiliary disease does not necessarily parallel that of colonic 
inflammation. Indeed, colitis can develop many years after liver transplantation with 
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variable disease activity [262]. Similarly, patients can develop PSC for the first time 
after total colectomy for colitis.  
 
1.8.2 Mucosal Genetics in PSC 
PSC has an insidious onset making recognition of identifiable triggers difficult 
although the strong relationship with IBD suggests a common pathway for liver and 
gut inflammation centred on dysregulated mucosal immunity. The prevalence of PSC 
among first-degree relatives of PSC patients is increased 100-fold relative to family 
members of a matched control population, the former of which also carry an increased 
lifetime risk of developing IBD [263–266]. The strongest genetic associations in PSC 
lay within the human leucocyte antigen (HLA) region (chromosome 6) that encode all 
MHC molecules, although mostly differ from those that predispose to IBD. However, 
several non-HLA genetic associations that relate to mucosal immunity are intricately 
shared between IBD and PSC [267]:  
a) The importance of IL-2/IL-2R polymorphisms is supported by the fact that mice 
lacking IL-2Rdevelop a T-cell mediated cholangitis together with colitis [268]. 
Moreover, liver-derived lymphocytes from PSC patients show reduced expression 
of the IL-2-receptor and an impaired proliferative response (264).  
b) Caspase-recruitment domain (CARD)-9 is an important downstream mediator of 
signalling from NOD2 and TLR, and genetic associations suggest a link between 
defective intestinal mucosal microbial handling and the development of PSC [270].  
c) Macrophage-stimulating (MST)-1 is one of the strongest non-HLA associations in 
PSC and also linked with UC and CD. MST-1 is expressed by biliary epithelium 
and involved in regulating innate immune responses to bacterial ligands, and also 
plays a role in lymphocyte trafficking in lymphoid tissues by modulating integrin-
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mediated adhesion [271–273]. MST-1 variants could therefore signify an important 
overlapping susceptibility locus for PSC and intestinal inflammation. Glutathione 
peroxidase (GPX)-1 is an anti-oxidant enzyme located close to MST-1, and GPX 
polymorphisms may also confer increased disease susceptibility [265], for Gpx1/2
–
/– 
mice develop ileocolitis with an increased frequency of colonic malignancy 
(269).  
d) Variants in Fut-2 encoding the enzyme galactoside 2-alpha-l-fucosyltransferase-2, 
alter recognition and binding of various pathogens to carbohydrate receptors on the 
epithelial mucosal surface, and associated with changes in the commensal phyla 
characterised by elevated firmicutes and reduced proteobacteria [275]. This is akin 
to changes found in Fut-2 mutations associated with Crohn‘s colitis, linking 
defective immune responses to the microbiota in PSC [275–277].  
e) Salt-inducible kinase (SIK)-2 influences expression of IL-10 in macrophages and 
the leucocyte transcription factor Nur77 [278]. The IL-10 gene is an established 
susceptibility factor for early onset colitis [279], and exposing Il10
–/–
 mice to a diet 
high in saturated fat has been shown to induce specific changes in the bile acid 
pool, consequential alteration in the gut microbiome and increased susceptibility to 
IBD [280]. A role for histone deacetylase (HDAC)-7 – a gene implicated in the 
negative selection of T-cells in the thymus [278] and development of immune 
tolerance – is supported by a genetic association at 19q13, where the most 
associated polymorphism is located within an intron encoding serine/threonine 
protein kinase (PRK)-D2. When T-cell receptors of thymocytes are engaged, 
PRKD2 phosphorylates HDAC7 resulting in loss of gene regulatory functions, 
apoptosis and negative selection of immature T-cells. This negative selection takes 
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place owing to a loss of HDAC7-mediated repression of Nur77 (regulated by 
SIK2) linking multiple new PSC loci to a common pathway [1,278]. 
 
1.8.3 Bacterial translocation, mucosal antigens and molecular mimicry 
Under normal circumstances gut commensals and pathogens are confined to the gut 
by mesenteric lymph nodes [89]. However in the context of colonic inflammation and 
a ‗leaky‘ mucosa, bacteria can enter the portal circulation, thereby the liver, leading to 
local immune activation which could initiate or potentiate inflammation in PSC. 
Although frank portal bacteraemia is rare in PSC, bacterial products can be detected 
in the portal vein; and despite a blunted response of the liver to endotoxin, Kupffer 
cells and HSEC can be activated by bacterial TLR ligands. A recent study in mice 
illustrates how changes in the gut microbiota as a consequence of defective 
inflammasome pathways and IL-18 can trigger the development of liver inflammation 
[119]. Herein, inflammation was driven by hepatic TNF activation as a consequence 
of TLR4 and TLR9 agonists in the portal circulation. Thus, defective pathogen 
sensing as a consequence of genetic polymorphisms might alter the gut microbiota 
leading to hepatic inflammation in liver diseases associated with IBD. This is 
supported by murine models in which alterations in the intestinal bacterial population, 
or direct infusion of bacterial antigens into the portal circulation, leads to 
pericholangitis and hepatic inflammation. Moreover, peripheral blood lymphocytes in 
PSC manifest significantly higher frequencies of Th17-cells on pathogen stimulation 
compared to other cholestatic liver diseases [16]. CARD9 and REL gene 
polymorphisms are thus of particular interest given their role in Th17 differentiation 
and transduction of TLR-signalling. 
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Patients with PSC have a particularly high prevalence of circulating anti-
Sacchromyces cerevisiae antibodies even in the absence of advanced disease and 
irrespective of IBD phenotype [281]. Moreover, it has recently been found that the 
pANCA isolated from PSC patients is reactive against the microbial cell division 
protein FtsZ present in virtually every bacteria of the intestinal microflora [282]. 
Some identified autoantibodies also bind to BEC and induce TLR4 and TLR9 
expression, activation of which results in the secretion of pro-inflammatory cytokines 
and chemokines [283,284].  
 
Further support of the PSC-microbiota hypothesis is lent by observations wherein 
patients manifest a leucocyte differential with increased neutrophils, even in the 
absence of signs or symptoms of overt cholangitis, which could suggest circulation of 
endotoxins or immune-reactive molecules. Moreover, antibiotics targeting the 
intestinal microbiome may improve surrogate biochemical endpoints [285]. More 
sophisticated analysis of intestinal permeability and the intestinal and hepatobiliary 
microbiome may yet reveal subtle defects that have not been apparent in previous 
efforts [286]. 
 
1.8.4 Bile acid modifications  
As already discussed, several lines of evidence implicate mucosal dysbiosis and 
restricted biodiversity of the intestinal microbiome as being a pivotal event in the 
pathogenesis of IBD. Enzymatic reactions catalysed by intestinal commensals may 
also be responsible for bile acid transformation, and it has been hypothesised that IBD 
associated dysbiosis could lead to abnormal bile acid metabolism in the gut lumen 
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[116]. Such a process could conceivably erase the anti-inflammatory effects of certain 
bile acids and thereby participate in the inflammatory loop of IBD [116].  
 
Genetic modification of bile has been shown to induce sclerosing cholangitis and 
biliary fibrosis in a number of animal models of PSC. Mice with targeted disruption 
of the Mdr2 (Abcb4) gene encoding a canalicular phospholipid flippase spontaneously 
develop cholangitis and periductal fibrosis mirroring some of the key features of 
human PSC [287]. Although Mdr2
-/-
 mice do not develop IBD, dextran sulphate 
sodium (DSS)-administration provoked colitis in heterozygous Mdr2
+/-
 mice and as a 
―two hit‖ model induced portal inflammation in animals that were otherwise free of 
hepatobiliary disease [288]. (Genome-wide studies have not thus far identified any 
significant associations with the human ortholog MDR3 and PSC; however, variants 
may still play an important role by altering bile composition, and by proxy 
aggressiveness of bile, influencing secondary responses to immune-mediated bile duct 
injury.  
 
1.8.5 Aberrant homing of mucosal lymphocytes to the liver 
PSC is characterised by a predominantly T-cell portal infiltrate and immune-mediated 
damage to bile ducts which progresses through an iterative inflammatory process to 
periductal and portal fibrosis and progressive ductopenia. Any model attempting to 
explain the development of PSC in the context of IBD needs to take into 
consideration that hepatobiliary disease usually runs an independent course to that of 
bowel inflammation. The existence of an enterohepatic immune system that allows 
surveillance across both liver and gut by memory T-cells capable of homing to both 
organs would provide a second line of protection against pathogens penetrating the 
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mucosal barrier. However, dysregulation of this system may allow the spread of 
uncontrolled inflammation from the gastrointestinal tract to the liver.  
 
Endothelial cells in the gut and liver are phenotypically distinct, the gut mucosa being 
characterised by high expression of MAdCAM-1 and CCL25, whereas, at least in 
humans, liver endothelium expresses VAP-1 and other atypical receptors such as 
LYVE-1 and CLEVER-1. However, in PSC, MAdCAM-1 is also found on portal vein 
endothelium and CCL25 on sinusoids, and ~20% of liver-infiltrating lymphocytes 
express CCR9
 
and [127,289], implying recruitment directly from the inflamed 
intestine. Most liver-infiltrating CCR9
+
 lymphocytes are CD45RA
– 
CCR7
– 
CD11a
hi 
and secrete IFN-in keeping with a long-lived memory phenotype [127]. There is 
also mounting evidence that monocyte-derived macrophages express CCR9, and 
recruitment through the CCL25 axis is able to activate HSC and promote liver fibrosis 
[140].  
 
Murine models of antigen-specific gut and hepatobiliary inflammation provide further 
support of the aberrant lymphocyte homing hypothesis. In the works by Seidel and 
Eickmeier, mice expressing the antigen ovalbumin (OVA) under control of an apical 
sodium bile acid transporter (ASBT) and intestinal fatty acid transporter (iFABP) 
develop T-cell mediated cholangitis and colitis, respectively, following adoptive 
transfer of OVA-specific T-cells [173,175]. Of interest, these animals illustrate well-
defined gut- and liver-specific lymphocyte homing patterns dependent on CCR9 and 
MAdCAM-1. 
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One anomaly with this hypothesis is the fact that PSC usually develops in patients 
with colonic inflammation whereas under non-inflamed conditions CCL25 is largely 
confined to Peyer‘s patches and small bowel mucosa; however, rigorous interrogation 
of CCL25 expression and CCR9
+
 leucocyte populations in the inflamed human colon 
has yet to be performed. Other mucosal chemokines may facilitate recruitment of 
these cells and both CCL28 and CXCL12 are capable of triggering α4β7-mediated 
adhesion of human lymphocytes to MAdCAM-1 in vitro [290,291]. After recruitment 
to the liver 47+ gut-derived lymphocytes may use other chemokines such as 
CXCL12 and CXCR6 to localise to biliary epithelium where they can destroy bile 
ducts. Some of the recruited α4β7+ T-cells may undergo local differentiation to 
express αEβ7+ providing another pathway to bind biliary epithelium [289]. 
Lymphocytes use VAP-1 expressed on sinusoidal endothelium to enter liver tissue 
and the surface expression of VAP-1 on intestinal endothelium is greatly increased in 
IBD, suggesting that liver-derived lymphocytes may be able to enter the inflamed 
bowel by using VAP-1 [2,292,293].  
 
The factors leading to aberrant expression of MAdCAM-1 and CCL25 in the PSC liver are incompletely understood but may 
liver are incompletely understood but may involve a combination of inflammation and activation of the enzymatic activity of 
activation of the enzymatic activity of VAP-1, which in addition to being an adhesion molecule is also an ectoenzyme with 
molecule is also an ectoenzyme with potent amine oxidase activity. It has recently been proposed that the products of VAP-1-
been proposed that the products of VAP-1-mediated deamination of dietary amines can lead to the activation NFκB in hepatic 
can lead to the activation NFκB in hepatic endothelial cells and in the presence of TNF this results in expression of 
TNF this results in expression of MAdCAM-1 ( 
Figure 1.7). Thus, in the presence of an inflamed gut, increased portal vein levels of 
biological amines could activate VAP-1-dependent hepatic MAdCAM-1 expression 
thereby promoting the recruitment of mucosal effector cells to the liver [294]. VAP-1 
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can catabolise a broad range of substrates, and several gut commensals and enteric 
pathogens such as Bacteroides fragilis, Salmonella typhimurium, Yersinia 
entercolitica, Escherichia coli and Clostridium perfringens secrete other branched 
chained amines which may be putative substrates [295], providing another potential 
link between the microbiota, mucosal immunity and the pathogenesis of PSC [1].  
 
The ability to imprint gut tropism on naïve lymphocytes is dependent on the capacity 
of APC to convert retinol to all-trans-retinoic acid (ATRA) [57], which complexes 
with intracellular retinoid receptors to activate transcription of CCR9 and α4β7. This 
ability can be conferred in vitro by the addition of exogenous ATRA suggesting that 
retinoids in bile or stored in HSC might be able to endow liver APC with ability to 
induce a gut-homing phenotype [126]. However, Eksteen et al. found that human 
hepatic DC and HSC were unable to induce high-level α4β7 and CCR9 expression on 
T-cells, suggesting the ability to imprint naïve lymphocytes with gut tropism is 
restricted to intestinal CD103
+
 DC [296]. This concept has recently been challenged 
by a murine study that demonstrated priming of naïve T-cells by antigen-presenting 
HSEC is able to induce the expression of 47 and CCR9 on CD4+ T-cells in a 
retinoic acid dependent manner [174]. These T-cells are dominated by regulatory 
functions and their preferential recruitment into the gut may support local tolerance of 
food antigens or control intestinal inflammation [176], and partly explain the paradox 
of finding relatively quiescent colitis in patients with PSC/IBD.  
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Figure 1.7: Aberrant lymphocyte homing hypothesis of PSC  
Under normal physiological conditions, intestinal lymphocytes activated by gut dendritic cells imprint a gut-homing 
phenotype characterised by expression of the chemokine receptor CCR9 and the integrin α4β7. These receptors direct 
migration of activated lymphocytes back to gut tissue where their respective ligands CCL25 and MAdCAM-1 are 
expressed. In PSC, hepatic VAP-1 expression is up-regulated. As well as supporting endothelial adhesion directly, 
VAP-1 is as an amine oxidase. Methylamine and other amines present in the diet or generated by enteric bacteria can 
enter the liver via portal vein and act as substrates for VAP-1 leading to the generation of catabolites, which in the 
presence of inflammation activate NFB-dependent expression of MAdCAM-1 on hepatic sinusoids. Hepatic CCL25 
expression is also increased in PSC, resulting in the recruitment of mucosal lymphocytes activated in response to gut 
antigens in the setting of IBD to the liver where they contribute to inflammation and biliary destruction upon 
reactivation [1]. 
 
MAdCAM, mucosal addressin cell adhesion molecule; PSC, primary sclerosing cholangitis; VAP, vascular adhesion 
protein; IBD, inflammatory bowel disease.  
 
 91 
 
1.8.5.1 Insights from other autoimmune diseases 
In addition to autoimmune hepatobiliary disease, IBD is associated with cutaneous, 
ocular and rheumatic manifestations. Subclinical inflammation of the terminal ileum 
is present in up to 68% of individuals with spondyloarthropathy and associated with 
up-regulation of IL-23 within intestinal Paneth cells residing in the inflamed mucosa 
[203,297]. The consequent increased levels of circulating IL-23 act on a population of 
RORtCD4- CD8- T-cells resident in the inflamed joint which secrete IL-17 and IL-
22 [298]. These cells express the transcription factor promyelocytic leukaemia zinc 
finger protein (PLZF), also expressed by MAIT-cells [97], potentially implicating a 
common cellular lineage. The role of MAIT-cells in maintaining mucosal 
immunostasis has also been illustrated in murine models of colitis [299]; and given 
their preferential recruitment to the human liver, their aetiopathogenic potential in 
PSC warrants further exploration. 
 
1.9 Vascular adhesion protein-1: an adhesion molecule and ectoenzyme 
VAP-1 was first identified as an adhesion molecule involved in leucocyte trafficking 
to sites of inflammation in humans [300]. Cloning and sequencing reveal homology 
within the semicarbazide-sensitive amine oxidase (SSAO) family [301], copper-
dependent class (Table 1.4). Oxidative deamination results in the production of 
aldehydes, ammonia, and hydrogen peroxide (enzymatic reaction: R-CH2-NH2 + O2 + 
H2O → R-CHO + NH3 + H2O2). The catalytic site contains a modified tyrosine 
residue, a topaquinone, which in the presence of a copper ion is responsible for 
enzymatic function. 
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Table 1.4: Classification of amine oxidases 
 FAD-containing Copper-containing 
MAO A+B PAO DAO Cell-surface Soluble Lysyl oxidases 
Expression mitochondria intracellular intracellular extracellular serum extracellular 
Archetypal 
substrates 
NA, DA, A,  
B-PEA, 
tryptophan, 
octopamine 
spermine 
spermidine 
cadaverine, 
histamine, 
putrescine 
benzylamine, 
methylamine 
lysine 
Inhibitors pargyline, 
clorgyline 
 semicarbazide 
Function neurotransmission cell growth Histamine 
degeneration, 
cell division 
amine catabolism,  
glucose uptake,  
leucocyte adhesion 
formation of 
ECM 
Cloned human SSAO 
AOC1 AOC2 AOC3 
amiloride binding protein 1 
(kidney diamine oxidase) 
retina amine oxidase vascular adhesion protein 1 
 
Amine oxidases are broadly classified on the chemical nature of the attached cofactor. The flavin adenine 
dinucleotide (FAD)–containing enzymes, monoamine oxidase (MAO) A + B and polyamine oxidases 
(PAO) are intracellular enzymes. The other classes contain a cofactor possessing one or more carbonyl 
groups, most often a topaquinone and include diamine oxidases (DAO), lysyl oxidase (LOX) and plasma 
membrane and soluble amine oxidases. These enzymes are collectively designated semicarbazide sensitive 
amine oxidases (SSAO) due to their sensitivity to inhibition by semicarbazide. Four copper-dependent 
amine oxidase (AOC) genes have been identified in mammals encoding a diamine oxidase (AOC1), a 
retina-specific amine oxidase (AOC2), vascular adhesion protein-1 (AOC3) and a serum amine oxidase 
(AOC4 – not shown). In some mammals, the product of the AOC4 gene is not functional due to the 
presence of an internal stop codon (humans) or truncation of the coding sequence (mice, rats) [302]. NA, 
noradrenaline; DA, dopamine; A, adrenaline; B-PEA, -phenylethylamine; ECM, extracellular matrix. 
 
 
1.9.1 Structural overview 
The transmembrane form of VAP-1 is a sialylated glycoprotein bearing a short 4 
amino acid N-terminal cytoplasmic tail, single transmembrane segment and a 
sequence of large extracellular domains (molecular weight ~90kDa) [303] Figure 
1.8). VAP-1 exists as a homodimer, each unit containing a copper atom, two calcium 
atoms and N-acetylglucosamine sugar units at two separate sites. The molecular 
structure is that of a ‗heart-shaped‘ copper dependent amine oxidase (amine oxidase 
copper dependent; AOC) consisting of the extracellular domains D2 (residues 55-
169), D3 (170-300) and D4 (301-761). D4 represents the most conserved domain, 
comprising many residues involved in enzyme cofactor (topaquinone) generation 
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and/or in the formation of the active site. Located at the C-terminal portion is the 
RGD motif (tri-peptide sequence Arg-Gly-Asp); a feature typical of integrin binding 
sites although there is currently no evidence to suggest that this motif is required for 
VAP-1 activity [304,305]. The domain structure of human (h)VAP-1 resembles that 
of other AOC family members with the exception of Escherichia-derived AOC which 
contains an additional N-terminal D1 domain [306].  
 
 
 
Figure 1.8: Vascular adhesion protein (VAP)-1 structure 
Molecular cloning of VAP-1 has revealed a homodimeric sialoglycoprotein. The proposed four domain 
extracellular structure is illustrated, with sites of potential glycosylation indicated in yellow in (A) 
[307].  
 
The four domains are shown as a ribbon diagram in (B) with the same structure rotated 90
o
 in (C); -
strands drawn as arrows and -helices as spirals. The C-terminal portion of the hVAP-1 dimer is 
stabilised by three disulfide bridges; in each subunit Cys734 and Cys741 form an intra-subunit bond 
whereas Cys748 x 2 form an inter-subunit disulfide bond. Domain colouring is as follows: D2, green; 
D3, blue; D4 of subunit A, orange and D4 of subunit B, grey. The copper atom of the active site is 
shown as a yellow sphere [306].  
 
The overall fold of domain 4 of the VAP-1 dimer is redrawn in (D), with the enzyme active site 
indicated by the black arrow [307]. 
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A large proportion of protein volume is occupied by cavities including those at the 
dimerisation interface (C1-3), and of particular note, the active site cavities A1 and 
B1 (present in subunit A and subunit B, respectively). Residues from the least 
conserved domain (D3) as well as the most conserved (D4) protrude into the active 
site cavity, modifying the shape and scope for molecular interactions (the RGD site 
being located at the mouth of the cavity). hVAP-1 also bears many potential 
glycosylation sites spread across the domains which are likely to play a vital role in 
interactions with inflammatory cells [301,308,309].  
 
1.9.2 Hepatic VAP-1 expression 
In the human body endothelial VAP-1 is stored in cytoplasmic granules and 
transported to the endothelial cell surface under inflammatory conditions, being 
located on the membrane of HEV, lymphatic endothelium and follicular DC in lymph 
nodes of highly vascularised tissues. Expression becomes up-regulated under pro-
inflammatory situations in the gut, synovium and kidney, where VAP-1 promotes 
leucocyte recruitment, and in some reports tumour development [292,310,311]. 
However, in the absence of inflammation cell surface VAP-1 expression is very low 
in non-lymphatic tissues, the one exception being liver. In man, hepatic endothelial 
VAP-1 expression is constitutively at a high level, and in some chronic inflammatory 
liver diseases such as PSC, lymphoid follicles develop in close association with portal 
tracts and contain CD34
+
 VAP-1
+
 neovessels with HEV-like morphology [289]. 
VAP-1 is also up-regulated on neovessels in septal areas and portal tracts in chronic 
hepatitis, implicating involvement in the organisation and development of such 
structures. VAP-1 has been shown to mediate adhesion and transendothelial migration 
in several experimental models of liver inflammation [212,213,312,313], and 
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facilitates recruitment of multiple leucocyte subsets including CD4
+
 helper T-
lymphocytes, cytotoxic CD8
+
 T-cells, as well as granulocytes and monocytes [312].  
 
The identity of the VAP-1 ligand remains elusive. Siglec-10 has been put forward 
following screening of a phage display library [314], wherein VAP-1 would 
enzymatically deaminate an arginine residue present on a surface exposed loop. 
Although Siglec-10 is highly expressed on the surface of B- and NK-cells, only low 
levels are detected on monocytes with a virtual absence on granulocytes, suggesting 
the presence of additional/alternative ligands. Siglec-9 has also been proposed as a 
putative ligand because expression on granulocytes facilitates VAP-1 mediated 
endothelial adhesion; a property partially dependent on SSAO enzyme activity and 
the presence of arginine residues [315]. The unusual choice of arginine in preference 
to conventional primary amine substrates, coupled with divergent species-specific 
Siglec sequences (mouse orthologues of Siglecs-9 and -10 do not bear arginine 
residues) indicate that further efforts are required to elucidate the ligand for VAP-1 
[67].  
 
1.9.2.1 Leucocyte recruitment 
The presence of an RGD motif in the C-terminal portion of the human protein was 
historically thought to be a prerequisite for adhesion. However, as eluded to earlier, 
variants in which the aspartate residue is substituted with alanine exhibit comparable 
binding properties, suggesting the RGD-motif is not an absolute requirement [314]. 
VAP-1 has the potential to interact with leucocytes via carbohydrate moieties present 
on the apical surface [308]; however primary amines presented by leucocyte surface 
proteins (e.g. N-terminus of a protein, amino-sugars) may also bind to the active site 
 96 
of VAP-1, resulting in transient covalent crosslinking of the leucocyte and endothelial 
cell [307]. These interactions may involve a common ligand, or require stepwise 
binding of soluble/cell-bound factors [316].  
 
Despite high constitutive expression of hVAP-1 in the liver, only low hepatic levels 
are detectable in mice compared to the more prominent expression observed in 
murine adipocytes [317–319]. Indeed, the hepatic parenchyma is largely negative for 
VAP-1 in healthy mice when examined either by immunohistochemistry, western 
blotting or at the transcriptional level. This contrasts with the relatively strong 
staining seen in human liver tissue. An ability to mediate hepatic lymphocyte 
recruitment has nevertheless been supported by several in vivo studies. Aoc3 knockout 
mice develop normally and have no overt phenotype, but exhibit a reduced capacity to 
support leucocyte adhesion on inflamed vascular endothelium associated with 
decreased transmigration into sites of inflammation [320]. Studies from the Kubes lab 
in Calgary suggest that VAP-1 is able to selectively recruit Th2 CD4
+
 T-cells in a 
concanavalin A (ConA)-induced model of hepatitis [212], in which mice demonstrate 
significantly reduced lymphocytic infiltration and markers of hepatic inflammation 
(serum ALT) upon VAP-1 inhibition or genetic deletion, but not inhibition of 
enzymatic activity [213]. Furthermore, Weston et al. have shown that although there 
is little difference between wild-type and Aoc3
–/–
 mice in the uninjured state, 
following chronic CCl4–induced hepatic inflammation knockout animals show a 
marked reduction in the numbers of liver-infiltrating CD8
+
 T-cells, CD4
+
 T-cells, B-
cells, NK-cells and NKT-cells, with significantly fewer inflammatory foci observed 
histologically [214]. Of interest, similar changes in infiltrate were observed in mice 
bearing a mutated form of VAP-1 in which a single amino acid substitution renders 
 97 
VAP-1 enzymatically inactive, which in part supports a role of SSAO activity in 
leucocyte recruitment. 
 
Function blocking antibodies and enzyme inhibitors both appear to reduce leucocyte 
binding to VAP-1 by approximately 50% in vitro, with little or no additive effect 
when administered concurrently [214,316]. There are also reports of attenuating 
leucocyte infiltration in vivo, albeit with differential impact on individual subsets: in 
mice, antibody-blockade has been shown to reduce the migration of CD8
+
 T-cells into 
tumour sites with little effect on leucocytes of myeloid lineage; whereas inhibition of 
amine oxidase activity significantly mitigated the infiltration of Gr-1
+
 CD11b
+
 
myeloid cells, with no impact on CD8
+
 T-cell recruitment [311]. The effects of small 
molecule inhibitors and antibody blockade on recruitment of Treg and 
immunosuppressive monocyte populations appear less consistent. Studies by Marttila-
Ichihara et al. suggest that inhibition via either mechanism did not alter homing of 
these cell populations in a murine non-liver tumour model [311]. However, VAP-1-
blockade was recently shown to synergistically enhance the effects of CLEVER-1 
inhibition on Treg transendothelial migration across human HSEC in vitro [66].  
 
In addition to its role as a primary adhesion molecule, VAP-1–mediated deamination 
gives rise to H2O2, a major reactive oxygen species that can cause cell damage in 
addition to serving as a potent signalling molecule. The liver sinusoidal bed is 
continually exposed to amines via the gut, and provision of such substrates can result 
in H2O2 release, enhance NFκB activation and up-regulate expression of chemokines 
and adhesion molecules [294,321]. Lalor et al. illustrated that provision of 
benzylamine promotes the expression of CXCL8, E-selectin, ICAM-1 and VCAM-1 
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on HSEC. Similarly, provision of the physiological substrate methylamine has 
recently been shown to up-regulate MAdCAM-1 in vitro and in vivo. Taken together 
these findings indicate how enzymatic functions of VAP-1 further modulate the 
ability of HSEC to recruit leucocytes under flow. 
 
1.9.2.2 Tissue fibrosis 
Catabolism of the VAP-1 substrate methylamine gives rise to the formation of 
formaldehyde; an extremely potent inducer of protein crosslinking as well as 
formation of advanced glycation end products (AGE) [322,323]. VAP-1 has been 
implicated in matrix remodelling because its overexpression in arterial smooth muscle 
cells leads to elastin deposition [324]. Together with its direct and indirect roles in 
leucocyte recruitment, these mechanisms may contribute to persistent inflammation 
and the progression of tissue fibrosis. VAP-1 small molecule inhibitors have been 
shown to significantly abrogate the recruitment of Gr-1
+ 
CD11b
+
 myeloid cells into 
tumours [310,311], which is important given that inflammatory Gr-1
+
 monocytes 
have been implicated in progression of liver fibrosis [154].  
 
In a landmark study, Weston et al. demonstrated increased VAP-1 expression in 
SMA+ cells in fibrotic septa in close association with infiltrating leucocytes [214]. 
Indeed, VAP-1 was detectable in cytoplasmic vesicles within HSC, and these cells 
were capable of de novo mRNA synthesis with expression being up-regulated 
following provision of TGF- or PDGF- Moreover, in a chronic CCl4 model, Aoc3
-
/- 
mice as well as wild-types treated with anti-VAP-1 antibody had significantly 
reduced hepatic fibrosis when compared with untreated wild-type mice. Expression of 
fibrotic genes was also reduced in mice harbouring the enzymatically-inactive variant 
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(described previously) suggesting that VAP-1 amine oxidase activity is a pre-requisite 
for tissue fibrogenesis. Of interest, epidemiological observations imply that increased 
consumption of caffeine (itself, a partial inhibitor of VAP-1 enzyme activity) is 
associated with lower rates of fibrosis progression across a variety of chronic liver 
diseases, including PSC [325–327]. However, hepatic fibrosis is also abrogated in 
murine models of liver injury following therapeutic VAP-1 antibody-blockade, an 
inhibitor that does not directly bind the enzyme active site or affect substrate 
deamination. It has thus been hypothesised that VAP-1 antibodies can limit access of 
endogenous, cell-associated substrates to the molecule‘s enzyme active site in vivo, 
which given the as yet unknown identity of the VAP-1 ligand is difficult to prove 
conclusively. An alternative proposal put forward by Koskinen et al. suggests that 
mediation of immune cell recruitment would require sequential enzyme dependent 
and independent steps; wherein blockade of either mechanism can inhibit cell 
recruitment [316].  
 
1.9.2.3 Soluble VAP-1 
A catalytically active, soluble form of VAP-1 (sVAP-1) can also be detected in serum 
and is thought to be generated by cleavage of membrane-bound protein from the 
surface of endothelial cells or adipocytes [328]. The mechanism mediating release 
into the circulation is unknown, although TNF-α-dependent release of soluble VAP-1 
has been observed in murine and human adipocytes — a process inhibited by the 
MMP inhibitor batimastat [319,329]. sVAP-1 appears to account for most of the 
circulating amine oxidase activity detectable in mouse and human serum [328,330], 
and elevated levels have been observed in a number of diseases including diabetes 
mellitus, atherosclerosis and cardiovascular disease, cardiac failure and steatohepatitis 
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[67,214,331]; noteworthy given the increased prevalence of diabetes and 
cardiovascular disease in PSC [332], and consistent with observations that adipocyte 
VAP-1 inhibits lipolysis and promotes glucose uptake [333–335]. Increased 
circulating levels also correlate with the severity of liver fibrosis in patients with fatty 
liver disease further implicating a role of VAP-1 in hepatic fibrogenesis. The precise 
role of sVAP-1 however is not yet known, although a recent study has illustrated that 
sVAP-1 is endowed with potent chemotactic properties and could therefore mediate 
distal effects on leucocyte recruitment [214]. 
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1.10 Proposal  
Hypothesis (1): CCL25 and CCR9 expression are upregulated in the human colon 
during times of active inflammation. 
Hypothesis (2): VAP-1 expression is increased in PSC, and through an increase in 
catalytic activity is directly responsible for upregulating expression of intraehepatic 
adhesion molecules that drive mucosal lymphocyte recruitment to the liver. 
Hypothesis (3): Serum VAP-1 levels and activity are increased in patients with PSC 
and correlate with fibroinflammatory burden of liver disease 
Hypothesis (4): An absence of VAP-1 enzyme activity is able to ameliorate or 
mitigate sclerosing cholangitis development in vivo. 
 
Specific aims: 
Aim (1): Determine expression of CCL25 and CCR9 in the inflamed human colon. 
Aim (2): Compare and contrast intrahepatic VAP-1 expression in PSC versus other 
chronic autoimmune liver diseases, and evaluate the functional consequences of 
enzyme activity in terms of endothelial MAdCAM-1 expression and 7-dependent 
leucocyte interactions. 
Aim (3): Quantify circulating serum VAP-1 levels and enzyme activity in patients 
with PSC, correlating values with clinical characteristics. 
Aim (4): Evaluate the therapeutic potential of VAP-1 enzyme inhibition in a murine 
model of sclerosing cholangitis. 
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2 Materials and Methods 
2.1 Human tissue 
All blood and tissues were acquired through the Queen Elizabeth Hospital Liver and 
Gastroenterology Unit (Birmingham, UK) unless otherwise specified. Peripheral 
blood was obtained prospectively from patients with PSC, PBC and AIH attending the 
autoimmune liver disease clinic, as well as individuals with IBD alone and healthy 
volunteers without evidence of liver disease. Human liver tissue was acquired from 
explanted organs removed at time of surgery; specifically, those affected by chronic 
end-stage disease. Control (unaffected) specimens were obtained from normal donor 
livers surplus to transplantation requirements, or the ‗distal-to-tumour (DT)‘ aspect as 
part of hepatic resections in patients with secondary hepatocellular cancer. Colonic 
tissue was acquired via mucosal biopsies taken during patient colonoscopy (provided 
kindly by collaborators at University Hospital, Jena), as well as colonic resection 
specimens from patients with treatment-refractory colitis or non-IBD associated 
colonic cancer.  
 
All human tissue and blood samples were collected with local research ethics 
committee approval and informed patient consent. 
 
2.1.1 Cell culture  
2.1.1.1 Generic solutions and plastics 
Human serum and foetal bovine serum (FBS) were obtained from Life Technologies.
 
Penicillin, streptomycin and glutamine (PSG) were purchased from Sigma-Alrich. 
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TrypLE Express (1x) containing stable Trypsin-like enzyme with Phenol Red was 
acquired from Invitrogen. Unless otherwise specified, phosphate buffered saline 
(PBS) was prepared from tablets (Oxoid, UK) according to manufacturer‘s 
instructions.  
 
Sterile 5, 10 and 20 mL pastettes, 75 cm
2
 culture flasks, 48-well and 96-well plates, 
15 mL and 50 mL tubes and 1.5 mL cryovials were all purchased from Corning 
Costar Incorporated, UK. 20 mL plastic tubes and 5 mL bijous were acquired from 
Ramboldi, Wheaton, UK. Sterile plastic gloves used daily were from Premier Nitric, 
UK. All tissue culture was carried out in a class II microflow safety cabinet. At all 
times aseptic technique was followed by swabbing the cabinets with industrial 
methylated spirit (IMS; Adams Healthcare, UK) before and after use. 
 
2.1.1.2 Culture and passage conditions 
Cells were cultured on tissue culture plastic in appropriate media (as indicated; Table 
2.1) and maintained at 37
o
C in a humidified, 5% CO2 incubator. Where indicated 
tissue culture plastic was pre-coated with rat-tail collagen (RTC) to promote cellular 
adhesion. Briefly, 4 mL RTC (diluted in PBS to a working dilution of 220 µg/mL; 
Sigma-Aldrich, UK) was aliquoted into a 75 cm
2
 flask, and following gentle agitation 
(~30 seconds), aspirated and discarded. The flasks were left to dry overnight 
(microflow chamber, ambient temperature) and rinsed (PBS) prior to use. 
 
Cell viability and growth were monitored using an inverted phase contrast microscope 
(Olympus IX50). Adherent cells become flattened and form spindle-projections when 
attached to the growth surface. In contrast, cells that remain in suspension retained a 
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rounded, symmetrical appearance. All cultures were examined daily by observing cell 
morphology, the colour of medium and density of suspension. 
 
Table 2.1: Cell media 
 Base media Supplementation Growth factors 
Complete lymphocyte 
media 
RPMI-1640
*
 
 
10% FBS 
1% PSG 
N/A 
Complete HSEC media 
Basal endothelial, 
serum-free media 
(SFM)
*
  
10% Human serum (HS)
#
 
1% PSG 
VEGF (10 ng/mL)
 §
 
HGF (10 ng/mL)
 §
 
3T3 culture media DMEM
* 
 
10% FBS 
1% PSG 
 
Adipogenic media 
$
  
Differentiation Induction media 
10% FBS 
1% PSG 
SingleQuots
 
PT3102B ` 
Maintenance  Maintenance media 
10% FBS 
1% PSG 
SingleQuots  
PT3102A `` 
* 
Life Technologies 
#
 Heat-inactivated – 56oC for 30 minutes 
§ 
Vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) obtained from 
Peprotech, UK 
$ 
Lonza, UK 
` Contains: recombinant human insulin, L-glutamine, MCGS, dexamethasone, indomethacin, 3-isobuty-
l-methyl-xanthine (IBMX), GA-1000; 1 vial added to 170 mL media.  
`` Contains: recombinant human insulin, L-glutamine, MCGS, GA-1000; 1 vial added to 170 mL media.  
 
 
 
Adherent cells were passaged using an appropriate volume of TrypLE (4 mL in a 75 
cm
2
 culture flask). Specifically, old media was discarded and adherent cells washed 
with PBS before adding warm (37
o
C) TrypLE. The flask was then agitated gently by 
hand to enable cellular detachment. Once detachment was complete, sterile PBS was 
added to the suspension, and the final mixture collected and centrifuged at 600 x g for 
5 minutes. The cell pellet was then re–suspended in appropriate media before re-
seeding for further culture. Non–adherent cells were passaged without trypsinization 
by centrifugation of the suspension at 600 x g for 5 min. The cell pellet was re–
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suspended in appropriate media and cells re–seeded in new culture flasks. Viability 
was always assessed using Trypan–blue (Life Technologies) exclusion and cells 
counted using a haematocytometer (MerckMillipore, UK) prior to re–
seeding/downstream application. 
 
2.1.1.3 Freezing and storing cells 
For long-term maintenance, cells were preserved in liquid nitrogen. After pelleting, 
cells were resuspended at a density of 10
6
/mL in freezing media (95% FBS+5% 
DMSO (Sigma-Aldrich, UK)). Cells were then transferred to cryovials and placed in a 
MrFrost freezing container (Wessington Cryogenics, UK) for a minimum of 24 hours 
at –80oC to permit gradual cooling and prevent crystal formation within the 
cytoplasm. The next day, cells were transferred to liquid nitrogen for long-term 
preservation. When required, cells were removed from storage, thawed and washed in 
media and centrifuged to remove cellular debris. Cells were counted and viability 
assessed using Trypan blue exclusion followed by resuspension in appropriate media. 
A minimum of 10 days in culture was given prior to utilising thawed cells for 
downstream experiments. 
 
2.1.2 Isolation of specific cell populations 
2.1.2.1 Peripheral blood lymphocytes 
Peripheral venous blood was collected into EDTA coated tubes, and the mononuclear 
fraction isolated by density gradient centrifugation over Lympholyte-H, (VH Bio, 
UK) according to manufacturer‘s instructions. Cells were counted and resuspended in 
the appropriate media at the appropriate density (application-dependent). 
 106 
2.1.2.2 Colon-infiltrating lymphocytes 
Mechanical digestion of retrieved tissue samples was performed using C-tubes 
(Miltenyi Biotec, UK) and a GentleMACs dissociator (Miltenyi) in preference to 
enzymatic digestion to reduce loss of cell-surface epitopes. Digested tissue was then 
passed through a 70 µm cell strainer (BD Biosciences, UK) and the filtrate layered 
atop a discontinuous gradient comprising 70% and 30% Percoll (GE Healthcare, UK) 
in a 1:1:1 ratio. Following brake-free centrifugation (600 x g, 25 minutes) the 
mononuclear cell band was aspirated, resuspended in PBS, washed x 2 and cell pellet 
resuspended appropriately for downstream application.  
 
2.1.2.3 Hepatic sinusoidal endothelial cells 
Human HSEC were isolated from liver tissue as previously described [312]. 
Approximately 30 g of whole liver tissue was finely diced and enzymatically digested 
using 5 mL 0.2% collagenase type 1A (Sigma) for 20 – 40 minutes, and then filtered 
in an excess of sterile PBS. The cell suspension was further washed by centrifugation 
in PBS (x4) and purified over density centrifugation (33/77% Percoll) at 550 x g for 
30 minutes. Cells were removed at the interface of the gradient media, washed in PBS 
then subjected to a negative selection step; specifically incubation with mouse anti-
EpCAM (clone HEA125, Progen Biotechnic, Germany; 50g/mL) for 30 minutes at 
37
o
C). Thereafter, cells were incubated with secondary antibody conjugated to 
magnetic beads (goat anti-mouse Dynabeads, Life Technologies; 10 l/prep.) for 30 
minutes at 4
o
C, and bead-labelled cells (indicative of BEC) removed by magnetic 
selection. The remaining cells were incubated with anti-CD31 antibody directly 
conjugated to Dynabeads (10 μg/mL; 30 min at 4oC). CD31+ cells were then extracted 
from the cell mixture by positive magnetic selection, resuspended in complete HSEC 
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media (Table 2.1) and cultured at 37
o
C in RTC coated flasks until confluent (~1.5 x 
10
6
 cells/flask), prior to further passage.  
 
2.1.3 Culture of human cell lines 
JY cells, an Epstein-Barr virus-immortalised B-cell lymphoblastoid line, engineered 
to constitutively express α4β7-integrin [336] were available in house (originally 
provided by Dr. N. Pullen, Pfizer, USA). Cells were cultured in complete lymphocyte 
media (Table 2.1) and maintained in a humidified atmosphere (5% CO2, 37
o
C). 
 
2.1.4 Serum extraction 
Peripheral blood was collected into uncoated clinical grade collection tubes and left to 
stand for a minimum of 30 minutes (max. 180 minutes) to allow clotting. Thereafter, 
blood tubes underwent centrifugation (1500 x g; 10 minutes) prior to retrieval of 
serum supernatant. Each sample was divided into 50 – 100 l aliquots prior to storage 
at –80oC in order to minimise subsequent freeze-thaw cycles. 
 
2.2 Cell phenotyping with flow cytometry  
Phenotypic analysis of leucocyte subsets was performed using multi-colour flow 
cytometry. Following extraction from tissue or isolation from peripheral blood, 
lymphocyte cell pellets were resuspended in flow cytometry MACS buffer (PBS + 
2% FBS + 2 mM EDTA) at a density of 10
6
/mL. 100 l of cell suspension was then 
incubated with appropriate fluorochrome-labelled antibodies or isotype-matched 
controls for 30 minutes at 4
o
C protected from light (Table 2.2). All cell labelling was 
performed in 5 mL polypropylene round-bottomed Falcon tubes (BD Biosciences). 
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Consequently, cell-antibody cocktails were washed with PBS and resuspended in 500 
L MACS buffer prior to analysis (CyAn ADP 3-laser, 9-colour flow cytometer; 
Beckman Coulter Inc, USA). Unlabelled cells were used to define appropriate 
forward- and side-scatter voltages/gain and single-colour antibody labelling 
conducted prior to multiple in order to perform colour compensation. Data analysis 
was performed using Summit software v.4.3 (Dako, USA). 
 
When analysing colon- or liver-infiltrating leucocyte populations, the entire cell-
suspension was first labelled with a viability marker (Near-IR, live/dead-fixable dye, 
Life Technologies), by co-incubating a 1/1000 dilution of the dye with the cells at 
ambient temperature and protected from light for 15 minutes, followed by washing 
the cells in PBS and subsequently resuspending in MACS buffer prior to labelling 
with antibodies of interest.  
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Table 2.2: Antibodies used for flow cytometry (human tissue) 
Conjugated antibodies 
(supplier) 
Isotype (clone) Stock Conc. 
Working vol. 
(l / 105 cells) 
Mouse anti-CD3 PE-Cy7 
(BioLegend) 
IgG1 
(SK7) 
0.2 mg/mL 5 
Mouse anti-CD4 V500 
(BD Horizon) 
IgG1 
(RPA-T4) 
0.2 mg/mL 5 
Mouse anti-CD4 FITC 
(BD Horizon) 
IgG1 
(RPA-T4) 
0.2 mg/mL 10 
Mouse anti-CD8 PE-CF594 
(BD Horizon) 
IgG1 
(RPA-T8) 
0.2 mg/mL 5 
Mouse anti-CD127 PerCPCy 5.5 
(BD Pharmingen) 
IgG1 
(HIL-7R-M21) 
0.2 mg/mL 5 
Mouse anti-CD127 FITC 
(BD Pharmingen) 
IgG1 
(HIL-7R-M21) 
0.2 mg/mL 10 
Mouse anti-CD127 APC 
(eBioscience) 
IgG1 
(eBioRDR5) 
0.2 mg/mL 5 
Mouse anti-CD25 Pac. Blue 
(BD Pharmingen) 
IgG1 
(M-A251) 
0.2 mg/mL 5 
Mouse anti-4 integrin APC 
(BD Biosciences) 
IgG1 
(9F10) 
0.2 mg/mL 2 
Rat anti-7 integrin PE 
(BD Pharmingen) 
IgG2a 
(FIB504) 
0.2 mg/mL 10 
Mouse anti-CCR9 AF 488 
(BD Pharmingen) 
IgG2a 
(112509) 
0.2 mg/mL 5 
Mouse anti-CCR9 AF 647 
(BD Pharmingen) 
IgG2a 
(112509) 
0.2 mg/mL 5 
Isotype-matched control (IMC)   
Mouse PE-Cy7 
(BD Pharmingen) 
IgG1 
(MOPC-21) 
0.2 mg/mL 5 
Mouse V500 
(BD Horizon) 
IgG1 
(X40) 
0.2 mg/mL 5 
Mouse FITC 
(BD Horizon) 
IgG1 
(X40) 
0.2 mg/mL 10 
Mouse PE-CF594 
(BD Horizon) 
IgG1 
(X40) 
0.2 mg/mL 5 
Mouse PerCPCy 5.5 
(BD Pharmingen) 
IgG1 
(MOPC-21) 
0.2 mg/mL 5 
Mouse Pac. Blue 
(BD Pharmingen) 
IgG1 
(MOPC-21) 
0.2 mg/mL 5 
Mouse APC 
(BD Pharmingen) 
IgG1 
(MOPC-21) 
0.2 mg/mL 5 
Rat PE 
(BD Pharmingen) 
IgG2a 
(R35-95) 
0.2 mg/mL 10 
Mouse AF 488 
(BD Pharmingen) 
IgG2a 
(G155-178) 
0.2 mg/mL 5 
Mouse AF 647 
(BD Pharmingen) 
IgG2a 
(G155-178) 
0.2 mg/mL 5 
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2.3 Polymerase chain reaction (PCR) 
2.3.1 RNA extraction and cDNA synthesis. 
Extraction of total RNA was performed from snap-frozen tissue samples (~30 mg) 
following mechanical digestion (GentleMACs M-tubes; program RNA 01_01) and 
purification using the QIAGEN RNeasy mini-kit (QIAGEN, Germany) as per the 
manufacturer‘s instructions. All samples were treated with DNAse I (RNase-free 
DNase set, QIAGEN) during the extraction process. RNA concentration (ng/L) and 
purity were then measured using a Nanophotometer (Geneflow, UK). Absorbance 
ratios of 260/280 at 1.8 – 2.0 were taken as acceptable ‗purity.‘ RNA was stored in 
aliquots of 1 – 3 g to minimise repeated freeze/thaw cycles. cDNA was synthesised 
using the iScript synthesis kit (Bio-Rad, USA) according to manufacturer‘s 
instructions. No-template (RNA-free) and no reverse-transcriptase (no-RT) samples 
were prepared in parallel as negative controls for downstream application. 
  
2.3.2 Conventional PCR and agarose gel electrophoresis 
The presence of CCL25 mRNA in human colon and small bowel was first 
investigated by conventional PCR (Table 2.3). Intron spanning primers were selected 
and amplicons of ~230 bp visualised on a 1.5% (w/v) agarose gel (diluted in Bionic 
buffer, Sigma) stained with SYBR DNA gel stain (Life Technologies). Hyperladder 
IV
 
(Invitrogen) was used as an amplicon length marker. 
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Table 2.3: Conventional PCR reaction primer sequences/constituents 
Primers Human CCL25 
Forward 5‘ – GCCTGCTGCGATATTCTACC – 3‘ 
Reverse 5‘ – TACTGCTGCTGATGGGATTG – 3‘ 
Exact amplicon length: 227 bp 
Reagent Vol. per-reaction (L) Stock conc. Source 
Master Mix kit 10 5 U/L QIAGEN 
Coral dye PCR buffer 2 5 U/L QIAGEN 
Forward primer 1 0.25 pmol/L Alta Bioscience, UK 
Reverse primer 1 0.25 pmol/L Alta Bioscience, UK 
cDNA 2 N/A* N/A 
Nuclease-free water 4 N/A* QIAGEN 
Cycle (35 cycles run) Temperature (
o
C) Time (min) 
 95 02:00 
Denaturation 95 01:00 
Annealing 60 01:00 
Extension 72 01:00 
 72 05:00 
* RNA concentration of 50g/mL prior to cDNA synthesis step (1 g /20 L) 
N/A Not applicable 
 
 
 
2.3.3 Quantitative real-time PCR (qRT-PCR) 
For analysis of relative expression of human and murine mRNA of interest, VIC- and 
FAM-labelled Taqman probes were used according to manufacturers instructions and 
qRT-PCR performed with cDNA using specific primers and cycling conditions (Table 
2.4). LightCycler 480 96-Multiwell plates (Roche Life Science, UK) were used with 
the LightCycler
®
 480 II (Roche). 
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2.3.3.1 Relative quantification of mRNA expression in human colonic tissue 
Relative quantification real-time PCR was performed on each sample in duplicate or 
triplicate (as indicated). The level of colonic mRNA expression was compared against 
an internal control to which the threshold cycle (CT) values of target genes were 
normalised using the LightCycler device software (E-analysis method; software 
version 1.5.0.39). 
 
2.3.3.2 Absolute quantification in human liver 
Human liver VAP-1 (AOC3) mRNA expression was also assessed by qRT-PCR. 
Given the absence of a single, known housekeeping gene that exhibits stability across 
all aetiologies and between varying stages of human liver injury [337,338], levels of 
expression were determined by absolute quantification of samples run in triplicate. In 
this regard, the number of copies of VAP-1 mRNA in matched amounts of starting 
total RNA from each tissue sample was determined from a calibration curve of known 
dilutions of a linearised plasmid encoding the VAP-1 gene ranging from 10 copies/L 
– 105 copies/L as described by Weston et al. [214].  
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Table 2.4: Primers/probes, assay mixes and consumables – qRT-PCR (human)* 
Target Primer/Probe assay ID Source 
CCL25 Hs00608373_m1 
Life Technologies 
CCR9 Hs01890924_s1 
TNFα Hs01113624_g1 
AOC3 Hs00186647_m1 
GUS- Hs00939627_m1 
Reaction mixture and consumables 
Reagent Volume (l) Source 
TaqMan Master mix 10 Life Technologies 
Probe/primer 1 Life Technologies 
cDNA  
(from 50 g/mL RNA) 
2 N/A 
Nuclease-free water 7 QIAGEN 
LightCycler
®
 480 
Multiwell Plate 96  
N/A Roche 
*Cycling conditions: 95
o
C for 10 seconds, 59
o
C for 30 seconds and 72
o
C for 1 second. 
2.4 Western blotting  
2.4.1 Preparation of protein lysates 
The presence of CCL25 protein in intestinal samples was analysed by western 
blotting, using small bowel and recombinant human CCL25 (R&D systems, UK) as 
positive controls. Human small bowel and colonic tissue blocks (70 – 100 mg) were 
placed in M-tubes (Miltenyi) and homogenised in ice-cold lysis buffer (10 mL 
CellLytic MT Buffer (Sigma) with 2 tablets PhospSTOP, 2 tablets cOmplete Mini 
protease inhibitor, 10 L of 5 U/mL DNase (Roche); 20 l buffer per-mg tissue) 
using the GentleMACs (program Protein 01_01). Thereafter, samples were 
centrifuged at 3000 x g for 3 minutes to maximise recovery from the C-tubes, mixed 
to form a uniform homogenate and subsequently transferred to a new micro-
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centrifuge tube. The lysates were then agitated for 1 hour at 4
o
C before a further 
centrifugation step (21200g, 10 minutes). Supernatants were aliquoted and stored at -
80
o
C till needed. 
 
Protein concentrations were determined using the bicinchoninic acid (BCA) assay 
(Pierce, Thermo Scientific, UK) according to manufacturer‘s instructions and utilising 
bovine serum albumin (BSA, Sigma) diluted in lysis buffer as a protein concentration 
standard. 
 
2.4.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were separated by electrophoresis through acrylamide gels using the 
Bio-Rad Mini Trans Blot Cell System. Initially, glass plates were assembled (1.5 cm 
thickness), resolving and stacking gels prepared (Table 2.5), sequentially poured into 
the glass space and left to set. Solubilised protein samples prepared in cell lysis buffer 
at standardised concentrations (2 mg/mL; 20 l) were diluted in 5x loading buffer 
(Table 2.5; 5 L) and boiled (100oC, 10 minutes). The mixture was set aside to cool 
and centrifuged before gel loading. Simultaneously, the gel apparatus was assembled 
and 1x electrophoresis buffer poured onto the tank ensuring full cover of the 
electrodes. 20 µL of each protein sample was slowly loaded into wells preformed in 
the stacking gel, in addition to pre–stained molecular weight markers (Page ruler, 
Pierce, 10 L). Electrophoresis was performed at 200 V for 30 minutes, or until the 
dye front reached the bottom of the gel. 
 
 115 
2.4.3 Western blot transfer 
Resolved proteins were transferred onto Hybond–ECL nitrocellulose membrane 
(Amersham Biosciences, UK) and directly immersed into transfer buffer in order to 
prime the membrane for protein binding. Pre-soaked membranes were placed on top 
of the gel, sandwiched between filter papers and sponges; which were also pre–
immersed in transfer buffer and the assembly placed into transfer buffer apparatus, 
positioned within the transfer tank containing an ice pack. Transfer buffer was added 
into the tank and a current of 100 V applied for 1 hour. Efficient transfer was evident 
from the appearance of rainbow markers on the membrane and impression of protein 
staining with Ponceau S solution [0.1% Ponceau S (w/v) in 5% acetic acid (v/v)] for 5 
minutes followed by rinsing (water) to visualise successfully transferred protein.  
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Table 2.5: Reagents used for western blotting 
Reagents (supplier) 
Trizma base (Sigma) 
Degassed acrylamide  
(30% acrylamide/methylene bisacrylamide – 37.5:1)  
(Bio-Rad Laboratories, UK) 
NaCl (Sigma) Ammonium persulfate, APS – 10% w/v (Sigma) 
Glycine (Sigma) N,N,N
‘
,N
‘ – tetra-methyl-ethylene-diamine, TEMED (Sigma) 
Sodium dodecyl sulfate (Sigma) -mercaptoethanol, -ME (Sigma) 
Methanol (Fisher Scientific, UK) Bromophenol blue (Sigma) 
Tween20 (Sigma) Glycerol (Sigma) 
Buffers 
Resolving (R) 1.5 M Trizma base (pH 8.8; adjusted with HCl) 
Stacking (S) 0.5 M Trizma base (pH 6.8; adjusted with HCl) 
Loading 
200 mM Trizma Base pH 6.8 + 20% glycerol, 10% SDS 0.05% bromophenol blue, 
10 mM β-ME 
Electrophoresis 
(10x) 
30.3 g Trizma base + 144g glycine + 10g SDS (to 1 L with dH2O) 
Transfer 6 g Trizma base + 28.8 g glycine + 400 mL methanol + 1g SDS (to 2 L with dH2O) 
Blocking PBS + 0.02% Tween20 + 5% non-fat milk 
Gels
*
 
  Buffer 
Degassed 
acrylamide 
10% SDS  10% APS
#
 TEMED
#
 dH2O 
Resolving (12%) 2.5 mL 3.3 mL 0.1 mL 0.06 mL 0.06 mL 3.3 mL 
Stacking (5%) 1.25 mL 1.7 mL 0.1 mL 0.06 mL 0.06 mL 6.8 mL 
*
 Quantity equivalent to x1 gel at 1.5cm thickness. 
#
 APS and TEMED were added just prior to pouring of gels into the glass spaces, as the oxygen free 
radicals released from the reaction between APS and the tertiary amine TEMED are responsible for the 
polymerisation of bis-acrylamide. 
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2.4.4 Membrane development  
Following protein transfer, membranes were blocked for at least 2 hours at RT in PBS 
containing 0.1% Tween20 (PBS-T) supplemented with 10% (w/v) non–fat dry milk 
(Marvel, UK) with continuous agitation. The blocking buffer was subsequently 
removed and membranes probed overnight at 4
o
C with primary detection antibody 
raised against human CCL25 (mouse anti-human monoclonal IgG1 – clone 52529, 
used at 0.2g/mL; R&D systems) diluted in fresh blocking buffer. After several 
washes in PBS–T, membranes were incubated with peroxidase–conjugated secondary 
antibody (goat anti-mouse horseradish peroxidase (HRP), used at 1/4000; Dako) 
diluted in blocking buffer for 1 hour at ambient temperature. After several washes 
with PBS–T, the blots were incubated with enhanced chemiluminescence reagent 
(ECL-plus; Amersham Pharmacia Biotech, UK). Enhanced chemiluminescence 
detection film (Amersham Biosciences) was exposed to the membrane and developed 
using a Kodak X–Omat 1000 processor. Semi-quantitative assessment of protein 
expression (relative to housekeeping targets) was performed using ImageJ software 
(v.1.6 NIH, USA) wherein band density was calculated using built in gel image 
analysis functions. Given the adoption of immunoprecipitation steps (see below), 
membranes were not stripped. 
 
2.4.4.1 Immunoprecipitation 
As chemokines in biological samples are often found at very low levels and subject to 
multimerisation [339], a prior immunoprecipitation step (IP) was incorporated to 
enrich and purify protein lysates where needed. Briefly, 20 L (0.6 mg) of protein G 
Dynabeads
®
 (Life Technologies) were aliquoted in a microcentrifuge tube, transferred 
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to a separation magnet and the supernatant discarded. Capture antibody (1 g goat 
polyclonal IgG anti-human CCL25; R&D systems) was diluted in 200 L PBS-T and 
then incubated with the beads (continuous rotation; 10 minutes ambient temperature); 
following which 100 L sample lysate at a known concentration (2 mg/mL) was 
added, and the lysate-antibody-bead complex was mixed with gentle pipetting. The 
complex was then incubated with continuous rotation for 1 hour (ambient 
temperature). Thereafter, the mixture was transferred to a magnet and the non-bound 
cleared lysate aspirated and kept for later analysis of housekeeping protein (anti -
actin, 1 μg/mL; Sigma) and as a negative internal control of primary target. The 
remaining sample was washed gently with PBS x 3, then beads, antibody and target 
proteins were dissociated by heating at 70
o
C for 20 minutes, and subsequently 
resuspended in sample buffer prior to analysis by western blotting as indicated in 
section 2.4.2.  
 
2.4.5 Quantification of CCL25 protein  
Intestinal CCL25 expression was quantified using a human CCL25 enzyme-linked 
immunosorbent assay (ELISA) approved for use in tissue lysates (Cusabio, 
2BScientific, UK). Tissue-protein lysates were obtained as described in section 2.4.1. 
Samples and internal standards were loaded in triplicate, and the assay run according 
to manufacturer‘s instructions. The threshold for detection was 25 – 1600 pg/mL. 
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2.5 Soluble VAP-1 measurements 
2.5.1 Patient characteristics and data collection  
All individuals with an established diagnosis of autoimmune liver disease or IBD 
under clinical follow-up from 2011 to 2014 were considered eligible for sampling. A 
standardised electronic record form was created and clinical data collected 
prospectively. Individual clinical and laboratory characteristics pertained to patient 
age, gender, severity of liver disease (pre-cirrhotic, cirrhotic compensated, cirrhotic 
decompensated), history of ascending cholangitis, IBD status (presence or absence 
thereof, distribution of inflammation, disease activity and severity), autoantibody 
status (anti-nuclear antibodies, ANA; anti-smooth muscle antibodies, ASMA; 
perinuclear anti-neutrophil cytoplasmic antibodies, pANCA), concomitant mediations 
at time of sampling (immunosuppression, immunomodulators, UDCA, antibiotics) 
and laboratory indices (serum alanine transaminase (ALT), aspartate transaminase 
(AST), alkaline phosphatase (ALP), bilirubin, albumin and platelets).  
 
Individual patient follow-up constituted a clinic review every 12 months in the 
absence of cirrhosis, and at 6-monthly intervals for patients with evidence of 
advanced disease. Study follow-up was until patient transplantation or death.  
 
2.5.2 Determining soluble VAP-1 levels 
Circulating VAP-1 levels in human serum were measured using a time-resolved 
immunofluorometric assay developed by BioTie Therapies Corp., Finland. The assay 
procedure (carried out by BioTie Therapies) is provided in Table 2.6 and Table 2.7. In 
sum, a biotin-conjugated mouse IgG2a monoclonal anti-VAP-1 capture antibody 
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(TK8-14, BioTie Therapies) was immobilised onto a streptavidin-coated microwell 
plate in which serum samples at known dilution were added. Bound sVAP-1 was then 
detected with a europium-coupled mouse IgG2a anti-VAP-1 tracer capture antibody 
(TK8-18, BioTie Therapies). Levels were then measured by time-resolved 
fluorescence at 615nm (Victor
3
 multi-label counter, PerkinElmer) by comparing to a 
reference sample (positive control) of highly purified human sVAP-1 (Biovian, 
Finland). The assay calibration ranged from 1.5 – 1500ng/mL and linearity (R2) of 
calibration curves 0.997 – 1.000. Two replicates of calibration standard, controls and 
test samples were run per-plate. A minimum of one quality control (QC) sample was 
run on each plate and at least two series of controls per sample batch.  
 
Fluorescence signal counts of calibration standards were plotted against nominal 
concentrations using data analysis software (Table 2.6). A nonlinear, weighted (1/x) 
4-parameter logistic model (Equation 2-1) was used to fit the calibration curve. The 
concentration of sVAP-1 in test samples was calculated from the fluorescence signal 
counts using the appropriate calibration curve.  
 
Equation 2-1: The four parametric fit (sigmoidal function) regression model:  
y = a + ( d - a) / ( 1 + ( x / c) ^b) , weighting 1/x,  
[c is the centre point (ED50), d is the upper limit, a is the lower limit, b is the relative slope around c]. 
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Table 2.6: sVAP-1 ELISA reagents and preparation 
Reagents 
Wash solution DELFIA wash concentrate (PerkinElmer, USA) 
Sample buffer DELFIA assay buffer (PerkinElmer) 
Enhancement solution DELFIA enhancement solution (PerkinElmer) 
Capture antibody Biotinylated anti-VAP-1 antibody, TK8-14 (BioTie)
*
 
Tracer antibody Europium coupled anti-VAP-1 antibody, TK8-18 (BioTie)
*
  
Positive control  Purified soluble human sVAP-1 (Biovian) 
Instruments and materials 
Victor
3
-1420-012- microplate reader + WorkOut 2.5 software (PerkinElmer)  
1296-026 DELFIA Plate washer (PerkinElmer) 
1296-003 DELFIA Plate shaker (PerkinElmer) 
1296-041 DELFIA Plate Dispenser (PerkinElmer)  
4009-0010 DELFIA Streptavidin 96-well plates (PerkinElmer) 
Preparation 
Wash solution DELFIA wash concentrate diluted 1:25 in ddH2O.  
Sample dilution Study samples diluted 1:10 
Calibration standards sVAP-1 reference material + sample buffer  
QC samples 4.5 ng/mL (low), 50 ng/mL (medium) and 1200 ng/mL (high)  
Capture antibody Diluted in sample buffer (3 g/mL) and sterile filtered 
Tracer antibody Diluted in sample buffer (2 g/mL) and sterile filtered 
*
 Mouse anti-human IgG2a 
 
Table 2.7: sVAP-1 ELISA protocol 
10 L calibration standards, QC samples and test serum (diluted) added per well  
50 L biotin-europium antibody solution added immediately to each well. 
Plate sealed with tape and incubated on plate shaker (2 hours, ambient temperature) 
Plate washed x 4 with wash solution 
200 L DELFIA enhancement solution added to each well and incubated on plate shaker (min. 5 
minutes – max. 60 minutes, ambient temperature) 
Time-resolved fluorescence measured at 615 nm 
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2.5.3 Quantifying SSAO activity 
VAP-1 mediated deamination results in the production of H2O2, the rate of production 
of which was used as a surrogate for assessing SSAO activity.  
 
2.5.3.1 Sample preparation – method 1 
Serum samples (10 L) were aliquoted in quadruplicate into a 96-well flat-bottomed 
plate, to which benzylamine 1 mM (per-well) was added as an artificial substrate of 
VAP-1 enzyme activity. In order to inhibit contributions to the reaction by other 
circulating amine oxidases, inhibitors of MAO-A (100 M Clorgyline; Sigma) and 
MAO-B (100 M Pargyline; Sigma) were included in the admixture, and the total 
volume was brought up to 100 l with sterile PBS. 
 
2.5.3.2 Sample preparation – method 2 
Unlabelled capture antibody (TK8-18) was diluted to a final concentration of 5 g/mL 
in carbonate coating buffer (Table 2.8) and 100 L was added to each well of a high-
affinity protein-binding ELISA microwell plate (Nunc-Immuno Maxisorp, Sigma) 
and sealed and incubated overnight (4
o
C). The next day, plates were brought up to 
room temperature and unbound antibody removed before washing the plate (x3) with 
wash buffer. 200 L blocking solution was then added to each well and the microwell 
plate was incubated at ambient temperature. After 8 hours, excess blocking solution 
was removed and the plate was washed (x3) before adding 100 L serum (test 
samples) per-well in quadruplicate (Figure 2.1) and incubating overnight (4
o
C). Non-
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antibody-bound sample was then removed and the plate washed (x3). Thereafter, 100 
L amine solution was added (1 mM benzylamine per-well, prepared in PBS).  
 
2.5.3.3 Detection system 
To be certain that all H2O2 detected was dependent on SSAO activity, substrate + 
VAP-1 inhibitor (250 M semicarbazide; Sigma) treated samples were run in parallel 
with every run (Figure 2.1). Finally, standard concentrations of H2O2 (0.2 – 3.0 M) 
were prepared and loaded into the plate. Amplex UltraRed Reagent was exploited as a 
stoichiometric fluorogenic substrate for HRP in order to quantify rate of H2O2 
production. Dulbecco‘s PBS (100 L) containing 20 mM Amplex UltraRed Reagent 
and 2 U HRP was added to each sample or standard as appropriate. Kinetic readings 
per-sample were obtained via rate of change of fluorescence as measured by a 
Synergy HT Multi-Mode Microplate reader (BioTek) according to protocol (Table 
2.8) and enzyme activity calculated from the slope of the standard curve. 
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Table 2.8: SSAO assay constituents 
Reagents Supplier 
Dulbecco‘s PBS* 
Sigma 
Benzylamine 
Semicarbazide 
Clorgyline 
Pargyline 
Horseradish peroxidase 
Amplex-UltraRed  Life Technologies 
Buffers  
Coating buffer 8.4 g NaHCO3 + 3.56 g Na2CO3 + ddH2O (to 1 L, pH 9.5) 
Wash buffer PBS + 0.05% Tween20  
Blocking solution PBS + 1% BSA 
Sample and standard diluent Dulbecco‘s PBS + 0.2% Triton X-100 
Kinetic reading protocol 
Excitation: 530nm (slit 25) 
Emission: 590nm (slit 35) 
Sensitivity: 20  
Shaking intensity 3; duration 2, before reading  
Kinetic reading: 10 readings/well; followed over 1 hour 
* Dulbecco‘s PBS (Sigma) used as opposed to tablet-prepared PBS (e.g. Oxoid) given the latter‘s 
tendency to affect the detection system 
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Figure 2.1: Layout and calculations in the SSAO enzyme assay 
Patient samples (e.g. S1) were loaded in quadruplicate (A) with two wells containing substrate only 
(blue) and the remainder containing semicarbazide (white). The calibration standards (green) contained 
increasing M concentrations of H2O2 and a standard curve generated plotting fluorescence versus 
known H2O2 concentration at a single point in time (B). For every sample pair, the mean change in 
fluorescence over time (C) was converted to a rate of H2O2 produced; the value from semicarbazide-
treated samples subtracted from that of substrate only to give a true reading of SSAO activity.  
 
 
2.6 Immunohistochemical staining  
Single colour chromogenic staining and dual colour immunofluorescence were used 
to visualise protein in tissue. At time of explant tissue processing, fresh liver or colon 
samples were cut into 1 cm
3
 cubes and either ‗snap frozen‘ in liquid nitrogen (stored 
at –80oC until time of application) or immersed in formal saline (4%; maximum 48 
hours) as preparation for paraffin embedding. 
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2.6.1 Frozen tissue 
Snap frozen tissue was embedded in TissueTek mount (Sakura, Netherlands) and 5 
m-thick sections cut using a Bright OTF cryostat (A-M systems, USA). Sections 
were then mounted on glass microscope slides (BDH, UK) coated in 0.01% Poly-L-
Lysine. Once mounted, sections were fixed in acetone (Thermo Fisher Scientific, 
UK), wrapped in foil and stored at - 20
o
C until use. Prior to staining, all slides were 
warmed to room temperature and bathed in acetone for 5 minutes.  
 
2.6.2 Paraffin embedded tissue 
5 m sections were cut from formalin-fixed paraffin embedded (FFPE) tissue blocks. 
Sections were deparaffinised and rehydrated by passing through fresh xylene (Leica, 
GmBH, Germany) and graded alcohols before undergoing heat-inactivated (slides 
immersed in pre-heated EDTA buffer – 0.37 g EDTA in 1 L distilled water (pH 6.0 – 
10.0) + 0.05% Tween20 and microwaving for 15 minutes) or proteinase K (Dako, 
UK) epitope retrieval.  
 
2.6.3 Chromogenic staining 
A wax pen (Dako) was used to draw around sections prior to staining. Targeted 
monoclonal antibodies and isotype-matched controls (IMC) used for 
immunohistochemical staining are summarised in Table 2.9. All incubation steps 
were conducted inside a humidified slide tray and at ambient temperature unless 
otherwise specified. First, sections were rehydrated in staining buffer (PBS + 0.1% 
Tween20) for 5 minutes. Endogenous peroxidase activity was then quenched (0.3% 
H2O2 in methanol, 5 minutes), followed by a subsequent buffer wash step (5 minutes). 
Sections were ‗blocked‘ with 2.5% horse serum (ImmPRESS kit, Vector labs, UK) 
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for 20 minutes, following which primary antibody was added at the appropriate 
concentration (diluted in staining buffer + horse serum) and left to incubate overnight 
(4
o
C) or 30 – 60 minutes (room temperature) depending on antibody. 
 
Next, slides were washed with staining buffer (x2) and incubated for 1 hour (room 
temperature) with the appropriate secondary antibody (ImmPRESS secondary, Vector 
labs, 2 – 4 drops of ready mixture per-section). Slides were then washed in staining 
buffer (5 minutes x 2) before addition of chromogenic detection agent as per 
manufacturers‘ instructions. The detection system was left in situ until desired 
staining intensity developed (<30 minutes), washed and slides fixed in mountant 
(DPX, Vector labs – unless otherwise specified) before being left to dry. Images were 
analysed on a Zeiss Axioscope microscope in conjunction with Axiovision software 
(Carl Zeiss, UK). Occasionally, sections were counterstained with Mayer‘s 
haematoxylin (~1 minute) and rinsed in tap water to allow blueing of cell nuclei prior 
to fixing in mountant.  
 
Assessment of staining was performed qualitatively via light microscopy and 
quantitatively using ImageJ software.  
 
2.6.4 Confocal immunofluorescence  
Sections were incubated with PBS + 0.3% Triton X-100 (Sigma) for 5 minutes at 
ambient temperature and thereafter in 10% goat serum (diluted in PBS + 0.1% Triton) 
for 10 minutes. Subsequently, primary antibody (Table 2.9) or IMC diluted in staining 
buffer (PBS/Triton) were incubated with tissue sections at the appropriate 
concentration (overnight, 4
o
C). Sections were washed (staining buffer x 2) followed 
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by addition of fluorescently tagged secondary antibodies (Table 2.10) (pre-
centrifuged at 14,000 x g to remove particulate matter, freshly diluted in staining 
buffer), incubated for 1 hour at room temperature. After another 3 wash steps, 
sections were mounted with ProLong Gold Anti-fade containing the nuclear stain 4‘, 
6-diamidino-2-phenylindole (DAPI, Life Technologies) and kept at 4
o
C protected 
from light until ready for visualisation. All sections were imaged by confocal 
microscopy on an LSM 510 microscope equipped with 63 x 1.32 objective. Images 
were acquired and analysed by LSM software. This was also used to create profiles of 
fluorescent intensity and enable graphical demonstration of overlapping fluorescent 
signals to confirm co-localisation. 
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Table 2.9: Primary antibodies for immunohistochemistry (human tissue) 
Antibody (supplier) Isotype (clone) Stock conc. Working dilution 
Mouse anti-VAP-1 
(BioTie) 
IgG2a 
(TK8-14) 
1 mg/mL 1/500 
Mouse anti-VAP-1 
(Hycult Biotech) 
IgG1 
(174-5) 
0.1 mg/mL 1/200 
Mouse anti-EpCAM 
(Progen) 
IgG1 
(HEA125) 
0.05 mg/mL 1/10 
Mouse anti-CD31 
(eBioscience) 
IgG1 
(WM59) 
0.5 mg/mL 1/400 
Mouse anti-MAdCAM-1 
(Serotec) 
1gG1 
(314G8) 
1 mg/mL 1/500 
Mouse anti-SMA 
(Sigma) 
IgG2a 
(1A4) 
2 mg/mL 1/400 
Mouse anti-CCL25 
(Peprotech) 
IgG1 
(1.2_4G1-1G4-1C9) 
1 mg/mL 1/50 – 1/200 
Mouse anti-CCL25 
(R&D systems) 
IgG1 
(52529) 
0.5 mg/mL 1/50 – 1/200 
Goat anti-CCL25 
(R&D systems) 
Polyclonal 
(Cat. # AF334) 
0.2 mg/mL 1/25 – 1/100 
IMC  
Mouse 
(Dako) 
IgG1 
(DAK-GO1) 
0.1 mg/mL Assay dependent 
Mouse 
(Dako) 
IgG2a 
(DAK-GO5) 
0.1 mg/mL Assay dependent 
Goat 
(R&D systems) 
Polyclonal 
(Cat. # AB-108-C)  
1 mg/mL Assay dependent 
 
 
Table 2.10: Secondary antibodies for immunofluorescence (human liver)  
Antibody (supplier) Target isotype Stock conc. Working dilution 
Goat anti-mouse AF488 
(Dako) 
IgG1 100 g/mL 1/500 
Goat anti-mouse AF546 
(Dako) 
IgG2a 100 g/mL 1/500 
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2.7 Tissue-specific SSAO activity 
Liver and colon tissue protein lysates (60 – 100 mg) were prepared essentially as 
indicated in section 2.4.1, with the exception of Dulbecco‘s PBS containing 0.2% 
Triton X-100 being used as the lysis buffer in order to preserve amine oxidase activity 
in tissue [320]. Protein lysate concentration was determined as described previously 
and samples were subsequently aliquoted and stored at –80oC until required. Prior to 
commencing the assay, samples were thawed and concentration standardised to 2 
mg/mL. 100 l of protein lysate was used per well and quantification of SSAO 
activity conducted as previously described (please see section 2.5.3). 
 
2.8 Evaluating substrate-dependent variations in enzyme kinetics 
Putative substrates of human VAP-1 were selected based on inclusion in the human 
metabolome database version 2.5 (http://www.hmdb.ca) and with reference to [Shen 
et al. 2012]; specifically cysteamine, methylamine, dopamine, ethylamine and 
phenethylamine (Sigma). Comparisons were drawn with kinetic rates observed using 
benzylamine as an internal standard. A 96-well flat-bottomed plate was loaded with 
50 ng recombinant (r)VAP-1 in 100 L Dulbecco‘s PBS. Increasing concentrations of 
test substrate were supplemented to test wells (three technical repeats) and H2O2 
standards were added in parallel as described previously (Figure 2.1). Enzyme activity 
was quantified using the Amplex-Red Ultra detection system and kinetic parameters 
estimated by Michaelis-Menten kinetics (please see Figure 2.2; Equation 2-2). 
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Equation 2-2: 
v ' = V max [S ]/Km + [S ]. 
Wherein: V max = k cat [E] o 
Figure 2.2: Michaelis-Menten kinetic modelling 
Substrate kinetic profiles were calculated as indicated by Equation 2-2; wherein The reaction rate 
increases with increasing substrate concentration, asymptotically approaching its maximum rate V max , 
attained when all enzyme is bound to substrate.  
 
[V max represents the maximum rate achieved by the enzyme system at saturating substrate 
concentrations; Km (Michaelis constant) the substrate concentration at which the reaction rate is half of 
V max; S is the concentration of substrate; and v ' the reaction rate. k cat, the turnover number, is the 
maximum number of substrate molecules converted to product per enzyme molecule per second; and 
[E]o the enzyme concentration]. 
 
 
2.8.1 Determining amine concentrations in human serum 
2.8.1.1 High-performance liquid chromatography (HPLC) 
Methylamine in human serum was quantified using fluorometric reverse-phase 
HPLC, using 9-fluorenylmethoxycarbonyl-chloride (FMOC, Table 2.11) as a 
derivatising reagent [340]. Serum samples (100 – 500 L) were homogenised in 1 mL 
5% acetic acid solution by gentle pipetting. 100 L of the resultant admixture was 
added to 600 L borate buffer (0.2 M, pH 10.4) containing 3 mL acetonitrile in a 
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glass test tube and vortexed to precipitate proteins. After full speed centrifugation 
(15,000 x g, 10 minutes), FMOC reagent (150 g in 100 L acetonitrile) was added to 
the supernatant. Methylamine standards at known concentration were also prepared in 
acidified 50% acetonitrile, and blank samples of serum and supernatant (no FMOC) in 
a similar manner.  
 
Acetonitrile underwent evaporation by flow of air (room temperature) using a fish-
pump and glass pastette with extraction of the resultant aqueous phase in 3.5 mL 
hexane. The hexane extract (containing methylamine) was dried under a flow of air at 
ambient conditions, and the residue dissolved in 250 L of acetonitrile solution (40% 
v/v). The mixture was transferred to a microfuge tube, centrifuged at full speed (and 
100 L of the resultant supernatant interrogated by analytical HPLC at a rate of 1 
sample/hour (Shimadzu HPLC system; Japan). Fluorescence of the derivatised 
product was detected at an emission wavelength of 630nm and an excitation 
wavelength of 254nm. 
 
Table 2.11: HPLC assay constituents 
Reagents Supplier 
Acetic acid  
Sigma 
Methylamine  
Acetonitrile  
Borate buffer (sodium tetraborate + boric acid) 
FMOC chloride  
Hexane  
Glass pipettes  Corning Costar 
Zebron B-5 HPLC column  
(Kinetic C18 column, 5 U, 250 x 4.6 mm) 
Phenomenex 
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2.8.1.2  SSAO deamination of serum-derived endogenous amine substrates 
In order to assess the putative contribution of VAP-1 substrates present in patient 
sera, a modified variation of the SSAO activity assay was conducted. In brief, a 96-
well flat-bottomed plate was loaded with 50l patient sera/well (± 250 M 
semicarbazide) in quadruplicate as indicated in Figure 2.1 without any exogenous 
substrate. In order to inhibit other circulating amine oxidases that may contribute to 
H2O2 production, inhibitors of MAO-A (100 M clorgyline) and MAO-B (100 M 
pargyline) were added to the serum samples and the final volume made to 100l with 
Dulbecco‘s PBS. The Amplex-Red Ultra detection system was subsequently 
employed to measure the evolution of H2O2 as described previously. 
 
2.9 Monitoring HSEC viability post amine exposure 
Prolonged, real-time image capture of HSEC was performed using a Cell-IQ system 
(CMTechnologies, Finland). A 24-well plate was coated with RTC (prepared as 
described previously) and left to dry overnight in a class II microflow cabinet. Pre-
isolated HSEC, grown to confluence in a 75cm
2
 flask were trypsinised, washed 
(PBS), pelleted and resuspended at 0.05 x 10
6
 cells/mL in complete HSEC media (see 
section 2.1.2.3). The RTC-coated plate was washed with PBS, and 1 mL cell 
suspension was then loaded into each well and left to adhere overnight at 37
o
C/5 % 
CO2. Once confluent, the supernatant of each well was removed and substituted with 
media containing amines of interest ± TNF (20 ng/mL, Peprotech, UK) at increasing 
concentrations (Table 2.12).  
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The inter-well spaces were filled with 1 mL sterile PBS (to maintain humidity) and 
the plate sealed with Cell-IQ well-plate lids (pre-warmed to 37
o
C) and black electrical 
tape. These specialised lids facilitate efficient sterile gas exchange (5% CO2 in air), 
and permit phase-contrast imaging of cells within the plate. The sealed plates were 
then inserted into the Cell-IQ, and output/input connectors and filter attached. The 
Cell-IQ software was set to record cell images every 5 minutes for 24 hours at 4 
different positions per-well (temperature set to 37
o
C). Thereafter, images were 
analysed offline to assess cell viability (Analyzer software, CMTechnologies). 
 
 
Table 2.12: Substrates tested in HSEC viability assay 
Amine Concentration range tested 
Benzylamine 20-640 M 
Cysteamine 5-400 M 
Dopamine 12.5-400 M 
Ethylamine 100-4000 M 
Methylamine 50-2000 M 
Phenethylamine 100-4000 M 
 
 
2.10 Flow-based adhesion assays 
2.10.1 Microslide preparation 
Flow-adhesion assays were conducted to assess the functional consequences of amine 
exposure and VAP-1 inhibition on HSEC-mediated lymphocyte recruitment. Six 
channel, flow-chamber Ibidi microslides (Figure 2.3) were RTC-coated and left to dry 
for a minimum of 4 hours, followed by 1 wash with endothelial SFM and 2 washes of 
PBS. Pre-isolated HSEC, grown to confluence in a 75 cm
2
 flask were trypsinised, 
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washed (PBS), pelleted and resuspended at 1.5 x 10
6
 cells/mL in complete HSEC 
media (section 2.1.2.3). Cell suspension (60µL) was injected into each slide channel 
and cells left to adhere (humidified incubator, 37°C, 5% CO2) on a slide rack. After 2 
hours, a media change was conducted and cells incubated under humidified 
conditions overnight. The following day, HSEC were stimulated with TNFα (20 
ng/mL; Peprotech) ± amine substrate supplemented HSEC media for four hours to 
induce MAdCAM-1 expression [294]. In order to minimise the effect of bovine VAP-
1, low serum endothelial media (2% FBS; no HGF/VEGF) was used during this step.  
 
2.10.2 Preparing the JY-cell line 
The JY cell line expressing α4β7 integrin was cultured in lymphocyte media and 
maintained in suspension (~1-1.5 x10
6
 cells) in 75 cm
2
 flasks. Prior to the flow-based 
adhesion assay, JY cells were centrifuged at 600x g for 5 minutes. The pellet was 
resuspended in 1 mL RPMI + 10% FBS and a small aliquot removed for viability 
assessment and quantification by Trypan blue exclusion. After counting, the 
remaining cells were pelleted and resuspended at 1 – 2 x 106 cells/mL in basal 
endothelial media (serum free) containing 0.1% BSA. 
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Figure 2.3: Flow adhesion assay  
The flow-adhesion assay setup consists of a 6-lane microslide (Ibidi, Germany) (A) placed directly on 
the microscope stage. A transparent chamber (not shown) is mounted on an inverted microscope and 
maintained at 37°C. Ports connect silicone tubing from one side of the microslide ports (outlet) to a 
syringe pump set to a specific withdrawal rate (B). An electronic solenoid valve allows switching 
between two syringe barrels containing either cells or media with no dead space. Silicone tubing from 
the valve connects to ports on the other side of the slide (inlet). An external monitor connected to a 
DVD-recorder was attached to the microscope in order to facilitate live image capture and offline 
analysis [341]. 
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2.10.3 Preparation of FAC-sorted peripheral blood lymphocytes (PBL) 
To obtain purified cell populations of interest, antibody-labelled (Table 2.2) 
peripheral blood lymphocytes were sorted using a MoFlo XDP High-Speed Cell 
Sorter (Beckman Coulter Inc.) in purity mode. Sorted lymphocytes were incubated 
overnight in a 48-well culture plate (Corning Costar) in lymphocyte media to allow 
their surface markers to recycle. The following day, cells were centrifuged, pelleted, 
and viability confirmed before being resuspended to 10
6
 cells/mL in basal endothelial 
media (serum free) containing 0.1% BSA. 
 
2.10.4 Evaluation of anti-VAP-1 antibody and enzyme inhibitors  
In order to test the functional significance of VAP-1 blockade on 7/MAdCAM-1 
dependent lymphocyte adhesion, the enzyme inhibitor semicarbazide (250 M; a 
concentration previously demonstrated to effectively induce enzyme inhibition yet 
preserve cellular viability [312]), and the anti-VAP-1 antibody TK8-14 (10 g/mL) 
were employed. In brief, enzyme inhibitor or antibody was added to HSEC at the 
same time as TNF and methylamine stimulation and HSEC were washed following 
1 hour incubation. This was followed by 3 further hours of stimulation with TNF 
and substrate and a further wash with media (x2) prior to running the assay. 
 
2.10.5 The assay 
Prior to initiating the experiment, the flow assay chamber was warmed to 37°C. A 50 
mL glass syringe was prefilled with 10 mL sterile distilled water and attached to 
silicone tubing and a syringe pump. The withdrawal rate of the pump was adjusted to 
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mimic that of low shear within the sinusoids of the human liver (0.05 Pa). The barrels 
of two 5 mL syringes were attached to in-flow ports of the flow-chamber electronic 
solenoid valve using silicone tubing. Another piece of tubing was attached to the out-
flow valve, which permits alternation between cell free wash buffer (serum-free, basal 
endothelial media + 0.1% (v/v) BSA) contained in one syringe barrel and lymphocyte 
suspension within the other.  
 
After treatment of the endothelial monolayer, the microslide was washed and fresh, 
ultra-low serum (0.5% FBS) media provided to each channel. Microslides were then 
placed on the stage of a thermostatically controlled video-microscope within the flow 
chamber. The silicone tubing from the syringe pump was connected to one port of a 
chosen microslide channel via a microslide adaptor, and silicone tubing from the 
outflow valve to the opposite port in a similar manner. JY or FAC-sorted cells were 
perfused over the endothelial monolayers at a constant shear stress for 5 minutes, then 
wash buffer was perfused over for 3 minutes and lymphocyte adhesion subsequently 
recorded to DVD over a 2 minute period. Adherent lymphocytes captured via 
molecular interactions with functionally expressed adhesion molecules by stimulated 
HSEC were visualised by phase contrast microscopy (x10 magnification). 
 
2.10.6 Analysis   
A minimum of 10 fields per-treatment condition were viewed offline for analysis. 
Total adhesion (and subsequent migration) were determined by counting all visible 
adherent and migrated cells in a number of fields of known dimension, then converted 
to give a value of adhesion/mm
2
, normalised according to the number of cells 
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perfused (Equation 2-3). Adhesion and migration are expressed as cells/mm
2
/10
6
 cells 
perfused, unless otherwise indicated.  
 
Equation 2-3: Quantifying proportion of cells undergoing adhesion 
A’ = a’ / (f x b x s) x (1/c)  
[A‘ represents the normalised adherent cell number, a‘ the average number of adherent cells per-field, f 
being the flow rate (mL/min), b indicative of flow bolus (mL), s signifying the surface area (mm
2
), and 
c the cell density (10
6
)]. 
 
2.11 Cell-based ELISA 
The expression of adhesion molecules on primary cell cultures was investigated by 
ELISA of cultured HSEC. Cells were cultured and stimulated as described in section 
2.10.1 before being fixed in 100% ice-cold methanol (Fisher Scientific) for 5 minutes 
and subsequently washed with PBS. Thereafter, cells were incubated with 2% normal 
goat serum (Sigma) for 45 minutes at room temperature (continuous shaking) to 
reduce non-specific antibody binding. The wells were washed twice with wash buffer 
(PBS + 0.1% BSA), following which primary antibody (Table 2.13) or IMC diluted in 
PBS were added and incubated with the cells for 45 minutes with continuous shaking. 
Following two further washes, cells were incubated with a relevant secondary 
antibody conjugated to HRP (diluted in PBS) for 45 minutes. Cells were then washed 
a further three times before development of the peroxidase enzyme conjugate using an 
OPD-based substrate (1,2-phenylenediamine dihydrochloride in tablet form; Dako) in 
accordance with manufacturer‘s instructions. Colour development was allowed to 
continue for up to 10 minutes before being stopped by addition of 0.5 M sulphuric 
acid (H2SO4; Fisher Scientific). Absorbance at 490nm was measured on an automated 
plate reader. Background absorbance was corrected by subtracting absorbance values 
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of an IMC antibody (Dako) and mean absorbance values calculated from readings of 
three technical repeats.  
 
Table 2.13: Antibodies used in HSEC-ELISA 
Antibody (supplier) Isotype (clone) Final concentration 
Mouse anti-ICAM-1 
(R&D systems) 
IgG1 
(14C11) 
5g/mL 
Mouse anti-VCAM-1 
(R&D systems) 
IgG1  
(HAE-2Z) 
5g/mL 
Mouse anti-CD31 
(eBioscience) 
IgG1 
(WM59) 
5g/mL 
Mouse anti-MAdCAM-1 
(AbD Serotec, UK) 
IgG1  
(314G8) 
5g/mL 
VE-Cadherin 
(Novus Biologicals) 
IgG1 
(MM0012-8A03) 
5g/mL 
Goat anti-mouse HRP 2
o
 (Dako) 
IgG (polyclonal) 
(Cat.# P0447) 
1/5000 dilution 
IMC (supplier)  
Mouse-IMC 
(R&D systems) 
IgG1  
(11711) 
5g/mL 
 
2.12 Mouse tissue 
2.12.1 Animal Husbandry 
Mdr2
–/–
 C57BL/6 mouse embryos (gifted from Professor Lohse; Austria) were 
transferred into the uterus of wild-type C57BL/6 females and stock derived from 
generation three (and beyond) offspring. For phenotyping, exclusively homozygotes 
were used so genotyping was not deemed necessary at this stage. Aoc3 point mutation 
knock-in mice lacking VAP-1 enzyme activity – were backcrossed onto a C57BL/6 
genetic background by genOway and supplied by a contract breeder (Charles River). 
Henceforth, this strain will be referred to as Ssao
–/–
. Mutant allele mice were crossed 
with Mdr2
–/–
 strains in order to establish Mdr2
–/– 
Ssao
–/–
 animals. Identification of 
homozygote double knockouts was conducted by qRT-PCR-based screening 
(Transnetyx, USA). 
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All animals were housed in accordance with established care protocols at the 
University of Birmingham, and subject to ethical approval in accordance with the UK 
Animals (Scientific Procedures) Act of 1986. 
 
2.12.2 Organ retrieval and preparation 
Longitudinal phenotypic assessment was performed on mice at 5–6, 11–12 and 22–24 
weeks (males and females). Blood samples were withdrawn by cardiac puncture 
during isofluorane anaesthesia, and mice consequently sacrificed by cervical 
dislocation. Previous investigators have reported that significant morphological, 
physiological, and structural differences exist between individual liver lobes affected 
with cholangiopathic injury, including the degree of ductular reaction, size of bile 
ducts and degree of fibrosis [342]. In this regard, a recent consensus statement has 
proposed a standardised work-up for mouse liver tissue. This technique was adapted 
and modified to permit quantification of liver-infiltrating leucocyte populations (flow 
cytometry) as well as assessment of intrahepatic VAP-1 enzyme activity (Figure 2.4). 
 
2.12.3 Extraction of lymphocytes from mouse liver and flow cytometry 
The appropriate liver lobe was homogenised (C-tube, GentleMACs) and the resultant 
suspension diluted to a minimum volume of 50 mL with RPMI. The entire cell 
suspension was passed through a cell strainer (70 m) and centrifuged at 3000 x g (3 
minutes). The sample was washed in media (x2) and resuspended in MACS buffer 
prior to cell labelling (Table 2.14) and flow cytometric analysis (detailed in section 
2.2). 
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Figure 2.4: Mouse liver preparation and processing 
Liver lobes are numbered consecutively according to size from 1-7. Lobe 1 was divided further into 2 
segments (1a and 1b; snap frozen and formalin fixation, respectively). Lobe 2 was placed in RPMI 
and processed for flow cytometry and 3 (attached to the gallbladder, GB) snap frozen for 
hydroxyproline assays. The remainder were snap frozen and kept for protein (lobes 4 and 5) and RNA 
(lobes 6 and 7) extraction [342]. VAP-1 enzyme activity was assessed using protein lysates derived 
from the appropriate lobes. 
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Table 2.14: Antibodies for flow cytometry (mouse tissue) 
Antibody (supplier) Isotype (clone) Stock conc. 
Working vol.  
(L / 105 cells) 
Rat anti-CD45 PerCPCy5.5 
(BioLegend
®
) 
IgG2b  
(30-F11) 
0.2 mg/mL 5 
Rat anti-CD45 BV510 
(BioLegend
®
) 
IgG2b 
(30-F11) 
0.06 mg/mL 10 
Rat anti-CD45 PE 
(BioLegend
®
) 
IgG2b 
(30-F11) 
0.2 mg/mL 5 
Rat anti-CD45 APC 
(BioLegend
®
) 
IgG2b 
(30-F11) 
0.2 mg/mL 2 
Rat anti-CD45 PB  
(BioLegend
®
) 
IgG2b  
(30-F11) 
0.5 mg/mL 5 
Rat anti-CD45 FITC 
(BioLegend
®
) 
IgG2b 
(30-F11) 
0.5 mg/mL 5 
Rat anti-CD3 BV510 
(BioLegend
®
) 
IgG2b 
(17A2) 
0.1 mg/mL 5 
Rat anti-CD4 PE 
(BD Bioscience) 
IgG2a 
(RM4-5) 
0.2 mg/mL 5 
Rat anti-CD8a APC 
(BD Bioscience) 
IgG2a 
(53-6-7) 
0.2 mg/mL 2 
Rat anti-CD19 Pac. Blue 
(BioLegend
®
) 
IgG2a 
(6D5) 
0.5 mg/mL 5 
Rat anti-CD49b FITC 
(BD Bioscience) 
IgM 
(DX5) 
0.5 mg/mL 5 
Rat anti CD11b FITC 
(BD Bioscience) 
IgG2b 
(M1/70) 
0.5 mg/mL 5 
Rat anti-F4/80 APC 
(eBioscience) 
IgG2a 
(BM8) 
0.2 mg/mL 2 
Rat anti-Gr1 PE 
(BD Pharmingen) 
IgG2b 
(RB6-8C5) 
0.2 mg/mL 5 
IMC  
Rat-PerCPCy5.5 
(BioLegend
®
) 
IgG2b 
(RTK4530) 
0.2 mg/mL 5 
Rat-BV510 
(BioLegend
®
) 
IgG2b 
(RTK4530) 
0.05 mg/mL 10 
Rat-PE 
(BD Bioscience) 
IgG2a 
(R35-95) 
0.2 mg/mL 5 
Rat-APC 
(BD Pharmingen) 
IgG2a 
(RTK2758) 
0.2 mg/mL 2 
Rat-Pac. Blue 
(BioLegend
®
) 
IgG2a 
(eB149) 
0.5 mg/mL 5 
Rat-FITC 
(BD Bioscience) 
IgM 
(R4-22) 
0.5 mg/mL 5 
Rat-FITC 
(eBioscience) 
IgG2b 
(eB149/10H5) 
0.5 mg/mL 5 
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2.12.4 Immunohistochemistry 
Staining protocols were common to that used in section 2.6.3 unless otherwise stated. 
Primary antibodies are listed in Table 2.15. 
 
Table 2.15: Antibodies for immunohistochemistry (mouse tissue) 
Antibody (supplier) Isotype (clone) Stock Working dilution 
Rat anti-CD45 
(eBioscience, UK) 
IgG2b (30-F11) 0.5 mg/mL 1/400 
Rabbit anti-CK19 
(Abcam, UK) 
IgG (polyclonal) 0.2 mg/mL 1/100 
Mouse anti-SMA 
(Sigma) 
IgG2a (1A4) 2 mg/mL 1/400 
IMC   
Rat IMC  
(AbD Serotec) 
IgG2b (MCA1125) 1 mg/mL 1/800 
Rabbit IMC 
(Abcam) 
IgG (polyclonal) 0.2 mg/mL 1/100 
Mouse IMC 
(eBioscience) 
IgG2a (20102) 0.5 mg/mL 1/100 
 
2.12.4.1 Mouse-on-mouse staining  
Immunodetection of SMA in mouse was performed on frozen sections of 0.7 m 
thickness using the Vector mouse-on-mouse (M.O.M) kit as per manufacturer‘s 
instructions (M.OM Elite Peroxidase Kit, Vector labs, UK). Novared (Vector labs) 
was utilised as a chromogen. Briefly, endogenous peroxidase activity was blocked 
and sections washed in Tris-buffered saline (TBS) before undergoing an avidin/biotin 
blocking step (Vector). Sections were further blocked for 1 hour in working solution 
of M.O.M mouse Ig blocking reagent, then washed and incubated with M.O.M diluent 
for 5 minutes. Excess diluent was then decanted and sections incubated with primary 
antibody for 60 minutes. Thereafter working solution of M.O.M biotinylated anti-
mouse IgG reagent (10 L stock; 2.5 mL M.O.M diluent) was incubated with slides 
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for 10 minutes, the slides were then washed and exposed to Vectastain Elite ABC 
reagent for 5 minutes. Sections were then washed prior to addition of peroxidase 
substrate solution (Novared – Vector labs). Finally, samples were washed and fixed in 
mountant (DPX). Quantitative analysis of staining was performed using ImageJ 
software.  
 
2.12.4.2 Sirius red staining 
Snap frozen or deparaffinised liver sections were rinsed in distilled water and covered 
in 0.5% phosphomolybolic acid (Sigma) for 5 minutes. Slides were then placed into a 
rocking glass bath containing 0.1% Sirius Red (Direct Red 80 in saturated picric acid 
– 1.3% aqueous solution; Sigma) for 30 minutes. Thereafter, sections were dipped 
sequentially in 0.1 M HCl, distilled water, graded alcohols and clearene, before 
mounting in DPX. Occasionally, a haematoxylin counterstain step was employed 
prior to dehydration. Quantitative analysis of staining was performed using ImageJ 
software.  
 
2.12.5 Hydroxyproline assay 
Liver tissue (50 – 100 mg) was manually homogenised in 1 mL ddH2O. Thereafter, 
125l 50% tricholoroacetic acid (Sigma) was added and samples incubated on ice for 
30 minutes. Samples were subsequently centrifuged for 5 minutes (15000 x g) in 
order to precipitate protein following which 500 L 6 N HCl (Sigma) was added to 
the pellet. Samples were transferred to 12 x 100 mm borosilicate glass tubes 
(Corning) and heated overnight to 120
o
C (oven). Acid was then allowed to evaporate 
over 48 hours (70 – 80oC) before resuspending the precipitate in 500 L distilled 
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water and vortexing. Samples were filtered and 50 L transferred to another glass 
tube. Volumes were made up to 1000 L with distilled water + 500l chloramine T 
(Table 2.16) and samples incubated at room temperature for 20 minutes. 
Subsequently, 500 L Ehrlich‘s solution was added to the samples, the admixture 
vortexed and then incubated at 65
o
C for 15 minutes. Samples were cooled (left to 
stand for 10 minutes) to room temperature and 200 L of each sample transferred to a 
96-well flat-bottomed plate. The optical density of each sample was read at 561nm 
versus hydroxyproline standards (trans-4-Hydroxy-L-proline (Sigma) prepared in 
0.001N HCl in ddH2O and reacted with Erlich‘s solution as described above). All 
samples and standards were run in triplicate and normalised to starting weight. 
 
Table 2.16: Hydroxyproline assay constituents (Sigma) 
Chloramine-T solution 
1) Buffer 
 25 g citric acid monohydrate   
 6.0 mL glacial acetic acid 
 60 g sodium acetate trihydrate 
 17 g sodium chloride  
Dissolved in water and brought up to 500 mL; thereafter added to 100 mL water containing 150 
mL n-propanol (pH 6.0) 
2) 1.75 g chloramine-T (sodium N-chloro-p-toluenesulfonamide) dissolved in 10 mL water, 10 
mL n-propanol and 80 mL buffer. 
Ehrlich solution (p-dimethylaminobenzaldehyde perchloric acid) 
7.5 g p-dimethylaminobenzaldehyde dissolved in 30 mL n-propanol in 50 mL flask, added to 13 
mL 60% perchloric acid slowly and made up to 50 mL with n-propanol (stored in dark). 
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2.12.6 qRT-PCR in mouse liver 
Quantitative PCR was performed on cDNA prepared as described in section 2.3.1. 
Probes and primers tested are listed in Table 2.17 and were purchased from 
Taqman®. 
 
 
Table 2.17: Primers/probes – qRT-PCR (mouse) 
 Primer/Probe assay ID 
SMA (Acta2) Mm01546133_m1 
Col11 (Col1a1) Mm00483387_m1 
VAP-1 (Aoc3) Mm00839624_m1 
18S (Rn18s) Mm04277571_s1 
 
2.12.7 Murine hepatic SSAO activity 
Murine intrahepatic VAP-1 enzyme activity was quantified using the Amplex-Red 
assay, method 2 (section 2.5.3.2). Different anti-mouse VAP-1 antibodies at several 
concentrations were tested with regard to protein capture capability (Table 2.18).  
 
As a positive control for murine VAP-1 enzyme activity, a 3T3 murine pre-adipocyte 
cell line was purchased from Sigma and differentiated toward adipocytes [295]. In 
brief, cells were grown to confluence in an RTC-coated 75 cm
2
 culture flask 
(DMEM/10% FBS/1% PSG), following which media was discarded and replaced 
with one inducing adipogenic differentiation (Table 2.1). Induction medium was 
substituted after 2 days with maintenance medium; changes of the latter occurring 
every 48 hours. Cells were inspected daily for morphology change and once 
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differentiation into adipocytes was apparent (typically 10 days), cells were lysed and 
protein extraction performed as described previously (section 2.7). 
 
 
Table 2.18: Murine anti-VAP-1 antibodies under investigation 
Antibody (supplier) Isotype (clone) Concentration range tested 
Rat anti-AOC3 
(University of Turku, Finland) 
IgG1 (7-106)  5–100 g/mL 
Rabbit anti-AOC3 
(University of Turku, Finland) 
IgG (polyclonal) 5-100 g/mL 
Rat anti-AOC3 
(BioTie) 
IgG1 (BTT1004) 
  
5-100 g/mL 
Goat anti-AOC3 
(Everest Biotech, USA) 
IgG (polyclonal) 5-100 g/mL 
 
2.13 Graphical representation and statistical analysis 
The distribution of continuous variables was assessed via the Kolmogorov-Smirnov 
method. Non-parametric data are presented using the median and interquartile range 
(IQR) unless otherwise specified. The Mann-Whitney (MW) test was conducted when 
comparing between two independent groups, and analysis of variance through 
Kruskal-Wallis (KW) test and Bonferroni-Dunn post-hoc correction for multiple-
groups. Statistically significant differences between related groups were tested using 
the Wilcoxon-signed rank test or paired t-test (as indicated) for paired data, with post-
hoc Bonferroni-Dunn correction (>2 groups). Non-parametric measures of statistical 
dependence between two continuous variables were conducted using Spearman‘s rank 
correlation coefficient. 
 
2.14 Population statistics and survival impact 
In longitudinal follow-up studies the primary endpoint was defined as liver 
transplantation or death; patients without a clinical event in this regard being censored 
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at time of last clinic follow up. The impact of continuous variables on clinical 
endpoints was evaluated by receiver operator (ROC) curve analysis, and where 
indicated an optimal cut-point for downstream polychotomisation selected therein. 
Univariate and multivariable Cox proportional hazards models were also fit in order 
to assess the impact of individual covariates on the instantaneous rate of events, with 
time-to-event analysis also being ascertained through Kaplan-Meier estimates. All 
analyses and graphical representations were conducted using Prism v.5.0 (GraphPad 
Inc, USA) or SPSSv.21 (IBM, USA). 
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3 Results I: CCL25 and CCR9 expression in the human colon 
3.1 Introduction  
The expression pattern of adhesion molecules, chemokine receptors and their 
respective ligands determine which cell types are recruited to tissues under 
homeostasis and at times of inflammation. Expression of CCL25 is constitutive in the 
small bowel where it mediates recruitment and positioning of CCR9
+
 lymphocytes 
within the intraepithelial compartment and lamina propria [142]. Intestinal CCL25 
expression is up-regulated under pro-inflammatory conditions, and an increased 
frequency of peripheral blood CCR9
+
 lymphocytes can also be detected in patients 
with active small intestinal Crohn‘s disease [343].  
 
The vast majority of patients with PSC have coexisting IBD [254] and it has been 
hypothesised that aberrant endothelial expression of CCL25 on peri-portal sinusoids 
facilitates recruitment of gut-primed CCR9
+
 lymphocytes bearing an effector memory 
phenotype; which, upon exposure to an as yet unidentified trigger can reactivate and 
initiate a pro-inflammatory response, driving hepatobiliary inflammation [127]. 
Despite the distribution of intestinal involvement in PSC being predominantly 
colonic, activity of the CCR9-CCL25 axis within the gut mucosa is largely restricted 
to the small bowel, with little expression being detected in the human or murine large 
bowel [142,145,148,343,344]. However, previous analyses of intestinal CCR9
+
 
lymphocyte populations have largely focussed on the murine setting [345], and the 
few in human studies were either performed on cells extracted from MLN and left in 
culture [343], lymphocytes extracted from non-inflamed colon (NC), or peripheral 
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blood of patients with colitis [142]. Moreover, reports of CCL25 expression are 
heavily reliant on semi-quantative measures and direct visualisation with 
immunohistochemistry and in situ hybridisation (ISH), again utilising non-inflamed 
human colonic tissue as study material [123,142]. As such, there is a dearth of studies 
directed at elucidating chemokine-chemokine receptor expression in human patients 
with active colitis. 
 
This chapter provides evidence for the selective enrichment of intestinal CCR9
+
 T-
cells in colitis when compared to tissue-infiltrating lymphocytes obtained from NC. 
Moreover, a systematic approach analysing CCL25 expression across varying degrees 
of colonic inflammatory activity is presented. 
 
3.2 Findings 
3.2.1 CCR9 expression by tissue-infiltrating lymphocytes in small vs. large bowel 
As a positive control for studying CCR9 expression, intestinal lymphocytes were 
isolated from the most distal portion of small bowel (terminal ileum), obtained from 
patients undergoing surgical resection for refractory colitis (pan-colectomy; n=3) or 
right-sided colon cancer (subtotal colectomy; n=2). Tissue-infiltrating leucocytes 
were isolated as described in Chapter 2. The frequency of CCR9+ lymphocytes was 
examined by flow cytometry, in which the total lymphocyte population cloud was 
subject to gating on the live CD3+ population of cells, and subsequently gated on 
expression of co-receptors. In this regard, a similar proportion of small bowel derived 
CD4+ and CD8+ T-cells were CCR9 positive (mean 62.4%, standard deviation (SD) 
± 19.7% vs. 68.2 ± 12.4%, respectively; p = n.s., MW-test). Fluorescence minus one 
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(FMO) controls were used in 2/5 experiments to determine the specificity of the 
staining for CCR9 (Figure 3.1). 
 
Next, intestinal lymphocytes were isolated from the colonic resection specimens of 
patients undergoing surgery for non-IBD associated cancer (n=5; n=3 from 
descending colon/rectum and n=2 from ascending), and the distal-to-tumour segment 
exploited for studying lymphocyte populations in the absence of colonic inflammation 
(confirmed by a histopathologist with expertise in IBD). In contrast to the terminal 
ileum, only a small number of tissue-infiltrating CD4
+
 and CD8
+
 T-cells were 
observed to express CCR9 in non-inflamed colon (mean 5.7 ± 0.5% vs. 4.9 ± 2.4%, 
respectively; p = n.s, MW-test, Figure 3.2). 
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Figure 3.1: CCR9 expression on lymphocytes isolated from small bowel 
The standard flow cytometry gating strategy to identify tissue-infiltrating lymphocyte populations is illustrated in 
(A): forward and side light scatter (FS and SS, respectively) and cell surface expression of CD3 with absence of 
dead cell staining defined live lymphocytes. Of this population, T-lymphocytes were sub-divided into CD4
+
 and 
CD8
+
 cell populations. Over 50% of terminal ileum/small bowel (SB) CD4
+
 and CD8
+
 T-cells expressed CCR9, as 
illustrated by the representative flow cytometry plots in (B). A summary figure of percentage populations from 5 
independent samples is shown in (C), with data presented as mean + SD. 
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Figure 3.2: CCR9 expression on lymphocytes from non-inflamed large bowel 
CD3
+
 CD4
+
 and CD3
+
 CD8
+
 T-cells isolated from non-inflamed large bowel expressed low levels of CCR9. 
Representative flow cytometry plots shown in (A); and summary of percentage positive cells from 5 
indpendent samples shown in (B). Data presented as mean + SD. 
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3.2.2 T-cells express CCR9 in active colitis 
The next step was to determine whether CCR9
+
 T-cells are present in the colon under 
pro-inflammatory conditions. In a similar manner to that described above, resected 
tissue was excised from individuals with active ulcerative colitis refractory to medical 
therapy undergoing pan-colonic resection (n=6). The frequency of CD4
+
 T-cells 
expressing CCR9 in colitis (92.6 ± 4.1%) was higher than that reported under the non-
inflamed circumstance (Figure 3.3; p<0.001, MW-test). The proportion of CD8
+
 T-
cells expressing CCR9 was also greater in patients with UC than NC (34.3 ± 3.8%; p 
= 0.013, MW-test).  
 
Conventionally, the distribution of inflammation in UC begins in the rectum, 
spreading proximally in a continuous manner [346]. Microscopic inflammation may 
not be apparent on initial inspection leading me to examine the lymphocytic infiltrate 
in resected segments of colon reported as being quiescent by the receiving 
pathologist, but that which harbours active colitis histologically (on antecedent 
colonoscopy). In a limited number of patients manifesting such a phenotype (n=3), 
the proportion of CD4
+
 and CD8
+
 T-cells expressing CCR9 was more variable (69.8 ± 
22.6% and 17.5 ± 7.2%, respectively) reflecting the varying degrees of underlying 
inflammatory activity (Figure 3.4).  
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Figure 3.3: Intestinal CCR9 expression on lymphocytes in active ulcerative colitis 
Representative flow cytometry data plots (of n=6) of CCR9 expression by isolation CD4
+
 and CD8
+
 
lymphocytes (gated on live cells) (A). Summary of percentage positive cells from independent 
experiments shown in (B). Data presented as mean + SD. 
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Figure 3.4: Lymphocytic CCR9 expression in macroscopically quiescent colitis 
Representative flow cytometry data plots (of n=3) of CCR9 expression by isolation CD3
+
 CD4
+
 and CD3
+ 
CD8
+
 lymphocytes (gated on live cells) infiltrating the colon in areas with evidence of microscopic 
inflammation only (A). Summary of percentage positive cells from independent experiments shown in (B). 
Data presented as mean + SD. 
 
3.2.2.1 Greater numbers of CCR9+ T-cells infiltrate inflamed vs. non-inflamed colon 
The proportion of CD4
+
 and CD8
+
 T-cells expressing CCR9 was compared between 
small bowel, macroscopically active colitis, colitis with evidence of microscopic 
inflammation only and non-inflamed colon. Significant differences identified via the 
previous statistical tests were adjusted for multiple comparisons using the Bonferroni 
method (Figure 3.5). There were significantly fewer CD4
+
 and CD8
+
 T-cells 
expressing CCR9 in NC colon versus small bowel. Moreover, a significantly greater 
proportion of colonic CD4
+
 and CD8
+
 CCR9
+
 T-cells were present in patients with 
 158 
UC compared to NC. There was a trend towards a greater proportion of CD8
+
 T-cells 
expressing CCR9 in UC versus NC although this failed to reach statistical 
significance on post-hoc testing. 
 
 
 
Figure 3.5: CCR9 expression in the intestine  
Frequencies of tissue-infiltrating lymphocytes expressing CCR9
+
 across the terminal ileum / small 
bowel (SB; n=5) and colon in patients with macroscopically active ulcerative colitis (UC; n=6), 
macroscopically quiescent colitis but with evidence of active inflammation microscopically ((n)UC; 
n=3), and those with non-inflamed colons as determined both macro- and microscopically (NC; n=5) 
are illustrated. Proportions represent the percentage of total CD3
+
 CD4
+
 CCR9
+
 (A) and CD3
+
 CD8
+
 
CCR9
+
 (B) cells. Data presented as mean + SD. Capped lines and asterisks indicate statistically 
comparisons between groups (p values) as per KW-test and Bonferroni-Dunn post-hoc correction. 
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The majority of CD4
+ 
CCR9
+
 T-cells were CD127
+
, with little or no expression of 
CD25. Collectively, these findings suggest that effector CCR9
+
 lymphocytes, but not 
regulatory T-cells (Treg), infiltrate the inflamed colon (Figure 3.6). 
 
 
 
Figure 3.6: Phenotype of CCR9
+
 T-cells 
Gated CD3
+
 CD4
+
 CCR9
+ 
T-cells in colitis were predominantly CD127-positive in keeping with an 
effector phenotype. 
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3.2.2.2 CCR9+T-cells infiltrate the inflamed colon in Crohn’s disease 
In contrast to UC, patients with Crohn‘s colitis can harbour discontinuous segments of 
disease, with areas of active inflammation interspersed with those that are truly 
quiescent (macroscopically and microscopically); so called ‗skip lesions‘ [347]. In 
this regard samples from patients with Crohn‘s colitis (n=2) undergoing resection for 
an inflammatory colonic stricture were evaluated. In both the cases, two pieces from 
the area of active inflammatory stricturing were studied, together with the 
neighbouring segments of quiescent disease either side, analysed as a composite 
sample. Approximately 90% of CD4
+
 and 30% of CD8
+
 T-cells infiltrating inflamed 
colon in an inflammatory stricture were CCR9 positive, as opposed to ~20% and 
~3%, respectively in areas of quiescent inflammation (Figure 3.7). 
 
 
Figure 3.7: CCR9
+
 expression in colonic Crohn’s disease 
Data presented for CCR9 expression on colon-infiltrating lymphocytes in quiescent vs. active Crohn‘s 
colitis segments from the same patient (A). FMO controls are indicated by the grey histograms (areas of 
inflammatory stricturing), and positively stained cells by the red histograms. Blue histograms indicate 
positively stained cell populations in paired samples of colon, without evidence of active colitis. 
Summary data for percentage CCR9 expression on colon-infiltrating T-cells from the two patients 
undergoing surgical resection for Crohn‘s colitis are presented in (B), wherein black triangles represent 
areas of active inflammatory stricturing, and white triangles neighbouring areas of quiescent disease. 
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3.2.3 CCL25 gene expression in normal versus inflamed colon 
Having identified that an increased proportion of tissue-infiltrating T-cells express 
CCR9 in colitis relative to non-inflamed large bowel, I proceeded to ascertain whether 
its cognate ligand, CCL25, is also detectable within colon.  
 
3.2.3.1 Qualitative PCR 
Whole tissue total RNA extraction was performed from samples of NC (n=10), UC 
resection specimens (n=10) and small bowel (n=3). Following a reverse transcriptase 
step and targeted PCR with exon-exon junction spanning primers, agarose gel-
electrophoresis demonstrated cDNA products at the expected size for CCL25 in small 
bowel but not NC samples. Moreover, bands were detectable in samples of large 
bowel obtained from patients with refractory UC (Figure 3.).  
 
Figure 3.8: Detection of CCL25 gene expression in the human intestine 
Semi-quantative PCR was performed by a standard protocol. A representative agarose gel following PCR 
and cDNA electrophoresis of samples, obtained from normal/non-inflamed human colon (NC) and 
ulcerative colitis refractory to medical therapy (UC). Terminal ileum / small bowel (SB) was exploited as 
a qualitative positive control for CCL25 gene expression. Colonic samples from UC illustrate strongly 
positive signals at the expected amplicon size for the CCL25 gene (227bp) comparable to those seen in 
SB, with a relative absence in NC specimens. 
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3.2.3.2 Quantitative real-time PCR 
While semi-qualitative PCR assessment of gene-expression demonstrated the 
absence/presence of CCL25 in tissue samples conventional end point analysis was not 
sensitive enough to differentiate expression levels between samples. I used qRT-PCR 
as a more robust method of evaluating transcription particularly given the apparent 
low levels of CCL25 expressed in normal colon shown in Figure 3.9. Moreover, qRT-
PCR permits accurate quantification of target gene expression relative to 
housekeeping; an aspect not accurately performed through semi-quantitative methods.  
 
3.2.3.2.1 Selection of reference genes 
The MIQE guidelines advocate that when performing qRT-PCR normalisation against 
a single reference gene is not acceptable unless evidence is provided for its invariant 
expression [348]. As such, absolute quantification of two commonly applied 
housekeeping genes – 18S and GUS – was compared between NC and UC samples 
Their choice for study was largely based on previously published literature in the IBD 
and colorectal cancer field [349–351]. Although no significant differences in 
expression between NC and UC were identified for either gene (MW test), 18S 
exhibited a wider range of crossing point (Cp) variation between samples (Figure 
3.9). In contrast, the median Cp value of GUS was largely conserved in colonic 
tissue and therefore was selected as housekeeping gene of choice. 
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Figure 3.9: Assessment of reference genes in human colon 
Absolute quantification (crossing point) of reference genes across distinct non-inflamed colon (NC, 
squares) and ulcerative colitis (UC, triangles) samples. Both 18S and GUS illustrate conservation  
between NC (n=14) and UC (n=14) although the degree of variability was much less with the latter. 
 
3.2.3.2.2 Relative expression of chemokine expression 
Differences in CCL25 gene expression were analysed in triplicate relative to GUSB 
using exon-exon junction spanning primers. Median delta (Cp across all colitis 
specimens was 9.6-4 (2.0-4 – 3.2-3) and all amplification curves appeared below 40 
cycles. No amplicons were detected in any of the NC samples, despite a stepwise 
increase of starting cDNA quantity from 50 to 150ng. The duration of experiment was 
thereafter increased from 45 to 55 cycles without successful amplicon detection in NC 
specimens, and it was therefore deemed that CCL25 was not present these samples. In 
this context, calculation as fold CCL25 expression (relative to NC control samples for 
instance) was not possible. Therefore all results are henceforth calculated and 
presented as Cp relative to GUS 
 
3.2.3.2.3 CCL25 gene expression by colonic site 
After identifying CCL25 in patients with colitis (please see 3.2.3.2.2 above), I 
investigated variation with regard to site of tissue sampling, treatment regimen, 
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patient age or gender. Regarding the former, most surgical resection specimens 
interrogated in the above analysis were provided en bloc and therefore it was not 
possible to differentiate colonic tissue by site. Moreover, all surgical resections were 
conducted for UC refractory to medical therapy, and such patients had been exposed 
to immunosuppression. This led me to study mucosal biopsies from 37 patients with 
an established diagnosis of UC undergoing flexible sigmoidoscopy or colonoscopy as 
part of routine standard of care. Individual patient characteristics for this cohort are 
provided in Table 3.1. Even with this approach, there were relatively few specimens 
from the descending colon, transverse colon, ascending colon and caecum, therefore 
the latter 4 compartments were grouped and analysed together (D.T.A.C).  
 
Statistical analysis revealed no significant differences in CCL25 expression levels 
between biopsy site (KW test), or when grouping patients by concurrent use of 
immunosuppression (steroids, thiopurines, calcineurin inhibitors, biological therapy). 
No significant correlations were observed with patient age, although women 
expressed slightly higher CCL25 levels than men (Figure 3.10).  
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Table 3.1: Characteristics of patients undergoing colonoscopic/sigmoidoscopy 
Male; N (%) 22 (60) 
Median age (IQR)  38yrs. (26 – 46) 
Biopsy site; N (%)  
- rectum 13 (35) 
- sigmoid 16 (43) 
- descending colon 3 (8) 
- transverse colon 1 (3) 
- ascending colon 2 (5) 
- caecum 2 (5) 
Endoscopic mayo score; N (%)  
0 11 (30) 
1 11 (30) 
2 10 (27) 
3 5 (14) 
PSC; N (%) 3 (8) 
Immunosuppression; N (%)
*
 21 (57) 
 
 
Figure 3.8: qRT-PCR of colonic CCL25 gene expression in ulcerative colitis 
CCL25 gene expression provided relative to GUSThe degree of gene transcription did not vary according to 
(A) biopsy site; specifically, rectum, sigmoid or colon proper (grouped as distal, transverse, ascending and 
caecum – D.T.A.C.); (B) exposure to immunosuppression, I.S; or (C) patient age at time of biopsy. Women 
were seen to express slightly higher CCL25 levels than men (D). Asterisks indicate statistically significant 
differences (crude; unadjusted). 
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3.2.3.2.4 CCL25 gene expression and inflammatory activity. 
To assess whether CCL25 expression correlated with inflammatory status I compared 
transcript levels with severity of disease. There are many disease activity indices in 
ulcerative colitis but for the purposes of this study I selected the Mayo endoscopic 
severity score given its widespread use and adoption as an endpoint in UC clinical 
trials with regard to mucosal healing [352–354].  
 
Having demonstrated stability of GUS as a housekeeping gene in NC vs. UC 
samples, I proceeded to assess conservation across ordinal degrees of colitic activity 
(Figure 3.9). GUS demonstrated no significant variation with Mayo score (KW test p 
= n.s) and retained validity as a suitable housekeeping gene in this context. 
  
 
 
Figure 3.9: Validation of GUS as a reference gene across UC Mayo scores 
Absolute quantification (crossing point) of GUSβ with colitis‘ according to endoscopic Mayo scores 0 
(n=11), 1 (n=11), 2 (n=10) and 3 (n=5) illustrated stable conservation across disease stages. 
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CCL25 gene expression was examined in duplicates relative to GUS, and 
statistically significant associations with Mayo severity score were revealed (KW test 
p = 0.0015; Figure 3.10). Using Dunn‘s multiple comparison test, patients scoring 
Mayo 0 expressed significantly lower levels of CCL25 than those with a score of 2 or 
3 (p <0.01 and <0.05, respectively), although apparent differences between lower tiers 
of inflammatory activity (0 vs. 1) did not reach statistical significance. Similarly, 
there was a degree of overlap with respect to CCL25 levels in those with higher Mayo 
score.  
 
 
 
Figure 3.10: Colonic CCL25 gene expression according to inflammatory activity 
CCL25 expressed relative to GUS. Levels presented in relation to Endoscopic Mayo scoring (0 representing 
no inflammation and 3 severe inflammation). Capped lines and asterisks denote statistically significant results 
(KW test).  
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To obtain further information on the relationship between CCL25 expression and 
disease activity in the colon, I used TNF as an inflammatory marker, chosen in this 
context given associations with treatment response and disease relapse in UC 
[355,356] as well as the emergence as a sustainable therapeutic target in patients 
[353]. Statistical analysis by Spearman‘s rank coefficient revealed a significant and 
striking correlation between CCL25 and TNF gene expression (Figure 3.11); 
consistent with in vivo models wherein increased intestinal mucosal CCL25 
expression is observed following TNF injection [136]. 
 
Given the previous association between CCL25 expression and gender, a multiple 
logistic regression model was created. CCL25 expression (independent variable) was 
dichotomised at the median to yield high vs. low values, and patient gender and 
endoscopic Mayo score evaluated as independent, fixed covariates. On multivariable 
analysis, only Mayo score retained a statistically significant association with CCL25 
expression (p<0.0001), indicating gender as a confounding factor and representative 
of female patients in our cohort bearing a larger inflammatory burden. Indeed, this 
model held true on substituting Mayo score with TNF as a covariate. 
 
Because we detected increased numbers of CCR9
+
 lymphocytes in UC versus NC 
samples, I looked to see if there was a correlation between CCL25 and CCR9 gene 
expression. However, CCR9 gene expression only appeared in late cycles (median Cp 
41; IQR 39 – 43) and did not change upon increasing cDNA concentration, 
suggesting that receptor transcription occurs at a very low level; or that there are 
relatively few T-cells compared to other cell populations. 
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Figure 3.11: Correlation between colonic CCL25 and TNF expression in UC 
Good correlation was observed between CCL25 and TNF gene expression in colitis (data expressed 
relative to GUS). Spearman‘s rank correlation coefficient was selected over Pearson‘s given that the 
scatter of CCL25 values did not conform to a Gaussian distribution.  
 
 
3.2.4 CCL25 expression at the protein level by western blotting 
The presence of CCl25 gene transcripts in the colon of patients with UC may not 
necessarily translate to increased protein. To address this issue, protein lysates were 
made from the bowel resection specimens (described in Section 3.2.3.1) and CCL25 
quantified using western blots. Colonic protein lysates were run in parallel to that 
derived from small bowel as a positive control and recombinant human CCL25 
(rCCL25) (Figure 3.12). 
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Figure 3.12: Western blot for CCL25 
Representative western blot probing for CCL25 in a colonic protein lysate derived from a patient with 
ulcerative colitis (UC). Small bowel (SB) sample from the same patient run in parallel. Additional 
positive control provided by recombinant (r)CCL25. Using a standard protocol resulted in bands that 
can be deemed positive albeit multimeric variants of protein, but also not-specific ‗smears‘ which 
precluded effective interpretation. 
 
 
A notable technical issue was the degree of protein self-association, resulting in 
appearance of multiple bands of various sizes and ‗smearing‘ on the film. Thus, 
positive protein bands could not be discerned from those that were non-specific, such 
as those ~100 kDa. To overcome this issue, 8 M urea was used as a chaotrope in the 
sample buffer to destabilise hydrophobic bonds and increased protein solubility 
[349,357]. However, this did not result in appearance of any bands which could be 
deemed specific for CCL25.  
 
Chemokines in biological samples are often found at very low levels in tissue and 
their propensity to multimerise is well described [339]. Therefore a prior 
immunoprecipitation step was adopted in order to enrich and purify the protein from 
tissue lysates. The IP step used a polyclonal goat antibody raised against human 
CCL25 for pull-down, with mouse monoclonal anti-hCCL25 for detection. This 
approach resulted in successful enrichment of colitis tissue for protein at the expected 
size for a CCL25 dimer (~28 kDa); supported by a similar appearance using small 
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bowel lysates, as well as purified rCCL25 protein not subject to immunoprecipitation 
(Figure 3.13). An additional albeit distinct band size was also detected at ~56 kDa, 
possibly corresponding to a persistent tetrameric variant of human CCL25. Little 
expression was detected in NC and maximum film exposure time (30 minutes) was 
required for visualisation of even faint CCL25 signals and in some cases CCL25 was 
absent (2/6 NC samples). As expected, no bands were detected in the cleared lysate 
when probing for CCL25 (rCCL25 run simultaneously as positive control). 
 
The total band densities (monomers + multimers per sample) were quantified relative 
to a housekeeping protein using ImageJ software as indicated in Chapter 2, and 
differences between NC and UC were tested for statistical significant (MW test). To 
take into account the use of immunoprecipitation to extract CCL25 prior to gel 
loading, unbound housekeeping protein was assessed in the matched, cleared lysate 
remnant. -actin was selected as a reference based on prior evidence of stability 
between human large bowel specimens independent of inflammatory activity 
[358,359], although variation has been reported between colon and small bowel 
specimens. A statistically significant difference in CCL25 protein expression between 
UC and NC samples was evident (Figure 3.14). 
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Figure 3.13: Western blots for CCL25 – post immunoprecipitation (IP) 
Summary of western blots probing for CCL25 (post-IP samples and paired cleared lysates) and -actin 
(cleared lysate only). rCCL25 was run with the cleared lysate as an in-run positive control. All 
membranes probing for CCL25 were exposed between 0.5 minutes (sufficient for SB, n=3; UC, n=7; 
and rCCL25, n=1) with increasing intervals up to 30 minutes (in n=4/6 NC specimens) until bands were 
visible. Membranes corresponding to cleared lysate in which housekeeping protein was probed were 
exposed for no more than 60 seconds. Breaks in the image represent where samples were run non-
contiguously. 
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Figure 3.14: Relative CCL25 protein expression in NC and UC 
Semi-quantative analysis of CCL25 protein expression by ImageJ analysis. Results presented for the 
sum of weighted average of all multimer bands in a given sample (A), the upper, tetrameric band only 
(B) and lower, dimeric bands only (C). All values are expressed relative to housekeeping protein (-
actin) and normalised to a sample of NC that demonstrated a positive CCL25 band in the dimeric 
position. 2/6 NC samples did not exhibit any detectable bands and were not included in the analysis. 
Data presented as median and IQR. Capped lines and asterisks indicate statistical significance with the 
MW-test. 
 
 174 
3.2.5 Measurement of CCL25 concentration by ELISA 
To confirm these findings, CCL25 concentrations were quantified using a tissue-
lysate ELISA. CCL25 concentrations in tissue were significantly greater in UC than 
NC specimens, consistent with the findings using western blotting (Figure 3.15). 
 
 
 
Figure 3.15: CCL25 concentration in human colon by ELISA 
Quantitative measurement of CCL25 protein concentration in colonic tissue lysates pertaining to UC 
and NC. Plots representative of median and IQR; capped lines and asterisks indicate statistically 
significant differences (MW test).  
 
3.2.6 Chemokine immunohistochemistry 
Next, attempts were made to locate the protein in tissue sections using 
immunohistochemical staining on SB frozen tissue sections (positive control); 
however, no staining was observed despite antibody titration (1:25 – 1:200) of three 
separate antibodies (detailed in Chapter 2). As a consequence, subsequent efforts 
focussed on identifying CCL25 in FFPE sections, but this yielded no positive staining 
with either mouse monoclonal or rabbit polyclonal antibodies after standard heat–
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induced epitope retrieval across a range antibody titrations and varying pH citrate 
buffers (pH 6.0, pH 8.0 and pH 10.0 tested). This was unexpected given the positive 
results obtained by others staining in the human liver [127]. Papadakis et al. have 
previously reported successful staining in the small bowel using antibody clone 
LS202 5A9 (mouse IgG1 [123,343]); however, this product has now been 
discontinued and is no longer available.  
 
Further attempts were made using proteinase K antigen retrieval; however, any 
staining was non-specific in nature (mouse monoclonal IgG1, clone 1.2_4G-1G4-
1C9 with no differences with control antibody of matched isotype. On reducing the 
antibody concentration, staining of any description was no longer apparent. A senior 
pathologist reviewed all stained sections. As a result of persistently negative staining 
in the small bowel, immunohistochemistry in colitic material was not pursued further. 
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3.3 Discussion 
Recruitment of mucosal T-cells to the liver in response to aberrantly expressed 
homing signals has been proposed to drive hepatobiliary inflammation in primary 
sclerosing cholangitis. This is exemplified by the ‗gut-homing‘ chemokine CCL25, 
which recruits intestinal CCR9
+
 effector cells to the PSC liver. However, previous 
studies report CCL25 expression and CCR9
+
 lymphocytes as being confined to the 
small bowel whereas PSC is typically associated with colonic inflammation.  
 
The data presented herein illustrate enrichment of CCR9
+
 tissue-infiltrating 
lymphocytes in patients with colitis relative to non-inflamed colon. This population 
are predominantly CD3
+
 CD4
+
 T-cells, bear cell surface markers indicative of an 
activated effector phenotype, and are manifest in the context of active microscopic 
inflammation in the absence of macroscopic colitis. Quantitative real time PCR was 
performed using genetic material of standardised concentration, measured quality, 
intron-spanning primers and reference genes of proven stability between non-
inflamed colon and across varying degrees of inflammatory activity. Although CCR9 
gene expression was not evident within whole colonic mucosa, transcription of the 
ligand CCL25 was increased in UC versus NC and correlated with inflammatory 
burden. Associations between patient age, colonic biopsy site and medication regimen 
were not detected, although a greater degree of CCL25 expression was noted in 
women relative to men this was lost on multivariate evaluation, being outweighed by 
the effect of colonic inflammatory activity. Moreover CCL25 was detectable at the 
protein level by western blotting; results substantiated through tissue ELISA.  
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3.3.1 Enrichment of CCR9+ lymphocytes in colitis 
The priming of intestinal lymphocytes during activation endows specific trafficking 
properties through imprinting of adhesion molecules and chemokine receptors, thus 
directing migration to specific tissues and microenvironments [344,356,360,361]. 
Selective induction of T-cells by DC from MLN or Peyer‘s patches confer CCR9 
expression [57,296,362] which plays a critical role in recruitment through interactions 
with mucosal CCL25 [123,142,148,343]. Much evidence especially in mice suggests 
this applies only to SB and not to the colon. Early studies revealed CCR9 restricted to 
CD4
+
 and CD8
+
 lymphocytes infiltrating the intestine, wherein receptor expression 
was near universal (>90%) amongst IEL and LPL populations within the jejunum 
[142]. In contrast, relatively few (~25%) T-cells infiltrating the non-inflamed human 
colon were seen to be CCR9 positive, and a virtual absence of CCR9
+
 T-cells was 
illustrated at other sites including chronic hepatitis C virus (HCV) infected liver. 
Moreover, only SB-derived lymphocytes were seen to undergo chemotaxis towards 
CCL25 in transwell migration assays [123]. In a similar vein, works from the Mt. 
Sinai group demonstrated that >60% of CD4
+
 T-cells infiltrating the terminal ileum 
are CCR9
+
 under homeostatic conditions although relatively fewer (~30%) CD4
+ 
CCR9
+
 cells were detected during active Crohn‘s disease [343]; findings substantiated 
in murine models of small bowel inflammation [145]. The latter phenomenon was put 
down to preferential activation-induced cell death (AICD) following recruitment of 
CCR9
+
 lymphocytes to the inflamed SB mucosa, and subsequent cell isolation and in 
vitro culture techniques.  
 
Investigators in the field therefore suggest that few CCR9
+
 lymphocytes infiltrate the 
colon (144,343), a hypothesis stemming from three observations: the first relates to 
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cultured T-cells isolated from MLN in which ~5–10% of colonic CD3+ lymphocytes 
expressed CCR9 irrespective of inflammatory status; second, relatively fewer 
peripheral blood circulating CD4
+
 T-cells expressed CCR9 in patients with colonic 
versus small bowel Crohn‘s disease; and finally, qualitative assessment through 
northern blotting was unable to detect CCR9 mRNA in colonic tissue. The same 
group report that only a small proportion of CD3
+
 lymphocytes isolated from colonic 
mucosa express CCR9 [123], although only non-inflamed segments of the bowel were 
studied. Nevertheless, upregulation of CCR9 expression gauged by median 
fluorescence intensity (MFI) has been reported on subsets of CD3
+
 T-cells and CD14
+
 
monocytes in the peripheral circulation of a small number of UC patients [363,364]. 
Subpopulations of IL-17
+
 CCR9
+
  T-cells have also been described in 
extraintestinal inflammation [365], and a significant increase of circulating  T-cells 
in patients with UC (~20%) are seen to be CCR9
+
 compared with healthy volunteers 
(~4% [366]).  
 
I was able to replicate findings of prior studies with regard to CCR9
+
 T-cell frequency 
in the small bowel, although proportions in the non-inflamed human colon were lower 
than expected. However, a selective enrichment of CCR9
+
 lymphocytes, 
predominantly CD4
+
 T-cells, was observed in the context of active colonic 
inflammation as gauged by flow cytometry. These observations do not contradict 
results of prior investigators per se, but rather represent an exploration of tissue-
infiltrating populations obtained directly from active colitis as opposed to in vitro 
cultured MLN-derived T-cells, lymphocytes from peripheral blood or non-inflamed 
colon. That CCR9
+
 lymphocytes are detectable in aspects of the colon wherein only 
microscopic activity was evident implies that such an infiltrate develops early in the 
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inflammatory response. The Samp1/YitFc model of murine ileitis mirrors this 
observation, wherein numbers of small bowel CCR9
+ 
T-cells infiltrate early in the 
disease course [145]. A detailed immunohistochemical assessment of chemokine 
receptors in normal versus inflamed human colon supports these findings, 
demonstrating overexpression of CCR9 in inflamed areas of IBD relative to NC 
utilising the same antibody clone exploited herein for flow cytometry [367], although 
cell-type expression was not reported.  
 
Despite the detection of a CCR9
+
 T-cell infiltrate there was little suggestion of CCR9 
mRNA expression in the inflamed colonic mucosa (examined in toto) as assessed 
using qRT-PCR. Cell-sorted populations of T-cells would be required to 
comprehensively evaluate chemokine receptor transcription [349]; the absence of 
such evaluation representing a limitation to my work. Reports from China and 
Sweden demonstrated increased CCR9 gene expression in a limited number (n=10 
and n=3 respectively) of colonic biopsies obtained from patients with UC suggesting 
that further study is commanded. The capacity to imprint CCR9 on naïve T-cells was 
not the focus of this project, but as previously discussed (please see Chapter 1) this 
function is dependent upon generation of all-trans retinoic acid (ATRA), and largely 
restricted to APC harbouring intrinsic RALDH activity [368]. Human colonic biopsy 
supernatants have been shown to induce expression of gut-homing markers 7 and 
CCR9 as well as CD103 on co-cultured peripheral blood-derived DC [369]. CD103
+
 
DCs can imprint gut-tropism on T-cells where they predominantly induce a 
tolerogenic phenotype in both mice and humans [128,370–372], undergoing relative 
loss in patients with active colitis [373]. APC from the inflamed colon exhibit 
increased production of retinoic acid [374] and an ability to imprint CCR9 on 
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stimulated T-lymphocytes has not been discounted [373]. A recent study by Sanders 
et al. illustrate that percentage RALDH activity as assessed by the Aldefluor assay 
was significantly up-regulated in both inflamed small and large bowel-derived 
myeloid DC, as well CD103
+
 and CD103
-
 DC subtypes and CD14
+
 intestinal 
macrophages [374]. The capability of colon-derived APC to imprint T-cells with a 
gut-tropic phenotype therefore supports the existence of an intra-colonic CCR9
+
 T-
cell population in patients with active colitis.  
 
A growing body of data suggests that substrates for RALDH activity may originate 
from a pool of biliary retinoids delivered by the liver [126], and that HSEC also 
possess capacity to imprint 7 and CCR9, at least in mice [174]. Murine HSEC 
contain functionally active RALDH1 and RALDH4 isoforms and induce a gut-tropic 
phenotype on CD4
+
 T-cells to a similar degree as co-culture with MLN DC. 
Moreover, HSEC primed T-cells exhibit preferential recruitment to the intestine in 
migration studies [174]. These additional concepts of enterohepatic lymphocyte 
circulation, yet to be validated in humans, could plausibly explain the clinical 
coincidence of dual pathogenesis between gut and liver inflammation. 
 
3.3.1.1 Phenotyping 
Colon-infiltrating CCR9
+
 T-cells were predominantly CD4
+
 CD127
hi
 CD25
–
, and 
although an exhaustive assessment of cytokine profile or putative cell-surface 
functional markers was not conducted, this suggests an activated effector phenotype. 
The Mt. Sinai group report that only a few intestinal CCR9
+
 T-cells express CD25, 
co-stimulatory molecules OX40 and CTLA-4 (also a cell surface marker of Treg) and 
instead exhibit high expression of CD45RO and CD69 [144], consistent with 
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activated memory cells in the quiescent state. In contrast CCR9
+
 T-cells isolated from 
Crohn‘s disease patients conform to a Th1 and Th17 profile [123,144] suggesting a 
pro-inflammatory phenotype in IBD. In the PSC liver, a long-lived population of gut-
tropic memory CCR9
+
 T-cells are also activated effector cells as evidenced by 
secretion of IFN, although in this setting CCR9+ T-cells predominantly comprised a 
CD8
+
 (~60%) as opposed to CD4
+
 (35%) population [127]. 
 
3.3.2 Colonic CCL25 expression  
Having identified an increased frequency of CCR9
+
 lymphocytes in the large bowel 
of patients with colitis, I next investigated whether the ligand CCL25 would also be 
present. CCL25 is selectively expressed on murine and human small intestinal 
epithelial cells [142,375]; however, epithelial-expressed chemokines may diffuse to, 
and be presented on, vascular endothelium [144,376]. CCL25 is highly expressed at 
the genetic level in small intestine, as evidenced by early studies using northern and 
Southern blots [361,375,377] but not the colon. However, expression studies of 
CCL25 have largely examined the large bowel under non-inflammatory conditions. A 
parallel has been observed in murine settings, wherein Ccl25 gene expression 
assessed via qRT-PCR was detected in the small bowel of wild type mice 
[79,345,378] as well as the Samp1/YitFc model [145]. With regard to the latter, 
transcription was preserved in early and chronic stages of ileitis, but absent from the 
large bowel despite development of a caecitis in older age groups. Similar results are 
reported in the TNFARE model of SB Crohn‘s [146], Rag2-/- mice [147] and studies in 
higher order mammals such as pigs [379].  
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Expression of CCL25 transcripts is evident in murine colitis induced by dextran 
sulphate sodium, DSS [380,381], as well as oxazolone [382]. Moreover, a paper 
published earlier this year reported CCL25 mRNA expression in human colitis in a 
small number of patients (n=10) undergoing colonoscopy [382]. Similar claims stem 
from the Karolinska Institute in Sweden where qRT-PCR performed in 3 colonic 
biopsy samples showed CCL25 expression augmented with corticosteroid therapy 
[363]; however, it is unclear why only 3 specimens were examined in the latter given 
a starting population in excess of 50 patients. We extended these observations to show 
a correlation between colonic CCL25 gene expression and inflammatory indices 
across a large sample size associated with detectable CCL25 protein and a CCR9
+
 
colon-infiltrating effector T-cell population. This is particularly pertinent given the 
correlation between inflammatory burden and colorectal cancer (CRC) risk in patients 
with colitis ± PSC, and the recent discovery of CCL25–CCR9 in meditating colonic 
tumour growth, invasion and metastasis [383]. 
 
Only two groups have reported direct visualisation of intestinal CCL25 protein by 
immunohistochemistry with ―patchy‖ staining detected over the small intestinal crypts 
in close proximity to areas of lymphocyte infiltration [123,142,343]. Only one 
published study looked at CCL25 staining in active colonic inflammation (Crohn‘s 
colitis) [343]. The Human Protein Atlas (http://www.proteinatlas.org/ 
ENSG00000131142-CCL25/tissue) report positive staining in small but not large 
bowel; however, only normal (non-inflamed) human tissue was used to create the 
profile, and the reported reliability was deemed ―uncertain‖ as only one antibody was 
tested. Certainly my own attempts at immunohistochemical staining (using small 
bowel as a positive control) with three different antibodies and varied epitope 
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retrieval steps did not yield any consistent staining in the positive control (SB) tissue 
precluding the use of immunohistochemistry in the colon. Unfortunately the 
previously tested antibodies claiming positive staining in the SB are no longer 
commercially available. 
 
A lack of detectable CCL25 immunohistochemical staining could be due to the patchy 
nature of CCL25 expression in the intestine, or factors affecting chemokine 
presentation and cleavage from the epithelial and endothelial surface. Chemokine 
function is heavily governed by binding to matrix components such as 
glycosaminoglycans and proteoglycans on the cell surface, which may be affected in 
vitro by tissue processing, epitope retrieval, enzymatic digestion and wash steps. 
Endothelial cells express atypical chemokine receptors which act as molecular decoys 
to remove and degrade chemokines [384]. Such variation in endothelial chemokine 
receptor expression and cell surface glycosaminoglycan composition may explain the 
observed difficulties with chemokine immunohistochemistry.  
 
Nevertheless, the western blot and ELISA data presented here clearly indicate CCL25 
expression at the protein level in colitis but not in NC samples supportive of colonic 
CCL25 expression being associated with active inflammation. These techniques were 
not without obstacle, however. Clear bands on western blots were only visualised 
following prior immunoprecipitation. This yielded clear bands albeit of 2 – 3 distinct 
sizes. Reassuringly, such a pattern was observed in small bowel and with recombinant 
human CCL25, suggesting the staining is specific and a consequence of the presence 
of chemokine multimers [339]. Validation of CCL25 protein expression was provided 
through ELISA. 
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A remaining question is which cell-type produces CCL25 within the large bowel? 
CCL25 is secreted and expressed by small bowel epithelium; specifically the crypts of 
Lieberkuhn and intestinal villi [142]. However CCL25 can also be detected on the 
surface of certain APC [377]; and detection of protein expression on liver sinusoids in 
patients with PSC implies that CCL25 is either locally secreted or captured from 
blood and presented on the surface of endothelial cells [376]. Given the inherent 
difficulties with chemokine immunohistochemistry, alternative methods at 
visualisation in tissue may be required. In-situ hybridisation has been trialled by one 
group [142], but as with prior immunohistochemistry efforts these attempts were 
restricted to small bowel and non-inflamed colon, and did not reveal any positive 
staining in the latter.  
 
3.3.3 Therapeutic considerations  
Activation of the CCL25/CCR9 axis is responsible for many functions in the small 
intestine. Ligand–receptor binding fosters engagement of gut-tropic T-cells to CAMs 
such as VCAM-1 and MAdCAM-1 through 1 and 7, respectively [385,386]. 
Such interactions facilitate recruitment to the gut lamina propria and are pivotal in the 
development of gut cryptopatches. Secondary interactions result in dampening of 
CCR9 expression and up-regulation of CD103 on CD8
+
 T-cells, promoting population 
of the intra-epithelial lymphoid compartment [345,387]. While CD8
+ 
T-cells rely on 
CCL25-CCR9 interactions to pass into the small bowel, entry of IgA-secreting B-cells 
and CD4
+
 T-cells can occur through CCR9–CCL25 independent mechanisms 
[131,137].  
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A pathological role for the CCR9–CCL25 axis in IBD was first suggested by studies 
in which circulating CCR9
+
 T-cells were detected in patients with active SB Crohn‘s 
[343], and paralleled by studies of murine IBD where expression of ligand and 
receptor were elevated in the context of active inflammation [145]. As previously 
discussed, immunoblockade of CCL25 and CCR9 in the Samp1/YitFc model 
tempered the induction of ileitis but with little effect on maintenance of remission, 
indicative of a role early in the mucosal inflammatory response. Rag2
-/-
 mice which 
lack mature B- and T-lymphocytes develop spontaneous ileitis but are relatively 
protected from intestinal injury when crossed with a Ccr9
-/-
 strain [147]. CCR9 
expression has also been reported on Treg and immunosuppressive plasmacytoid 
(p)DC [146,147,388,389] and upon adoptive transfer of CD4
+
 T-cells, Ccr9
-/- 
Rag2
-/-
 
mice develop SB intestinal inflammation, suggesting that a critical absence of non–T-
cell CCR9
+
 populations in this model is responsible for maintaining tissue tolerance, 
putatively CD103
+
 CCR9
+
 plasmacytoid DC and CCR9
+
 Treg. Furthering the 
argument, Wurbel et al. claim that CCR9–CCL25 interactions are critical for 
modulating protective responses against large intestinal inflammation. In acute [380] 
and chronic [384] models of DSS colitis, both Ccr9
-/-
 and Ccl25
-/-
 mice exhibited 
increased susceptibility to large bowel inflammation independent of T-cell colonic 
recruitment despite preserved Treg development and function. Instead, these animals 
demonstrated augmented trafficking of innate immune subsets with pronounced 
accumulation of activate macrophages (acute model [380]) and increased Gr-1
hi
 
CD11b
hi
 neutrophil populations infiltrating MLN and LP (chronic model [381]). 
Although the pDC population was unaffected in the chronic model, conventional 
CD103
+
 (CD11b
+
 and CD11b
–
) subtypes are reduced in number following adoptive 
transfer of wild-type T-cells, supporting a tolerogenic role of conventional as well as 
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plasmacytoid DC in the murine colon. These changes were accompanied by an 
increase in CD103
–
 CD11b
+
 DC, a subset reported to increase the sensitivity of CD4
+
 
T-cell responses to bacterial antigens [390].
 
 
 
Given the pathological consequences of targeted deletion of CCR9 or CCL25 in 
murine models of colitis, Wurbel et al. raise concerns that therapeutic targeting could 
lead to detrimental effects in patients with IBD. Whilst congenital absence of ligand 
or receptor may prove harmful under specific circumstances, targeting the CCL25–
CCR9 axis in the context of early, established disease could yield therapeutic benefit 
in patients with small and large bowel intestinal inflammation. An orally bioavailable 
CCR9 antagonist (CCX282-B; Chemocentryx, USA) was shown to not only inhibit 
chemotaxis of CCR9
+
 T-cells in vitro, but resulted in near complete protection of 
intestinal injury in the TNFARE model of murine ileitis [391]. Similar results were 
obtained in a hapten-induced colitis model, wherein a significant reduction of pro-
inflammatory infiltrating iNKT-cells associated with disease improvement in mice 
exposed to oxazolone [382]. These results have been translated into phase-II clinical 
trials in which CCX282-B was well tolerated and resulted in a superior rate of 
remission in patients with (mixed small and large bowel) Crohn‘s disease at 52-weeks 
of therapy [151]. A recently published case report also details the successful treatment 
of a patient with refractory UC through CCR9 targeted leucapheresis [364] with 
clinical and endoscopic remission being associated with a dramatic reduction in 
CCR9 expression by MFI on circulating CD3
+
 T-cells and CD14
+
 monocytes.  
 
Monocytes migrate into the intestinal LP via CCR2-dependent mechanisms, where 
they undergo differentiation into pro- and anti-inflammatory macrophages [392]. 
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However, in T-cell mediated colitis differentiation is impaired and linked with a 
significant increase in pro-inflammatory subsets. Activated macrophages undergo 
chemotaxis along CCL25 gradients [377], and CCR9
+
 macrophages induce acute liver 
inflammation in the concanavalin A model of acute hepatitis [393]. TNFproducing 
CCR9
+
 macrophages activate stellate cells during the initiation of CCl4-induced liver 
injury and remain during liver fibrosis [140]; a process attenuated in the absence of 
CCR9. Increased tissue expression of CCR9 has also been reported in early, pre-
invasive colorectal cancer [383], although this is disputed by other groups [349]. 
Nonetheless, colorectal cancer cells migrate in response to CCL25 chemokine 
gradients in transwell and Boyden chamber assays, and ligand expression is a 
prerequisite for metastasis in certain xenograft tumour models. This is noteworthy 
given the association between hepatobiliary inflammation and fibrosis, and colitis and 
pre-malignant potential in PSC-IBD. Extending therapeutic applications beyond small 
bowel disease may be effective, given the role of CCL25 and CCR9 in PSC 
lymphocyte recruitment, liver inflammation and fibrosis, colitis and colorectal cancer.  
 
3.3.4 Summary  
This chapter has shown CCR9 expression on the majority of colonic CD4
+
 and a 
proportion of CD8
+
 T-cells in colitis. Preliminary data suggest that these are effector 
T-cells, and their presence in patients with only microscopic colitic activity implies 
recruitment early in the inflammatory response. The cognate ligand CCL25 is 
overexpressed in the inflamed large bowel where expression correlates with 
inflammatory activity in UC patients.  
 188 
4 Results II: Consequences of hepatic VAP-1 enzyme 
expression 
4.1 Introduction 
In chapter 3, data were presented showing an increased expression of CCL25 in 
colitis as well as an influx of CCR9
+ 
T-cells in the human colon associated with a 
greater inflammatory burden. The aberrant lymphocyte homing hypothesis of PSC 
proposes that 7+ CCR9+ T-cells traffic from gut to liver in a process dependent 
upon hepatic endothelial expression of MAdCAM-1 and CCL25 [1,2,127,289,293], 
and that reactivation of effector memory populations bearing this phenotype drives 
hepatobiliary inflammation. The precise factors contributing to aberrant expression of 
normally ‗gut-restricted‘ adhesion molecules in the PSC liver are incompletely 
understood. However, recent studies have demonstrated that deamination of certain 
amines catalysed by the enzymatic activity of VAP-1 can augment expression of 
functional CAMs on the endothelial surface in an NFB-dependent manner 
[294,321]. Such amines can be derived from several sources, including foodstuffs and 
gut bacteria, which could traverse the ‗leaky‘ inflamed gut in patients with colitis, 
entering liver via the portal circulation where they act as VAP-1 substrates.  
 
In this chapter, tissue VAP-1 expression and enzyme activity is determined in the 
PSC liver and contrasted with other autoimmune liver diseases (PBC and AIH). 
Variations in enzyme activity with alternative substrate provision are also presented 
prior to addressing functional sequelae; specifically with regard to CAM expression 
and 7 dependent adhesion to HSEC. 
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4.2 Findings 
4.2.1 Hepatic VAP-1 gene expression 
Gene transcription was measured using qRT-PCR on cDNA derived from human liver 
tissue (as described in Chapter 2). Unlike other solid organs, there is little published 
data on genes specific to human liver tissue which manifest stable expression 
(housekeeping) between aetiologies or conservation across varying degrees of 
inflammatory activity [337,338,394]. Therefore a calibration curve was created from 
known dilutions of a linearized plasmid encoding human VAP-1, in which 
quantification by copy number was pre-determined [214]. To ensure inter-experiment 
validity, near identical real-time PCR amplification efficiencies for the calibration 
curve as well as a sample of target cDNA were confirmed on every run prior to inter-
plate comparisons.  
 
Utilising the absolute quantification method, VAP-1 gene expression was determined 
in cirrhotic, end-stage human liver diseases of parenchymal (AIH and alcoholic liver 
disease, ALD) and biliary (PBC and PSC) aetiology, and compared with that 
observed in resected non-diseased/non-cirrhotic liver (NL). The aim was to evaluate 
VAP-1 expression in PSC; with primary biliary cirrhosis being chosen as a 
comparator biliary disease and AIH and ALD as diseases characteristic of 
parenchymal injury. All starting mRNA concentrations were standardised and the 
qRT-PCR reaction performed using 100ng starting material run in triplicate wells. 
VAP-1 gene expression was significantly greater in diseased versus non-diseased liver 
as assessed by the MW test (median 44,200 copies, IQR 29,400 – 77,925 copies vs. 
22,100 copies, 3840 – 47,650 copies; p = 0.028). Probing differences further, the 
biliary diseases had more copy numbers than parenchymal injury (Figure 4.1) and 
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comparison of individuals revealed statistically significance differences between PSC 
and NL samples. Of note, there was marked spread within the different disease groups 
suggesting that many factors affect VAP-1 transcription in human liver.  
 
 
 
 
 
Figure 4.1: VAP-1 gene expression in human liver  
Absolute quantification of VAP-1 gene expression in explanted liver tissue is presented. Aetiology 
grouped as parenchymal liver disease (median 33,750 copies, IQR 23,450 – 42,200 copies), biliary liver 
disease (62,900 copies, 35,800 – 97.925 copies) or non-diseased/non-cirrhotic liver (NL; 22,100 copies, 
3,840 – 47,650 copies) (A); or according to individual diagnoses (B). Parenchymal diseases consist of 
autoimmune hepatitis (AIH: 33,700 copies, 11,715 – 39.274 copies), alcohol induced liver injury (ALD: 
35,700 copies; 23,450 – 48,850 copies), and biliary diseases comprise primary biliary cirrhosis (PBC: 
58,100 copies, 46,675 – 93,725 copies) and primary sclerosing cholangitis (PSC: 69.350 copies, 26,575 – 
121,325 copies). Capped lines and asterisks indicative of statistical comparisons (p values according to 
KW-test and Bonferroni-Dunn post-hoc correction). In (B), the post-hoc test was conducted for PSC vs. 
all other aetiologies after the intitial KW-test. 
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4.2.2 VAP-1 immunohistochemistry  
To determine whether differences in VAP-1 gene transcription between diseases were 
reflected at the translational level, protein expression in tissue sections was localised 
using immunohistochemistry. Snap-frozen tissue sections were prepared from 
explanted or resected human liver as detailed in Chapter 2, and stained using methods 
described therein.  
 
In NL specimens, VAP-1 was largely confined to vessels and hepatic sinusoids. 
However, on qualitative assessment expression appeared markedly increased in all 3 
autoimmune liver diseases; particularly PSC (Figure 4.2). Increased VAP-1 staining 
was seen in stroma and fibrotic scar tissue, as well as within neovascular structures in 
septa.  
 
Colocalisation experiments using multi-colour confocal immunofluorescence were 
used to confirm cell-type specific VAP-1 expression in PSC liver. VAP-1 did not co-
localise with biliary markers (portal bile ducts or proliferating bile ductules; Figure 
4.3) but was colocalised with CD31
+
 and particularly SMA+, indicative of 
endothelial and myofibroblast expression, respectively (Figure 4.4). Furthermore, 
despite the strong expression of VAP-1 and MAdCAM-1 on HSEC, these two 
adhesion molecules did not colocalise. VAP-1 exhibited predominantly a pericytic 
distribution, whereas MAdCAM-1 expression was largely restricted to a cytoplasmic 
pattern; as illustrated by Liaskou et al. previously [294]. 
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Figure 4.2: Tissue expression of VAP-1 in human liver – immunohistochemistry 
Immunohistochemical staining of VAP-1 is presented for NL, AIH, PBC and PSC. ImmPACT DAB was utilised as chromogen. Filled arrowheads indicate 
fibrotic scar tissue. Examples of sinusoidal vessels are indicated by empty arrowheads; and intra-scar vessels by asterisks. IMC – isotype matched control. 
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Figure 4.3: VAP-1 does not co-localise with biliary epithelium or MAdCAM-1 
Co-expression of VAP-1 was investigated with the biliary epithelial marker (EpCAM) and with 
mucosal addressin cell adhesion molecule (MAdCAM)-1 via multi-colour confocal 
immunofluorescence in PSC liver. 
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Figure 4.4: Co-localisation of VAP-1 in human liver 
Multi-colour confocal immunofluorescence was conducted in order to confirm sites of VAP-1 
expression in PSC liver. Cell-specific markers adopted are as follows: myofibroblasts, SMA; 
endothelial cells, CD31; and nuclei staining, DAPI. VAP-1 staining was predominantly pericytic in the 
diseased liver: lower expression on endothelial vessels and the majority co-localisation being with 
SMA positive cells. 
 
4.2.3 Quantification of hepatic SSAO activity 
Having illustrated VAP-1 expression in human liver, a comparative assessment of 
amine oxidase activity was performed between the three autoimmune liver diseases. 
Several methods have been described for quantification of amine oxidase activity; 
some rely on absorbance and are incompatible with measurements of activity in 
biological samples; whereas others require equipment not immediately attainable such 
as luminometers, oxygen electrodes or radiocarbon labelling of substrate [295,395]. 
Therefore the Amplex Red fluorescence-based method was chosen for my studies 
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given that it yields rapid, reproducible quantification of enzyme activity and was 
possible to conduct with available apparatus. This coupled reaction works on a 
principle wherein the rate of increase in fluorescence is directly proportional to the 
amount of H2O2 produced (detailed in Chapter 2). 
 
The deamination of substrates by VAP-1 evolves H2O2, the rate of production of 
which was normalised to starting protein quantity in prepared liver tissue lysates and 
used as a surrogate for enzyme activity. Given the presence of other cellular and 
circulating amine oxidases in mammalian tissues, inhibitors of MAO-A and MAO-B 
where included in preliminary experiments. The Amplex red detection system can be 
subject to auto-oxidation over time, which may give rise to false-positive signals. 
Therefore to ensure a further level of control, parallel assays contained semicarbazide 
(ScZ) – a urea derivative which inhibits VAP-1 enzyme activity but not that of other 
amine oxidases and which gives rise to the classification of VAP-1 as an SSAO. The 
rate obtained from ScZ-containing wells was then subtracted from that of untreated 
samples to give a net/corrected value as detailed in Chapter 2. All enzyme activity 
values as thus presented as ‗semicarbazide corrected‘ readings normalised to curve 
generated from serial dilutions of H2O2. Fixed concentrations of benzylamine (1 M) 
and semicarbazide (250 M) were used in all experiments unless otherwise indicated. 
Using this technique, statistically more VAP-1 enzyme activity was detected in PSC 
liver compared with PBC and AIH (Figure 4.5); in keeping with gene-expression 
studies.  
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Figure 4.5: Tissue VAP-1 enzyme activity following MAO-A/MAO-B inhibition 
Amine oxidase activity was determined in protein lysates extracted from explanted human liver. Values 
correspond to absolute amine oxidase activity in a given sample minus that of residual/background 
following addition of semicarbazide (VAP-1 enzyme inhibitor). Rates presented for AIH (32 pmol 
H2O2/min/mg protein, IQR 23 – 36 pmol H2O2/min/mg protein), PBC (25 pmol, 19 – 28pmol) and PSC 
(98 pmol, 70 pmol – 114 pmol). Each symbol represents one case (mean) of three technical replicates. 
Capped lines and asterisks indicative of statistically significant differences on post-hoc testing (KW-
test with Bonferroni-Dunn post-hoc correction for multiple comparisons). 
 
The necessary inclusion of several amine oxidase inhibitors and retained pigments 
from human liver may have effected the fluorometric readings And in order to 
overcome these potential confounders, a modification to the assay was made wherein 
tissue VAP-1 was first captured and immobilised from protein lysates using plate-
bound VAP-1 antibody TK8-18, prior to addition of substrate and quantification of 
reaction rate (please see Chapter 2). This permitted exclusion of MAO-A and MAO-B 
inhibitors in the reaction although semicarbazide was still incorporated in parallel 
wells to confirm catalytic specificity, and enzyme activity results expressed as 
semicarbazide corrected values.  
 
The use of this method increased the catalytic activity measurements threefold higher 
for each disease. This could be a consequence of improved orientation of VAP-1 for 
substrate binding to the active site compared with the enzyme being ‗freely‘ mobile in 
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solution; or possible induction of conformational changes which increase enzyme 
activity. Nevertheless VAP-1 enzyme activity was validated as being significantly 
greater in PSC liver compared to lysates derived from AIH, PBC and NL specimens 
(Figure 4.6). As with gene expression experiments there was variability between 
patients in the different disease groups. Given clinical associations with IBD, VAP-1 
enzyme activity was next measured in colonic protein lysates and VAP-1 enzyme 
activity was not significantly different in large bowel compared to PSC liver (Figure 
4.6).  
 
 
 
Figure 4.6: Tissue VAP-1 enzyme activity following capture and immobilisation 
Enzyme activity was determined in protein lysates extracted from explanted human liver and colon 
following protein capture by immobilised antibody. Values correspond to absolute amine oxidase 
activity (in the presence of 1 mM benzylamine) in a given sample minus that of residual/background 
following addition of semicarbazide (250 M). Each symbol represents one case (mean) run in 
technical repeats. Data presented for AIH (median 119 pmol H2O2/min/mg protein, IQR 102 – 129 
pmol), PBC (155 pmol, 87 – 218 pmol), PSC (227 pmol, 169 – 340 pmol), NL (109 pmol, IQR 60 – 
123 pmol) and colon (197 pmol, 173 – 222 pmol). Capped lines and asterisks indicative of statistically 
significant differences on post-hoc testing via the Bonferroni-Dunn method (KW-test, p <0.001). 
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4.2.4 VAP-1 enzyme activity promotes 7/MAdCAM-1 dependent adhesion  
Having detected increased enzymatically active VAP-1 in PSC liver, I next 
investigated the putative functional consequences. Previous work from our group has 
illustrated an up-regulation of 7/MAdCAM-1 dependent adhesion to HSEC under 
flow following stimulation with TNFwhich was enhanced by provision of the 
VAP-1 substrate methylamine [294]. I was able to reproduce these findings in a 
similar flow-based adhesion assay, wherein HSEC stimulated with TNF and 
methylamine (MA) supported adhesion of the 7+ JY (-lymphoblastoid) cell line 
to a greater degree than when treated with TNF alone (Figure 4.7), although 
differences were only apparent using 100M methylamine rather than 50 M as 
described by Liaskou et al. (detailed in Figure 4.17). No adhesion was observed when 
endothelium was treated with amine alone, suggesting that a pro-inflammatory 
environment is required for MAdCAM-1 expression on HSEC 
 
Figure 4.7: Flow adhesion assay of 7+ JY-cells over stimulated HSEC  
7-expressing JY-cells were perfused over HSEC under flow rates simulating physiological shear of 
human liver. The degree of lymphocyte adhesion was assessed following HSEC treatment conditions 
as indicated for 4 hours (TNF, 10 ng/mL; MA 100 M). Data representative of the mean (±SD) of 3 
independent experiments using different isolates of HSEC (10 recorded fields of view in each); capped 
lines and asterisks indicative of statistically significant differences (Friedman matched sample test with 
Dunn‘s post-hoc correction). 
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To study the effects of VAP-1 inhibition on 7-dependent adhesion and 
transmigration, I obtained a purified population of 7+ T-cells from peripheral 
blood. This was necessary as transmigration of JY-cells across HSEC was not 
observed possibly because they are large blast cells and show defective migration 
responses through an endothelial cell monolayer in vitro. Using fluorescence-
activated cell (FAC)-sorting, I was able to enrich a T-lymphocyte population to over 
90% purity from peripheral blood for use in downstream flow adhesion assays (Figure 
4.8). 
 
Figure 4.8: Fluorescence activated cell-sorting of 7+ T-cells 
7 positive lymphocytes were sorted from peripheral blood following gating on forward scatter 
(FS,) side scatter (SS), CD3+ (not shown); and subsequently 4 and 7. Post-sort purities were 
routinely >90%, and sorted cells maintained in RPMI +10% FBS +1% PSG for 24 hours. to allow 
surface receptors to recycle, prior to downstream application. 
 
Transmigrated cells are easily distinguished from those that remain firmly adherent; 
the former appearing ‗phase-dark‘ whereas the latter remain ‗phase-bright.‘ To 
examine the effect of VAP-1 enzyme inhibition, semicarbazide was added at 
previously determined concentrations known to affect activity, whilst preserving 
HSEC viability (250 M) [396]. The latter was confirmed herein through direct cell 
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visualisation following ScZ exposure and prior to each run of the flow adhesion 
assay. 
 
Inclusion of ScZ to the HSEC media for the first hour of endothelial cell stimulation 
(TNF/MA) was shown to inhibit 7+ T-lymphocyte adhesion by approximately 
50% (Figure 4.9). ~25% reduction in adhesion was also evident using a neutralising 
VAP-1 antibody (TK8-14; 10 g/mL); however, neither agent significantly affected 
migration. The latter suggests MAdCAM-1 is involved in adhesion but not 
transmigration in the lymphocyte adhesion cascade.  
 
 
Figure 4.9: Flow adhesion assay of 7+ sorted cells over stimulated HSEC  
7+ sorted T-cells were perfused over HSEC under conditions simulating physiological shear in the human 
liver. The extent of lymphocyte adhesion (A) and transmigration (B) were assessed following HSEC treatment 
with TNF (10 ng/mL) and methylamine (100 M) ± inclusion of semicarbazide (250 M) or neutralising 
antibody (TK8-14, 10 g/mL). Data representative of the mean (± SD) of 3 independent experiments using 
different blood donors and different isolates of HSEC (10 fields of view each); capped lines indicative of 
statistical comparisons and asterisks highlight significant differences/p values between conditions (KW-test 
with with Dunn‘s post-hoc correction). 
 
The effect of VAP-1 antibody on 7 T-cell adhesion was somewhat unexpected, 
for although this agent is a function-blocking anti-VAP-1 monoclonal antibody it is 
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reportedly devoid of enzyme inhibitory functions and therefore should not contribute 
to 7/MAdCAM-1-dependent attachment. The epitope on VAP-1 that is 
recognised by TK8-14 is not known. Therefore to confirm that binding of the 
antibody to VAP-1 does not impact on enzyme activity, assays were performed 
wherein increasing concentrations of rVAP-1 were incubated with 1 mM benzylamine 
and either TK8-14 (5 g/mL, 1g/sample) or semicarbazide (250 M); the latter used 
as a positive control for 100% VAP-1 inhibition. Only a small, non-significant degree 
of enzyme inhibition was observed with TK8-14 – the extent of which was 
independent of rVAP-1 concentration (mean 17.5%; SEM 7.2%; Figure 4.10). 
 
 
Figure 4.10: Comparison of TK8-14 vs. ScZ mediated VAP-1 enzyme inhibition 
The inhibitory effect of TK8-14 (1 g/sample) and semicarbazide (250 M) were assessed over a range 
of rVAP-1 concentrations (1 mM benzylamine utilised in all wells). Asterisk indicates a significant 
difference in enzyme activity from the untreated state (paired t-test). 
 
The inhibition of adhesion by anti-VAP-1 suggests that 7 T-cells may be able to 
engage directly with VAP-1 on HSEC. Although the identity of the VAP-1 ligand is 
not known, Siglec-9 and Siglec-10 have been shown to bind VAP-1 and act as 
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enzyme substrates in vitro. However, CD3
+
 7+ T-cells expressed very little 
Siglec-10 and only a small proportion expressed Siglec-9 (Figure 4.11).  
 
Figure 4.11: Siglec-9 and Siglec-10 expression by CD3
+
 + T-cells  
CD3
+
 gated, 7+ T-cells were analysed by flow cytometry for expression of putative VAP-1 ligands. Representative 
plots shown for n=3 experiments (3 different blood donors) in (A); percentage positive expression from all experiemtns 
summarised in (B). 
 
4.2.5 Adhesion and transmigration of CCR9+ T-cells under flow 
Following the demonstration that 7+ T-cells adhere to stimulated HSEC under 
flow, I investigated whether the extent of binding was dependent upon CCR9
 
expression. Cell populations were obtained via FAC-sorting from peripheral blood. 
The 7+ CCR9+ subset constituted a minor proportion (~3%) of the circulating 
7+ lymphocyte population (healthy controls), therefore isolation through FAC-
sorting required large volumes of whole blood from individuals undergoing 
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venesection (according to clinical need) in order to obtain enough cells for functional 
studies (Figure 4.12). 
 
Figure 4.12: CCR9
+
 47+ T-cells derived from peripheral blood 
Circulating CD3
+
 T-cells were sorted based on expression of 7 and CCR9. 
 
In flow assays, 7+ CCR9+ T-cells showed a trend to greater adhesion and 
transmigration than their CCR9
–
 counterparts, although the differences fell short of 
reaching statistical significance (p = 0.097 and p = 0.6, respectively; Figure 4.13). 
 
 
Figure 4.13: Flow adhesion assay of 7+ sorted cells over stimulated HSEC  
7+ T-cells were perfused over TNF (10 ng/mL) and MA (100 M) stimulated HSEC under 
conditions simulating physiological shear in the human liver. The degree of lymphocyte adhesion (A) and 
transmigration (B) were compared between CCR9
+
 vs. CCR9
–
 subtypes. 
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4.2.6 Enzymatic efficiency is substrate dependent 
The proposal that in the presence of an inflamed gut, increased portal vein levels of 
methylamine activate VAP-1-dependent hepatic MAdCAM-1 expression – thereby 
promoting recruitment of mucosal effector cells to the liver – fuelled further 
investigation into alternative amine substrates that might be relevant to disease 
pathogenesis.  
 
Amine substrates of human VAP-1 were selected based on their inclusion in the 
human metabolome database version 2.5 (http://www.hmdb.ca); specifically 
cysteamine, methylamine, dopamine, ethylamine and phenethylamine. The enzymatic 
activity of a fixed quantity of rVAP-1 (50 ng) was determined across varying 
substrate concentrations under atmospheric conditions (21% O2), and comparisons 
drawn with kinetic rates observed using benzylamine – an archetypal VAP-1 substrate 
(Figure 4.14). As this series of experiments was conducted with purified rVAP-1, it 
was not deemed necessary to incorporate a semicarbazide step.  
 
Following a series of dose finding studies, enzymatic efficiency as illustrated by the 
highest apparent kcat/Km was greatest with cysteamine; the lowest effects observed 
with ethylamine and phenethylamine (Table 4.1). This was of particular interest given 
that cysteamine is frequently adopted in experimentally induced colitis models [397–
403]. It is worth noting however, that the Km (substrate concentration at which the 
reaction rate is half of maximum) was greater for all amines relative to methylamine 
and benzylamine. 
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Figure 4.14: VAP-1 enzyme activity with alternating substrate provision 
Non-linear fit curves illustrating VAP-1 activity across a range of substrates at varying concentrations and enzymatic rates as measured by the Amplex Red 
assay using 50 ng rVAP-1 as the catalyst. Each dot point represents the mean of 3 technical replicates. The kinetic constants were defined as V max = k cat [E] 
o (V max, maximum rate achieved by the enzyme at saturating substrate concentrations; k cat, the turnover number; and [E] o, the substrate concentration). 
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Table 4.1: VAP-1 substrate kinetic profiling 
Substrate V max  Km (M) k cat (s
-1
) k cat
app
/Km
app
 
Ethylamine 8.59 ± 0.60 88.44 ± 34.90 242.63 2.74+06 
Phenethylamine 9.89 ± 0.69 65.69 ± 19.43 279.46 4.25+06 
Dopamine 78.94 ± 5.97 43.70 ± 13.07 2229.94 5.10+07 
Methylamine 11.49 ± 0.77 8.55 ± 3.45 324.58 3.80+07 
Cysteamine 84.55 ± 13 44.52 ± 16.74 2388.42 5.36+07 
Benzylamine 8.92 ± 0.70 9.90 ± 3.360 251.98 2.55+07 
 
4.2.7 HSEC viability following amine substrate exposure 
Having demonstrated the potency of cysteamine and other biogenic amines as VAP-1 
substrates, I decided to assess the functional consequences of differential substrate 
provision to HSEC. In addition to generating H2O2, the enzymatic activity of VAP-1 
could affect endothelial cell survival through the effects of aldehydes and ammonia, 
oxidative stress and glutathione depletion [397,399,402,404,405]. Therefore, I carried 
out viability assays in HSEC that had been incubated with increasing concentrations 
of the 5 amine substrates for 24 hours. Representative images of the cells after 
exposure to the maximum concentrations dictated by enzyme kinetic studies are 
illustrated in Figure 4.15. No gross morphological changes or evidence of cell death 
were evident for any of the treatments at the concentrations studied. 
 
HSEC were then incubated with the 3 most potent substrates (cysteamine, dopamine, 
methylamine), as well as TNF, in order to simulate treatment conditions 
undertaken in flow-adhesion assays. As expected, HSEC adopted a more elongated, 
‗spindle-shaped‘ conformation in response to activation by TNF but viability was 
not affected (Figure 4.16).  
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Figure 4.15: HSEC viability with variant substrate exposure 
HSEC viability was monitored following exposure to several amine substrates. Representative images shown of maximum trialled concentrations at 0, 4 and 24 hours. X 
10 magnification (Cell-IQ). 
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Figure 4.16: HSEC viability and morphology with variant substrate ± TNF exposure 
HSEC viability and morphology were monitored following exposure to selected substrates and TNF at standard concentrations prior to assessment in functional assays. 
x 10 magnification (Cell-IQ).  
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4.2.8 Effects of differential substrate provision to HSEC 
As cysteamine was readily deaminated by VAP-1 it was compared with methylamine 
in flow-based adhesion assays. HSEC were stimulated with TNF± methylamine or 
equivalent concentrations of cysteamine. Substrate concentrations were selected based 
on the previous studies suggesting 50 – 100 M methylamine–treated HSEC supports 
lymphocyte adhesion and kinetic assays showing the rate of H2O2 at a plateau beyond 
100 M for both amines (see Figure 4.14). Using the JY-cells to study 
7/MAdCAM-1 adhesion, a greater degree of attachment was observed in a dose 
dependent fashion with escalating amine concentrations (100 M > 50 M). 
Moreover, cysteamine treated HSEC supported 7–dependent adhesion to a 
significantly greater degree than equivalent concentrations of methylamine (Figure 
4.17). 
 
 
Figure 4.17: Effects of differential amine provision on 7 dependent adhesion 
Flow adhesion assay of 7+ cells across HSEC stimulated with TNF in addition to methylamine 
(MA) or cysteamine (CA) at 50100 M. Data representative of the mean (± SD) of 3 independent 
experiments (10 fields of view each). Capped lines and asterisks indicative of statistically significant 
differences (KW-test with Bonferroni-Dunn‘s post-hoc correction).  
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4.2.9 HSEC ELISA 
In addition to affecting endothelial expression of MAdCAM-1, the enzymatic activity 
of VAP-1 is known to up-regulate expression of other members of the 
immunoglobulin superfamily through NFB activation [321]. To assess how 
induction of other CAMs is affected by different substrates, endothelial cells were 
stimulated with MA, CA or DA, and the effects on expression of MAdCAM-1, 
ICAM-1 and VCAM-1 compared. VE-cadherin was also included in HSEC ELISAs 
as this adhesion molecule is not known to be influenced by NFB-dependent 
mechanisms (although VE-cadherin itself can activate NFB [406]) and was thus 
deemed a suitable comparator. 
 
HSEC were grown to confluence in a 96-well ELISA plate, and then incubated with 
TNF (10 ng/mL) supplemented with methylamine, dopamine or cysteamine. 
Increased expression of ICAM-1, VCAM-1 and MAdCAM-1 were observed on 
HSEC following provision of TNF and each of the 3 amine substrates when 
compared to TNF alone (Figure 4.18). Expression of ICAM-1 and MAdCAM-1 was 
particularly marked using cysteamine relative to dopamine and methylamine although 
differences between substrates were not significantly different. However, differences 
in MAdCAM-1 expression were significantly greater using cysteamine + TNF 
versus TNFalone, supporting the results of enzyme kinetic studies and those of 
prior flow adhesion assays. As expected, no changes in VE-cadherin expression were 
observed following amine exposure relative to TNF stimulation alone. 
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Figure 4.18: HSEC ELISA following VAP-1 susbstrate provision 
HSEC evaluated for expression of cell adhesion molecules following stimulation with TNF alone, in 
addition to methylamine (MA) or cysteamine (CA). Data presented as mean (± SD) with capped lines 
and asterisks indicative of statistically significant differences (overall KW-test; and also of TNF and 
CA vs. TNF alone). 
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4.3 Discussion 
Vascular adhesion protein-1 is constitutively expressed in human liver and up-
regulated under pro-inflammatory conditions [214]. As an adhesion molecule VAP-1 
promotes hepatic inflammation and fibrosis via recruitment of B-cells, T-cells, 
macrophages and neutrophils; a process enhanced by enzymatic generation of 
aldehydes and H2O2. The latter is proposed to up-regulate expression of other 
adhesion molecules, and in autoimmune hepatobiliary diseases complicating IBD, 
particular attention has been drawn to the typically ‗gut-restricted‘ molecule 
MAdCAM-1 and interactions with mucosal 7+ lymphocytes [294]. 
 
This chapter provides evidence that hepatic expression of VAP-1 and enzyme activity 
are elevated in PSC liver relative to AIH and PBC, and hepatic enzyme activity in the 
former closely resembled that of human colon; noteworthy given clinical associations 
with IBD. VAP-1 expression was elevated in diseased versus non-inflamed/non-
cirrhotic liver with expression observed at sites of fibrotic scar tissue formation in 
addition to its known endothelial distribution. These findings were paralleled by an 
increase in measured hepatic enzyme activity. The efficiency of VAP-1 amine 
oxidase activity varied with different substrates; the most potent of which was 
cysteamine – an agent that induces colitis when applied to the colon in mice. The 
most consistent increase in CAM in response to cysteamine was MAdCAM-1. This is 
of particular interest because MAdCAM-1 does not respond as consistently to 
standard pro-inflammatory cytokines as ICAM-1 and VCAM-1 and it contributes to 
augmented 7+ lymphocyte adhesion under flow.  
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4.3.1 VAP-1 distribution in human liver 
The distribution of VAP-1 in normal and diseased human liver has recently been 
detailed by Weston et al. [214]. Under homeostatic conditions, most VAP-1 is 
detected in endothelial cells, with staining largely restricted to vascular structures, 
portal vessels, central veins and sinusoids. However, in parenchymal liver disease, 
markedly increased staining was detected in in fibrotic septa and hepatic stroma. 
Confocal immunofluorescence confirmed co-localisation with myofibroblasts, 
implicating VAP-1 in liver fibrosis for the first time (although there is emerging 
evidence of a similar role in renal disease [407]).  
 
VAP-1 expression studies in PSC liver confirmed the vascular distribution described 
for parenchymal liver diseases and demonstration in the hepatic scar provided further 
support for a role in fibrosis. However, in confocal immunofluorescence experiments 
there was heavy VAP-1 staining in addition to that which colocalised with SMA and 
CD31. In this regard, more contemporary stromal targets discerning HSC and 
myofibroblasts, such as CD90 or vimentin, are needed to discriminate VAP-1 
expression by cells of stromal versus non-stromal origin. The study by Weston et al. 
has shown VAP-1 co-localisation with these markers in human liver, wherein HSC 
associate closely with HSEC and act as pericytes, which contribute to the regulation 
of endothelial differentiation, function and blood flow. HSC proliferation and trans-
differentiation into myofibroblasts contributes to ECM deposition during fibrogenesis, 
and both HSC and particularly activated myofibroblasts have recently been reported 
to secrete enzymatically active sVAP-1. [214]. Thus it is likely that VAP-contributes 
through several mechanisms to hepatic leucocyte recruitment, tissue inflammation 
and fibrosis in parenchymal and biliary liver diseases.  
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VAP-1 staining was more prominent in PSC relative to normal liver, and when 
compared to the other autoimmune liver diseases AIH and PBC. The histological 
hallmark of PSC is the fibrotic duct lesion together with a prominent ductular 
reaction. However, VAP-1 was not expressed by EpCAM
+
 biliary epithelium. 
Interestingly VAP-1 did not co-localise with the adhesion molecule MAdCAM-1, 
which was also detected on HSEC. These findings are in keeping with reports of prior 
investigators that used antibodies against the same targets [214,294], and implies that 
despite both being ostensible vascular adhesion molecules, VAP-1 and MAdCAM-1 
are either expressed by distinct areas of the hepatic endothelium or are rapidly shed 
into the extracellular space. 
 
4.3.2 Hepatic VAP-1 quantification 
An important goal of this chapter was to evaluate differences in expression between 
PSC and other autoimmune liver diseases. To do this quantitative assessment of 
message was done with qRT-PCR, and absolute enumeration obtained through 
extrapolation from a plasmid-generated calibration curve. Although commonly 
employed for studying variant cell populations [214], the absolute quantification 
approach is rarely used for assessing mRNA levels in whole tissue and the 
identification of a valid reference gene with low variability between aetiologies and 
disease stages has not yet been published. For instance, one study demonstrated little 
conservation of commonly tested housekeeping genes between ordinal degrees of 
liver injury from hepatitis, fibrosis to cirrhosis; including 18s RNA, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), -actin and arginine/serine-rich splicing factor 
(SFRS4)) [337]. Congiu et al. further report poor performance of hypoxanthine 
phosphoribosyltransferase-1 (HPRT1) [338], with GUS- only slightly better 
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preserved across varying stages of chronic hepatitis C infection. Comparative 
assessments between PBC and PSC raise similar concerns, wherein ubiquitin was the 
only one of nine tested candidate genes illustrating consistent hepatic gene expression 
between aetiologies [408].  
 
I observed high levels of VAP-1 gene expression and enzymatic function in PSC 
compared with other autoimmune hepatobiliary diseases and non-inflamed/non-
cirrhotic specimens. However, within any given aetiology there was a broad range of 
copy numbers, and not all differences between diseases amounted to statistical 
significance. It is probable that additional factors to disease aetiology influence VAP-
1 gene expression in human liver, such as the level of inflammation or the extent of 
vascularisation in tissue. Nevertheless, hepatic VAP-1 gene expression was 
significantly greater in diseased, versus non-diseased liver specimens, providing 
further support for a role in propagation of hepatobiliary injury.  
 
Perhaps more notable were the findings of in-tissue enzyme activity analysis between 
diseases. Aside from liver, enzymatically active VAP-1 in humans has previously 
been detected in adrenal glands, gallbladder, intestine, kidneys, lungs, pancreas, 
thyroid, spleen and adipose tissue [409]. Despite high-level constitutive expression of 
VAP-1 in non-inflammatory settings, enzyme activity in human liver is reportedly 
lower than that reported in gut or human vasculature [409]. A recent study from 
Finland has proposed that alternative splice variants of VAP-1 may exist with varying 
enzyme activity [410]. It is thus possible that a form with lesser enzyme activity is 
present in non-diseased liver, with up-regulation of the more active form during 
disease. To my knowledge, the data presented in this chapter represent the first 
quantification of tissue enzyme activity in liver diseases. The variation in VAP-1 
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amine oxidase activity within any given aetiology was quite broad and paralleled the 
pattern seen in gene expression studies. However, the PSC liver cohort demonstrated 
significantly greater enzyme activity overall, as assessed by two different techniques, 
compared with AIH, PBC and non-inflamed/non-cirrhotic liver.  
 
The consequences of increased enzyme activity could include direct effects on 
leucocyte adhesion, and particular attention has been drawn to pro-inflammatory 
myeloid subsets in this regard [316]. More recently purified sVAP-1, possibly derived 
from activated HSC and liver myofibroblasts, has been shown to mediate enzyme-
dependent chemotaxis of peripheral blood lymphocytes in migration assays [214]. I 
have shown that hepatic enzyme activity in PSC was comparable to that observed in 
the colon, suggesting a degree of conservation between mucosal sites. It is thus 
tempting to speculate that in the context of an increased amine substrate burden – 
perhaps that secreted by enteric bacteria – VAP-1 enzyme activity increases in the 
colon. Consequently, a ‗leaky‘ inflamed gut in patients with colitis would allow 
translocation of such substrates to the portal circulation, where hepatic VAP-1 
mediated deamination could increase liver inflammation. One consequence could be 
the 'relatively selective expression of MAdCAM-1 induced by local VAP-1 activity in 
hepatobiliary diseases complicating intestinal inflammation. In this context a driver of 
substrate provision could be inflammasome-mediated dysbiosis in patients with non-
alcoholic fatty liver disease (NAFLD) or PSC [119]). Elevated hepatic VAP-1 levels 
can be detected in patients with NAFLD [214] and correlate with inflammatory 
activity and outcome, which is of interest given the reported changes in intestinal 
microbiome composition in obese individuals dependent upon the presence or 
absence of liver disease [411,412]. VAP-1 substrates are also implicated in 
modulating glucose transporters in isolated rodent and human adipocytes, and in ex 
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vivo human liver [333–335]. This is of particular interest given the proposed role of 
VAP-1 in mediating steatosis, steatohepatitis and fibrosis in NAFLD. Moreover, 
NAFLD and PSC not only share increased hepatic VAP-1 expression but also an 
increased risk of diabetes, cardiovascular disease and colonic neoplasia [332,413]. 
 
An important caveat to any technique attempting to quantify hepatic VAP-1 
expression is that for absolute distinction between diseases, tissue samples should be 
taken from areas of liver bearing comparable vascular and stromal volume (as VAP-1 
is widely distributed on vessels and fibrotic scar tissue). In reality this approach is 
rarely feasible and would require laser capture microdissection of precision cut tissue 
slices with prior immunohistochemical detailing. A further avenue to be explored is 
the difference in VAP-1 expression between diseases by western blotting. However, 
correct interpretation of the latter would similarly require sampling of comparable 
specimens of liver tissue between diseases. Another limitation to the studies presented 
in this chapter is the use of tissue from end-stage cirrhotic livers, which prevents me 
from commenting on whether hepatic VAP-1 expression exhibits similar differences 
between aetiologies in the pre-cirrhotic state. Of note, there is a distinct paucity of 
hepatic VAP-1 expression in acute liver failure and fulminant hepatitis [330,414], 
suggesting that VAP-1 is particularly up-regulated in chronic liver disease.  
 
4.3.3 Differential substrate provision 
Little is known about the pathophysiological substrates for VAP-1 amine oxidase 
function or whether different substrates produce different downstream consequences. 
Selection of substrates from the human metabolome database highlighted five amines 
for study with benzylamine included as a positive control and archetypal substrate. 
 219 
All were evaluated in enzyme kinetic assays with data fitted to the Michaelis-Menten 
equation. There is debate as to whether measuring VAP-1 kinetic constants via 
Michaelis-Menten analysis is wholly appropriate, as some mammalian amine 
oxidases display non-hyperbolic behaviour [415]. Kinetic plots with rodent, porcine 
and other human AOC enzymes reveal a peak in initial velocity but reduced reaction 
rates at higher substrate concentrations. This may imply amines are binding to a 
second site, or more plausibly an altered form of enzyme than that which is present 
during initial phases of the catalytic reaction. Holt et al. propose that low affinity 
binding of cations present in buffers, to a reduced form of enzyme during the reaction 
could stabilise the catalyst, resulting in lower ‗measured‘ reaction rates in the 
presence of higher substrate concentrations [415]. Notwithstanding the proposed 
effects of cations on AOC activity, it might be argued that true kinetic constants are 
those obtained in the absence of any competing cations which is difficult to assess 
given the generation of ammonium ions during the deamination reaction, and that 
those obtained in bench-top assays are ‗apparent‘ values [415]. This raises questions 
as to what constitutes a ‗true‘ reaction rate.  
 
Notwithstanding these observations, the aim herein was to compare and contrast 
enzyme efficiency with different substrates rather than try to obtain absolute kinetic 
constants for each substrate. I decided to use the Amplex Red assay to detect rate of 
H2O2 production as opposed to previously described methods reliant upon oxygen 
consumption [295] because it allowed the assessment of amine contributions under 
normoxic conditions. As such, the substrate associated with highest VAP-1 enzymatic 
efficiency was cysteamine; noteworthy given the ability of local cysteamine to induce 
experimental colitis (17). A similar hierarchy of kinetic rate was however observed 
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(between the 6 amines chosen) when analysed under hypoxic conditions by Shen et 
al. [295].  
 
Cysteamine production in the gut is regulated by vanin-1, an epithelial ectoenzyme 
belonging to the pantetheine hydrolase family that recycle pantothenic acid (vitamin 
B5). Vanin-1 deficient animals are relatively protected from oxidative stress injury in 
the gut, such as that induced by non-steroidal anti-inflammatories (NSAIDs), tri-
nitrobenzene sulfonic acid (TNBS) or Schistosoma mansoni infection [401,402]. 
However, resistance to oxidative stress can be abolished and colitic injury initiated in 
vanin-1
–/–
 mice following administration of exogenous cysteamine [401,402]. Vanin-1 
polymorphisms are associated with IBD disease severity [403], and epithelial 
expression can promote inflammation driven carcinogenesis in murine colitis models 
[416]. It is thus plausible that the pro-inflammatory effects in colitis are directly 
attributable to an excess of cysteamine production by vanin-1.  
 
Cysteamine belongs to the aminothiol family of compounds and is produced as a 
degradation product of cysteine. Amino acid metabolism differs between 
gastrointestinal sites, and cysteine biosynthesis by enteric flora is largely restricted to 
the colonic microbiome [417]. Previous studies suggest that methylamine, another 
potent inducer of VAP-1 enzyme activity, predominates in the proximal colon [418]; 
of interest given that the phenotype of IBD in PSC is predominantly a right-sided 
colitis. This would imply that cysteamine and methylamine not only contribute to 
development of colitis, but also induction of hepatic VAP-1 activity, thereby 
enhancing leucocyte recruitment to the liver and driving hepatobiliary inflammation. 
Notably, the aldehyde by-product of cysteamine deamination is 3-
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mercaptopropionaldehyde [419], an agent associated with abnormal collagen cross-
linking and thus a potential contributing factor in fibrogenesis.  
 
4.3.4 Functional consequences of enzyme activity by different substrates 
Increased hepatic VAP-1 expression probably drives inflammatory liver disease 
through increased pro-inflammatory cell recruitment and consequent hepatic 
fibrogenesis. In PSC a particular role has been ascribed to MAdCAM-1 in recruiting 
mucosal T-cells to the liver and the ability of hepatic VAP-1 enzyme activity to 
induce aberrant expression of MAdCAM-1 in the liver may be contribute to the role 
of gut lymphocytes in the hepatic manifestations of this disease. Liaskou et al. [294] 
first published data to support this hypothesis and consistent with their findings I saw, 
an increase in 7+ lymphocyte adhesion to TNF stimulated HSEC which was 
increased further by provision of VAP-1 substrate methylamine It is possible that 
amine substrates have direct toxic effects on endothelial cells [420], which could 
affect leucocyte adhesion and transmigration independent of VAP-1 enzyme activity. 
Because amines are inherently lysosomotrophic, they could interfere with receptor 
recycling and alter the density of surface exposed CAMs. However, if endocytic 
effects were predominant, they would occur independently of TNF provision. 
Further support implicating a direct role for VAP-1 in this process was provided by 
the observation that lymphocyte adhesion was reduced by 50% by prior enzyme 
inhibitor treatment; near identical to that observed using targeted antibodies against 
MAdCAM-1 or 7 [294].  
 
The residual degree of adhesion following VAP-1 enzyme inhibition may be due to 
the involvement of other adhesion molecules which facilitate attachment of 
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lymphocytes under flow including CD44, ICAM-1, VCAM-1 and CLEVER-1. That 
administration of an anti-VAP-1 antibody reduced adhesion by ~25% without 
significantly affecting enzyme function, provides support for a non-enzymatic 
contribution from VAP-1 as reported before. Alternatively, anti–VAP-1 treatment 
could have resulted in the internalisation of enzyme, reducing the availability of 
enzyme on the HSEC surface. Human T-cells are not known to express the putative 
VAP-1 ligands Siglec-9 or Siglec-10 [421], and this held true for the FAC-sorted 
4+7+ lymphocytes used in the flow-adhesion assays. It is of course plausible that 
the usage of separate 4 and 7 antibodies (rather than a combined 47 antibody) 
may have resulted in a proportion of CD3
+
 +7+ cells being included herein. 
However, these would still be T-lymphocytes, which are known to express very little 
Siglec-9 or Siglec-10 [67]. 
 
The identity of the VAP-1 ligands is a topic of much speculation and conjecture [67], 
and it is possible that gut-tropic and liver-tropic T-cells express the same as yet 
unknown ligand/substrate. It is worth mentioning that neither enzyme inhibition nor 
antibody blockade affected the relative percentage of cells undergoing 
transendothelial migration, supporting prior observations that MAdCAM–1/7 
interactions are primarily involved in the attachment and adhesion steps of the 
leucocyte adhesion cascade [422].  
 
Mucosal lymphocytes expressing 7 and CCR9 infiltrate the PSC liver [127] [289]. 
In Chapter 3, data were presented indicating that a large proportion of colon-
infiltrating T-cells express CCR9 in active inflammation, noteworthy given the 
association of PSC with colitis. In an endeavour to investigate the 
adhesion/transmigration of CCR9
+
 T-cells to HSEC, I used flow adhesion assays to 
 223 
compare peripheral blood 7+ T-cells FAC-sorted into CCR9+ and CCR9– subsets. 
CCR9
+
 T-cells constitute a minor proportion of the circulating lymphocyte pool and 
despite the use of >500 ml peripheral blood for cell-sorting per isolation, only 0.5 – 
1.0 million CCR9
+
 T-cells could be obtained (~4 – 6 hours FAC-sorting time). Thus it 
was only possible to perform ‗head-to-head‘ comparisons between CCR9+ and CCR9– 
subsets twice. Nevertheless, on both occasions a greater absolute number of CCR9
+
 
T-cells underwent adhesion and transmigration compared with CCR9
–
 T-cells in the 
same experiment. If validated through an increased number of repeats, these findings 
would warrant further, detailed assessment of chemokine ligand (e.g. CCL25) 
expression by TNF and amine stimulated HSEC, as well as detailing the functional 
profile of 7+ CCR9+ versus CCR9- liver/colon-infiltrating T-cells. 
 
As cysteamine was the most efficient enzyme substrate I assumed this would also be 
associated with the greatest efficacy in the adhesion assay. Stimulating HSEC with 
cysteamine induced significantly more 7+ lymphocyte adhesion than methylamine 
at identical concentrations. Moreover, ELISA confirmed induction of MAdCAM-1 on 
HSEC and again levels were significantly greater with cysteamine as a VAP-1 
substrate. Increased expression of other IgSF members was also seen following amine 
supplementation to TNF treatment Collectively; these observations support the 
hypothesis that gut-derived amines can facilitate recruitment of mucosal lymphocytes 
to HSEC via elevated VAP-1 enzyme activity.  
 
A notable confounding factor to interpreting any functional data, is that 
supplementation with serum is mandatory to ensure HSEC viability. All mammalian 
serum contains some VAP-1 although this may vary between species. It is thus 
possible that the presence of small volumes of serum could contribute non-HSEC 
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derived VAP-1. Nevertheless, as standardised serum concentrations are used across 
all experiments it is likely that the differences between conditions are due to 
membrane-bound protein. 
 
4.3.5 Potential for therapeutic targeting 
The evidence that enzymatically active VAP-1 is involved in the pathogenesis of PSC 
highlights an avenue of therapeutic interest. The availability of enzyme inhibitors 
with greater sensitivity and specificity than semicarbazide, as well as neutralising 
antibodies against VAP-1, are novel and attractive anti-inflammatory therapies in 
PSC.  
 
VAP-1 knockout mice develop normally, albeit displaying aberrant lymphocyte 
homing to lymphoid organs in vivo [320]. In particular, an absolute reduction in 
lymphocyte populations within the gut (Peyer‘s patches, PP) is observed and these 
animals exhibit defective microbial handling and attenuated T- and B-cell responses 
to oral vaccination [423]. These potentially harmful effects are not observed when 
administering antibody or enzyme inhibitors to fully developed wild-type mice, which 
display intact antimicrobial activity in vivo. Koskinen et al. therefore propose that 
life-long absence of VAP-1 may give rise to compensatory mechanisms in 
development that negatively alter cellular or humoral components of the immune 
system involved in anti-microbial defence, not apparent in pharmacologically treated 
mice (49).  
 
VAP-1 knockout mice treated with CCl4 injection to induce liver injury, inflammation 
and fibrosis show a marked reduction in nearly all liver infiltrating mononuclear cell 
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types from as early as 2 weeks following toxin administration [214]. The influence on 
leucocyte recruitment early in the disease course was paralleled by a reduction in 
hepatitis as well as parenchymal and portal tissue fibrosis. Mice bearing a 
catalytically inactive form of VAP-1 (henceforth referred to as Ssao
–/–
) fed a 
methionine-choline deficient (MCD) diet to induce steatohepatitis showed similar 
reductions in hepatic CD4
+
 and NK1.1
+ 
T-cells (4 – 6 weeks of age) to knockout mice 
lacking the whole VAP-1 gene and this led to reduce fibrosis relative to wild-type 
counterparts [214]. This suggests that VAP-1 is an important driver of inflammation-
induced fibrosis. 
 
The effects of enzyme inhibitors and highly selective antibody blockade have been 
tested in vivo. VAP-1 expression although predominantly restricted to the liver and 
lymphoid tissues in healthy animals can be up-regulated on extra-hepatic sites such as 
the synovium and gut under non-homeostatic conditions. LJP1207 is a potent 
inhibitor of VAP-1 function, the administration of which in oxazolone induced colitis 
reduces mortality, improve body weight as well as significantly improve colonic 
inflammation; most likely due to reduction of Th2 immune cell responses [424]. Such 
reagents have also proven useful in controlling multiple inflammatory (peritonitis, 
arthritis, ischemia-reperfusion injury, lung inflammation, septic shock, hepatitis, 
colitis, organ transplantation) and fibrotic (kidney, liver) responses inherent to several 
in vivo mouse models [212–214,309,312,407,424–429]. 
 
Antibody-treated mice are also protected from the development of liver fibrosis 
following or during administration of the MCD diet [214], evidenced by reduced 
SMA expression and collagen deposition. This is despite the fact that the antibody 
used does not inhibit amine oxidase activity in vitro suggesting it works by a 
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reduction in the infiltration of NK T-cells and CD11b
+
F4/80
+
 macrophages. A direct 
comparison of 4 versus VAP-1 inhibition was recently performed in the 
concanavalin A model of hepatitis [213], wherein the latter reduced influx of CD4
+
 
(but not CD8
+
) T-cells, attenuated early liver inflammation (reduced serum ALT at 8 
hours following injury) and reduced peri-portal inflammation. The anti-VAP-1 effects 
on lymphocyte recruitment were predominantly restricted to T-cells bearing a Th2 
cytokine profile; whereas 4-blockade was associated with significant exacerbation 
of hepatitic injury through increased production of IFN and reduced hepatic 
infiltration of protective myeloid-derived suppressor cells (MDSC). Of interest, a 
modest (non-significant) reduction in serum ALT was also observed with SSAO 
inhibitor (BTT-2052), with a similar reduction in Th2 CD4
+
 T-cells infiltrating the 
liver [212,213]. There is little to suggest an additive effect through combining 
antibody and enzyme-inhibition [316], and in part this could be due to an absence of 
suitable in vivo agents which confer 100% enzyme inhibition.  
 
4.3.6 Summary 
I have shown VAP-1 expression to be increased in autoimmune hepatobiliary disease. 
Elevated enzyme activity was particularly marked in PSC liver, with comparable 
levels detected in the human colon. The amine oxidase activity of VAP-1 depends on 
the nature of available substrate provided; and in this regard amines generated by the 
inflamed human colon are likely to play a role in promoting gut-liver lymphocyte 
migration and hepatic fibrosis. 
 
Given that hepatic VAP-1 enzyme activity is elevated in PSC patients, and can be 
modulated in a substrate dependent manner by gut-derived amines to induce 
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MAdCAM-1 expression on HSEC therapeutic exploration in PSC-specific models 
represents an avenue commanding further investigation.  
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5 Results III: Soluble VAP-1 in PSC 
5.1 Introduction 
In the previous chapter, I provided evidence for elevated hepatic VAP-1 expression 
and enzyme activity in diseased human liver with the strongest expression and highest 
levels of enzymatic activity observed in PSC. This and my finding that cysteamine, a 
substrate produced by the inflamed colonic epithelium and gut bacteria, was the 
substrate with the highest enzymatic efficiency that translated into functional sequelae 
supports the hypothesis that liver injury is driven by intestinal inflammation in PSC 
 
The VAP-1 expression studies conducted in chapter 4 were confined to end-stage 
explanted liver tissue. This significant limitation is inevitable given that the current 
standard of care for PSC minimises the use of liver biopsy. VAP-1 also exists in a 
soluble form (sVAP-1) released from the liver possibly by cleavage from the 
endothelial cell surface and release by activated liver myofibroblasts 
[214,328,330,414]. This allowed me to investigate the clinical utility of peripheral 
blood sVAP-1 and enzyme activity as a biomarker in a large cohort of PSC patients at 
different diseases stages.  
 
5.2 Findings 
5.2.1 Serum VAP-1 assessment 
5.2.1.1 Characteristics of the patient population 
Peripheral blood samples were prospectively collected from a cohort of patients with 
an established diagnosis of PSC (n=134). Their demographic characteristics (Table 
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5.1) were comparable to those reported in population-based epidemiological studies 
[430], with a male preponderance and onset of disease in the 4
th
 decade of life.  
 
Over the course of the study period, 56 patients progressed to liver transplantation 
(n=44) or death (n=12) and these were selected as endpoints. Given the open nature of 
the cohort, Kaplan–Meier curves were used as a product limit estimator for evaluating 
endpoint function over time. This approach was taken in order to conduct time-to-
endpoint analysis across inevitably different follow-up periods between patients, and 
is commonly adopted in large-scale population studies working with open cohorts 
[431,432]. Setting time zero as point of blood sampling, the median transplant-free 
survival obtained via Kaplan–Meier survivorship estimates was equivalent to the 
point at which 50% of patients experienced any clinical endpoint (39 months, IQR 32 
– 46 months; Figure 5.1). This relatively short period reflects the fact that patients 
were attending a tertiary hepatology unit (Queen Elizabeth hospital, Birmingham), 
and thus a high proportion were referred only for consideration of transplantation 
once they had reached an advanced stage of liver disease. 
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Table 5.1: Characteristics of the PSC cohort 
Patient age *  42yrs. (29 – 59yrs.) 
Male gender 83 (62) 
Ethnicity 
 
Caucasian 109 (81) 
Black 6 (4) 
Indian 6 (4) 
Pakistani/Bangladeshi 8 (6) 
Other/Misc. 5 (4) 
Cirrhosis * 91 (70) 
Decompensated  23  
Ascending cholangitis 
§
 25 (19) 
w/in 2 mo. of sampling 16  
Small-duct disease  3 (2) 
Hepatobiliary malignancy 
$
 8 (6) 
IBD 106 (79) 
Colonic IBD  106  
Active IBD * 27 
Colectomy (pan + subtotal) 19  
Pouchitis 5  
Colonic dysplasia/cancer 
$
 9 (7) 
Immunosuppression 33 (25) 
Steroids 6 
Anti-purinergic 7 
Steroids + anti-purinergic 18 
Calcineurin inhibitor 1 
Anti-TNF 1 
UDCA (>6 mo) * 96 (72) 
Antibiotic exposure w/in past 2 mo. 36 (27) 
Laboratory parameters * 
 
AST 66 IU/L (34 – 100 IU/L) 
ALT 61 IU/L (34 – 105 IU/L) 
ALP ratio (to ULN) 2.14 (1.03 – 3.45) 
Bilirubin 20 mol/L (11 – 48 mol/L) 
Albumin 43 g/dl (38 – 45 g/dl) 
Platelets 200 x 10
3 
cells/mm
3
 (128 – 298 x 103 cells/mm3) 
INR 1.1 (1.0-1.2) 
Na
+
 141 mmol/L (139 – 142 mmol/L) 
Creatinine 72 mol/L (58 – 82 mol/L) 
UKELD score 48 (45 – 51) 
IgG 14.17 g/L (11.77 – 17.71 g/L) 
ANA positive 60 (45)  
ASMA positive  41 (31) 
pANCA positive 50 (37) – test not performed in 26 patients 
Data for categorical variables expressed as number (percentages in parenthesis). Continuous variables 
expressed as median (IQR in parenthesis).  
* At time of sampling 
§ Previously treated – not present at time of sampling. 
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Figure 5.1: Kaplan–Meier survivorship estimates across the PSC cohort 
Time to event depicted in months following blood sampling for sVAP-1 analysis. ‗Patients at risk‘ indicate the population at given time points remaining under follow-up, free of the indicated 
clinical event. The objective lifetime risk was calculated as incidence rate (I.R.); specifically, the probability that a particular event would occur before a given time (overall event number 
divided by total patient follow-up time) and presented for each indicated measure: liver transplant or death (A), liver transplantation only (B), and liver transplantation/liver-related death (C). 
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The comparator groups consisted of patients with PBC (n=90), AIH (n=97), IBD 
without PSC (n=50) and healthy controls (HC; n=20). Observing our study 
populations in their entirety, notable differences were apparent with respect to patient 
age, gender predominance, and frequency of transplantation and mortality incidence 
between autoimmune diseases (Table 5.2 and Figure 5.2) consistent with the 
characteristics of AIH, PBC and PSC [152,433]. The significantly poorer transplant-
free survival in the PSC group reflects the severity for this disease and the lack of an 
effective treatment to date has been shown to retard disease progression. 
 
Table 5.2: Demographic variation across the three autoimmune liver diseases  
 PSC PBC AIH IBD HC p value  
Patient age, yrs. 
*
 42 (29 – 59) 57 (49 – 66) 49 (29 – 61) 35 (26 – 54) 34 (38 – 37) <0.0001 ^ 
Male gender 83 (62) 9 (10) 21 (21) 31 (62) 9 (45) <0.0001 
$
 
Cirrhosis  95 (71) 54 (51) 45 (46) 
 
<0.001 
$
 
Decompensated 28 12 4  
Clinical event 
§
 56  16  4 <0.0001
€
 
LTx 44  11 0  
Death 12 5 4  
Data for categorical variables expressed as number with percentages in parenthesis. Continuous variables expressed as 
median (IQR).  
* At time of sampling 
§ During follow-up 
^ Kruskal-Wallis test 
$ Chi-squared test 
€ Log-rank test 
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Figure 5.2: Severity and survival analysis in autoimmune liver disease 
Proportions (%) of patients with evidence of cirrhosis at time of blood sampling are illustrated in (A); capped line and asterisks indicate statistically significant differences (chi-
squared test). Kaplan–Meier survivorship estimates across all three autoimmune liver diseases (autoimmune hepatitis, AIH; primary biliary cirrhosis, PBC; and primary 
sclerosing cholangitis, PSC) are indicated in (B). Incidence rate of clinical events per-100 patient years calculated as follows: AIH 1.2; PBC, 11.7; and PSC, 25.6. Capped lines 
indicate significant differences (log-rank test). 
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5.2.1.2 Quantification of sVAP-1 levels in human serum 
Serum VAP-1 levels were measured in all patients by ELISA (detailed in Chapter 2), 
and the most immediate observation was that the range of values in the study 
population did not conform to a Gaussian distribution (KS p <0.001; Figure 5.3).  
 
 
Figure 5.3: Distribution of sVAP-1 levels across the PSC study cohort 
Quantile-quantile (Q-Q) plots of sVAP-1 levels indicate deviation from the expected normal 
distribution (diagonal) reference line (A). Extent of deviation from normal across the sample 
population is provided in the detrended Q-Q plot in (B). 
 
 
Individuals with autoimmune liver disease (AIH, PBC and PSC) collectively 
demonstrated significantly higher serum sVAP-1 levels than those without evidence 
of liver disease (median 484 ng/mL, IQR 391 – 622 ng/mL vs. 421 ng/mL, 341 – 476 
ng/mL; p <0.001; Figure 5.4a), although variation within any given aetiology was 
considerable (min. 156 ng/mL, max. 1836 ng/mL). When analysed by aetiology, 
patients with PSC had the greatest sVAP-1 levels (532 ng/mL, 432 – 668 ng/mL) 
compared to patients with IBD alone (413 ng/mL, 348 – 489 ng/mL), healthy controls 
(425 ng/mL, 336 – 466 ng/mL) and those with PBC (470 ng/mL, 374 – 653 ng/mL) or 
AIH (433 ng/mL. 355 – 548 ng/mL). Differences between the cholangiopathies fell 
short of retaining statistical significance on post-hoc testing (Figure 5.4b). 
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Figure 5.4: sVAP-1 quantification in human serum 
sVAP-1 levels presented for patients with established liver disease (LD) and with no liver disease (N-LD) in (A). Levelss across the spectrum of 
autoimmune liver diseases are presented in (B); specifically AIH, PBC and PSC. Levels in those with inflammatory bowel disease without PSC (IBD) 
and healthy controls (HC) included for comparison. Data presented as median and IQR. Capped lines and asterisks indicate statistically significant 
differences on MW testing in (A) and on post hoc correction via the Bonferroni–Dunn method in (B) following the KW test (p <0.001). 
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5.2.2 sVAP-1 levels and clinical correlates 
As the range of values varied greatly across all aetiologies I investigated whether 
sVAP-1 levels are associated with particular clinical characteristics. Previous studies 
have illustrated that sVAP-1 levels remains stable upon storage, enabling longitudinal 
studies to be conducted [331]. Adopting the PSC group as a derivation cohort, clinical 
data were collected from patient records and a correlation analysis carried out on 
sVAP-1 levels and the collected variables (Table 5.3). No significant associations 
were observed between sVAP-1 levels and IBD status, patient gender, treatment 
regimen with UDCA or antibiotics or immunosuppression, ascending cholangitis 
flares, or autoantibody positivity; nor was there any correlation with liver 
biochemistry, renal indices, IgG levels or UKELD score (the latter representing a 
medical scoring system used to allocate liver allografts in the UK). 
 
However, indices of advanced liver disease, specifically cirrhosis and 
thrombocytopenia, did correlate with sVAP-1 levels; consistent with the data 
presented in Chapter 4 showing increased hepatic VAP-1 expression in end-stage 
liver disease. No significant difference in sVAP-1 levels was detectable between 
patients with compensated versus decompensated cirrhosis (MW test p = 0.380).  
 
Given that a greater degree of PSC patients were cirrhotic relative to the PBC and 
AIH cohorts studied, a restricted analysis was performed exclusively in non-cirrhotic 
patients. Significant differences between the diseases were retained, the highest levels 
being observed in PSC patients (AIH: median 399 ng/mL, IQR 304 – 470 ng/mL; 
PBC: 411 ng/mL, 338 – 507 ng/mL; PSC: 469 ng/mL, 412 – 550 ng/mL; KW p = 
0.039). 
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Table 5.3: sVAP-1 levels according to clinical covariates 
Categorical associations sVAP-1 levels (ng/mL) p value 
Gender    
M vs. F 529 (432-627) 567 (457-698) 0.325 
Disease severity *     
Pre-cirrhotic vs. cirrhotic 462 (406-547) 578 (413-736) 0.006 
Ascending cholangitis *    
Presence vs. absence 550 (376-646) 532 (438-672) 0.350 
IBD     
Presence vs. absence 532 (431-653) 542 (438-663) 0.668 
Active vs. inactive 523 (387-626) 533 (443-672) 0.466 
Colectomy vs. colon intact 534 (443-710) 532 (434 -651) 0.939 
Immunosuppression *    
Exposure vs. absence 516 (418-621) 549 (438-663) 0.630 
UDCA *    
Exposure vs. absence 534 (451-681) 457 (413-571) 0.053 
Antibiotic exposure *    
Exposure vs. absence 566 (395-621) 529 (436-672) 0.600 
ANA     
Positive vs. negative 517 (432-696) 551 (435-631) 0.857 
ASMA     
Positive vs. negative 508 (421-627) 543 (436-676) 0.462 
pANCA    
Positive vs. negative 517 (436-667) 552 (436-663) 0.794 
Continuous variable 
correlations* 
Spearman’s rho p value 
Patient age 0.194 0.027 
AST -0.002 0.993 
ALT -0.076 0.691 
ALP ratio (to ULN) -0.205 0.278 
Bilirubin 0.217 0.250 
Albumin -0.819 0.318 
Platelets -0.585 0.001 
INR 0.014 0.941 
Na
+
 0.135 0.475 
Creatinine -0.242 0.197 
UKELD 0.001 0.995 
IgG 0.195 0.303 
Continuous data presented as median (IQR in parenthesis). Significant differences between groups are 
italicised (crude; not adjusted for multiple observations) and marked in bold (corrected for multiple 
comparisons via the Bonferroni-Dunn method – 24 observations, with an adjusted significance 
threshold of p = 0.002).  
* At time of sampling. 
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5.2.3 sVAP-1 levels and clinical outcome in PSC 
Having identified an association with indices of advanced disease in PSC patients, the 
ability of sVAP-1 to predict clinically significant endpoints was evaluated. As 
relatively few (<10) individuals developed hepatobiliary malignancy during follow-
up, clinical endpoint analysis was restricted to liver transplantation and death. 
Accuracy testing of sVAP-1 was first performed by ROC-curve analysis, as the 
predictor under assessment (sVAP-1) is gauged on a continuous scale. Moreover, the 
area under the ROC curve (AUROC) method represents the most commonly adopted 
technique for evaluating discriminatory power of continuous variables [431,434]; 
with a maximum score of 1.0 indicating 100% sensitivity and specificity, and 0.5 
suggesting no predictive power.  
 
Initially, the ability of sVAP-1 to predict overall transplant-free survival was only 
moderate power (Figure 5.5a), with marginal improvement when restricted to 
predicting liver transplantation only (Figure 5.5b), or liver transplantation and liver-
related death only (Figure 5.5c). A small number of individuals with PSC were listed 
for transplantation at time of blood sampling, which may inadvertently have led to 
pre-selection bias in terms of outcome prediction. The average waiting time for 
transplantation following listing is ~ 4 – 5 months (UK NHS Blood and Transplant; 
www.organdonation.nhs.uk), following satisfactory anaesthetic and surgical 
assessment (~1 – 2 months). In this regard, Kaplan–Meier survivorship estimates 
were re-calculated for only those sustaining a clinical event >6 months after blood 
sampling (Figure 5.6a-c). Re-examination of sVAP-1 levels by ROC-curve analysis in 
the remaining cohort illustrated marked improvement in predictive capacity (Figure 
5.6d-f). 
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Figure 5.5: Accuracy of sVAP-1 in predicting transplant-free survival. 
Receiver operator characteristic (ROC)-curve analysis of sVAP-1 levels in predicting clinical outcome; specifically, liver transplantation or death (A), liver transplantation 
only (B), and liver transplantation and liver-related death (C). Area under the curve (AUROC) calculated in relational to diagonal reference line and presented with 95% 
confidence intervals in parenthesis. Data inclusive of all PSC patients from time of sampling. 
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Figure 5.6: ROC and Kaplan–Meier curves following exclusion of clinical events in the first 6 months 
Kaplan–Meier survivorship estimates (A – C) and ROC-curves (D – F) exclusively for those individuals in whom follow-up exceeded 6 months. 
Clinical endpoints are indicated as transplant–free survival (A, D), liver transplantation only (B, E) and liver transplantation/liver-related death (C, F).  
 241 
ROC-curves were used to estimate a cut-off level of sVAP-1 that demonstrated 
maximum sensitivity and specificity with respect to outcome prediction. As the 
primary endpoint was overall transplant-free survival, cut-points were derived from 
this respective ROC-curve in which a levels of 529 ng/mL yielded sensitivity 75% 
and specificity of 60%. This cut-point retained predictive value for liver 
transplantation only (sensitivity 76%, specificity 57%) as well as liver 
transplantation/liver-related death (sensitivity 77%, specificity 60%). Improvement in 
predictive ability of liver transplantation only was obtained using a discriminatory 
value of 579ng/mL (sensitivity 72%, specificity 73%). This, however, did not perform 
as well when including mortality as an endpoint.  
 
Dichotomising the PSC cohort based on the cut-point of 529 ng/mL, patients with an 
elevated sVAP-1 levels were observed to have significantly poorer clinical outcome 
with regard to transplant-free survival, liver transplantation alone, or liver transplant 
and liver related death (illustrated in Figure 5.7a – c). Similar discrimination was 
illustrated using 579 ng/mL as a cut-off for the transplantation alone endpoint (Figure 
5.7d).  
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Figure 5.7: Kaplan–Meier survivorship estimates following derivation of sVAP-1 cut-points in PSC 
Adopting a cut-point of 529ng/mL, a differential clinical course was observed across the PSC cohort in terms of overall transplant-free 
survival (A), liver transplantation and liver related death (B), and incidence of liver transplantation alone (C). Kaplan–Meier curves 
also provided for liver transplantation incidence using the 579ng/mL cut-point (D). Statistically significant differences in survival 
calculated via log-rank method. 
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As an additional method of analysing survival, Cox proportional hazards‘ models 
were created for the derived cut-points. Cox regression (hazards ratios, HR) involves 
durational modelling and possesses the ability to account for survival rates over time, 
being able to take full advantage of the time dimension compared to static models 
such as logistic regression (odds ratios, OR) that are limited in their ability to 
determine the likelihood of events at a singular time point.  
 
An sVAP-1 levels >529 ng/mL was associated with significantly increased risk of 
progression to liver transplantation or death (Table 5.4). The resultant HR represents 
magnitude of risk, wherein patients with a levels >529 ng/mL have ~4 times higher 
risk than individuals with sVAP-1 levels below the cut-point. Performing a similar 
analysis for all other accrued clinical variables, the presence of thrombocytopenia, 
hypoalbuminaemia or the collective index of liver cirrhosis; elevated serum AST; 
ascending cholangitis flares ± associated antibiotic treatment, were all predictive of 
poorer clinical outcome in the PSC cohort.  
 
On multivariable analysis taking a weighted account of all risk factors, statistical 
significance was retained for serum AST (weak predictor), cirrhosis, ascending 
cholangitis and serum sVAP-1 levels (Table 5.4). This suggests elevated sVAP-1 
levels are an independent predictor of poor clinical outcome; however, one cannot 
discount potential confounding effects from the presence of cirrhosis. In an effort to 
resolve this issue, survival analysis was restricted to patients with pre-existing 
evidence of cirrhosis. Even across this pre-defined cohort, a levels >529 ng/mL 
significantly associated with adverse outcome (HR 2.02, 1.17 – 3.51; p = 0.012; 
Figure 5.8) implying independent and additive predictive utility to cirrhosis. 
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Table 5.4: Covariates associated with future risk of death or liver transplantation     
 
Univariate analysis 
Multivariable analysis  
(adjusted for platelet count and serum albumin) 
Multivariable analysis  
(adjusted for cirrhosis) 
Unadjusted 
HR (95% CI) 
p value 
Adjusted 
HR (95% CI) 
p value 
Adjusted 
HR (95% CI) 
p value 
Cirrhosis 6.02 (1.83-20.00) 0.003 N/A 7.69 (2.04-27.03) 0.002 
Ascending cholangitis 2.62 (1.20-5.72) 0.016 3.40 (1.46-7.90) 0.004 4.23 (1.72-10.42) 0.002 
Antibiotic exposure 1.91 (1.24-2.92) 0.003 n.s. n.s. n.s. n.s. 
Thrombocytopenia  
(per 50x 10
3 
cells
 
dec.)* 
1.22 (1.02-1.42) 0.028 n.s. n.s. N.A 
Hypoalbuminaemia 1.21 (1.12-1.30) <0.001 1.18 (1.08-1.28) <0.001 N.A 
Elevated serum AST 1.01 (1.00-1.01) 0.006 1.01 (1.00-1.02) 0.003 1.02 (1.01-1.02) <0.001 
sVAP-1  
(per-100ng inc.)* 
1.11 (1.11-1.22) 0.002 (not included) (not included) 
sVAP-1: > 529ng/mL 3.76 (1.68-8.47) 0.001 2.70 (1.03-714) 0.043 3.85 (1.57-9.34) 0.003 
* Values in parenthesis indicate that the degree of risk (indicated by HR values in the adjacent columns) varies according to magnitude change in the 
given variable. 
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Figure 5.8: Predictive value of sVAP-1 in PSC cirrhosis 
Kaplan–Meier survivorship estimate restricted to cirrhotic PSC patients. Statistically significant 
differences in survival calculated via the log-rank method. 
 
 
5.2.4 Assessment of serum SSAO activity 
In a manner similar to that described in Chapter 4 the rate of production of H2O2 was 
used as a proxy for measuring enzyme activity, and normalised to a given volume of 
serum. Initially enzyme activity was measured following inclusion of MAO-A and 
MAO-B inhibitors and presented as residual activity following semicarbazide 
correction (Figure 5.9). As with hepatic enzyme activity and serum sVAP-1 levels, 
patients with PSC exhibited greater serum enzyme activity (median 115 pmol 
H2O2/min/mL serum, IQR 101 – 188 pmol) than patients with AIH (78pmol, 51 – 125 
pmol), PBC (54 pmol, 33 – 91 pmol), IBD alone (60 pmol, 39 – 73 pmol) or healthy 
controls (84 pmol, 78 – 106 pmol), although the distribution across any given 
aetiology was broad. As expected, there was a significant correlation with serum 
sVAP-1 levels, suggesting that VAP-1 accounted for the majority of semicarbazide 
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sensitive amine oxidase activity in human circulation, in keeping with current 
literature [214,414]. 
 
 
 
 
Figure 5.9: sVAP-1 enzyme activity and correlation with levels 
Enzyme activity was assessed (method 1) in human serum across the 3 autoimmune liver diseases, 
IBD alone and healthy controls (A) – data presented as median and IQR, with capped lines and 
asterisks indicating statistically significant differences (KW-test and post-hoc correction via the 
Bonferroni-Dunn method). Correlation between enzyme activity and sVAP-1 concentration for 
PSC patients is provided in (B).  
 
 
This preliminary series of experiments included relatively few patient samples; and as 
previously discussed the technique involving addition of MAO inhibitors was later 
substituted in favour of enzyme capture and immobilisation using high affinity 
binding Maxisorp plates. Using the residual of samples available following sVAP-1 
ELISA, amine oxidase activity was measured in patients with PBC, PSC, and IBD 
alone and healthy controls. Unfortunately, serum samples from AIH patients were no 
longer available at this point.  
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Across this relatively large sample set, sVAP-1 enzyme activity displayed 
considerable deviation from a normal distribution (Figure 5.10). Contrary to previous 
results, significant differences between PSC, PBC and healthy controls were no 
longer evident on post-hoc testing (Figure 5.11). Patients with IBD however, 
continued to demonstrate persistently low sVAP-1 enzyme activity. 
 
 
 
Figure 5.10: Distribution of sVAP-1 enzyme activity across the PSC study cohort 
Quantile-quantile (Q-Q) plots of enzyme activity indicate deviation from the expected normal distribution 
(diagonal) reference line (A). Extent deviation from normal across the sample population is provided in the 
detrended Q-Q plot in (B). 
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Figure 5.11: sVAP-1 enzyme activity following protein capture 
sVAP-1 enzyme activity presented for patients with PBC (median 108 pmol H2O2/min/mL serum; IQR 
69 – 140 pmol), PSC (109 pmol; 90 – 153pmol), IBD alone (72 pmol; 46 – 105 pmol) and HC (118 
pmol; 71 – 150 pmol). Capped lines and asterisks indicative of statistically significant differences on 
post-hoc testing via Bonferroni-Dunn method (KW test p <0.001). 
 
 
In the PSC cohort, there was no significant association or correlation between serum 
enzyme activity and any assessed clinical parameters, with the exception of patient 
gender (Table 5.5); noteworthy given that population studies report a male 
predominance of PSC. Of note, although elevated enzyme activity was observed in 
patients with cirrhosis relative to pre-cirrhotic individuals, these did not reach 
statistical significance unlike sVAP-1 levelss (MW test). Given the observed 
associations between sVAP-1 levels and disease stage as well as clinical outcome, 
survival analysis was conducted against serum enzyme activity. However, ROC-
curves demonstrated poor predictive performance (AUROC 0.497, 0.274 – 0.721; p = 
0.980) and such assessments were not conducted any further. 
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Table 5.5: sVAP-1 enzyme activity according to clinical covariates 
Categorical associations 
sVAP-1 activity  
(pmol H2O2/min/mL serum) 
p value 
Gender    
M vs. F 131.86  
(103.26-201.63) 
89.96  
(76.19-104.72) 
0.003 
Disease severity *     
Pre-cirrhotic vs. cirrhotic 104.64  
(86.33-120.82) 
133.49  
(97.57-203.99) 
0.062 
Ascending cholangitis *    
Presence vs. absence 107.46  
(96.00-149.03) 
114.89  
(89.64-176.25) 
1.000 
IBD     
Presence vs. absence 108.97  
(89.01-171.18) 
118.16  
(106.77-140.79) 
0.669 
Active vs. inactive 118.25 
(88.38-185.85) 
108.97  
(90.94-160-13) 
0.804 
Colectomy vs. colon intact 99.72  
(93.53-131.07) 
116.78  
(89.64-176.25) 
0.326 
Immunosuppression *    
Exposure vs. absence 89.64 
(87.14-131.86) 
116.78 
(97.57-171.77) 
0.327 
UDCA *    
Exposure vs. absence 108.92 
(88.39-151.84) 
115.68  
(99.61-185.85) 
0.540 
Antibiotic exposure *    
Exposure vs. absence 140.79 
(95.63-168.83) 
108.92  
(89.64-167.30) 
0.649 
ANA     
Positive vs. negative 101.87  
(79.72-151.84) 
114.89  
(99.61-201.63) 
0.131 
ASMA     
Positive vs. negative 104.29  
(88.39-130-36) 
116.78 
(92.93-181.04) 
0.418 
pANCA    
Positive vs. negative 133.49 
(90.34-201.63) 
106.77 
(89.01-149.03) 
0.523 
Continuous variable correlations* Spearman’s rho p value 
Patient age 0.073 0.463 
AST -0.103 0.326 
ALT -0.199 0.055 
ALP ratio (to ULN) -0.23 0.816 
Bilirubin 0.106 0.294 
Albumin 0.017 0.865 
Platelets -0.021 0.829 
INR -0.074 0.498 
Na
+
 -0.012 0.910 
Creatinine 0.033 0.737 
UKELD 0.099 0.326 
IgG -0.052 0.620 
Data for categorical variables expressed as number (percentages in parenthesis). Continuous variables 
expressed as median (IQR in parenthesis).  
* At time of sampling. 
§ Previously treated – not present at time of sampling. 
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Unexpectedly, serum VAP-1 levels and enzyme activity no longer retained a 
significant correlation following assessment of the latter via the Maxisorp method 
(Figure 5.12).  
 
 
Figure 5.12: sVAP-1 enzyme activity (MaxiSorp) vs. sVAP-1 levels 
Correlation between sVAP-1 enzyme activity and sVAP-1 levels in PSC serum following assessment 
of the former with the MaxiSorp method.  
 
 
This observation could have been due to a number of factors the concentration of 
TK8-18 antibody (5 g/mL; 100 L/well = 0.5 g/well) may not have been sufficient 
to capture high levelss of sVAP-1 in PSC sera. A stepwise restriction analysis based 
on 100ng/mL increments of sVAP-1 was conducted and compared across respective 
enzyme activity in the same samples. Only in the presence of sVAP-1 levels <400 
ng/mL did enzyme activity correlate with circulating concenrations (Table 5.6). The 
number of individuals lacking paired serum sVAP-1 measurements and enzyme 
activity measurements is a recognised limitation, and may also have contributed to 
discrepancies from incomplete data. Further dose finding/optimisation steps are 
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therefore necessary with the Maxisorp method, incorporating incremental TK8-18 
antibody concentrations to ensure maximum protein capture. 
 
Table 5.6: Correlation between sVAP-1 levels and enzyme activity across cut-offs 
Serum sVAP-1 levels  No. of XY pairs
§
 Levels vs. enzyme 
correlation coefficient *  
p value * 
<400ng/mL 10 0.770 0.013 
<500ng/mL 21 0.292 0.199 
<600ng/mL 36 0.083 0.631 
<700ng/mL 40 0.123 0.451 
<1500ng/mL ^ 45 0.175 0.517 
* Spearman‘s rank correlation coefficient. 
§ Number of cases with paired serum sVAP-1 levels and enzyme activity. 
 
 
Another possibility to consider was whether the capture antibody TK8-18 exerts an 
inhibitory effect on enzyme activity. To test this hypothesis, recombinant VAP-1 at 
increasing concentrations was incubated with 5 g TK8-18, utilising benzylamine as 
the archetypal substrate. Semicarbazide (250 M) was utilised in parallel as a positive 
control for 100% enzyme inhibition. Only a small, non-significant degree of 
inhibition was seen with TK8-18 (mean 9.5%, SEM 3.7; Figure 5.13), in keeping with 
error of technical replicates within the assay. 
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Figure 5.13: Enzyme inhibition of VAP-1 by TK8-18 vs. semicarbazide 
Effects on enzyme inhibition were compared by TK8-18 and semicarbazide in the Amplex Red assay. 
Data points representative of the mean of 2 independent experiments (each consisting of 3 technical 
replicates). Asterisks denote statistically significant inhibition from untreated samples (paired t-test). 
 
5.2.5 Detection of methylamine by HPLC 
In Chapter 4 data were presented outlining the ability of different biological amines to 
act as substrates for VAP-1 enzyme activity. As some of these are physiological 
amines or produced by gut bacteria I investigated whether patients have elevated 
circulating levels of these substrates. Several methods of amine quantification have 
been described, particularly for methylamine. However, none have been deemed 
sufficiently sensitive or selective for use in human blood and tissues due to 
interference from background proteins, and more so the very low boiling point 
(methylamine evaporates at –6oC). For the purposes of this study I adapted 
fluorometric HPLC using FMOC as a derivatising reagent as recently described by 
Xiao et al. [340]. 
 
First, known concentrations of methylamine were prepared and serial chromatograms 
recorded. Using this technique FMOC peaks were clearly visible in chromatograms at 
~20 – 25 minutes but absent from FMOC-free samples (Figure 5.14).  
 253 
 
Serum-free samples were spiked with increasing concentrations of methylamine in the 
presence or absence of FMOC; an amine peak only being manifest in samples bearing 
both agents. The area under each peak corresponded to the quantity of amine present 
within any given sample and was used to generate a standard curve (Figure 5.15a).  
 
Unfortunately this method was not able to confidently discern methylamine 
concentration in serum, largely due to an excess of background noise peaks in human 
sera (Figure 5.15b), which may have been a consequence of the extraction procedure. 
Furthermore, the protocol was not deemed appropriate for high throughput use, 
mostly due to prolonged evaporation times (>4 hours for 2 samples) and consequently 
an inability to process multiple samples simultaneously. Following repeated attempts 
at validation, efforts to quantify methylamine using this approach were abandoned. 
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Figure 5.14: Quantification of methylamine by HPLC 
Methylamine quantification was attempted using high-performance liquid chromatography (HPLC). Representative peaks 
presented for FMOC (derivatising agent) containing samples ± methylamine. Heights of the peaks are measured in 
milliabsorbance units. The corresponding peaks for FMOC (peak 1) are illustrated in the FMOC containing samples (A). 
The methylamine peak (peak 2) is seen in the sample containing 50M methylamine, but not in blank (0M) samples, or 
those free of FMOC (B). Non-specific signals (noise peak 3) were common, and attributed to solvents used in the 
procedure. 
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Figure 5.15: Determination of methylamine concentration in serum 
Using the area under the curve (height in milliabsorbance units x duration of peak) a standard curve 
was created corresponding to known methylamine concentrations (A). Analysis of serum methylamine 
was not possible due to the presence of several possible methylamine peaks – representative specimen 
illustrated (B). 
 
5.2.6 Assessing intrinsic putative substrate concentrations 
As an alternative to quantifying methylamine concentration, efforts were made to 
indirectly measure amine substrate contributions in human serum. Adapting the 
Amplex red assay, serum sVAP-1 activity was measured without addition of any 
exogenous substrates in the presence of MAO inhibitors and in parallel to 
semicarbazide treatment (method 1). The rationale for doing so was that in the 
absence of exogenous substrate, any detectable sVAP-1 activity would be attributable 
to pre-existing substrates in a given sample. However, no detectable differences were 
illustrated between semicarbazide–treated versus semicarbazide–free samples (Figure 
5.16), possibly indicating that whatever substrate was present in serum has long since 
evaporated, had been consumed in enzymatic reactions prior to sampling, was present 
at too low concentrations (< Km) to undergo rapid catalysis, or produced quantities of 
H2O2 below sensitivity limit of the assay.  
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Figure 5.16: Substrate-free enzyme activity in human sera 
Background serum sVAP-1 enzyme activity was assessed in the absence of exogenous substrate across 
autoimmune liver disease and HC samples. Amine oxidase activity attributable to sVAP-1 was 
determined based on differences following inclusion of semicarbazide, ScZ (VAP-1 enzyme inhibitor). 
Representative results shown of n=6 cases per aetiology run in triplicate. 
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5.3 Discussion 
Herein, I demonstrate that serum sVAP-1 levels are elevated in patients with chronic 
autoimmune hepatobiliary disease. Serum VAP-1 levels were greatest in PSC patients 
and correlated with surrogate indices of cirrhosis. A notable proportion of patients in 
our PSC cohort were cirrhotic relative to PBC or AIH, a factor likely contributing to 
significantly poorer outcome. Nevertheless, when a restricted analysis was performed 
exclusively in non-cirrhotic patients, sVAP-1 levels were still greatest in the PSC 
population.  
 
Elevated sVAP-1 concentration was a significant predictor of poor long-term outcome 
in PSC patients; specifically, progression to liver transplantation and early mortality – 
the latter likely attributable to liver-related death. Moreover, sVAP-1 retained 
independent predictive capacity on robust statistical testing, following adjustment of 
other covariates influencing clinical outcome such as liver disease severity. Moreover, 
sVAP-1 retained predictive capability in the cohort of individuals with evidence of 
cirrhosis at baseline, suggesting independent and additive predictive value in PSC 
patients with pre-existing cirrhotic liver disease. 
 
In contradistinction, serum sVAP-1 enzyme activity although elevated in PSC patients 
relative to those with IBD alone, was not significantly greater than healthy controls; 
neither did it correlate with any specific clinical parameter, except gender. An 
assessment of circulating methylamine concentration via HPLC was also conducted, 
which although partly successful was not deemed practical for high throughput 
application.  
 258 
5.3.1 Quantification of serum sVAP-1 levels in autoimmune liver disease 
In Chapter 4, data were presented illustrating elevated VAP-1 gene expression and 
enzyme activity in chronic liver disease tissue relative to non-inflamed/non-cirrhotic 
liver with particularly high levels seen in patients with PSC. The liver is a major 
source of sVAP-1, which is proposed to enter circulation via proteolytic cleavage 
from the surface of endothelial cells and adipocytes [328], with additional secretion 
by activated liver myofibroblasts [214]. The mechanism of release however remains 
poorly understood although there is some evidence to implicate a metalloproteinase 
[319]. Soluble VAP-1 levels are also increased in patients with NAFLD independent 
of age and metabolic phenotype; and correlate with histological disease severity 
(inflammation and fibrosis) and outcome [214] using the same assays for sVAP-1 
quantification as my study.  
 
Previous studies measuring sVAP-1 in patients with autoimmune liver disease did not 
report higher levelss in PSC compared with AIH or PBC [414]. However, these 
techniques were performed on small number of retrospectively collected samples and 
the methodology used a chemiluminescence sandwich ELISA as opposed to 
europium–coupled time-resolved immunofluorescence (ECRIF) used in this chapter. 
Dissociation-enhanced lanthanide fluoroimmunoassays are reportedly the most 
sensitive and reliable immunoassay platforms, able to achieve sensitivities several 
orders of magnitude superior to colorimetric assays. Incorporation of lanthanide 
chelates like europium and time-resolved detection systems have been proposed to 
eliminate background interference, as lanthanide decay occurs over a prolonged time 
period compared to natural fluorescence [435]. Moreover, time resolution enables 
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fluorescence specific to europium to be quantified and proposed as conferring the 
highest degree of sensitivity.  
 
Using this technique I found that sVAP-1 levelss were significantly higher in PSC 
patients compared to other disease groups. Given that sVAP-1 levels correlated with 
indices of advanced liver disease (cirrhosis as a combinatory parameter, or platelet 
count as an isolated covariate), a restricted analysis in non-cirrhotic individuals was 
performed; in which elevated sVAP-1 levels retained significant association with 
PSC. The low values in patients with IBD-alone is perhaps unsurprising and in 
keeping with the studies by Koutroubakis and Kurkijarvi who report similar serum 
values in UC, Crohn‘s disease and healthy controls [330,436] and with a recent study 
in colorectal cancer [437]. These findings support evidence that the source of sVAP-1 
is from the liver in patients with PSC, not the gut.  
 
Perhaps the most striking finding however, was the independent ability of sVAP-1 
levels to predict clinical outcome; specifically, transplant-free survival. Several other 
liver disorders are associated with increased circulating levels of soluble adhesion 
molecules for example soluble VCAM-1 and soluble E-selectin with PBC disease 
stage and soluble ICAM-1 with PBC disease activity and severity of cholestasis [438–
440]. More recently our group reported that in a cohort of NAFLD patients (n=144), 
those who subsequently died during follow-up had higher initial sVAP-1 levels than 
survivors [214]. Although this study was not designed for risk stratification by sVAP-
1 (no survival analysis or correction of time-factor) there was suggestion of an 
association between higher protein levels and all-cause mortality. In a prospective 
cohort study over 9 years, Finnish individuals with elevated sVAP-1 levels but 
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without documentary evidence of liver disease had a significantly increased risk of 
major cardiovascular events independent of known hazard factors comprising the 
well-known Framingham risk score [331]. Individuals with cardiovascular risk factors 
often have underlying NAFLD in the absence of symptoms [441,442]; and 
reciprocally, morbidity and mortality in patients with NAFLD is most often 
attributable to cardiovascular events. [413] Of note, NAFLD patients also harbour an 
increased risk of colonic neoplasms, and PSC also exhibits higher rates of diabetes 
and cardiovascular events relative to a matched control population [254,332]. A 
common pathogenic link with VAP-1 cannot therefore be discounted.  
 
Early recognition of PSC patients with a predicted poor long-term outlook would be 
very helpful in patient management allowing effective triage into clinical trials and 
early referral for transplantation and this could become an important clinical use of 
measuring sVAP-1 levels. The association with increased tissue expression, 
circulating levels and enzymatic activity of VAP-1 in PSC provides further support of 
a pathogenic role in PSC. Given the relatively short clinical follow-up time in the 
current PSC cohort, obtaining serial readings in a meaningful number of patients was 
not possible, and it remains to be seen whether a change in circulating levels (sVAP-
1 over time) corresponds to better or worse clinical outcome.  
 
The shortened clinical follow-up time also precluded assessment of long-term 
transplant-free survival as a ‗hard‘ end-point in our cohort. Further external validation 
of our results will be important although challenging given the considerable 
challenges to long-term prospective studies in PSC provided by the slowly 
progressive nature of the disease, its relative rarity and the absence of routine 
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histological evaluation as part of standard of care. The predictive performance would 
also benefit from being compared to other potential biomarkers including transient 
elastography [443], for which further validation is required to determine its value as a 
predictor of liver fibrosis and long-term outcomes in PSC. 
 
5.3.2 Serum enzyme activity 
sVAP-1 enzyme activity has been shown to closely correlate with serum protein 
levels [214]. In keeping with the tissue expression and circulating levels of sVAP-1, 
enzyme activity was significantly greater in PSC compared with other liver diseases, 
healthy controls and patients with IBD alone. Circulating sVAP-1 accounts for most 
of the amine oxidase activity detected in mouse and human serum [328,330,414]; 
however, the need to eliminate contributions from other circulating amine oxidases 
(MAO-A/MAO-B for instance) in the analysis led me to modify the Amplex Red 
assay (please see Chapters 2 and 4). This allowed a more accurate estimation of intra-
hepatic VAP-1 enzyme activity but when applied to serum yielded results that were 
different from those seen using the conventional method. As such, correlations 
between serum protein level and enzyme activity were lost leading me to investigate 
why this might have occurred. Reassuringly, the capture antibody TK8-18 did not 
inhibit enzyme activity. The fact that a correlation between enzyme activity and 
serum levels were seen at the lower range of sVAP-1 values suggests further 
optimisation of the enzyme capture and immobilisation method is needed, perhaps 
using higher antibody concentrations for extracting protein. Unfortunately not all 
serum samples in which sVAP-1 levels was measured were available for assessment 
of enzyme activity and I was unable to obtain more samples from the AIH patient 
cohort, thus enzyme activity in this aetiology was not assessed with the new method. 
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Alternatively, it is possible that an SSAO variant is present in the serum that is not 
recognised by the TK8-18 antibody [410]. Differences between tissue and serum 
activity could also arise as a consequence of differences in sample processing; for 
instance the absence/presence of lysis buffer in the former, or perhaps stearic 
hindrance due to high density of VAP-1 in well-plates artificially reducing enzyme 
activity. 
 
The possibility remains that serum enzyme activity may not differ between diseases, 
despite detectable differences in circulating protein levels. It is plausible that older 
methods were affected by background fluorescence on the Amplex Red fluorogen, 
yielding falsely elevated readings that are no longer apparent with the protein capture 
method. Another explanation may reside in alternatively spliced variants of VAP-1 
bearing different enzyme activities [410]. This aspect has not yet been explored in 
gastrointestinal or liver disease, but if alternative forms of VAP-1 exist then perhaps 
variants with higher enzyme activity are retained in the liver during active 
inflammation whereas formats with lower activity have a higher turnover and cleaved 
into the circulation. This would not however explain the close correlation between 
protein levels and enzyme activity observed with previous methods of assessment.  
 
5.3.3 Possible roles of soluble VAP-1  
The physiological or pathological function of circulating sVAP-1 is unclear. Akin to 
the membrane-bound endothelial form, sVAP-1 is decorated with sialic acid moieties 
that are proposed to confer the molecule with its adhesive properties. Given the ability 
to induce lymphocyte chemotaxis [214], sVAP-1 may represent a compensatory 
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regulatory mechanism for reducing cell surface expression and tissue specific 
lymphocyte recruitment (negative feedback).  
 
Alternatively, Kurkijarvi et al. propose that prior binding of sVAP-1 to the surface of 
lymphocytes confers an increase in their adhesive status, and results in overexpression 
and/or avidity of other cell-surface adhesion molecules (a positive feedback 
mechanism) [330]. The investigators created endothelial VAP-1 transfectants and 
observed increased lymphocyte binding following pre-incubation with sVAP-1. 
However, when lymphocytes were pre-incubated in sVAP-1 free conditions, adhesion 
was significantly attenuated. Moreover, lymphocyte binding to mock-transfected 
endothelial cell lines did not increase despite pre-incubation with sVAP-1. Therefore 
it is plausible that lymphocytes recognise endothelial adhesion molecules, expression 
of which depends on VAP-1 enzymatic function. This would fit with PSC patients 
having increased hepatic VAP-1 expression and enzyme activity and increased local 
expression of MAdCAM-1 and other IgSF members on the endothelial surface. 
Increased circulating sVAP-1 concentrations could also increased avidity and cell-
binding capabilities of circulating lymphocytes, and collectively these mechanisms 
would facilitate increased lymphocyte-HSEC adhesion under pro-inflammatory 
conditions. 
 
The role of circulating VAP-1 enzymatic activity is also unclear. Such a presence is 
speculated to induce a scavenging effect on circulating amines, and lead to the 
production of potentially cytotoxic aldehydes [414]. Generation of H2O2 from the 
deamination reaction may also contribute free radical generation in hepatobiliary 
disease. VAP-1 is highly expressed by adipocytes, and provision of amine substrates 
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has been shown to stimulate glucose uptake and inhibit lipolysis in a mechanism 
dependent upon H2O2 [334,335]. This is of particular importance given the 
association of both NAFLD and PSC with elevated hepatic and sVAP-1 levels, as 
well as increased diabetes and cardiovascular risk.  
 
5.3.4 Quantifying serum methylamine 
In Chapter 4, I showed that certain amines induce VAP-1 enzyme activity with 
greater efficiency and efficacy than others, with particular potency demonstrated for 
dopamine, cysteamine and methylamine. Based on these results, I attempted to 
quantify VAP-1 substrates in human tissue. Our previous studies of VAP-1 enzyme 
activity used methylamine to induce functional consequences in vivo [294] and so I 
focussed by investigations on this amine.  
 
Methods for analysing methylamine in foodstuffs have been reported although none 
has been validated as sufficiently sensitive or selective for microanalysis in blood and 
human tissue. Quantitative assessment in biological samples is hampered due to 
volatility (melting and boiling point –93oC and –6oC, respectively) and 
hydrolipophilicity; as well as interference by complex biological constituents. A 
technique developed by Xiao et al. in which methylamine was conjugated to FMOC 
and analysed in a HPLC system was claimed to overcome several analytical 
difficulties [340]. However I was unable to replicate their success despite multiple 
attempts, largely due to an overwhelming contribution of background signal from 
various biological components. Moreover, the volatility of methylamine meant that 
solvent evaporation had to be undertaken cautiously over several hours per-sample, 
and was impractical for multiple sample processing. With later enzyme kinetic assays, 
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it became evident that cysteamine is the substrate associated with highest enzyme 
efficiency (see Chapter 4), and HPLC techniques for quantifying cysteamine from E. 
coli have recently been reported [444]. The relatively higher melting point (~95
o
C) 
would theoretically provide increased stability in solution and is an opportunity yet to 
be explored in human sera. 
 
An alternative approach to assess circulating substrates in PSC patients is to simply 
assess background amine oxidase activity in serum following MAO-A and MAO-B 
pre-inhibition without addition of exogenous substrate. However, no amine oxidase 
activity was detectable using this approach (no difference between untreated versus 
semicarbazide treated wells). This is probably due to the volatility of amines (e.g. 
methylamine) resulting in their evaporation at the benchside; or perhaps more likely 
that any circulating substrates would be consumed by circulating sVAP-1 amine 
oxidase activity prior to analysis. One possible avenue to circumvent these technical 
obstacles would be to precipitate all VAP-1 from serum at the time of sample 
collection, and then supplement rVAP-1 at a known concentration. This would mean 
any measured differences in enzyme activity between samples would be directly 
attributable to differences in endogenous substrate quantity. If successful, such an 
endeavour could also be applied to tissue protein lysates from human liver. 
 
5.3.5 Summary 
Soluble VAP-1 levels, were increased across the spectrum of autoimmune 
hepatobiliary diseases with the highest levels recorded in patients with PSC. Within 
each disease there was a wide range of values probably reflecting disease severity. 
The finding that sVAP-1 levels correlate with clinical outcome is novel and given the 
 266 
dearth of reputable biomarkers in PSC of potential clinical use. However it needs to 
be verified by independent external validation. Putative functional consequences of 
increased hepatic and soluble VAP-1 have been proposed, which could plausibly 
enhance lymphocyte-HSEC adhesion through up-regulation of cell recruitment 
pathways normally restricted to the gut.  
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6 Results IV: VAP-1 enzyme inhibition in vivo 
6.1 Introduction 
The previous chapters show that intrahepatic VAP-1 expression and enzyme activity 
are up-regulated in PSC, the functional consequences of which may contribute to 
increased lymphocyte recruitment. That enzyme activity is substrate specific, possibly 
influenced by the delivery via the portal vein of amines from the gut, provides further 
support to the hypothesis that the intestine has a pivotal role in driving hepatobiliary 
inflammation in PSC. Moreover, elevated circulating sVAP-1 levels are detected in 
PSC probably arising from the injured liver, and predict clinical outcome.  
 
Therapeutic targeting of VAP-1, through its adhesion molecule properties and enzyme 
activity, may not only reduce pro-inflammatory lymphocyte recruitment to the liver 
directly thereby reducing inflammation and fibrosis, but may also attenuate the 
expression of other cell adhesion molecules implicated in PSC disease pathogenesis. 
This led me to determine whether we could establish a murine model of PSC and use 
it to confirm the role of VAP-1 in disease pathogenesis. This would also provide a 
preclinical model in which to test the potential of inhibiting VAP-1 therapeutically in 
PSC. In this regard, a mouse model of sclerosing cholangitis (Mdr2
–/–
) was 
established in-house and crossed with mice bearing a mutated variant of VAP-1 in 
which VAP-1 distribution in tissue is normal but due to a single amino acid mutation 
the molecule has no amine oxidase activity. I refer to these animals as Ssao KO or 
Ssao
–/–
 mice [214,320]). The resultant Mdr2
–/–
Ssao
–/–
 mice were carefully phenotyped 
through assessment of the inflammatory infiltrate, biliary injury and severity of liver 
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fibrosis. The notable challenge of assessing VAP-1 enzyme activity in mice is also 
discussed in this chapter. 
 
6.2 Findings 
6.2.1 Characterisation of the Mdr2–/– mouse 
Several animal models of PSC have been developed, although none recapitulate all 
features of the human condition [445]. The most widely studied model as evidenced 
by literature search is the Mdr2 knockout mouse [342,446]. The lack of MDR impairs 
handling of several factors including non-micellar bound bile, resulting in a toxic 
injury and inflammatory response leading to histological features of a sclerosing 
cholangitis. However the model does not recapitulate all the features of PSC and in 
particular is not associated with colitis [447]. Most previous studies with Mdr2
–/–
 
mice have been conducted on an FVB/N background. Given our intent to establish a 
cross with the Ssao
–/–
 strain (C57BL/6), mice bearing a targeted deletion of the MDR2 
biliary transporter on the same background strain were obtained (a kind gift from 
Prof. Lohse; Hamburg, Germany), and phenotyped in house to establish a baseline. 
Due to project license limitations, it was not possible to yield comparative results 
against C57BL/6 wild-type mice (free of any liver injury) as a negative control.  
 
6.2.1.1 Inflammatory liver injury 
The suitability of various serum tests to monitor cholestasis and hepatobiliary 
inflammation has been a topic of debate [448]. Whilst serum ALP is often applied to 
stratify biliary disease in the clinical setting [449] and may accurately reflect 
cholestasis in certain mouse models [448], there is emerging evidence that most ALP 
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in mice on a C57BL/6 background is not derived from the liver or gut [450]. FVB/N 
Mdr2
–/–
 mice exhibit a steady elevation in serum ALT and ALP levels in line with 
development of histological cholangitis, levels plateauing beyond six weeks of age. 
Matched C57BL/6 Mdr2
–/–
 mice however, illustrate the highest ALP levels early in 
life at a time when bone growth is most prominent, with a sharp decline toward 
normal values as they grow older (Figure 6.1) [451]. Given these observations, serum 
ALT rather than ALP, was chosen as a biochemical surrogate of liver inflammation 
[452]. 
  
 
Figure 6.1: Liver biochemistry in the Mdr2
-/-
 model according to age 
Serum ALT and ALP were measured in FVB/N (open bars) and C57Bl/6 (filled bars) Mdr2
 
null mice of 
different ages (4 – 11 mice per group). Whilst a stable elevation in serum liver-derived enzymes is 
evident in FVB/N mice from as early as 6 weeks of age, ALP in C57Bl/6 strains exhibit a sharp decline in 
older mice (at a time when bone growth has completed. Male and female mice used. Data presented as 
median and IQR; asterisks indicative of statistically significant differences (p<0.001; Kruskal–Wallis 
test) [451].  
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Mdr2
–/–
 C57BL/6 mice exhibited marked elevation in serum ALT as early as 6 weeks 
old, with no significant differences between the genders (Figure 6.2). Biochemical 
indices of liver injury worsened with age and were worse in females.  
 
 
Figure 6.2: Liver biochemistry in the Mdr2
-/-
 model according to gender 
Serum ALT in the Mdr2 knockout model (C57Bl6 background) according to age and gender. Data 
presented as mean + SD. Capped lines and asterisks indicate statistically significant differences 
between age groups (MW-test). Data from uninjured wild-type (C57BL/6) mice in other studies 
suggest that normal serum ALT is in the order of 30 – 40 IU/L, although the assays chosen varies 
widely between reports. 
 
 
Immunohistichemical staining for CD45 and H and E staining were used to evaluate 
inflammation. Hepatobiliary inflammation was most prominent in the portal/peri-
portal region from early life (Figure 6.3). In keeping with results of biochemistry, 
progressive liver injury was observed in older age groups (Figure 6.4 and Figure 6.5). 
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Figure 6.3: Hepatobiliary inflammation in Mdr2
–/–
 mice 
Haematoxylin and eosin (H&E) and CD45 (leucocyte marker) histochemical staining at increasing magnification. Representative images shown for female 
mice at ~6 weeks of age, and illustrate inflammatory infiltration of the portal region, particularly noticeable around the bile ducts. Structural denotation as 
follows: asterisks (adjacent to) central veins; portal vein, PV; bile ducts, BD; arteriole, A. 
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Figure 6.4: H&E staining with increasing age in Mdr2
–/–
 mice 
Histochemical staining in Mdr2
–/–
 mice is presented for animals at 6 weeks and 12 weeks of age. 
Progressively worse inflammation of the portal tracts is noted with increasing age. Structural 
denotation as follows: asterisks (adjacent to) central veins; arrows, portal triads; PV, portal veins. 
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Figure 6.5: CD45
+
 leucocyte infiltration with increasing age in Mdr2
–/–
 mice 
CD45 immunohistochemical staining in Mdr2
–/–
 mice at 6 weeks and 12 weeks of age. Histochemical 
staining in Mdr2
–/–
 mice is presented for animals at 6 weeks and 12 weeks of age. Progressively worse 
inflammatory injury is noted with increasing age, and particularly marked in the portal regions. 
Structural denotation as follows: asterisks (adjacent to) central veins; arrows, portal triads; PV, portal 
veins. 
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For quantification of inflammation, digital image analysis (ImageJ) was used to assess 
CD45 staining (Figure 6.6). All analysis was performed on the same day with results 
expressed in terms of pixel count above a set threshold, and as a percentage of total 
viewed area (x200 and x400 magnification as indicated in Figure 6.6). For any given 
slide (2 slides per mouse liver), 10 independent areas were selected at random and the 
mean pixel densitometry calculated.  
 
The CD45
+
 infiltrate increased at 12 weeks of age, although differences did not reach 
statistical significance (MW-test), even when analysed according to distribution of 
inflammatory injury (portal vs. lobular).   
 
  
Figure 6.6: Quantification of CD45
+
 leucocyte infiltration  
Quantitative assessment of CD45 infiltration by ImageJ analysis according to Mdr2
–/–
 mouse age (females only). 
Data provided by percentage surface area at x200 magnification (A), and x400 magnification specifically assessed 
in portal and lobular areas (B). 10 fields of view visualised per mouse liver section/slide (4 – 5 mice in each group). 
Data presented as mean ± SD, and capped lines indicative of comparisons approaching statistical significance on 
MW-test. 
 
Higher magnification views showed conspicuous bile duct lesions, although 
inflammation was more evident at the 6-week time-point (CD45 staining) as 
opposed to older age groups (Figure 6.7). 
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Figure 6.7: Biliary injury in the Mdr2
–/–
 model with increasing age. 
H&E and CD45 histochemical staining in 6-week and 12-week-old mice show dense portal 
infiltrates and bile duct inflammatory lesions (x400 magnification). Structural denotation as 
follows: hepatic arteriole, A; portal veins, PV; bile ducts, BD 
 
CD45 is a pan-leucocyte marker, and for deeper phenotypic evaluation of liver-
infiltrating cell populations flow cytometric analysis was conducted. There are several 
techniques for extraction of liver-infiltrating leucocytes; most of which rely on 
density gradient centrifugation. Given familiarity with Lympholyte-H in the 
purification of human peripheral blood lymphocyte populations, I chose to use 
Lympholyte-M. Despite good lymphocyte yields the yield of myeloid-lineage cell-
types was poor; confirming that Lympholyte should only be used for studying 
lymphoid sub-types. I next tested a discontinuous Percoll gradient which had been 
used successfully to extract infiltrating leucocytes from human colon (detailed in 
Chapter 2 and Chapter 3). Unfortunately, this was associated with contamination by 
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parenchymal cell populations (probable hepatocytes, stellate cells, etc.) and was 
therefore not considered further.  
 
Good lymphoid and myeloid cell yields from mouse liver have been reported using 
Optiprep [214,453]. Although providing the ‗cleanest‘ of all gradients tried so far as 
well as respectable leucocyte populations, several additional problems were 
encountered with this method; particularly the infrequency with which a leucocyte 
band was visible at the interface (<50% of attempts).  
 
Given the intermittent success, I proceeded to identify cell populations without the 
use of a gradient to purify cells. Mouse liver cell suspensions were labelled 
immediately following cell strainer filtration and wash steps (detailed in Chapter 2), 
and at time of analysis all leucocytes were gated based on viability and expression of 
CD45. This resulted in percentage yields comparable to those obtained with Optiprep. 
 
There are several ways in which to quantify the liver-infiltrating leucocyte population. 
The most common are either absolute cell counts using counting beads and 
normalising readings to liver weight; or alternatively to express cell phenotypes of 
interest as a percentage of the total infiltrating CD45 population. Given that I did not 
use gradient centrifugation, its was deemed inappropriate to use the counting bead 
method due to a high likelihood of obtaining erroneous readings (e.g. from beads 
binding to cell debris). Therefore I adopted the latter approach. At 6 weeks, the T-cell 
population comprised predominantly CD3
+
 CD4
+
 cells, with lesser contribution from 
CD3
+
 CD8
+
 subsets (Figure 6.8); similar to that observed for mice on an FVB/N 
background [452] by 12 weeks the situation was reversed, with a predominantly CD8
+
 
 277 
T-cell infiltrate. This is noteworthy given that CD8
+
 T-cells have been implicated as 
key mediators of bile duct destruction in autoimmune cholangitis models [454]. 
However, the majority of infiltrating leucocytes were CD19+ in keeping with reports 
that ~50% of the infiltrating lymphocytes in liver fibrosis models utilising C57BL/6 
mice are B-cells [246]. The remaining lymphocyte population was composed of NK-
cells as identified by CD49b expression [455], which were present with slightly 
increased frequency in male mice at older age groups. Myeloid cells were detected by 
expression of CD11b and included equal contributions of F4/80
+
 macrophages, and 
pro-inflammatory (Gr1
+
) vs. anti-inflammatory (Gr1
–
) monocyte subsets. No 
significant differences were observed between genders or age groups of Mdr2
–/–
 mice.  
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Figure 6.8: Phenotyping of the inflammatory infiltrate in Mdr2
–/–
 mice 
Flow cytometric analysis of infiltrating CD45
+
 leucocytes in the Mdr2
–/– 
model according to mouse age 
and gender. Liver infiltrating lymphocytes were characterised as follows: CD3
+
 CD4
+
 T-cells (A); 
CD3
+
 CD8
+
 T-cells (B); B-cells (not performed for male mice aged 12 weeks – C) and NK-cells (D). 
Myeloid lineage cells were defined as CD11b
+
F4/80
+
 macrophages (E); and putative myeloid-derived 
suppressor cells, CD11b
+
Gr1
+
 (F). Data expressed as mean ± SD. Capped lines and asterisk indicative 
of statistically significant differences. 
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6.2.1.2 Liver fibrosis 
Assessment of liver fibrosis at the transcriptional level was carried out using alpha-
smooth muscle actin (SMA) and collagen 1(Col11) as markers of activated 
HSC. It has been reported that hepatobiliary injury and cholangitis in the Mdr2
–/–
 
model are more pronounced in female mice relative to males [456], although the latter 
display increased predisposition toward hepatocellular carcinoma [457]. Thus, all 
future experiments were conducted exclusively in female animals unless otherwise 
specified. 
 
Gene expression of SMA and Col11 was studied in 6-week and 12-week old mice 
by qRT-PCR using 18sRNA as a reference gene [458]. The absence of wild-type 
controls precluded strict analysis via the CT method relative to an uninjured 
control, and results are expressed relative to reference gene only. As such, mice in 
younger age groups demonstrated a greater degree of SMA and Col11 gene 
expression than their aged counterparts, suggesting greater transcription of fibrotic 
markers in early life (Figure 6.9). 
 
Figure 6.9: Transcription of fibrosis related genes in the Mdr2
–/–
 model by age 
Expression of SMA (A) and Col11 (B) at the mRNA level in female mice at 6-weeks and 12-weeks 
of age. Data presented as mean ± SD. Capped lines and asterisk indicate statistically significant 
differences (MW-test). 
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Immunohistochemistry revealed a significantly increased stainig for aSMA by 
quantitative digital image analysis in 6-week versus 12-week old mice (Figure 6.10) 
confirming early HSC and myofibroblast activation. However, the immunostaining of 
SMA was highly variable and was reduced on stored samples: Figure 6.11 illustrates 
the same mouse section stained for SMA using identical conditions >6 months apart 
with notably different staining intensity. This may indicate that for future 
comparisons, all sections should be stained simultaneously.  
 
Validation of fibrosis was assessed using (Picro)Sirius red staining (Figure 6.10). This 
allows for direct collagen staining and is widely used in both clinical and research 
settings [459]. Fibrotic septa and even cirrhotic nodules were seen in younger mice 
and increased with age, indicating the progressive nature of liver fibrosis in the Mdr2
–
/–
 model.  
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Figure 6.10: Liver fibrosis in the Mdr2
–/–
 model with increasing age 
Alpha smooth muscle actin (SMA) and (Picro)Sirius red staining in 6-week and 12-week-old 
female mice. Asterisks indicate central veins; arrows indicate fibrotic septae (x100 magnification). 
Quantification of fibrotic injury performed via ImageJ analysis is shown in the lower panel. Mean 
± SD are presented for 4 – 5 mice per group.10 fields of view obtained for each mouse taken at 
x200 magnification. Capped lines and asterisks indicative of statistically significant differences 
(MW-test). 
 
 
 282 
 
Figure 6.11: Variability in SMA immunohistochemistry 
Section of mouse liver (6-week old female Mdr2
–/–
 mouse) wherein immunohistochemical 
staining was performed 3 months apart with the same antibody batch (x100 magnification). 
 
 
Another commonly used technique for determining the degree of liver fibrosis is 
the hepatic hydroxyproline assay [342] which measures the hydroxylation product 
of proline, a major component of collagen. Indeed, hepatic hydroxyproline content 
was significantly greater in mice aged 12 weeks than 6-week old animals (Figure 
6.12).  
 
 
Figure 6.12: Hepatic hydroxyproline assessment in Mdr2
–/–
 mice by age 
Liver fibrosis quantified by hydroxyproline content. Data indicative of 4 – 5 mice per group; box 
and whiskers depict mean ± SD. Capped lines and asterisks indicate statistically significant 
differences (MW-test). 
 
 283 
6.2.2 Assessment of murine VAP-1 enzyme activity 
As alterations in the enzyme activity of VAP-1 were observed in human chronic liver 
disease, I investigated the catalytic capacity of the protein in the murine 
cholangiopathy model. However, little VAP-1 is detected in murine liver by qRT-
PCR, northern and western blots; with minimal staining on immunohistochemistry 
[67,313,317,318,460]. Nevertheless, congenital deletion or therapeutic targeting of 
VAP-1 is associated with attenuation of hepatobiliary inflammation and tissue fibrosis 
in certain mouse models [212–214]; suggesting a pivotal role for VAP-1 in leucocyte 
recruitment and fibrosis in the mouse liver.  
 
Intra-hepatic VAP-1 enzyme activity was assessed using a modification of the protein 
capture and immobilisation method described in Chapter 4. Both mice and humans 
express high levels of enzymatically active VAP-1 in white adipose tissue [460]. 
Therefore a positive control for murine VAP-1 enzyme activity was generated via 
adipocyte differentiation of the fibroblast 3T3 cell lineage. Differentiated adipocytes 
were distinguished by the presence of vacuoles and lipid droplets (Figure 6.13). 
 
 
Figure 6.13: Adipocyte differentiation of 3T3 cells  
The murine 3T3 fibroblast cell line was differentiated into adipocytes (x 250 magnification).  
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A series of anti-VAP-1 antibodies were tested for their ability to capture murine VAP-
1 from lysates of adipocyte differentiated 3T3 cells. Antibodies were selected based 
on their availability, and quality of immunohistochemical staining [214]. A dose 
titration was performed, and the resultant enzyme activities from the highest trialled 
concentration of each antibody (20 mg/mL) are illustrated in Figure 6.14a. Protein 
captured by antibody clone 7-106 had the greatest enzyme activity with little/no 
inhibitory effects at elevated concentrations (Figure 6.14b).  
 
 
Figure 6.14: Establishing a technique to assay murine VAP-1 enzyme activity 
Four different murine antibodies were tested in their ability to capture VAP-1 from murine cells and 
then subject to the Amplex
®
 red assay (A). Antibody 7-106 (number II from panel A) was deemed the 
most potent (i.e., captured the greatest quantity of enzymatically active protein), and exhibited slight 
variation across concentrations (B). Histogram bars represent the mean from 3 technical replicates per 
condition. 
 
 
Mice bearing a point mutation in which VAP-1 is devoid of all enzyme activity, but 
otherwise functionally competent (Ssao
–/–
), have recently been described [214]. 
Mdr2
–/–
 x Ssao
–/–
 mice were generated through a breeding program established in-
house and confirmation of genotype was obtained via qRT-PCR (Transnetyx, USA). 
At time of writing, only 4 mice with confirmed Mdr2
–/– 
Ssao
–/–
 genotype (aged 6 
weeks; all female) were available for study.  
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To confirm absence of hepatic VAP-1 enzyme activity in double knockouts, the 
Amplex red assay using 7-106 as capture antibody was performed on murine liver 
tissue protein lysates (Figure 6.15). This confirmed there was no enzyme activity in 
the liver of Mdr2
–/–
 Ssao
–/–
 mice. Enzyme activity was detected in Mdr2
–/–
 animals 
although itis worth noting that murine hepatic VAP-1 enzyme activity is several 
orders of magnitude lower than that observed in human liver (fmol vs. pmol. range). 
 
 
Figure 6.15: Hepatic VAP-1 enzyme activity in single and double knockouts 
Amplex
 
red assay was performed on liver protein lysates prepared from Mdr2
–/–
 and Mdr2
–/–
 Ssao
–/–
 
mice; no enzymatic activity was observed in the latter. Data representative of semicarbazide corrected 
values (mean ± SD) derived from 4 mice per group (aged 6 weeks; all female); 3 technical repeats per 
animal.  
 
 
6.2.3 Phenotyping of Mdr2 Ssao double knockouts 
In contrast to age and sex-matched Mdr2
–/–
 mice, double knockouts demonstrated 
significant elevations in serum ALT levels (Figure 6.16). As mentioned previously, 
comparisons with wild-types was not possible, but levels were >10 times than in 
uninjured animals or Ssao
–/–
 mice in previous studies [214]. 
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Figure 6.16: Serum ALT in single vs. double knockouts 
Biochemistry measured in Mdr2
–/– 
vs. Mdr2
–/– 
Ssao
–/–
 mice (all female; 6 weeks of age). Data 
represented as mean ± SD. Capped lines and asterisks indicative of statistically significant differences 
(MW-test). 
 
Mdr2
–/–
 Ssao
–/–
 mice displayed dense septal leucocytic infiltrates associated with 
severe parenchymal and portal inflammation and early bridging fibrosis between 
portal tracts (Figure 6.17) (Figure 6.18). Differences in total immunohistochemical 
CD45
+
 staining between single and double knockouts did not however reach 
statistical significance (MW-test). 
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Figure 6.17: Inflammatory infiltrate in Mdr2
–/–
 vs. Mdr2
–/– 
Ssao
/–
 mice 
H&E staining in single and double knockouts, illustrating relatively greater infiltration in the latter; 
particularly marked in the portal and septal areas. Central veins indicated by adjacent asterisks, portal 
tracts by arrows and portal vein as PV. 
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Figure 6.18: CD45
+
 cell infiltration in Mdr2
–/–
 vs. Mdr2
–/– 
Ssao
–/–
 mice 
Representative CD45 immunostaining in single versus double knockouts. A greater Asterisks indicative of 
central veins (adjacent); arrows highlight portal triads; PV demonstrates portal veins (A). Quantitative 
assessment of positive staining provided by percentage surface area at x200 magnification (B) and x400 
magnification specifically assessed in portal and lobular areas (C). 10 fields of view visualised per mouse; 
4 mice in each group. Data presented as mean ± SD. 
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Flow cytometric analysis of the hepatic infiltrate revealed no statistically significant 
differences between Mdr2
–/–
 and Mdr2
–/–
 Ssao
–/–
 animals albeit the total numbers were 
small (n=4, MW-test) (Figure 6.19). However, morphologically the severity of biliary 
injury appeared more pronounced in all double relative to single knockouts, with 
dense peri-ductal infiltrates associated with bile duct injury (Figure 6.20). Mice of 
both strains exhibited marked duct loss, with many portal tracts lacking an identifiable 
biliary structure. 
 
 
Figure 6.19: Phenotyping of infiltrating leucocyte populations 
Liver infiltrating leucocytes were phenotyped by flow cytometry (n=4 in each group); specifically, 
expression of CD3
+
 CD4
+
 T-cells (A); CD3
+
 CD8
+
 T-cells (B); B-cells (C); NK-cells (D); 
CD11b
+
F4/80
+
 macrophages (E); putative myeloid-derived suppressor cells (F). Data represented by 
mean ± SD. 
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Figure 6.20: Biliary injury in Mdr2
–/–
 vs. Mdr2
–/–
Ssao
–/–
 mice 
H&E (A) and CD45 (B) immunostaining in single vs. double knockouts (x400 magnification). Marked periductal inflammatory injury was evident in all animals. Portal vein, 
PV; bile duct, BD; and hepatic arteriole, A. 
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Although no differences were seen with regard to inflammatory infiltrate or biliary 
injury between Mdr2
–/–
 and Mdr2
–/–
 Ssao
–/–
 animals, it remained possible that fibrosis 
could be attenuated through an absence of SSAO generated aldehyde production. 
However, transcription of SMA and Col11 were significantly up-regulated in 
double knockouts, possibly reflecting increased HSC activation and turnover of 
collagen in these mice (Figure 6.21). 
 
 
Figure 6.21: Transcription of fibrotic markers in the single vs. double knockouts 
Expression of SMA (A) and Col11 (B) at the mRNA level in Mdr2–/– vs. Mdr2–/–Ssao–/– mice. Data 
represented by mean ± SD. Capped lines and asterisk indicate statistically significant differences (MW-
test). 
 
 
Sirius red staining of Mdr2
–/–
 Ssao
–/–
 mice indicated clear evidence of fibrotic liver 
disease, although nodule formation appeared somewhat incomplete relative to age and 
sex-matched Mdr2
–/–
 counterparts (Figure 6.22). Quantitative differences in Sirius red 
surface area staining did not however reach statistical significance.  
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Figure 6.22: Sirius red staining in Mdr2
–/–
 vs. Mdr2
–/– 
Ssao
–/–
 mice  
Qualitative assessment of liver fibrosis between single and double knockouts was performed via 
Sirius red staining. Arrows indicate positively stained fibrous septae. Representative images (x100 
magnification) of 4 mice per group. Quantification of staining area performed via ImageJ analysis, 
wherein 10 fields of view analysed at x200 magnification. Data presented as mean ± SD. 
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Further investigation of fibrotic indices was conducted using the hydroxyproline 
assay with all Mdr2
–/–
 mouse liver specimens run at the same time as Mdr2
–/–
 Ssao
–/–
 
animals to ensure comparability. These results were similar to that observed by Sirius 
red staining, wherein a trend toward fibrosis reduction could be observed in Mdr2
–/– 
Ssao
–/– 
mice (MW-test, p = 0.124; Figure 6.23). 
. 
 
 
 
Figure 6.23: Hydroxyproline quantification in Mdr2
–/–
 vs. Mdr2
–/–
Ssao
–/– 
mice 
Validation of severity of liver fibrosis in single vs. double knockout mice with the liver 
hydroxyproline assay. Data represented as mean ± SD of 4 mice per group, each with 3 technical 
repeats (all female; aged 6 weeks). 
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6.3 Discussion 
In the previous chapters, it was demonstrated that hepatic VAP-1 expression is 
increased in diseased human liver, with elevated enzyme activity particularly marked 
in end-stage PSC. Through effective substrate provision, VAP-1 modulated 
expression of downstream cell-adhesion molecules, promoting lymphocyte 
recruitment; a mechanism that could further contribute to pro-inflammatory pathways 
in immune-mediated hepatobiliary disease. sVAP-1 levels were elevated in PSC sera, 
possibly as a consequence of release by activated hepatic stellate cells and 
myofibroblasts, leading us to hypothesise that VAP-1 is a potential therapeutic target 
in PSC. To test the merit of targeted intervention in PSC, a murine model (Mdr2
–/–
) 
mimicking several pathological features of the human condition was chosen and 
crossed with a strain harbouring specific mutation in the VAP-1 gene that renders the 
protein catalytically inactive whilst leaving the distribution and structural 
conformation of VAP-1 unaffected. 
 
6.3.1 Choosing a PSC mouse model  
The relatively low incidence of PSC (3 – 16/100,000 population; [258]), difficult 
accessibility of the human biliary tract for longitudinal studies, and variation in 
clinical course make it a difficult disease in study in humans. Therefore, well-defined 
and easily reproducible animal models for PSC would be invaluable research tools. 
The major attributes of an ―ideal PSC model‖ have been recently been summarised by 
Marion Pollheimer and Peter Fickert [342,445,446]. Ideally, an immunogenetically 
predisposed animal would develop fibrous-obliterative cholangitis of the intra- and 
extrahepatic bile ducts in association with gastrointestinal inflammation (colitis). 
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Moreover, specific immunological phenotypes of inflammatory lymphocytes (e.g. 
CD3
+
 7+ CCR9+) infiltrating portal tracts should exist associated with injury to 
the biliary epithelium. To date, however, no such animal model has been.  
 
Perhaps the best studied is the Mdr2
–/–
 mouse, which accurately recapitulates the 
obliterative fibro-sclerotic bile duct lesions seen within human PSC liver. Moreover, 
mutations in the human orthologue of Mdr2 (MDR3) are associated with several 
intrahepatic cholestatic liver disorders [98]. For these reasons the Mdr2
–/–
 mouse has 
been proposed as a model in which to test novel therapies in vivo. Several bile acid 
based treatments, nuclear acid receptor agonists as well as anti-fibrotic therapies have 
ameliorated hepatobiliary inflammation and fibrosis in the Mdr2
–/–
 model [461,462]. 
We thus chose this model, and given the putative consequences of VAP-1 function in 
PSC hypothesised that an absence of amine oxidase activity would also provide 
protection. 
 
6.3.2 Non-effect of SSAO ablation in the Mdr2–/– mouse 
In our hands the hepatobiliary phenotype of Mdr2
–/–
 on a C57BL/6 background was 
comparable to published findings using the FVB/N strain, with significant 
inflammation and fibrosis present in early life and progressing with age. The catalytic 
activity of VAP-1, which was detectable within diseased mouse liver, was ablated in 
Mdr2
-/-
 Ssao
-/-
 mice. However, we did not see a reduction in the hepatic infiltrate in 
Mdr2
–/–
 Ssao
–/–
 when compared to Mdr2
-/-
 animals either by total CD45
+
 cell staining 
or flow cytometry (Figures 6.16, 6.17, 6.18). This was unexpected given recently 
published data where absence of SSAO activity resulted in a significantly reduced 
CD4
+
 and NK1.1
+
 infiltrate in murine models of fatty liver injury [214]. Martilla-
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Ichihara et al. demonstrated that small-molecule inhibitors of VAP-1 enzyme activity 
reduced the recruitment of intra-tumoural CD11b
+
 Gr1
+
 myeloid cells, which 
resemble myeloid-derived suppressor cells [463], in a murine xenograft model [311]. 
Murine Gr-1 is composed of two components – Ly6C and Ly6G, which are now more 
commonly adopted for defining myeloid subsets. Ly6G is exclusively expressed on 
neutrophils; whereas Ly6C
hi
 defines an inflammatory monocyte subset, Ly6C
int
 is 
associated with neutrophils and eosinophils, and Ly6C
lo
 the patrolling (potentially 
immune-regulatory) population. The absence of further definition of the infiltrating 
myeloid populations represents a significant limitation to my studies, and future work 
will entail deeper immunophenotypic characterisation. It is possible however, that a 
lack of SSAO results in a failure to recruit of regulatory subsets leading to the 
inflammatory phenotype we saw in Mdr2
–/–
 Ssao
–/–
[193].  
 
In contrast, while antibody blockade or deletion of the VAP-1 gene reduced injury in 
a ConA-induced model of hepatic injury in mice [213], the provision of an SSAO 
inhibitor to these animals had a minimal effect. Therefore a redundant role for VAP-1 
in the Mdr2
-/-
 model of liver injury cannot be discounted until the effects of anti-VAP-
1 antibody have been investigated. 
 
6.3.3 Remedial advantage of full VAP-1 deletion  
Inhibition of enzyme activity or neutralising adhesion molecule properties of VAP-1 
(without affecting amine oxidase function) have similarly inhibitory effects on 
leucocyte recruitment in vitro, with little to suggest enhanced inhibitory effect when 
applied in tandem [316]. VAP-1 has been shown to promote wound-healing responses 
and enhance expression of pro-fibrotic genes COL1A1 and lysyl oxidase homolog 
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LOXL2 [214], suggesting that VAP-1 may have a direct effect on HSC. Göktürk et al. 
have illustrated overexpression of VAP-1 in arterial smooth muscle cells, which 
promotes elastin deposition [324]. However, the specific contribution of enzyme 
activity to such properties remains less clear as accelerated healing in scratch-assays 
appear independent of enzyme activity, and expression of pro-fibrotic genes 
unaffected by the transfection of a stellate cell line (LX2) with catalytically inactive 
VAP-1 [214].  
 
Published studies of VAP-1 deletion in mice (Aoc3
–/–
) clearly outnumber those 
assessing enzyme inhibition; and it appears that the former approach confers a greater 
degree of protection against liver injury in vivo. In the CCl4 model of hepatitis, Aoc3
–
/–
 mice show a marked reduction in nearly all liver infiltrating mononuclear cell types 
and pro-inflammatory myeloid cells from as early as 2 weeks, [214]. The influence on 
leucocyte recruitment early in the disease course was paralleled by a reduction in 
hepatitis and reduced parenchymal and portal fibrosis. In a murine model of 
steatohepatitis (methionine choline deficient (MCD) diet), Ssao
–/–
 mice showed a 
similar reduction in hepatic CD4
+
 and NK1.1
+ 
T-cells assessed by flow cytometry to 
Aoc3
–/–
 mice at 4 – 6 weeks of age, although biochemical indices of hepatobiliary 
inflammation (serum ALT) was no different to wild-type counterparts on the same 
chow [214]. This suggests that the absence of enzyme activity alone is not as 
protective as complete Vap-1 deletion. Improvement in fibrotic liver injury has also 
been documented in Aoc3
–/–
 mice exposed to a high-fat diet, despite no significant 
differences in any one particular immune-cell population [214]. This suggests that 
VAP-1/SSAO operates through effects on leucocyte adhesion, attenuation of 
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myofibroblast activity and reduced production of aldehydes to ameliorate the fibrotic 
response. 
 
6.3.4 Congenital deletion vs. therapeutic manipulation  
Aoc3 knockout animals develop normally, although they display mildly dysregulated 
leucocyte homing [320]. Absolute reduction in lymphocyte populations within the gut 
(Peyer‘s patches, PP) has been reported; and despite a relative increase in the numbers 
of PP CD4
+
 and CD8
+
 T-cells, these animals manifest attenuated T- and B-cell 
responses to oral vaccination and defective microbial handling [423]. These effects 
are not observed when administering antibody or enzyme inhibitors to fully developed 
wild-type animals leading Koskinen et al to propose that life-long absence of VAP-1 
may give rise to compensatory mechanisms in development that alter components of 
anti-microbial defence.  
 
The ability of enzymatically active VAP-1 in human PSC liver to induce expression 
of functional cell adhesion molecules on hepatic endothelium suggests novel 
therapeutic possibilities using enzyme inhibitors or neutralising antibodies against 
VAP-1.  
 
As previously discussed cell-surface expression of VAP-1 although predominantly 
restricted to the liver, can be up-regulated on extra-hepatic sites such as synovium and 
gut under non-homeostatic conditions. LJP1207 is a potent inhibitor of both aspects of 
VAP-1 function; and in oxazolone induced colitis was shown to reduce mortality, 
improve body weight and improve colonic inflammation by inhibiting Th2 immune 
cell responses [424]. Such reagents reduce other inflammatory responses including 
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peritonitis, arthritis, ischemia-reperfusion injury, lung inflammation, septic shock, 
hepatitis, colitis and fibrotic (kidney, liver) responses in several mouse models [212–
214,309,312,407,424–429]. 
 
Anti-VAP-1 antibody-treated mice are protected from the development of liver 
fibrosis in response the MCD diet [214]. This is despite the antibody in question being 
free of enzyme-inhibition in vitro. A direct comparison of 4 versus VAP-1 inhibition 
in the concanavalin A model of hepatitis [213] reported thatVAP-1 reduced influx of 
CD4
+
 (but not CD8
+
) T-cells, attenuated early liver inflammation (lower serum ALT 
at 8 hours following injury) and lessened peri-portal inflammation. The anti-VAP-1 
effects on lymphocyte recruitment were predominantly restricted to T-cells bearing a 
Th2 cytokine profile; whereas 4-inhibition associated with significant exacerbation 
in hepatitic injury through increased production of IFN and reduced hepatic 
infiltration of protective myeloid-derived suppressor cells (MDSC). A modest (non-
significant) improvement in serum ALT was observed with the enzyme inhibitor 
(BTT-2052) associated with a reduction of liver-infiltrating Th2-cells [212,213]. 
There is little to suggest an additive effect through combining antibody and enzyme-
abrogation.  
 
My results suggest that loss of SSAO and the absence of VAP-1 in Aoc3
–/–
 animals 
exacerbate liver injury in the Mdr2 knockout mouse. The mechanisms of this effect 
are not clear but there are several possibilities. Defective microbial clearance has been 
associated with an absence of VAP-1. Recurrent episodes of ascending cholangitis are 
a feature of PSC that are associated with a worse clinical outcome (see chapter 5). 
Thus if lack of VAP-1/SSAO increases [423] hepatobiliary infection it could 
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exacerbate inflammatory responses; particularly in older female mice who develop 
choledocholithiasis [464]. These effects would not necessarily occur with 
pharmacological inhibition, and may prove conducive to further study. Secondly 
VAP-1/SSAO may be important for the recruitment of anti-inflammatory cells 
including MDSCs, Treg or reparative macrophages; and their failure to be recruited to 
the injured liver could exacerbate PSC.  
 
6.3.4.1 Is there a more appropriate model? 
The Mdr2
–/–
 mouse model may not be appropriate for examining the influence of 
VAP-1/SSAO activity however as unlike human PSC, Mdr2
–/–
 mice neither exhibit 
features of colitis nor do they express MAdCAM-1 in the liver [342]. The absence of 
such features questions the rationale of targeting gut-liver homing in such mice. 
Several animal models have been proposed for studying certain aspects of disease 
pathogenesis although to date none allow a detailed study of the enterohepatic 
migration of T-cells. Seidel et al. have recently developed a strain expressing OVA on 
cholangiocytes, wherein OA-specific T-cells are primed in liver and draining lymph 
nodes, but despite acquiring effector function do not cause significant hepatobiliary 
inflammation [175]. However, when crossed with mice in which antigen-specific 
priming of T-cells is achieved in GALT, the investigators illustrate that gut-activated 
and not liver activated lymphocytes were responsible for the induction of immune-
mediated cholangitis in vivo. Moreover, ~60% of LILs were 7+; and although the 
authors did not comment on VAP-1 and MAdCAM-1 within mouse liver, expression 
of ICAM-1, VCAM-1 and CCL25 were all up-regulated (assessed by qRT-PCR on 
whole liver). Furthermore, only gut-primed T-cells infiltrating the liver were shown to 
co-express CCR9 [173]. Using the same mice, Neumann et al. have shown that liver-
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primed 7+ CCR9- T-cells are programmed with regulatory functions, in contrast to 
gut-primed 7 CCR9+ T-cells which were more in keeping with an effector 
phenotype [174]. It is plausible therefore, that such models may allow more rational 
targeting of immune pathways than based on the gut-liver homing hypothesis. 
 
6.3.5 Summary 
Despite findings of increased VAP-1 expression and enzyme activity on the livers of 
patients with PSC liver, absence of VAP-1 amine oxidase activity in vivo does not 
abrogate hepatobiliary injury in Mdr2
–/–
 mice. Although a limited number of animals 
were examined, the data suggest worse inflammation in Mdr2
–/–
 Ssao
–/– 
mice 
suggesting a protective role for SSAO in this model. Whether this is due to defective 
microbial handling and recurrent ascending cholangitis or a failure to recruit anti-
inflammatory cells to the liver or defective fibrosis is open to conjecture; and 
delineation of disease phenotype in older mice, as well as the Mdr2
–/–
 x Aoc3
–/– 
cross 
an area of on-going investigation. 
 
The lack of supportive evidence to support a pathological enterohepatic circulation of 
gut-primed effector T-cells in this model of sclerosing cholangitis suggests that 
challenging the gut-liver homing hypothesis may require better, more suited mouse 
models, with well-defined lymphocyte recruitment pathways. 
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7 Conclusions and future work 
Inflammatory bowel disease is frequently associated with concurrent skin, joint and 
eye inflammation. In contrast, autoimmune hepatobiliary diseases developing in the 
context of IBD usually run an independent course to that of gut inflammation. This 
clinical observation led to the proposal of a disease model wherein mucosal effector 
memory T-cells are recruited to the liver secondary to aberrantly expressed 
endothelial cell adhesion molecules and chemokines that are normally ‗gut-restricted‘. 
These cells reactivate in the liver to drive hepatobiliary damage following exposure to 
an as yet unidentified, shared antigenic trigger [2].  
 
The well-established roles of CCL25–CCR9 and MAdCAM-1–7 in lymphocyte 
recruitment to the gut are mirrored by their involvement in homing to the liver in 
PSC; however, a caveat exists because intestinal CCL25–CCR9 interactions have 
been reported to be restricted to small bowel whereas PSC is most commonly a 
complication of colonic inflammation. The putative contribution of VAP-1 in 
furthering mucosal lymphocyte recruitment to the inflamed liver has also recently 
been described [294]. 
  
The aims of this thesis were to investigate the contribution of CCL25–CCR9 
interactions in colitis, and consequences of hepatic VAP-1 expression with regards to 
lymphocyte homing in PSC. 
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7.1 CCL25–CCR9 expression in colitis 
I have shown for the first time that CCR9 is expressed at high frequencies on effector 
T cells in the inflamed human colon. I was also able to show that CCL25, the CCR9 
ligand is increased in the inflamed colon and correlates with inflammatory activity 
providing further evidence that the CCL25–CCR9 axis is active in patients with 
colitis.  
 
Unfortunately attempts at CCL25 localisation within tissue (immunohistochemistry) 
were unsuccessful. CCL25 is expressed by mucosal epithelium and plays a key role in 
leucocyte recruitment to the gut, and under specific pro-inflammatory conditions, the 
liver [132]. The presence of CCL25 on hepatic endothelium demonstrated in previous 
studies, and on mucosal endothelium in the gut illustrated by other peoples‘ work 
[127] may reflect secretion by the intestinal epithelium and subsequent capture and 
presentation by the endothelial glycocalyx. Constitutive CCL25 expression by small 
bowel epithelium (isolated cells and tissue sections) has been demonstrated by in situ 
hybridisation [142,375]; an avenue yet to be explored in the inflamed human colon. 
An alternative technique toward determining cellular source of colonic CCL25 could 
be evaluation of epithelial/endothelial cells by flow cytometry, although a lack of 
reliable and commercially available fluorescence-conjugated human antibody toward 
human CCL25 currently precludes such analysis. Along similar lines however, 
isolation of purified cell populations could facilitate qualitative and quantitative 
analysis of CCL25 transcription and protein expression via established techniques of 
qRT-PCR, western blotting and immunocytochemistry.  
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The factors mediating CCL25 expression within human intestinal tissue are largely 
unknown, in part due to chemokine transcription diminishing following cell culture 
[378]. In mice, members of the lymphotoxin (LT) / TNF family of cytokines can 
regulate constitutive expression of homeostatic and inflammatory chemokines in 
secondary lymphoid organs and small intestine. Rodents subject to intra-peritoneal 
TNFinjection exhibit diffuse CCL25 reactivity (immunohistochemistry) in almost 
the entire lamina propria contrasting with the relatively sparse distribution observed in 
uninjured mice [136]. However, Ericcson et al. report a similar degree of CCL25 
mRNA expression in the small intestine of LT–/–, LT–/–, and TNF receptor (R1) 
knockout mice, with levels remaining fairly constant despite intravenous LPS 
injection and in germ-free conditions [378]. Moreover, CCL25 transcription was 
unaltered in several intestinal epithelial cell lines (mouse small intestine: MODE-K, 
S1-H10 mICcl2; human small intestine: CCL-241; human colorectal adenocarcinoma: 
HT-29, Caco-2) following TNFand IFN stimulation. Caudal-related homeobox 
(Cdx)-1 and Cdx-2, transcription factors that are restricted to gut epithelium in adult 
mice, enhanced the activity of a murine CCL25 promoter in MODE-K small intestinal 
cell lines. The authors concluded that CCL25 expression is neither dependent on 
intestinal microfloral colonisation nor enriched by the effect of inflammatory 
cytokines. However MODE-K cells failed to express CCL25 mRNA at levels seen in 
freshly isolated murine small intestinal epithelial cells despite CDX transfection. 
Additional factors must therefore be required for maintaining constitutive expression 
in tissue. 
 
Until now, the aberrant lymphocyte homing model of PSC/IBD, has been challenged 
by a lack of supportive evidence implicating the CCL25–CCR9 axis in colonic 
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lymphocyte recruitment [123,142,148,343]. Previous studies were largely restricted in 
their examination of large bowel under non-inflammatory conditions, and several 
lines of evidence implicate activity of this pathway in murine colitis [380,382]. Data 
presented in this thesis (Chapter 3) further illustrate involvement of the CCL25–
CCR9 pathway in human colonic IBD, which correlates with severity of intestinal 
inflammation.  
 
If CCL25 expression is driven by colitis activity, and colonic CCR9
+
 T cells are 
responsible for driving hepatobiliary inflammation in PSC, then it should follow that 
the risk of PSC increases with intestinal activity; which clinically is not the case. 
However, pre-exposure of primed CCR9
+
 T-cells to high CCL25 levels in the gut 
during the onset of active IBD, may be capable of modulating subsequent migratory 
responses [136] (Figure 7.1). In such a model, pro-inflammatory mucosal CCR9
+
 T-
cells would preferentially undergo local recruitment during the onset of active colonic 
disease, due to high levels of intestinal CCL25 expression [136]. Thereafter, mucosal 
T-cells down-regulate expression of active CCR9, favouring retention in the intestine 
for as long as inflammation persists. On achieving remission from a colitis flare, the 
colonic CCL25 gradient is attenuated, and primed mucosal CCR9
+
 lymphocytes now 
become permissive to enterohepatic recirculation and are recruited to the liver 
sinusoids in response to aberrant hepatic endothelial CCL25 expression [127]. 
Support of this hypothesis is lent by Hosoe et al., who show that pre-exposure of 
CCR9
+
 intraepithelial lymphocytes (IELs) or lamina propria lymphocytes (LPLs) to 
CCL25 drastically attenuates the migratory response in vitro (―chemokine 
desensitisation‖ [136]). A similar response can also been observed following pre-
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incubation of 7+ lymphocytes to soluble recombinant MAdCAM-1 prior to HSEC 
flow adhesion assays (own data; unpublished).  
 
To prove such a hypothesis in humans would require the study of liver biopsies from 
patients with IBD who do not have any clinical or biochemical evidence of liver 
disease (clearly unethical). Nevertheless, Bungay et al. report radiological features of 
sclerosing cholangitis in ~20% of individuals with asymptomatic colitis, despite the 
presence of normal liver biochemistry [465], suggested that subclinical hepatobiliary 
disease exists in a greater proportion of patients with IBD than currently recognised.
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Figure 7.1: CCL25 desensitisation and the mucosal lymphocyte homing hypothesis in PSC/IBD 
In patients with active colitis (A) overexpression of CCL25 and MAdCAM-1 in the gut microenvironment would desensitise 
CCR9-mediated lymphocyte recruitment to extraintestinal sites, resulting in preferential trafficking and retainment of mucosal 
T-cells within the colon. During periods of prolonged IBD remission (B), low-level colitic activity down-regulates CCL25 
expression in the gut, allowing locally primed CCR9
+
 lymphocytes to now migrate to the liver where CCL25 is aberrantly 
expressed by hepatic endothelial cells.  
 
 
The capacity to imprint lymphocytes with gut-tropism is restricted to intestinal rather 
than liver DCs [296]. However recent studies in mice report that priming by HSEC 
induced α4β7-expression on naïve T-cells [174] dominated by regulatory, 
immunosuppressive properties [176]. This may in-turn account for the relatively mild 
IBD phenotype observed in PSC patients, as well as relatively increased colonic 
cancer risk posed by IBD alone. There is also emerging evidence to suggest that 
functional characteristics of tissue-infiltrating 7+ T-cells are distinct depending on 
site of priming [173], with liver-primed lymphocytes (CCR9
–
) being 
 308 
immunoregulatory and gut-primed lymphocytes (CCR9
+
) bearing predominantly 
effector functions. If proven, this may have significant therapeutic implications in 
PSC wherein focussed antagonism of effector CCR9
+ 
T-cells would minimise off-
target effects associated with pan-7 inhibition. Detailing whether such concepts 
apply to the human setting is an avenue under on-going investigation. 
 
7.2 Hepatic VAP-1 expression studies 
In addition to CCL25–CCR9 interactions, enterohepatic mucosal lymphocyte 
recruitment involves the endothelial addressin MAdCAM-1 and its integrin receptor 
7 [289]. The Birmingham group has implicated another endothelial molecule, 
VAP-1, in leucocyte recruitment to the human liver [67]; and shown that through its 
amine oxidase activity how VAP-1 can modulate expression of other cell adhesion 
molecules [67]. Using similar methodology, I was able to reproduce these findings 
wherein treatment of HSEC with VAP-1 substrates was shown to up-regulate 
MAdCAM-1 expression and increase adhesion of 7+ lymphocytes in vitro 
(Chapter 4); fuelling deeper investigation into the role of VAP-1 in PSC. 
 
VAP-1 transcription in liver tissue was increased in end-stage PSC cirrhosis relative 
to non-diseased specimens and other inflammatory diseases, representing the first 
study to detail VAP-1 expression at the message level across different aetiologies. 
The significant differences between PSC and other diseases led me to investigate 
tissue localisation and enzyme activity. I found VAP-1 expressed by endothelium in 
normal human liver and showed marked increase by immunohistochemistry in 
fibrotic scar tissue in a range of autoimmune liver diseases, consistent with that 
reported by others [214]. I then went on to show for the first time that this was 
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reflected by elevated VAP-1 amine oxidase activity in PSC liver; whereas under non-
inflammatory situations hepatic enzyme activity was significantly lower than that in 
the gut [409].  
 
The high-level enzyme activity in colon may be secondary to an increased burden of 
dietary and microbe-derived amines that regularly enter the gut. Given links between 
enteric dysbiosis and an inflamed colon in PSC patients, it is perhaps unsurprising 
that the degree of amine oxidase activity is similar between afflicted disease sites, 
further strengthening associations between gut and liver inflammatory disease 
processes. As little is known about the physiological or pathophysiological substrates 
that active VAP-1 in vivo, I went on to study a range of potential amine substrates. In 
so doing, I found that the most efficient substrate was cysteamine, which was more 
efficient than methylamine at inducing functionally active MAdCAM-1 on HSEC. 
Cysteamine is produced by gut bacteria, as well as generated through intestinal 
epithelial vanin-1 activity. Moreover, when instilled into the colon in mice cysteamine 
induces colitis providing another theoretical link between gut and liver.  
 
7.3 Soluble VAP-1 in PSC 
The most notable limitation of the tissue studies was the restriction to end-stage liver 
disease. However because VAP-1 exists as a circulating soluble form in human serum 
I was able to study sVAP-1 levels in patients with all stages of disease and look for 
correlation with clinical characteristics or disease course. I prospectively collected 
serum samples from our autoimmune liver disease clinic and measured sVAP-1 levels 
across a range of genders, age groups, aetiologies and disease stages. In summary, 
sVAP-1 levels were significantly greater in patients with liver disease, particularly 
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those with PSC whether they were cirrhotic or non-cirrhotic. Moreover, sVAP-1 
levels predicted clinical disease progression, underlining its worth as a putative 
biomarker in liver disease patients.  
 
Previous studies have reported correlation between serum amine oxidase activity and 
serum sVAP-1 protein. I was unable to confirm this using the capture and 
immobilisation (Maxisorp
 
plate) method but when I repeat a limited analysis in 
patients for with sVAP-1 levels below 400 ng/mL the correlation was demonstrated. 
Efforts to quantify methylamine in serum were also unsuccessful, probably due to the 
presence of extensive non-specific background signals and/or inherent volatility of the 
compound. This was confirmed when I used whole serum + addition of MAO-A and 
MAO-B inhibitors and was unable to detect SSAO activity, suggesting that 
endogenous VAP-1 substrates has either evaporated or been consumed prior to 
experimentation.  
 
Thus, several unanswered questions remain with respect to serum amine oxidase 
activity and substrate quantification. Optimisation of both techniques would further 
our understanding of the role of serum VAP-1 in PSC as well as liver disease in 
general. In addition to optimising capture antibody levels for the enzyme assay, there 
is merit in a ‗head-to-head‘ comparison of Amplex Red techniques, as well as an 
appraisal of exogenous substrate-free enzyme activity on freshly collected specimens. 
Quantification of substrates other than methylamine is not well described for human 
bodily fluids, although theoretically feasible provided the amine being assessed 
exhibits stability under ambient conditions. Another major hurdle in trying to 
determine specific amine concentrations stems from the difficulty in differentiating 
test subject from related biogenic compounds – specifically other amines. Zhang et al. 
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claim to have circumvented this problem as well as that of prolonged sample pre-
treatment times, through prior distillation and micro-trapping of volatile aliphatic 
amines [466].  
 
Based on my findings I have proposed a revised PSC pathogenesis model unifying 
pre-existing concepts of enteric dysbiosis, a leaky inflamed gut, and aberrant mucosal 
lymphocyte homing (Figure 7.2). In a genetically predisposed individual, immune 
dysregulation leads to a change in the microbiome with increased frequencies of 
bacteria that generate VAP-1 substrates including cysteamine. The increased 
intestinal derived amines enter the portal circulation through the weakened epithelial 
lining resulting form colitis and are delivered to hepatic sinusoids where they active 
VAP-1 on hepatic endothelial cells. The resulting increased amine oxidase activity 
drives an increase in chemokine and adhesion molecules including MAdCAM-1 that 
promote homing of mucosal lymphocytes. Elevated VAP-1 expression has direct 
effects on leucocyte recruitment, and through amine oxidase activity augments 
fibrogenesis tissue fibrosis. Increased release of sVAP-1 may further exacerbate 
inflammation by driving leucocyte chemotaxis and recruitment to afflicted sites.  
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Figure 7.2: Putative aetiopathogenic pathways in PSC 
Alterations in commensal flora (e.g. as a result of Fut2 variants) and defective microbial handling 
(e.g. a consequence of NOD2/CARD9 variants) can lead to the translocation of various bacterial 
components via an inflamed ‗leaky‘ colon. In the liver, these products may behave as ligands for 
pattern recognition receptors (PRR) such as TLRs the activation of which triggers cytokine release 
from Kupffer cells (KC) and endothelial cells. Cytokine release is followed by the recruitment and 
activation of neutrophils, macrophages and lymphocytes to portal tracts through increased 
expression of chemokines and adhesion molecules. Bacterial derived amines, as well as those 
generated by intestinal epithelial inflammation (e.g. via vanin-1) can behave as substrates for VAP-
1 enzyme activity resulting in upregulation of MAdCAM-1, ICAM-1 and VCAM-1 on HSEC. 
Soluble VAP-1 release into serum (not depicted) may exert local and distal chemotactic effects that 
potentiate recruitment of pro-inflammatory leucocyte subsets to the liver. Mutations in genes such 
as MST-1 and components of the IL-2 pathway may further affect innate and adaptive immune 
responses leading to chronic inflammation.  
 
Bacterial components may also act as antigens (e.g. FtsZ) and stimulate production of antibodies 
that bind biliary epithelial cells leading to increased TLR4 and TLR9 expression and enhanced 
responses to bacterial products. Activation of these PRR perpetuates the secretion of pro-
inflammatory cytokines and chemokines, the persistence of chronic inflammation and eventually 
biliary fibrosis, progressive cholestasis and secondary biliary cirrhosis [1].  
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7.4 Genetic inactivation of SSAO in murine sclerosing cholangitis 
There are several lines of evidence to suggest that VAP-1 enzyme inhibition would 
lead to reduced leucocyte infiltration in PSC. The research group from Turku have 
illustrated that enzyme activity is crucial in mediating the rolling and transmigratory 
functions of VAP-1 [316,425], and that enzyme inhibition attenuates leucocyte 
extravasation. Provision of the archetypal substrate benzylamine also results in NFκB 
activation and increased chemokine and adhesion molecule expression as reported 
previously [321], enhancing the ability of HSEC to recruit leucocytes under flow 
(detailed in Chapter 6). VAP-1 can be found in the heart, lungs, spleen and blood 
vessels of mice; although in contrast to humans little can be detected on the hepatic 
endothelial surface under homeostatic conditions [67,212,213]. Nevertheless recent 
reports suggest an absence of VAP-1 enzyme activity confers protection against liver 
fibrosis and a reduction in the infiltration of CD4
+
 T-cell subsets in vivo [213,214].  
 
Extrapolating techniques applied to human tissue lysates, I was able to confirm that 
low levels of VAP-1 enzyme activity can be detected in the livers of Mdr2
–/–
 mice, 
although due to current project license restrictions any comparisons with wild-type 
animals were precluded. Mdr2
-/-
 mice were crossed onto Ssao
-/-
 mice in which wild 
type VAP-1 was replaced by an enzyme dead mutant; but despite an absence of VAP-
1 enzyme activity I was unable to detect a protective effect on hepatobiliary injury. 
Moreover, serum indices of hepatobiliary inflammation appeared more prominent in 
double knockout animals. Although, the number of animals studied was small and 
restricted to female mice, the findings suggest that a lack of enzymatic activity might 
exacerbate liver injury. The findings need to be confirmed in older mice and in 
models lacking all VAP-1 knockout functional properties, which, based on previously 
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published studies, I would expect to reduce the infiltration of pro-inflammatory cell 
populations [213,214]. Conversely, if the hypothesis proposed by Koskinen et al. 
holds true [316], then perhaps Mdr2
–/–
 strains should only be challenged 
therapeutically with targeted antibodies and/or enzyme inhibitors, or through creation 
of a strain allowing targeted deletion after birth (e.g. a Cre-LoxP facilitated deletion). 
 
The fact remains that hepatic VAP-1 expression in mice is relatively sparse, and there 
is no evidence to suggest the presence of MAdCAM-1 or CCL25 in the Mdr2
–/–
 
mouse liver suggesting it may not be a good model to test the mucosal lymphocyte 
homing hypothesis, and as proposed in previous chapters may require better-suited 
animal models [173,175].  
 
7.5 Future work 
The accepted doctrine in any realm of scientific research is that more questions will 
arise than answers generated. The existing series of studies suggest several aspects 
wherein future research efforts should be directed in order to better characterise 
contributions of mucosal lymphocyte homing in PSC disease pathogenesis. In this 
respect future studies should involve:  
 
Determining CCL25 localisation and expression patterns in tissue 
 Identifying the cell-types as well as factors responsible for CCL25 expression in 
the human colon are of critical importance. Isolation of human colonic epithelial 
and endothelial cell populations would allow analysis of CCL25 expression pre- 
and post-stimulation with inflammatory cytokines and bacterial products. 
Analysis of CCL25 expression could ostensibly be performed via flow-cytometry 
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should a suitable conjugated antibody become available, or through techniques 
performed on whole tissue described in Chapter 3. 
 
 Given the emergence of data in mice illustrating ability of HSEC-primed T-cells 
to home to the gut, it is plausible that lymphocytes derived from human liver can 
adhere to isolated colonic endothelial cells. To investigate this hypothesis, liver-
derived lymphocytes could be obtained via FAC-sorting, and a comparison 
between 7+ (CCR9+ and CCR9–) versus a collective CD3+ population drawn 
in flow-based adhesion assays across colonic endothelial cells that express 
CCL25. As HSEC purportedly imprint 7+ expression onto T-cells together 
with a tolerogenic phenotype, targeting CCR9 in vivo (selectively gut-primed T-
cells) may confer a therapeutic advantage – provided the hypothesis can be tested 
and confirmed in man. 
 
Detailed phenotypic characterisation of CCR9
+
 T-cells 
 Having illustrated that the majority of colonic CCR9+ T-cells are CD127+ but 
CD25
–
, studies confirming the cytokine expression profile are of utmost 
importance in order to validate the functional characteristics of this 
population. 
 Validation of murine data [173,174], wherein HSEC were able to prime naïve 
T-cells with a gut-tropic phenotype are in need of translation to the human 
setting. An appraisal of antigen presentation by APC subtype across the gut 
and liver (e.g. DC, HSEC, HSC, B-cells, BEC, tissue macrophages) is 
envisaged in which HLA expression is determined by flow cytometry, 
subsequent to which RALDH activity would be assessed through previously 
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published techniques (ALDEFLUOR
TM
 assay). Comparisons between gut- 
versus liver-primed 7 CCR9+ / CCR9– T-cells would then be drawn 
through detailing immunoregulatory (e.g. CD39
+
, TGF/IL-10 secreting) 
versus cytotoxic (e.g. IL23R
+
, granzyme/perforin/IL-17/TNF-secreting) 
phenotypes, and co-expression of other homing receptors determined (e.g. 
CCR10, CXCR3). Furthermore, qRT-PCR on cellular (as opposed to tissue-
derived) genomic material would depict expression of key transcription factors 
(e.g. ROR, STAT3) and ELISA/western blotting to substantiate downstream 
protein translation. 
 
Given the pivotal influence of CD103
+
 DC in mediating human colitis, it is 
envisaged that 7+ CCR9+ T-cells are gut-primed, effector T-cells; whereas 
7+ CCR9– T-cells (liver-derived) are endowed with a more regulatory, 
immunotolerant phenotype. In this context, selective targeting of CCR9 in 
vivo may pose a distinct therapeutic advantage. 
 
Quantification of VAP-1 protein in gut and liver  
 Using western blots and tissue ELISA, tissue protein lysates from varying 
aetiologies can be used to quantify hepatic and colonic protein expression of 
VAP-1. Thus far, quantitative protein differences have only been 
demonstrated for gene expression and enzymatic activity. However, given the 
inherent variation in tissue sampling, normalisation of enzyme activity to a 
given quantity of VAP-1 protein would yield a more accurate determination of 
inherent differences.   
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 HSEC ELISA (Chapter 4) delineated the functional consequences of VAP-1 
expression in terms of inducing downstream CAMs. However, further 
evaluation by flow-based adhesion assays are required to determine whether 
induction by VAP-1 amine substrates + TNF are meaningful in terms of cell-
recruitment to HSEC. Moreover, the development of newer, more potent 
antibodies and enzyme inhibitors directed toward VAP-1 warrants testing in a 
similar regard. Obtaining an anti-MAdCAM-1 and/or and anti-7 inhibitor 
for parallel experimentation would also be of benefit. Nevertheless, the data 
presented in this thesis suggests that VAP-1 inhibition would likely mitigate 
the degree of 7-dependent adhesion to HSEC in vivo irrespective of the 
amine substrate used. 
  
Substantiate the effects of soluble VAP-1  
 Assessment of enzyme activity in human serum clearly requires further 
optimisation. A setup wherein escalating recombinant VAP-1 amounts are 
contrasted with increasing capture antibody concentrations represents the most 
‗straight-forward‘ approach, and would require validation in serum samples 
bearing low, intermediate and high sVAP-1 levels prior to widespread 
application. 
 The chemotactic effect of purified human sVAP-1 has been recently described 
for CD4
+
 T-cells in Boyden chamber assays [214]. Given the diverse range of 
sVAP-1 levelss observed in patients, it would be of interest to see whether 
serum samples from varying aetiologies harbour different chemotactic 
potential. As the identity of the VAP-1 ligand is not yet known, this series of 
 318 
experiments would require parallel investigation with highly specific anti-
VAP-1 antibodies and/or enzyme inhibitors. 
 
Evaluate consequences of targeting VAP-1 across different cholangitis models 
 The preliminary results presented in Chapter 6 suggest an absence of VAP-1 
enzyme activity is not protective against murine sclerosing cholangitis – at 
least in young, female Mdr2
–/–
 mice. The Mdr2
–/–
 Ssao
–/–
 model necessitates 
further evaluation at older age groups and in a larger numbers of animals 
(from different litters). Phenotypic characterisation of Mdr2
–/–
 mice crossed 
with animals having a full VAP-1 knockout (Aoc3
–/–
) requires investigation in 
a similar regard; with detailed assessment of infiltrating leucocytic populations 
that are potentially protective (e.g. MDSC, Treg). 
 Given the described harmful consequences with regard to defective microbial 
handling in Aoc3
–/–
 animals and a potentially increased risk of biliary sepsis in 
sclerosing cholangitis, a parallel appraisal of anti–VAP-1 antibodies and 
enzyme inhibitors in fully developed Mdr2
–/–
 mice may be in order.  
 SSAO substrate specificity may also differ between species, and detailing the 
variation in enzymatic efficiency through varying amine provision may 
provide additional insights into current findings. 
 The availability of cholangiopathy models that exhibit intestinal inflammation, 
and with better-characterised gut and liver homing pathways is attractive, and 
Ova-Bil x Ova-iFABP mice would theoretically be more conducive to 
therapeutic exploration of VAP-1 neutralisation, 7-inhibitors and CCR9 
blocking antibodies. Evaluation of VAP-1 expression in the gut and liver of 
these mice represents another avenue of intended exploration. 
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